CURRICULUM VITAE Wiernik CV.doc · Web viewCURRICULUM VITAE Date of Preparation March 13, 2014...

Peter H. Wiernik, M.D.Curriculum Vitae

CURRICULUM VITAE

Date of Preparation March 13, 2014

Name: Peter H. Wiernik, M.D.

Date and Place of Birth: June 16, 1939, Crockett, Texas

Citizenship: United States

Education: 1961 B.A. (with distinction), University of Virginia

1965 M.D., University of Virginia

Postdoctoral Training: 1965-66 Straight Medical Internship, Cleveland Metropolitan General Hospital, Western Reserve University, Cleveland, Ohio

1966-69 Fellow in Medical Oncology, National Cancer Institute

1969-70 Assistant Resident in Medicine, Cleveland Metropolitan General Hospital, Cleveland, Ohio

1970-71 Senior Resident in Medicine, Osler Service, Johns Hopkins Hospital, Baltimore, Maryland

Medical Licenses and Certification : New York, Maryland, and Virginia state licenses. Certified in Internal Medicine, ABIM 1973; Certified in Medical Oncology, ABIM Subspecialty Board of Medical Oncology, 1973.

Military Service: USPHS July 1966 – June 30, 1981

C:\My Documents\pwcv.doc

1


Professional Organizations and Societies: American Association for the Advancement of Sciences, Elected to Fellowship, 1977

American Association for Cancer Research, 1970-Clinical Cancer Research Committee, 2002-2005

American College of Clinical Pharmacology, Elected to Fellowship, 1974; Member, Honors and Awards Committee, 1999-2002; Academia/Hospital Advisory Board, 2002- 2004; Credentials Committee, 2004- ; Member, Board of Regents 2012-17

American College of Physicians, Member l972, Fellow l974; MKSAP VII Hematology Committee, 1983-86, MKSAP 13, 16 and 17 reviewer.

American Federation for Medical Research, 1968-; Councilor, Eastern Division, 2010-13, Councilor at Large, National Council, 2011-2015, Chair-Elect, Eastern Division, 2013, Chair, Eastern Division, 201-15.

American Radium Society, 1981-; Member, Membership & Credentials Committee,1984-89; Member, Scientific Program Committee, 1987-90; Member, Executive Committee, 1988-95; Member, Publications Committee, 1988-92, and Chairman, 1991-2; Member, Resident Awards Committee, 1990; Member, Nominating Committee, 1994-95; Member, Long Range Planning Committee, 1994-96. Elected Secretary, 1990-92; President-Elect, l992-93, President, 1993-94, Member, Scientific Program Committee, 2008-2009.

American Society of Clinical Oncology, 1970-; Member Program Committee 1972-73, 1976- 79 and 1989-90; Chairman, Committee on Cancer Education and Training 1976-79, and 1984-5; and Deputy Chairman 1983-84. Member, Nominating Committee, 1978; Chairman, Subcommittee on Clinical Investigation, 1980-1983, Member Publications Committee, 1985-91; Member, Public Issues Committee, 1991-94; Member Awards Selection Committee, 1996-2000; Member, Health Services Research Committee, 2000-2004; Program Committee, 2000; Reviewer, Lymphoma, ASCO Journal Review, ASCO OnLine, 2001-, Statesman Award, 2008.

American Society for Clinical Pharmacology and Therapeutics, 1981-

American Society of Hematology, 1970, Member Education Committee 1977-1979, Member Program Committee, 1982.

Association for Patient Oriented Research (founding member), 1999-2014. Membership committee 2010-2014, Board of Directors 2010-2014.

Association of Subspecialty Professors, 1994- ; Membership Committee, 2010-14.

Baltimore Blood Club, Program Committee, 1975-76, Chairman, 1976-77

European Association for Cancer Research, 1982-


2


Professional Organizations and Societies (cont.):

European Haematology Association, 1996-

European Society for Medical Oncology, 1996-

International Association for Comparative Research on Leukemia and Related Diseases, 1977 1985.

International Society for Experimental Hematology, 1975-

International Society of Hematology, Elected to Fellowship, 1972; International Advisory Committee, 1984-1994.

International Society for Preventive Oncology, 1982-

IntraScience Research Foundation, Associate Member, 1974-

Johns Hopkins Medical and Surgical Society, 1971- New York Academy of Medicine, Fellow 1986- New York Academy of Sciences, 1979- New York Cancer Society, Inc., 1984-; Member, Program Committee, 1986-90. Polish Society of Clinical Oncology, 1998- Royal Society of Medicine (London), Affiliate, 1972, Elected to Fellowship, 1974- Society for the Study of Blood, Member 1984-

Academic Appointments:

July 1971 - June 1974 Assistant Professor of Medicine, University of Maryland School of Medicine, Baltimore, MD

July 1974 - June 1976 Associate Professor of Medicine, University of Maryland School of Medicine, Baltimore, MD

July 1976 - Oct. 1982 Professor of Medicine, University of Maryland School of Medicine, Baltimore, MD

July 1971 - Oct. l982 Instructor in Medicine (part-time) John Hopkins University School of Medicine,


3


Baltimore, MDAcademic Appointments (cont.):

Oct. l982 - Oct. 1998 Gutman Professor of Oncology, Albert Einstein College of Medicine, New York, NY

July 1996 - Oct. 1998 Professor of Radiation Oncology, Albert Einstein College

of Medicine, New York, NY

Oct. 1998 – July 2009 Professor of Medicine and Radiation Oncology, New York Medical College, Valhalla, NY

Hospital Appointments:

July 1971 - May 1976 Chief, Section of Medical Oncology, National Cancer Institute, Baltimore Cancer Research Program, Baltimore, Maryland

May 1976 - July 1981 Chief, Clinical Oncology Branch, National Cancer Institute, Baltimore Cancer Research Program, Baltimore, Maryland

Sept. l976 - July l98l Acting Associate Director for BCRP, Division of Cancer Treatment, National Cancer Institute, Baltimore, Maryland

July 1981 - Oct. l982 Director, Baltimore Cancer Research Center, University of Maryland, Baltimore, Maryland

Oct. l982 - Aug. 1993 Chief, Division of Medical Oncology, Albert Einstein College of Medicine; Associate Director for Clinical Research, Cancer Center, Albert Einstein College of Medicine; Chairman, Dept. Oncology, Montefiore Medical Center, New York, NY

Aug. 1993 - Oct. 1998 Associate Director for Clinical Research, Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, NY

Oct. 1998 - July 2008 Director, Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New


4


York Medical College, New York, NY

Hospital Appointments (cont.)

July 2008 – May 2009 Director, Comprehensive Cancer Center,Montefiore Medical Center-North Division,Bronx, NY

Nov 2010 – Nov 2012 Director, Leukemia Program, Continuum Cancer Centers of New York, St. Lukes – Roosevelt Hospital Center, and Beth Israel Medical Center, New York, NY


5


Honors:

Undergraduate Certificate of Intermediate Honors, University of Virginia College of Arts and Sciences, 1960 Phi Beta Kappa, 1961; Elected to Phi Beta Kappa Associates, 1991- Z Society Award, University of Virginia, College of Arts and Sciences, 1961 Phi Sigma Society Undergraduate Award, University of Virginia College of Arts and Sciences, 1961

Medical School

Walter Reed Society Undergraduate Research Award, Univ of Va Medical School, 1964

Alpha Omega Alpha, University of Virginia Medical School, 1965

Byrd S. Leavell Hematology Award, University of Virginia Medical School, 1965

Later American Medical Association Physicians Recognition Award, 1969-2006 American Society of Clinical Investigation, 1978- Sigma Xi, 1979 Doctor Honoris Causa, Faculty of Medicine, University of the Republic, Montevideo, Uruguay, April 4, 1982. Listed in Who's Who in the East, 1979-2014; Who's Who in America, 1980-2014; Who's Who in the World, 1980-2014; Who's Who in Science and Technology, 1984-1987; Who's Who in Cancer, 1985; Who's Who in Science and Engineering, 1994-2007; Who's Who in Medicine and Healthcare, 1998-2012, Who’s Who in Finance and Business, 2002-2007, Who’s Who in American Education, 2004-2007. William F. Johnson Award, St. Joseph’s Hospital and Medical Center, Paterson, NJ, 1990.

Sociedad de Hematologia del Uruguay, elected to honorary membership1990

Harvey Society, Member 1991- Polish Oncologic Society, elected to honorary membership l992


6


Honors (cont):

President, American Radium Society, 1992-93. Janeway Medal, American Radium Society, 1996.

Osserman Award, Israel Cancer Research Fund, 1998. First Foreign Corresponding Member, National Academy of Medicine of Uruguay, 1999

Gold Medal, First Congress of Polish Oncology, 2002. Listed in “Guide to America’s Top Physicians, “ 2004-2014 editions Statesman Award, American Society of Clinical Oncology, 2008. Celgene Career Achievement Award for Clinical Research in Hematology, 2009.

Chair, Eastern Division, American Federation for Medical Research, 2014-15.

Fellowship and Grant Support

Past Support

1P50CA32107 - Specialized Center Support for a Cancer Research Center, P.H. Wiernik, principal investigator, $1,400,000 direct year 01. National Cancer Institute. 10/10/81- 10/09/82.

1R10CA31983 - Participation in CALGB, P.H. Wiernik, principal investigator, $61,224 direct year 01. National Cancer Institute. 4/1/82-3/31/83.

RD-142 - Research Development Program Grant to Baltimore Cancer Research Center, P.H. Wiernik principal investigator, $50,000 direct year 01. American Cancer Society. 10/10/81 - 10/09/82.

R01CA33164 - In vitro assay for predicting breast metastases, P.H. Wiernik, principal investigator, $82,147 direct year 0l. National Cancer Institute. 07/01/82-06/30/85.

5U10CA14958 - Participation in ECOG, P.H.Wiernik, principal investigator, $190,877 direct year 01. National Cancer Institute. 06/01/85-05/31/99.

5U10CA14958-S1 - ECOG supplement for enrollment of minorities in clinical trials, P.H. Wiernik, principal investigator, $32,197 direct year 01. National Cancer Institute. 06/01/85-05/31/93


7


Past Support (cont.)

5U10CA14958-S2 - ECOG supplement for IL-2/LAK cell studies in melanoma, colon cancer, and renal cell carcinoma, P.H. Wiernik, principal investigator, $442,506 direct year 01. National Cancer Institute. 02/01/86-01/31/87.

P30CA13330 - Core Support for Cancer Research Center, P.H. Wiernik, Associate Director for Clinical Research, $1,953,609 direct year 15 for clinical core program. National Cancer Institute. 06/01/82 - 10/06/99

NO1-CM-73705 - Clinical Trials of Activated Human Leukocytes, P.H. Wiernik, principal investigator, $624,759 direct year 01. National Cancer Institute. 06/30/87-06/29/91.

Einstein Dean's Award for New Initiatives in Collaborative Disease-Specific Research (1 of 10 awarded throughout the College): Molecular Genetics of Familial Hematologic Malignancies, - P.H. Wiernik and Jack Lenz, Co-P.I., $100,000/yr direct. 07/01/97-06/30/99.

Clinical Development of Arsenic Trioxide in Acute Leukemia, P.H. Wiernik, principal investigator, $100,000 direct year 01. Leukemia Society of America. 09/01/98-08/31/2001.

Frontier Science & Technology Research Foundation (subcontract from CA21115-24) - P.H. Wiernik, subcontract principal investigator. 05/01/98-04/30/99. $229,341 direct

1RO3CA79399-01- Phase II Study of Arsenic Trioxide in Leukemia, J.P. Dutcher, principal investigator, P.H. Wiernik, co-principal investigator, $50,000 direct year 01. National Cancer Institute. 07/01/98-06/30/2000.

Academic Medicine Development Company Foundation, Inc – Spiral CT Scan Screening of Heavy Smokers, P.H. Wiernik, principal investigator, $325,000 direct year 01. 09/01/00-08/31/02.

1U10CA91151-01- Minority-Based Community Clinical Oncology Program, P.H. Wiernik, principal investigator, $234,368 direct year 01. National Cancer Institute. 06/01/01-05/31/07

Numerous Pharmaceutical Industry Grants totaling over $8M 1974-present.

Present Support

Levine Family Foundation – General Support, P.H. Wiernik, principal investigator, $20,000/ year for 5 years 12/01/10 – 11/30/15


8


Pending Grants

Clinical trial negotiaitions with Celgene, Novartis and Bristol Meyers- Squibb in progress

Departmental and University Committees

University of MarylandMember, Human Experimentation Committee 1974-5Chairman, Cancer Committee 1977-82

Member, Radiotherapy Chair Search Committee 1978-80

Albert Einstein College of MedicineMember, Credentials Committee, Dept. Medicine 1982-95Member, Finance Committee, Dept. Medicine 1986-95Chairman, Clinical Oncology Committee 1982-96Member, Radiotherapy Chairman Search Committee 1982-3Member, Pharmacology Chairman Search Committee 1983-4Member, Committee on Promotions to Professor 1983-5; Co-Chairman, 1985-86,

Chairman 1986-87Member, Promotions Procedure Review Committee, 1989Member, Pathology Chairman Search Committee, 1991Member, Surgery Chairman Search Committee, 1991Member, Executive Committee, Cancer Center, 1982-1993 and 1995-97Member, CME Executive Committee, 1996-98

Montefiore Medical CenterMember, Clinical Research Center Advisory Committee 1982-84Member, Research Committee 1982-88Member, Institutional Review Board 1982-94Chairman, Clinical Oncology Committee 1983-96Member, Research Policy Advisory Committee 1984-94Member, Medical Committee of the Board of Trustees 1986-93Member, Medical Executive Committee, 1985-89Member, Financial Advisory Committee to the Administration, 1990-94Member, Pharmacy and Therapeutics Committee, 1996-98

Bronx Municipal Hospital CenterChairman, Clinical Cancer Committee, 1984-96Member, Pharmacy and Therapeutics Committee, 1984-98

Our Lady of Mercy Medical Center, New York Medical CollegeMember, Institutional Review Board, 1998-2009

Chair, Ad Hoc Faculty Committee on Finances, 2000 Member, Pharmacy and Therapeutics Committee, 2001-2009 Member, Annual Ball Physician’s Committee, 2005


9


Departmental and University Committees (cont.)

Beth Israel Medical Center Institutional Review Board, Member 2011-2013


10


Teaching Experience and Responsibilities

1. Annual lecture on pharmacology of cancer drugs, University of Maryland School of Medicine, Second year students (approximately 100 students per class), 1971-1980.

2. Chairman, Sympossium on "Recent Advances in the Management of Disseminated Sarcoma," American Society of Clinical Oncology National Meeting, Atlantic City, NJ, April 10, 1973.

3. Chairman, Acute Leukemia Teaching Session, American Society of Hematology Meeting, Chicago, IL, December 1973.

4. Chairman, Oncology Teaching Session, American Society of Hematology, Atlanta, GA, 1974 and Dallas, TX, 1975

5. Faculty Member, ACP-ASH Course on Granulocyte Disorders at Colby College, Waterville, ME, July 1977

6. Faculty member, UICC Course on Cancer Chemotherapy, Montevideo, Uruguay, November 1977.

7. President, UICC Postgraduate Course on Antineoplastic Chemotherapy and Clinical Oncology, Buenos Aires, Argentina, April 23-28, 1979.

8. Visiting Professor, Center for Advanced Medical Studies, University of Alabama Medical School, Birmingham, AL, September 22-24, 1982

9. Course Director, Advances in Cancer Treatment, co-sponsored by Amer. Soc. Clin. Oncol. at National Amer. Coll. Phys. meeting, Philadelphia, PA, April 26-29, 1984.

10. Chairman, Educational Workshop on Allogeneic Bone Marrow Transplantation, Amer. Soc. Clinical Oncology, Houston TX, May 26, 1985

11. Visiting Professor in Hematology, Mayo Clinic, Rochester, MN, March 16-17, 1987.12. Visiting Professor in Oncology, McGill University and University of Montreal,

Montreal, Canada, February 20-21, 1996.13. Visiting Professor, Institute of Hematology, University of Belgrade Medical School,

Belgrade, Yugoslavia, June 12-18, 1996.14. Chair Weekly Leukemia/Lymphoma Teaching Conference for housestaff and fellows

(average attendance 25). CME accredited. 1982-201115. Attending on inpatient medical unit at Roosevelt Hospital, 1 month/yr 2011-201216. Physical Diagnosis Preceptor for Columbia students at Roosevelt hospital, 1 mo/yr 2011-

2012.17. Medical Oncology Fellowship Director, University of Maryland School of Medicine

1971-1983, Albert Einstein College of Medicine, 1983-1991, Our Lady of Mercy Medical Center (NY Medical College) 1991-1998

Other Professional Activities

a) Editorial Boards

Acta Haematologica Polonica, Member 1995-American Journal of Clinical Oncology, Member, 1977-2003American Journal of Medical Sciences, Co-editor, Oncology Rounds, 1976-82American Journal of Therapeutics, Associate Editor for Oncology, 1994-2000


11


a) Editorial Boards (cont.)

Bilten Za Hematolohiju (journal of the Yugoslav Society of Hematology, 1998-2006Cancer Research Bulletin, Member, 1984-85Cancer Investigation, Associate Editor, 1988-1995; Section Co-Editor, Controversies In

Patient Management 1985-1995; Co-Editor, Original Articles Section, 1998-2007Cancer Treatment Reports, Co-editor, 1972-76Faculty of 1000 Biology, Faculty Member 2007-Hematology & Oncology, Member 2003-Journal of Cancer Research and Clinical Oncology, Member 1983-86; North American Editor, 1986-91Journal of Clinical Medicine: Oncology, Editor-in-Chief, 2007-2010Journal of Clinical Oncology, Member, 1989-1991. Consultant Editor, Diagnosis In Oncology 2009-2013Journal of Clinical Pharmacology, Section Editor, Oncology, 1985-2007Journal of Neuro-Oncology, Member, 1989-2001Leukemia, Member 1986-2003Leukemia & Lymphoma 1989-2005Leukemia Research, Member 1976-86, 1991- 2005Leukemia Reviews International, Associate Editor, 1983-85 Medical Oncology, Associate Editor, 1987-93; Editor, 1993-2014.Nowotwory, Member Editorial Board, 2001-Oncologist's Clinical Update, Co-Editor, 1990-1995Oncology News, Member, l992-2007Open Leukemia Journal (The), 2008-Polish Journal of Clinical Oncology, 1998-Resident and Staff Physician, Member 1984-98

CPCKИ APXИB (Serbian Archives of Medicine), Member 2005-

a) Manuscript Reviewer for:

Acta HaematologicaAmerican Journal of HematologyAmerican Journal of MedicineAnnals of Internal MedicineAnnals of OncologyArchives of Internal MedicineBiotechnology ProgressBloodBone Marrow TransplantationBritish Journal of CancerBritish Journal of HaematologyCancerCancer Chemotherapy and PharmacologyCancer Control Journal of the Moffitt Cancer Center


12


a) Manuscript Reviewer for (cont.):Cancer InvestigationCancer Journal, Scientific AmericanCancer ResearchCancer Treatment ReportsChestClinical Cancer ResearchDrugsEuropean Journal of CancerEuropean Journal of HaematologyExpert Opinion on PharmacotherapyGynecologic OncologyExperimental HematologyHematological ReviewsInternational of Journal of CancerInternational Journal of Laboratory HematologyInternational Journal of Radiation OncologyJournal of the American Geriatric SocietyJournal of the American Medical AssnJournal of Biological Response ModifiersJournal of Clinical GastroenterologyJournal of Clinical InvestigationJournal of Clinical OncologyJournal of Critical IllnessJournal of Cutaneous PathologyJournal of ImmunologyJournal of Laboratory and Clinical MedicineJournal of Molecular MedicineJournal of the National Cancer InstituteJournal of Neuro-OncologyJournal of Neuro-OphthalmologyJournal of Postgraduate MedicineLancet OncologyLeukemiaLeukemia & LymphomaLeukemia ResearchLungMedical Letter, The

Medical Pediatric Oncology Molecular Cancer Therapeutics

New England Journal of MedicineNew York State Journal of MedicineOncologist, ThePatient CareScience


13


a) Manuscript Reviewer for (cont.):

Southern Medical JournalWestern Journal of Medicine


14


b) Committees :

Academic Medicine Development Company (AMDeC)Member, Scientific Advisory Committee, 2002-2006

Member, Microarray Core Advisory Committee, 2002-2006

Alliance for Academic Internal Medicine (AAIM)Member, Advocacy Committee (representing Association of Specialty Professors)

2007-

American Cancer SocietyMember, Board of Directors, Baltimore City Unit 1971-77Chairman, Patient Care Committee, Baltimore City Unit 1972-75Member, Professional Education Committees, Baltimore City Unit and Maryland Division 1976-78 and 1981-83Member, Professional Education and Grants Committee, New York CityDivision 1983-90, Steering Committee 1988-90; Member, subcommittee on colon

and rectum cancer, 1984-85Member, National Medical Affairs Advisory Group on Clinical Awards, 1985-1996

American College of Physicians Reviewer for MKSAP 17, September 2013, April 2014.

Cancer and Leukemia Group BStudy Chairman, various protocols and Principal Investigator, 1971-1982Chairman, Adult Leukemia Committee, CALGB, 1976-1982

Eastern Cooperative Oncology GroupPrincipal Investigator, 1982-1993, 1995-2009Hematology Steering Committee, member 1982-presentBone Marrow Transplant Steering Committee, member 1986-1993Executive Committee, member 1986-1989Study Chair E2491, E4998, E1904Study Co-Chairman, various protocolsChairman, Gynecology Committee 1986-1988Chairman, Leukemia Committee 1989-1993Member, Institutional Review Committee, 1997, 2005, 2007Chairman, Nominating Committee, 2004-2007Member, Fiscal Oversight Committee, 2005-2012

Federation of American Societies for Experimental Biology (FASEB) Member, Excellence in Science Award Committee 2012-2015

Food and Drug AdministrationConsultant to Review Panel on New Drug Regulation, FDA, 1976Grant Application Review Panel (Hem/Onc09), 2008

b) Committees (cont.) :C:\My Documents\pwcv.doc

15


National Cancer InstitutePrincipal Investigator, NCI-PAHO Collaborative Cancer Research Project, 1979-

1982; Consultant, Hematology Tumor Disease Site Committee, 1984-95Member, Testicular Tumor Study Group, 1972-1977Member, Working Group on Leukocyte Procurement, 1972-1977Member, Osteosarcoma Study Group, 1972-1978Member, Clinical Research Subcommittee, DCT, 1972-1978Member, Clinical Trials Contract Review Committee, DCT, 1975-1979Member, Decision Network Committee, DCT, 1976-1980Chairman, USA-USSR Working Meeting on Lung Cancer, Moscow, 1980Numerous grant application site visits for DCT, 1974-1993Member, Phase I and II Working Groups 1972-1993Member, PDQ Editorial Board 1988-1994Chairman, Minority Satellite Supplement Working Group Meeting, Bethesda, MD

June 7, 1989.Co-Chairperson, Ad Hoc Grant Review Committee, Minority-BasedCommunity Clinical Oncology Program, March 14-16, 1990Member, Special Emphasis Panel: Early Clinical Trials on New Anti-Cancer Agents,

2002Member, Special Emphasis Panel: Paul Calabresi Award for Clinical Oncology, 2004

American Board of Internal MedicineMember, Subspecialty Board on Medical Oncology 1981-1987

Accreditation Council for Graduate Medical EducationPre-reviewer, Medical Oncology Programs 1985-1997

HCA Health PlansMember, National Board of Consultants, 1985-1994

International Bone Marrow Transplant RegistryAcute Leukemia Working Committee, Member 1996-Chronic Lymphocytic Leukemia Working Committee, Member 1997-Lymphoma Working Committee, Member 1996-Multiple Myeloma Working Committee, Member 1997-

U.S. Committee for Chernobyl Help, Inc.Member, Medical Advisory Board, l992-1993

Fonds de la Recherche en Sante du QuebecGrant Reviewer, 1994-2000

b) Committees (cont.) :


16


Medical Research Council of CanadaGrant Reviewer, 1994-2000

Israel Cancer Research FundGrant Reviewer, 1995-98

Other Study and Advisory GroupsMember, Medical Advisory Committee, National Leukemia Assn., 1976-89,

Chairman, 1989-Member, Selection Panel, Oncology Fellowship Program, Am. Soc. Hosp. Pharm.

1977-83Member, Working Group on Trials of New Drugs, National MS Soc., 1982-85.Member, Grants Review Panel, Netherlands Cancer Foundation 1983-87Member, Grants Review Panel, NCI of Canada 1978-96Scientific Consultant, Vermont Regional Cancer Center, 1987-96Member, Medical Advisory Board, Adria Laboratories, 1989-90Member, Oncology Advisory Committee, Lederle Laboratories, 1989-91Consultant, American Medico-Legal Foundation, 1989-95Consultant, Association of Consulting Toxicologists, 1989-93

Consultant, American Hospital Association Editorial Advisory Board on ICD-9-CM Coding, 1989-90

Member, Cancer Technology Review Group, Office of Minority Health, DHHS, 1990-93

Chairman, Idarubicin Advisory Board, Adria Laboratories, 1990-93Member Interleukin-2 New Drug Application Advisory Committee, Cetus

Member Commemorative Postage Stamp Committee, Radiology Centennial, Inc., 1991

Member, Board of Scientific Counselors, Cancer Treatment Research Foundation, 1994-95

Member, Working Group on Physician Assisted Suicide, New York Academy of Medicine, 1996

Member, Medical Advisory Council, The Strang Network, 1998- 2004 Member, Grant Review Committee, Louisiana Board of Regents Health Excellence

Fund, 2000Member, Special Emphasis Panel, Center for Disease Control (CDC), 2004Referee, Faculty Promotions, United Arab Emirates University Medical School, 2004Referee, Grant Applications, Ministry of Science and Environmental Protection,

Republic of Serbia, 2005Ad Hoc Grant Application Reviewer, Terry Fox Research Institute, Vancouver, BC,

Canada, 2008

b) Selected Invited Participation


17


1. Current Concepts in Therapy of Acute Leukemia." Presented at the Three State Regional Meeting of the American College of Physicians, Baltimore, November 3, 1973.

2. "Splenic Hodgkin's Disease: Detection, Incidence, Prognostic Significance." Presented at Symposium on Histopathology of the Spleen, Cluj, Romania, May 1973.

3. Invited paper, "Spontaneous Regression in Hematologic Malignancies." Presented at Symposium on the Spontaneous Regression of Cancer, Johns Hopkins Hospital, Baltimore, MD, May 1974.

4. Program Committee Member for "Symposium on the Spontaneous Regression of Cancer," Johns Hopkins Hospital, Baltimore, MD, May 1974.

5. Co-Chairman, Hematology Session, National American Federation of Clinical Research Meeting, May 1974.

6. Co-Chairman, Clinical Investigations Session, American Association for Cancer Research Annual Meeting, March 1974.

7. Chairman, Medicine Session of the National Meeting of U.S.P.H.S. Commissioned Officers Association, April 1974.

8. Moderator, Current Trends in Medical Oncology, Lunch and Learn Sessions, Annual Meeting, Medical and Chirurgical Faculty of the State of Maryland, April 1974.

9. Member, Surgical Oncology Curriculum Committee, College of Surgeons, Chicago, March 1974.

10. Annual banquet speaker, Alpha Epsilon Delta Honor Premedical Society of the Johns Hopkins University, May 1974.

11. "The Evolution of Effective Therapy for Acute Leukemia." Presented at the annual meeting of The Saint George Society, (University of Maryland - Johns Hopkins Medical Student Association), Baltimore, 1974.

12. Invited paper, "Grounds for Optimism for the Therapy of Acute Non-lymphocytic Leukemia - Current Studies at the Baltimore Cancer Research Center." Modern Trends in Human Leukemia Conference, Hamburg, Germany, June 1975.

13. Invited paper, "Acute Myelogenous Leukemia." American College of Physicians - American Society of Hematology Course entitled, "Topics in Clinical Hematology: Granulocyte Disorders," Philadelphia, PA, April 1976.

b) Selected Invited Participation (cont.)


18


14. Co-Chairman, Acute Leukemia Session, International Congress of Hematology, Tokyo, Japan, September 1976.

15. Invited by the Polish Academy of Sciences to participate in "The Therapy of Bone Tumors," Warsaw, Poland, October 1976.

16. Faculty member, ACP Board Review Course, Baltimore, MD, August 1977.

17. Consultant, National Cancer Institute of Canada, October 1977.

18. Invited paper, "The Treatment of Pediatric Acute Nonlymphocytic Leukemia." Presented at the 2nd International Symposium on Therapy of Acute Leukemias, Rome, Italy, December 1977.

19. Invited paper, "Current Status of the Therapy of Hematologic Neoplasms." Presented at the Hematology Institute, Warsaw, Poland, December 1977.

20. Co-Chairman, "Clinical Investigations I," American Association for Cancer Research National Meeting, San Francisco, April 1978.

21. Co-Chairman, "Leukemia and Other Hematologic Malignancies,” American Society of Clinical Oncology National Meeting, San Francisco, CA, April 1978.

22. Co-Chairman, Oncology I, Joint AAP, ASCI, AFCR Subspecialty Session, San Francisco, CA, April 30, 1978.

23. Invited paper, "A Comparison of Daunorubicin and Adriamycin Therapy of Acute Non-lymphocytic Leukemia." Symposium on Anthracyclines in the Treatment of Leukemia, International Society of Hematology, Paris, July 1978.

24. "Therapeutic Utility of Terminal Deoxynucleotidyl Transferase in Acute Nonlymphocytic Leukemia." American Society of Hematology Meeting, New Orleans, LA, December 3, 1978.

25. "Current Controversies in Hodgkin's Disease." Medical Grand Rounds, Cleveland Metropolitan General Hospital, Cleveland, OH, March 21, 1979.

26. "The Biology, Treatment, and Curability of Acute Nonlymphocytic Leukemia." 4th Annual Symposium on Advances in Cancer Treatment Research, University of Maryland School of Medicine, Baltimore, MD, April 20, 1979.

27. Chairman, Clinical Cancer Treatment Session, Conference on Experimental Cancer Chemotherapy, Radziejowice, Poland, May 28-30, 1979.



19


28. Invited paper, "Hodgkin's Disease." 3rd Congress on Oncology, Varna, Bulgaria, June 2, 1979.

29. Invited paper, "Management of Hodgkin's Disease." 4th Argentine Congress of Clinical Oncology, Buenos Aires, Argentina, August 30, 1979.

30. "Treatment of Acute Leukemia." 1st Bianca Huff Memorial Lecture, University of Rochester School of Medicine, Rochester, NY, September 26, 1979.

31. Chairman, Platelet Transfusion Poster Session, International Society of Blood Transfusion Meeting, Warsaw, Poland, November 24, 1979.

32. Invited presentation, "Sequential Studies on Anthracyclines in ANLL." Eighth New Drug Seminar, Bethesda, MD, December 18, 1979.

33. "Hodgkin's Disease Treatment, Symposium on Advances in Cancer Treatment Research, University of Maryland Hospital, Baltimore, MD, March, 1980.

34. Chairman, 6th USA-USSR Working Meeting on Lung Cancer, Moscow, USSR, March 30-April 5, 1980.

35. Co-Chairman, Leukemia Session, American Society of Clinical Oncology Annual Meeting, San Diego, CA, 1980.

36. Co-Chairman, Joint American Society of Clinical Oncology - American Association for Cancer Research Session, San Diego, CA, 1980.

37. Chairman, Lymphoma Session at the II Working Meeting of the Pan American Health Organization - NCI Collaborative Cancer Research Project, Bogota, Colombia, June 18, 1980.

38. Invited presentation, "The therapeutic significance of an E lesion." NCI-CCIRC symposium, Contemporary Issues in Hodgkin's Disease, San Francisco, CA, Sept. 10, 1981.

39. Invited paper presentation, "Current Results from the Treatment of Acute Nonlymphatic Leukemia", and "Recent Trends in Hodgkin's Disease Treatment Research", University of Montreal, Montreal, September 19, 1980.

40. Invited paper presentation, "Protective Environment in Leukemia Therapy", NCI-EORTC Symposium on Nature, Prevention and Treatment of Clinical Toxicity of Anticancer Agents. Institut Jules Bordet, Brussels, September 25-26, 1980.


20



41. Invited paper presentation, "Treatment of Hodgkin's Disease", University of Minnesota School of Medicine, Minneapolis, October 13, 1980.

42. Invited paper presentation, "Chemotherapy of Adult Acute Leukemia", Jenny Leukemia Trust Symposium, Sydney, Australia, October 20, 1980.

43. Invited paper presentation, "Immunology and Immunotherapy of Solid Tumors", Silver Jubilee Meeting, Royal College of Pathologists of Australasia, Sydney, Australia, October 23, 1980.

44. Invited paper presentation, "Adult Acute Leukemia: Present Day Management", Boston University Seminars in Oncology, December 11, 1980.

45. Invited paper presentation, "The Problem of Remission Maintenance in Adult Acute Nonlymphocytic Leukemia", Walter Reed Army Medical Center, February 3, 1981.

46. Guest speaker, Medical Grand Rounds, University Clinic, Vienna, Austria, March 12, 1981: discussion of leukemia and lymphoma patients presented by housestaff.

47. Guest speaker, Medical Grand Rounds, Cleveland Metropolitan General Hospital, May 19, 1981: "Some new thoughts about the management of chronic myelogenous leukemia."

48. Guest speaker, Annual meeting of the Association of Hematologists-Oncologists of Quebec, May 28-29, 1981, Pointe-au-Pic, Quebec: "Remission maintenance in acute Nonlymphocytic leukemia" and "Supportive care of the leukemia patients."

49. Guest speaker, Medical Grand Rounds, University of North Carolina School of Medicine, June 18, 1981: "Current thoughts on maintenance in acute leukemia."

50. Invited paper presentation, "The therapeutic significance of an E lesion." NCI-CCIRC Symposium, Contemporary Issues in Hodgkin's Disease, San Francisco, California, September 10, 1981.

51. Invited paper, "Combined modality therapy for Hodgkin's disease". Children's Hospital, San Francisco, CA, September 11, 1981.

52. Co-Guest Editor, Seminars in Oncology, Vol. 8, No. 3, September 1981.

53. Invited paper, "Marrow transplantation in leukemia: a critique." Hematology and Oncology Symposium, American Federation for Clinical Research, Eastern Section Meeting, Boston, MA, October 23, 1981.


21



54. Invited paper, "Relationship of clinical research to cancer care in the community hospital." New York State Cancer Programs Assn. Annual Meeting, Binghamton, NY, October 24, 1981.

55. Invited paper, "Rationale for maintenance chemotherapy for ANLL." International Blood Cells Club, Galveston, TX, Nov. 6, 1981.

56. "Treatment of Acute Leukemia," Medical Grand Rounds, Bowman Gray School of Medicine, Winston Salem, NC, Nov. 18, 1981.

57. Invited presentation, "Neuraminidase-treated cells" and Chairman, Sessions on Prediction of Induction Failure and on Alternatives to Conventional Induction Therapy in High Risk Patients. Acute Myelocytic Leukemia Workshop, National Cancer Institute, Bethesda, MD, Dec. 10-11, 1981.

58. Invited presentation, "Chemotherapy of Hodgkin's Disease." Student Cancer Day, University of Virginia School of Medicine, Charlottesville, VA, March 26, 1982.

59. Invited presentation, "Current Results of Acute Leukemia Treatment." LSU Medical Center, New Orleans, LA, April 12, 1982.

60. Invited presentation, "Selection of Antibiotics for the Granulocytopenic Patient." 6th Annual Oncology Seminar, Spartanburg General Hospital, Spartanburg, SC, April 17, 1982.

61. Invited presentation, "Current Status of Adriamycin and Daunorubicin for the Treatment of Acute Leukemia", Symposium on Old and New Anthracyclines, Tirrenia, Italy, May 26, 1982.

62. Poster session chairman, Acute Leukemia, International Society of Hematology, Budapest, Hungary, August 8, 1982.

63. Invited Lecture, "Advances in chemotherapy for AML, " 13th International Cancer Congress, Seattle, WA, September l2, l982.

64. Invited lecture, "Treatment of acute leukemia," 6th Annual Scripps Memorial Hospital Cancer Symposium, San Diego, CA, October l3, l982.

65. Invited lecture, Chemotherapy Foundation Symposium V, "Secondary therapy for relapsed nonlymphocytic leukemia," and "Studies with recombinant leukocyte A Interferon, "Mount Sinai Hospital, New York, NY, November l982.


22



66. Invited lecture, Medical Grand Rounds, "Prevention and treatment of infection in the compromised host," St. Vincent's Hospital, Jacksonville, FL, November l2, l982.

67. Co-Chairman, Lymphoma and plasma cell dyscrasia session, American Society of Hematology annual meeting, Washington, DC, Dec. 7, l982.

68. Plenary session paper entitled, "Prognostic factors in Acute leukemia", and Co-Chairman, Treatment of ANLL session. 3rd. International Symposium on Therapy of Acute Leukemias, Rome, Italy, Dec. l0-l4, l982.

69. Invited lecture, "Infection in Leukemia Children", Children's Hospital, Denver, CO, April 7, 1983.

70. Co-Chairman, Oncology II, AAP/ASCI/AFCR National Meeting, Washington, DC, May 1, l983.

71. Invited lecture, "Curable Cancer", Seventy-fifth anniversary lecture, Hospital de Clinicas, Montevideo, Uruguay, July 20, l983.

72. Invited lecture, "New Drugs for the treatment of acute leukemia", 13th Int. Cong. Chemother., Vienna, Austria, September 1, 1983.

73. Second Corinne V. Imber Memorial lecture, "Hodgkin's disease". Reading Hospital and Medical Center, Reading, PA, October 26, 1983.

74. "Small Cell Carcinoma of the Lung", 7th Annual Cancer Symposium, Scripps Memorial Hospital Cancer Center, La Jolla, CA, October 31, 1983.

75. "Hodgkin's disease 1983", ACS Cancer Conference, Sarasota, FL, November 5, 1983.

76. “Breast Cancer Update", Cleveland Metropolitan General Hospital, Cleveland, OH, January 31, 1984.

77. "The Biology of Acute Leukemia", Medical College of Wisconsin, Milwaukee, WI, February 22, 1984.

78. "Critical reevaluation of the Ann Arbor staging classification," Hodgkin's disease session, Leukemias and Lymphomas - Recent Progress in Diagnosis and Treatment, National Cancer Institute of Italy, Milan, April 2, 1984.

79. "New thoughts concerning the blastic phase of CML," Oncology Seminar, Yale University School of Medicine, New Haven, CT., April 10, 1984


23



80. ."Management of Acute Leukemia," Medical Grand Rounds, Vanderbilt University School of Medicine, Nashville, TN, May 31, 1984.

81. Chairman, Symposium on Malignant Lymphomas; Co-Chairman, Symposium on Hodgkin's Disease; Plenary Lecture: Diagnosis and Treatment of Non-Hodgkin's Lymphomas; International Society of Hematology, Buenos Aires, Argentina September 1-7, 1984.

82. "Current Management of Hodgkin's Disease," 4th annual Charles C. Sprague Lecture, Tulane University Medical Center, New Orleans, LA, October 19, 1984.

83. "Leukemia Cell Differentiation," Chemotherapy Foundation Symposium, NY, NY, November 7, 1984.

84. "Infectious Complications in Neutropenic Patients," University of Miami Cancer Center, Miami, FL, January 31, 1985.

85. "The Lymphomas," Trinity College, Dublin Ireland, March 7, 1985.

86. "Management of Acute Leukemia," Royal College of Medicine, Dublin Ireland, March 8, 1985.

87. New Trends in the Management of Hodgkin's Disease," Plenary session, 8th meting of the International Soc. Haematol., European and African Division, Warsaw, Poland September 9, 1985.

88. "Acute Leukemia Treatment," Oncology Institute, Warsaw, Poland, September 10, 1985.

89. "Non-Hodgkin's Lymphoma," Medical Academy of Cracow, Poland, September 11, 1985.

90. "Acute Leukemia in Adults," 3rd Annual Theodore Segal Memorial Lecture, Dept. Medicine, University of Louisville, Louisville KY, November 21, 1985.

91. "Advances in the Therapy of Hematologic Malignancies," Medical Grand Rounds, Cleveland Metropolitan General Hospital, Cleveland OH, April 16, 1986.

92. "New Directions in Hodgkin's Disease," Betts F. Komer Memorial Lecture, Arnot Ogden Hospital, Elmira, NY, April 24, 1986.

93. Chairman, adult ALL session, Intl Soc Hematology, Sydney, Australia, May 12, 1986.

94. "Chemotherapy of Leukemia," plenary session paper, International Society of Hematology,


24


Sydney Australia, May 13, 1986.


95. Chairman, poster session on malignant lymphoma and myeloma, International Society of Hematology, Sydney Australia, May 15, 1986.

96. "The treatment of acute nonlymphocytic leukemia in remission," Cross Cancer Center, University of Alberta, Edmonton, Ala., Canada, October 30, 1986.

97. "Therapy of acute leukemia in remission," 2nd Sicilian Leukemia Conference, Catania, Sicily, November 29, 1986.

98. Invited presentation, "Micronutrients in-patients treated with interleukin-2 and LAK cells," Hammer Workshop on Immunological Innovations in Cancer Research, Salk Institute, San Diego, CA., January 5, 1987.

99. Invited presentation, "A critical analysis of acute leukemia treatment," Montreal Blood Club, Montreal, Canada, February 20, 1987.

100. Invited presentation, "A critique of therapy for non-Hodgkin's lymphoma," University of South Florida Cancer Center, Tampa, FL, March 19, 1987.

101. Invited participation, US-USSR scientific exchange planning meeting, NCI, Bethesda, MD, April 9-10, 1987.

102. Consulting reviewer, "Selected Abstracts on Bone Marrow Transplantation in Cancer," International Cancer Research Data Bank, NCI, April 1987.

103. Chairman, Educational Session on Acute Leukemia, Am. Soc. Clin. Oncol. National Meeting, Atlanta, GA, May 17, 1987.

104. Invited presentation, "Hodgkin's Disease," Oncology Grand Rounds, Mt. Sinai Hospital, NY, NY, June 4, 1987.

105. Annual Honoree, Dayton Oncology Society, Dayton, OH, June 12, 1987.

106. Chairman, Plenary Session on Antineoplastic Drugs, American College of Clinical Pharmacology Annual Meeting, Philadelphia, PA, October 16, 1987.

107. Chairman, Bone Marrow Transplantation Session; Invited presentation, "Myelodysplastic Syndromes," 2nd Uruguayan Congress of Hematology, Montevideo, Uruguay, November 4-5, 1987.


25



108. Invited presentations, "Autologous Bone Marrow Transplantation in the Management of Ovarian Cancer," and "Biological Response Modifiers," 6th Annual Ella T. Grasso Memorial Conference, Yale University School of Medicine, New Haven, CT, November 18, 1987.

109. Invited participation, "Armand Hammer Conference on Biologic Response Modifiers," Salk Institute, La Jolla, CA, January 4-6, 1988.

110. Invited presentations at three Meet the Professor sessions at the national American College of Physicians meeting: "Treatment of Acute Leukemia," "Treatment of Chronic Leukemia," and "Treatment of Lymphoma." New York, NY, March 3-4, 1988.

111. Chairman, Fourth Scientific Session, American Radium Society Annual Meeting, Seattle, WA, April 20, 1988.

112. Invited presentation, "Hodgkin's Disease," Medical Grand Rounds, Columbia-Presbyterian Medical Center, NY, NY, May 26, 1988.

113. Invited commentary on article by Buzaid et al, "Oncology Journal Club," JR Bertino, editor, 1:15, 1988.

114. Invited presentation, "Risk of AIDS to Health Care Workers," Medicine and Law Committee Section, Annual Meeting of the American Bar Association, Toronto, Canada August 8, 1988.

115. Co-Chairman, Symposium on "Differential Antiblastic Therapies in the Elderly and in Infancy," International Society of Hematology, Milan, Italy, September 1, 1988.

116. Invited Lecture, "Treatment of Relapse in ANLL," Leukemia 1988 Symposium, Genoa, Italy, November 6, 1988.

117. Invited Lecture, "Advances in Hodgkin's Disease and Lymphoma Therapy," Chemotherapy Foundation Symposium VIII, NY, NY, November 16, 1988.

118. Invited Lecture, "Adult Acute Leukemia Studies at the Albert Einstein Cancer Center," Grand Rounds, Dana-Farber Cancer Institute, Boston, MA, February 15, 1989.

119. Invited Lectures, "Adult Leukemia Update," and "Update of the Lymphomas," Cancer Symposium, Cedars Hospital, Miami, FL, February 24, 1989.

120. Co-Chairman, Lymphoma Session, American Radium Society Annual Meeting, St.


26


Thomas, USVI, April 18, 1989.


121. Guest Editor, Seminars in Oncology Vol. 16, supplement 2, 1989: Idarubicin: A new presence in leukemia.

122. Chairman, Minority Supplement Working Group Meeting, NCI, Bethesda, MD, June 7, 1989.

123. Invited Lecture, "Biologic Response Modifiers," Medical Grand Rounds, Englewood Hospital, Engelwood, NJ, June 8, 1989.

124. Invited Lecture, "Hodgkin's Disease," Department of Neoplastic Diseases, Mt. Sinai Hospital, NY, NY, July 7, 1989.

125. Invited Lecture, "Non-Hodgkin's Lymphoma," Medical Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, August 30, 1989.

126. Invited Lecture, "Malignant Lymphomas," Hematology-Oncology Rounds, Columbia Presbyterian Hospital, New York, NY, October 12, 1989.

127. Invited Lectures, "Malignant Lymphoma Treatment,"and "Lymphokine Therapy of Cancer," British Hospital, Montevideo, Uruguay, October 28, 1989.

128. Invited Lecture, "Management of Adult Acute Leukemia," Hematologic Oncology Special Seminar, Memorial-Sloan Kettering Cancer Center, NY, NY, November 6, 1989.

129. Invited Lecture, "Lymphokines in Cancer Treatment," Medical Grand Rounds, Valley Hospital, Ridgewood, NJ, November 7, 1989.

130. Invited Lectures, "Management of Advanced Stage Lymphomas," "Treatment of Adult Acute Lymphocytic Leukemia," and "Interferon Treatment for Colorectal Cancer," Limassol, Cyprus, February 10-11, 1990.

131. Invited Lecture, "Management of Advanced Hodgkin's Disease," EORTC Meeting, Genoa, Italy, March 31, 1990.

132. Invited Lecture, "New Concepts of Acute Leukemia Treatment," MD Anderson Cancer Center, Houston, TX, April 13, 1990.

133. Invited Lecture, "Advances in the Treatment of Hodgkin's Disease," presented at Human Cancer: From Precurable to Curable (in Commemoration of the 65th Birthday of James F. Holland), Mount Sinai Medical Center, NY, NY, May 29, l990.


27



134. Invited Lecture, "Biologic Response Modifiers," Jornades Hemato-Oncologicas, National Police Hospital, Montevideo, Uruguay, October 5, 1990.

135. Chairman, Symposium on Acute and Chronic Leukemia, Mid-Year Meeting, American Society of Clinical Oncology, Anaheim, CA, October 27, 1990.

136. Presentation, Meet the Professor Session (Acute Leukemia), Mid-Year Meeting, American Society of Clinical Oncology, Anaheim, CA, October 27, 1990.

137. .Invited Participant, Keystone (UCLA) Workshop on Curing Leukemia, Martha's Vineyard, MA, November 26-28, 1990.

138. Chairman, Symposium on Present and Future Treatment of Acute Myelogenous Leukemia, Joint Meeting of the International and American Socities of Hematology, Boston, MA, November 30, 1990.

139. Chairman, Symposium on Anthracyclines: Recent Progress in Pharmacology and Therapy, at Leukemia: Advances in Biology and Therapy-Progress and Controversies, sponsored by Keystone (UCLA) Conferences, Big Sky, MT, April 10, 1991.

140. Invited Presentations, "Intergroup Study of Trans-Retinoic Acid in Acute Promyelocytic Leukemia," and "U.S. Studies with Taxol," National Cancer Institute of Canada Clinical Trials Group Meeting, Toronto, Canada, April 21-22, 1991.

141. Invited Presentation, "New Drugs for the Treatment of Leukemia," Danish Hematological Society, Rikshospitalet, Copenhagen, Denmark, May 27, 1991.

142. Invited Presentation, "PEG-IL-2 in-patients with AML in Second Remission," NCI-INSERM Workshop on the Use of Interleukin-2 in Hematologic Malignancies, Bethesda, MD, September 12-13, 1991.

143. Chair, review committee for abstracts on leukemia and myeloproliferative disorders submitted to the American Society of Hematology Program Committee, September 1991.

144. Invited Presentation, "Intensive Chemotherapy in Advanced Stages of Hodgkin's Disease," 2nd International Symposium on Hodgkin's Disease, Colonge, Germany, October 4, 1991.

145. Invited Presentation, "Acute Myeloid Leukemia-Current Status and Future Possibilities," Medical Grand Rounds, Dana-Farber Cancer Institute, Boston, MA, October 16, 1991.

146. Chairman, Session on New Advances in the Treatment of Acute Leukemia, 5th


28


International Symposium on Therapy of Acute Leukemias, Rome, Italy, November 3, 1991.


147. Invited Presentation, "Idarubicin for the Treatment of AML," 5th International Symposium on Therapy of Acute Leukemias, Rome, Italy, November 3, 1991.

148. Co-Chairman, Session on Clinical Leukemia, American Society of Hematology Annual Meeting, Denver, CO, December 9, 1991.

149. Invited Presentation, "New Treatments for Acute Myeloid Leukemia," Pittsburgh Cancer Institute, Pittsburgh, PA, January 10, 1992.

150. Invited Presentation, "New Agents for Induction Therapy of AML," University Clinic, Essen, Germany, February 9, 1992.

151. Invited Presentation, "Supportive Care of the Cancer Patient," Cancer Center, Kielce, Poland, April 23, l992.

152. Invited Presentation, "Lymphokines in Cancer Treatment," Polish Oncology Society, Warsaw, Poland, April 24, l992.

153. Invited Presentation, "New Drugs for Cancer Treatment," Symposium on New Approaches to Cancer Treatment, Maria Sklodowska-Curie Memorial Cancer Institute, Warsaw, Poland, April 25, l992.

154. Invited Presentations at Leukemia l992: "Idarubicin in AML," "Multicenter Randomized Trials of Induction Therapy for AML in the USA," "ECOG Post-Remission AML Studies," and "Taxol in Acute Leukemia," Genoa, Italy, July 4-7, l992.

155. Co-Chair, Session on New Advances in the Treatment of Hematologic Malignancies, Leukemia l992, Genoa, Italy, July 4, l992.

156. Invited Presentations," Treatment of Non-Hodgkin's Lymphoma," "New Developments in Hodgkin's Disease," and "New Anti-Cancer Treatments," 30th Annual Scientific Meeting, Haematology Society of Australia, Canberra, Australia July 30, l992.

157. Invited Presentation, "Recent Advances in the Treatment of Leukemia," Wesley Clinic for Haematology and Oncology, Brisbane, Australia; Peter MacCallum Institute, Melbourne, Australia; and Westmead Hospital, Sydney, Australia, August l, 4 and 5, l992.

158. Invited Presentation, "Taxol Treatment of Malignant Melanoma," Second National Cancer Institute Workshop on Taxol and Taxus, Alexandria, VA, September 24, l992.


29


159. Invited Presentation, "Dose-Response in AML," Plenary Session, Keystone Symposium on Bone Marrow Autotransplants, Keystone, CO, November l7, l992.


160. Invited Presentation, "Progress in AML Therapy," Clinical Investigational Research Conference, Department of Hematology, MD Anderson Cancer Center, Houston, TX, January 7, l993.

161. Invited Presentation, "The Treatment of Adult AML," National Heart, Lung and Blood Institute, Bethesda, MD, March 2, l993.

162. Invited Presentation, "New Agents for the Treatment of Adult Acute Myeloid Leukemia", Symposium on Leukemia...The Next Questions, MD Anderson Cancer Center, Houston, TX, March 25, 1993.

163. Invited Presentation, Management of Adult Acute Leukemia, Cipto Mangun Kusumo Hospital, Jakarta, Indonesia, May 29, 1993; Second National Indonesian Society of Oncology Conference, Surabaya, Indonesia, May 30, 1993; Malaysian Oncology Society, Kuala Lumpur, Malaysia, June 6, 1993; Sun Yat-Sen Cancer Center, Taipei Medical College, Taipei, Taiwan, Rep. China, June 8, 1993; Medical Grand Rounds, Seoul National University Hospital, Seoul, Korea, June 10, 1993; Special Meeting of the Philippine Society of Hematology and Blood Transfusion and the Philippine Society of Medical Oncology, Manila, Philippines, June 11, 1993.

164. Invited Presentations, Treatment of Hodgkin's Disease, Recent Advances in the Treatment of Acute Leukemia, and Advances in the Treatment of Non-Hodgkin's Lymphoma, Associacion Medica Argentina, Buenos Aires, Argentina, October 22-24, 1993.

165. Invited Presentation, Advances in the Treatment of Acute Myeloid Leukemia, 23rd National Congress of Hematology, Istanbul, Turkey, October 2, 1993.

166. Invited Presentations, Treatment of Acute Promyelocytic Leukemia, Hodgkin's Disease-State of the Art, Autologous Bone Marrow Transplantation in Breast Cancer, Treatment of Relapsed or Refractory Acute Myeloid Leukemia, V Congreso Uruguayo de Hematologia, Montevideo, Uruguay, October 27-30, 1993.

167. Invited Presentation, "Treatment of Adult Acute Leukemia," Conference on Advances in the Treatment of Acute Leukemia, Madrid, Spain, November 22, 1993.

168. Invited Presentation, "Treatment of Acute Myeloid Leukemia," Hematology-Oncology Conference, Northwestern University Medical School, Chicago, IL, March 15, 1994.

169. Chairman, and Presenter Symposium on Anthracyclines in Acute Myeloid Leukemia, International Society of Hematology Meeting, Cancun, Mexico, April 19, 1994.


30


170. Presidential Address at the American Radium Society Annual Meeting, "The Escalating War on Health," Bermuda, April 23, 1994.


171. Invited Presentation, "Therapy of Acute Leukemia in Adults", Cancer Institute, Sun Yat-sen University of Medical Sciences, Guangzhou, June 5; First Affiliated Hospital, Xian Medical University, Xian, June 7; Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, June 8; Institute of Hematology, Beijing Medical University, Beijing, June 10; First Affiliated Hospital, China Medical University, Shenyang, June 11; Rui jin Hospital, Shanghai Second Medical University, Shanghai, China, June 14, 1994.

172. Co-Chair, International Symposium: Oncology '94, Sponsored by the Israel Medical Association, the Albert Einstein College of Medicine, and the European School of Oncology, Herzlia, Israel, October 17-20, 1994.

173. Invited Presentation, "Overview of Acute Myeloid Leukemia," 1st All-India Institute of Medical Sciences-Asian Oceanic Clinical Oncology Association Meeting, New Delhi, India, October 30, 1994.

174. Invited Presentation, "Adult Acute Leukemia," plenary session, Society of Hematology of Thailand, annual meeting, Bangkok, Thailand, January 17, 1995.

175. Invited Presentation, "Postremission Therapy for Adults with Acute Myelogenous Leukemia," Medical Grand Rounds, National Medical University, Singapore, January 19, 1995.

176. Invited Presentation, "Current Management of Adult Acute Leukemia," Symposium on Hematology and Oncology, Istanbul University, Istanbul, Turkey, February 9, 1995.

177. Chair, Plenary Session on Malignant Lymphomas, American Radium Society Annual Meeting, Paris, France, May 2, 1995.

178. Invited Presentation, "Etiology of Hodgkin's and non-Hodgkin's Lymphoma," Plenary Session on Lymphomas, American Radium Society Annual Meeting, Paris, France, May 2, 1995.

179. Co-Chair, Session on Genetic Basis of Disease, 9th Symposium on Molecular Biology of Hematopoiesis and Treatment of Leukemias and Lymphomas, Genoa, Italy, June 25, 1995.

180. Invited Presentation, "Progress in Induction Therapy - Are We Stuck?," Plenary Session on Future Directions in the Therapy of Acute Myelogenous Leukemia, 9th Symposium on Molecular Biology of Hematopoiesis and Treatment of Leukemias and Lymphomas, Genoa, Italy, June 26, 1995.


31


181. Abstract Reviewer, Acute Leukemia Sessions, American Society of Hematology National Meeting, September 8-10, 1995.


182. Invited Presentation, "Current Status of Acute Leukemia Therapy," XV National Congress of the Brazil College of Hematology, Águas de Lindóia, Brazil, October 21, 1995.

183. Invited Presentation, "Hodgkin's Disease-Complications of Cure," New York Roentgen Society, New York, NY, October 30, 1995

184. Visiting Professor, Marshfield Clinic, Marshfield, WI, November 8-9, 1995.

185. Invited Presentation, "Future Directions in AML," Acute Leukemia Forum '95, San Francisco, CA November 10, 1995.

186. Co-Chair, Acute Leukemia V Session, American Society of Hematology National Meeting, Seattle, WA, December 5, 1995.

187. Invited Presentation, "The Intergroup APL Study," US-Japan Joint Seminar (sponsored by NCI), Oakland, CA, March 2, 1996.

188. Scientific Advisor, International Society of Experimental Hematology Meeting, New York, NY, August 23-27, 1996.

189. Invited Discussion, "Multimodality Therapy of Malignant Fibrous Histiocytoma," American Radium Society Annual Meeting, San Francisco, CA, April 3, 1996.

190. Invited Presentations, "Continuous Infusion Protocols for Non-Hodgkin's Lymphoma," "GM-CSF and G-CSF Studies in Acute Myeloid Leukemia," and "Peripheral Blood Stem Cell Transplantation in Lymphoma," M. Sklodowska-Curie Memorial Institute, Warsaw, Poland, April 11-16, 1996.

191. Invited Presentation, "Chronic Myeloproliferative Disorders," Patricia Reynolds Memorial Lecture, Reading Hospital and Medical Center, Reading, PA, April 24, 1996.

192. Co-Chair, Session on Allogeneic and Autologous Bone Marrow Transplantation, International Society of Experimental Hematology Meeting, New York, NY, August 24, 1996.

193. Invited Presentation, "Should Maintenance Therapy for Acute Myeloid Leukemia be Revisited?, International Society of Experimental Hematology Meeting, New York, NY, August 26, 1996.

194. Plenary Session Presentation, "Reversal of Drug Resistance," Impact of Cancer


32


Biotechnology on Diagnostic and Prognostic Indicators in Predictive Oncology and Therapy, Nice, France, October 28, 1996.


195. Member, Organizing Committee, 10th Symposium on Molecular Biology of Hematopoiesis and Treatment of Leukemias and Lymphomas, Hamburg, Germany, July 3-6, 1997.

196. Invited Lecture, "AML in the Elderly," Hematology-Oncology Conference, Cleveland Clinic Foundation, Cleveland, OH, September 20, 1996.

197. Chair, Session on Metastasis, and Co-Chair, Session on Drug Resistance, Impact of Cancer Biotechnology on Diagnostic and Prognostic Indicators in Predictive Oncology and Therapy, Nice, France, October 26-28, 1996.

198. Co-Chair, Session on Biology and Prognostic Factors, Acute Leukemia Forum '96, The Buttes, Tempe, AZ, November 8, 1996.

199. Chair, Session on Acute Leukemia and Bone Marrow Transplantation, Update on Biologics and New Therapies, Sass Foundation for Medical Research, Melville, LI, NY, November 18, 1996.

200. Co-Chair, Symposium on Acute Leukemia and Lymphoma, and Invited Presentation, "Progress in the Treatment of Acute Myeloid Leukemia," American Society of Hematology Annual Meeting, Orlando, FL, December 6, 1996.

201. Invited Plenary Session Papers, "Quimioterapia y Factores de Crecimiento en el Tratamiento de las Hemolinfopatias Malignas," and "Transplante Autologo de Medula Osea en Tumores Solidos," presented at First International Course on Hematopoietic Growth Factors, Faculty of Medicine, University of the Republic, Montevideo, Uruguay, April 7, 1997.

202. Invited Presentation, "Spontaneous Regression of Lymphoma," International Symposium on Spontaneous Regression of Cancer, Heidelberg, Germany, April 19, 1997.

203. Invited Presentation, "Current Treatment of AML in the USA," Hokkaido University School of Medicine, Sapporo, Japan, June 13, 1997.

204. Invited Presentation, "Postremission Therapy of AML," 2nd Conference on New Perspectives in Hematological Malignancies, Tokyo, Japan, June 14, 1997.

205. Invited Presentation, "Acute Promyelocytic Leukemia," Kyushu University, Fukuoka, Japan, June 16, 1997.

206. Invited Presentation, "Molecular Biology and its Implications for Treatment of AML,"


33


Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan, June 18, 1997.

b) Selected Invited participation (cont.)

207. Co-Chair, Session on Treatment of Elderly Patients with Acute Myeloid Leukemia, 10th Symposium on Molecular Biology of Hematopoiesis and Treatment of Leukemias and Lymphomas, Hamburg, Germany, July 6, 1997.

208. Invited Presentation, "Post-remission Therapy for Elderly Patients with AML," 10th Symposium on Molecular Biology of Hematopoiesis and Treatment of Leukemias and Lymphomas, Hamburg, Germany, July 6, 1997.

209. Invited Presentation, "Acute Myelocytic Leukemia," Medical Oncology Board Review Course, George Washington University, Arlington, VA, October 19, 1997.

210. Invited Presentation, "Hodgkin's Disease," National Hematology-Oncology Fellow Symposium, Amelia Island, FL, October 31, 1997.

211. Invited Presentation," What is Optimal Post-Remission Therapy for Elderly Patients with AML in Remission ?," Immunex Symposium at the Annual meeting of the American Society of Hematology, San Diego, CA, December 7, 1997.

212. Member, Program Committee, American Federation for Medical Research, 1998-2000.

213. Co-Chair, Session on Myelodysplasia, Acute Leukemia Forum 1998, San Francisco, CA, March 6, 1998.

214. Co-Chair, Session on Acute Myeloid Leukemia, 24th Annual Meeting, European Group for Blood and Marrow Transplantation, Courmayeur, Italy, March 24, 1998.

215. Invited Presentation, "Progress in postremission therapy of AML," 24th Annual Meeting, European Group for Blood and Marrow Transplantation, Courmayeur, Italy, March 25, 1998.

216. Co-Chair, Session on Basic Biology and Demographics, Symposium on Biology and Therapy of Bacterial and Fungal Infections in Leukemia, Lymphoma, and Bone Marrow Transplantation, San Diego, CA, May 15, 1998.

217. Invited Presentations, "Selection of Patients for Leukemia Clinical Trials," and "A History of Anthracycline Development, International Leukemia Symposium (E. J. Freireich, Chair), Siguenza, Spain, May 22, 1998.

218. Invited Presentation, New Prospects for the Treatment of Acute Leukemia," Toronto Hematology/Oncology Fellow's Day, Toronto-Sunnybrook Regional Cancer Centre, Toronto, Canada, November 17, 1998.


34



219. Chair, "Beyond Chemotherapy: The Scientific Bases for New Cancer Treatments," American Federation for Medical Research, Experimental Biology '99, Washington, DC, April 17, 1999.

220. Invited Presentations, “Treatment of Adult Acute Myeloid Leukemia,” “Treatment of Adult Acute Lymphocytic Leukemia,”and “New Directions in Hodgkin’s Disease,” First International Course on the Treatment of Hematologic Disorders, Montevideo, Uruguay, June 7-9, 1999.

221. Scientific Advisor, Turkish Society of Hematology Adult Hematological Oncology Clinical Trials Meeting, Ankara, Turkey, October 23, 1999.

222. Invited Presentation, “Maintenance Therapy Revisited,” New Clinical Approaches in the Treatment of Acute Myeloid Leukemias, American Society of Hematology Annual Meeting, New Orleans, LA, December 3, 1999.

223. Invited Participation, State of the Science in Acute Myeloid Leukemia, National Cancer Institute, Rockville, MD, February 1-2, 2000.

224. Invited Presentation,“Three Lymphoma Stories,”Dr. Maria Roque Cohen Memorial Lecture, Our Lady of Mercy Medical Center, NY Medical College, Bronx, NY, March 2, 2000.

225. Chair, American Federation for Medical Research Symposium on Cancer Genetics, presented at Experimental Biology 2000, San Diego, CA, April 15, 2000.

226. Invited Presentation, “Treatment of HIV-Related Lymphoma,” Optimal Treatment of Malignancies Associated with Hyperuricemia Symposium sponsored by the University of Tennessee at the American Society of Hematology annual meeting, San Francisco, CA, December 1, 2000.

227. Invited Presentation, “The Present Role of Hormone Therapy in Prostate Cancer,” American Radium Society Annual Meeting, San Diego, CA, April 28, 2001.

228. Invited Presentation, “Management of Non-Hodgkin’s Lymphoma – Today and Tomorrow,” 5th Congress of the Polish Society of Clinical Oncology, Warsaw, Poland, December 14, 2001.

229. Invited Presentation, “Familial Aspects of Lymphoma,” Hereditary Hematological Conference, Creighton University Medical Center, Omaha, NE, August 19, 2001


35


230. Co-Chair, Lymphoma Session, American Radium Society National Meeting, San Juan, Puerto Rico, April 30, 2002.

231. Keynote Address, “ How the Study of Leukemia Taught us to Treat the Common Solid Tumors,” First Congress of Polish Oncology, Gliwice, Poland, September 11, 2002.

b) Selected Invited participation

232. Invited Prseentation, “Multigenerational Familial CLL,” International Familial CLL Consortium Meeting, National Cancer Institute, Bethesda, MD, September 23, 2002.

233. Invited Presentation, “ Familial Hematologic Malignancies,” Board of Directors, Leukemia and Lymphoma Society, New York City Chapter, New York, NY, March 26, 2003.

234. Invited Commentator, Presentation by Mark McClellan, Administrator, Centers for Medicare and Medicaid Services, Manhattan Institute for Policy Research, New York, NY, June 15, 2004.

235. Invited Presentations, “New Approaches to Lymphoma Treatment,” and “Controversies Concerning Bone Marrow Transplantation,” X Uruguayan Hematology Congress, Montevideo, Uruguay, November 3-5, 2004.

236. Invited Presentation, “Mechanisms for Moving Cancer Clinical Research into Communities,” President’s Cancer Panel, Memorial Sloan-Kettering Cancer Center, New York, NY, January 24, 2005.

237. Invited Presentation, “New Thoughts About Hodgkin’s Disease,” 37th Southeastern Wisconsin Cancer Conference (Update I Lymphoid Malignancies), Milwaukee, WI, March 19, 2005.

238. Panel Member, NCRI Haematological Oncology Clinical Studies Group Progress Review, London, UK June 21, 2005.

239. Invited Presentation,” What kind of position do I want and where can I find it ?,” Finding and Negotiating a Start-Up Package for Clinician-Scientists, Symposium of the Associate Member Council, Am Assn Cancer Research Annual Meeting, Washington, DC, April 2, 2006.

240. Invited Presentations, ”Familial Hodgkin’s and non-Hodgkin’s Lymphoma” and “Philadelphia Chromosome (Ph)-Positive Acute Lymphocytic Leukemia (ALL): Current and Future Prospects,” 5th Jordanian Cancer Conference, Amman, Jordan, April 13-15, 2006.

241. Invited Presentation, “Management of Non-Hodgkin’s Lymphoma,” Focus on Non-Hodgkin’s Lymphoma, Colorectal, Breast, and Non-Small Cell Lung Cancers (A symposium for hematology and oncology fellows), Am Soc Clin Oncol Annual Meeting, Atlanta, GA, June 3, 2006.


36


242. Chair, Poster Session Discussion: Leukemia, Myelodysplasia and Transplantation, American Society of Clinical Oncology Annual Meeting, Atlanta, GA, June 4, 2006.

243. Poster Presentation, “Phase II study of lenalidomide monotherapy in relapsed/refractory aggressive lymphoma,” European Hematology Association, Amsterdam, Netherlands, June 15, 2006.


244. Oral Presentation, “Phase II study of lenalidomide monotherapy in relapsed/refractory aggressive lymphoma,” 3rd International Conference on Innovative Therapies for Lymphoid Malignancies, Palermo, Italy, September 30, 2006.

245. Invited Presentation, “Ask the Expert About Non-Hodgkin’s Lymphoma,” Sponsored by the Leukemia and Lymphoma Society, Gilda’s Club, White Plains, NY, October 24, 2006.

246. Member, Independent Data Monitoring Committee, EORTC study 06011, November, 2006.

247. Invited Presentation, “The Role of Immunomodulatory Agents in Lymphomas,” Immunomodulation : Assessing the Science in Hematologic Malignancies (American School of Oncology), American Society of Hematology, Orlando, FL, December 8, 2006.

248. Oral Presentation,” Preliminary results from a phase II study of lenalidomide monotherapy in relapsed/refractory aggressive non-Hodgkin’s lymphoma, American Society of Hematology Annual Meeting, Orlando, FL, December 11, 2006.

249. Invited Presentation, “Immune Thrombocytopenic Purpura,” Clausen Symposium, XXXI World Congress, International Society of Hematology, Montevideo, Uruguay, March 22, 2007.

250. Invited Participation, Chairman, Acute Leukemias Session, XXXI World Congress, International Society of Hematology, Montevideo, Uruguay, March 24, 2007.

251. Invited Presentation, “Acute Myeloblastic Leukemia,” XXXI World Congress, International Society of Hematology, Montevideo, Uruguay, March 24, 2007.

252. Invited Presentation, “Radioimmunotherapy of Lymphoma,” American Radium Society, Amsterdam, The Netherlands, May 8, 2007.

253. Invited Presentation, “Chemotherapy of Acute Myeloid Leukemia,” 1st International Congress of Leukemia, Lymphoma, Myeloma, Fethiye, Turkey, May 24, 2007.

254. Invited Remarks, First Day of Issue Ceremony for Postage Stamp honoring Prof. Roberto DeBellis, Montevideo, Uruguay, October 29, 2008.


37


255. Invited Presentation, “Immunomodulating Agents for the Treatment of Hematologic Malignancies,” British Hospital, Montevideo, Uruguay, October 29, 2008.

256. Invited Presentation, “Lymphoma Therapy – Present and Future,” Hospital de Clinicas, Montevideo, Uruguay, October 30, 2008.


257. Invited Presentation, “mTOR Inhibition as Therapy for Renal Cell Carcinoma,” Taiwan Joint Cancer Conference, Taipei, Taiwan, ROC, May 2, 2009.

258. Invited Presentations, “The rationale for Temsirolimus and Everolimus Therapy in Renal Cell Carcinoma,” China Medical University Hospital, Taichung, Taiwan, ROC, May 4, 2009, and Tainan City Hospital, Tainan, Taiwan, ROC, May 5, 2009.

259. Invited Presentation, “New Directions in the Treatment of Metastatic Renal Cell Carcinoma,” National Taiwan University Hospital, Taipei, Taiwan, ROC, May 6, 2009.

260. Invited Presentations, “IMiDS in Hematologic Malignancies” (Keynote Address) and “Treatment of Resistant and Relapsed Hodgkin’s Disease,” XI Uruguayan Congress of Hematology, Punta del Este, Uruguay, November 19-21, 2009.

261. Reviewer, Epilepsy, Neurologic Pearls, and Neuro-oncology Sections, MKSAP 16, American College of Physicians, September, 2010.

262. Invited Participation, Commentaries of the Expert: Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Monoclonal Gamopathy, Acute Myeloid Leukemia and Myelodysplasia Panels, Terapéutica Adaptada a Edad y Riesgo, British Hospital, Montevideo, Uruguay, September 27-29, 2010.

263. Invited Presentation,”Perspectives in Mantle Cell Lymphoma” Satellite Symposium on Clinical Investigations in Lymphoma, Spanish Hematology Society Annual Meeting, Las Palmas, Grand Canary Island, Spain, October 30, 2010.

264. Invited Presentation, “Evolving Treatment Options for Waldenström’s Macroglobulinemia, Oncology Conference, University of Pittsburgh Cancer Center, Pittsburgh, PA, November 18, 2010.

265. Co-Chair Eastern Division Am Fed Med Res Oral Presentation Session, Annual Meeting, Washington, DC, April 27, 2011.

266. Reviewer, Men’s Health, and Common Symptoms Sections, MKSAP 16, American College of Physicians, May, 2011.


38


267. Co-Chair Eastern Division Am Fed Med Res Oral Presentation Session, Annual Meeting, Washington, DC, April 17, 2012.


268. Co-Chair Eastern Division Am Fed Med Res Scientific Session II, Annual Meeting, Washington, DC, April 17, 2013.

269. Invited Discussant, Case Presentations, Annual Oncology Conference, British Hospital, Montevideo, Uruguay, October 8-9, 2013.

270. Co-Chair Eastern Division Am Fed Med Res Scientific Session I, Annual Meeting, Washington, DC April 7. 2014.

271. .Reviewer, Oncology and Hematology Sections, MKSAP 17, American College of Physicians, June, 2013, April, 2014.

272. Chair, Eastern Division, Amer Fed Med Res 2014-15.

273. Chair ECOG-Acrin Institutional Review Panel, Fox Chase Cancer Center, Philadelphia, July 8-9, 2014.

274. Member, Writing Committee, Acute Leukemia Group, Society for Immunotherapy of Cancer, 2014-


39


Publications A. Original, Peer Reviewed Articles

1. Burnett AL, Davidson R, Wiernik P: On the presence of a feeding hormone on the nematocyst of Hydra pirardi. Biol Bull 1963;125: 226-233.

2. Wiernik PH, MacLeod RM: The effect of a single large dose of 9α-fluoroprednisolone on nucleodepolymerase activity and nucleic acid content of the Rat thymus. Acta Endocrinol 1965; 49: 138-144.

3. *Wiernik PH, MacLeod RM: Vinblastine effect on nucleic acids and ribonuclease of lymphoid tissue. Proc Soc Expl Biol Med 1965; 119:118-120.

4. *Wiernik PH: Rheumatic heart disease occurring in sickle cell disease and trait. South Med J 1968; 61:404-407.

5. Heath CW, Bennett JM, Whang-Peng J, Berry EW, Wiernik PH: Cytogenetic findings in erythroleukemia. Blood 1969; 33:453-467.

6. *Wiernik PH, Serpick AA: Clinical significance of serum and urine muramidase in leukemia and other hematologic malignancies. Am J Med 1969; 46: 330-343.

7. *Wiernik PH, Serpick AA: Pulmonary embolus in acute myelocytic leukemia. Cancer 1969; 24: 581-584.

8. *Wiernik PH: Effect of starvation of intact and adrenalectomized mice bearing lymphosarcoma P1798 on tumor regression and ribonuclease activity. Cancer Res 1970; 30: 280-282.

9. *Wiernik PH, Serpick AA: Granulocytic sarcoma (chloroma). Blood 1970; 35: 361-369.

10. *Wiernik PH, Serpick AA: An analysis of factors effecting remission induction and survival in adult acute non-lymphocytic leukemia (ANLL). Medicine 1970; 49: 505-513.

11. Presant CA, Wiernik PH, Serpick AA: Effects of phenylalanine and related compounds on serum alkaline phosphatase activity. Clin Chim Acta 1971; 32: 465-469.

12. *Mehlman DJ, Bulkley BH, Wiernik PH: Serum alpha fetoglobulin with gastric and prostatic carcinomas. N Engl J Med 1971; 185: 1060-1061.

13. *Wiernik PH: Amyloid joint disease. Medicine 1972; 51: 465-479.


40


Publications A. Original, Peer Reviewed Articles (cont.)

14. *Wiernik PH, Serpick AA: A randomized clinical trial of daunorubicin and a combination of prednisone, vincristine, 6-mercaptopurine, and methotrexate in adult acute nonlymphocytic leukemia. Cancer Res 1972; 32: 2023-2026.

15. Greene W, Huffman D, Wiernik P, Schimpff S, Benjamin R, Bachur N: High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity. Cancer 1972; 30: 1419-1427.

16. Schimpff S, Young VM, Greene WH, Vermeulen G, Moody M, Wiernik PH: Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med 1972; 77: 707-714.

17. *Wiernik PH: Treatment of acute granulocytic leukemia in adults. N Engl J Med 1972; 287: 308. (letter to the editor).

18. Schimpff SC, Wiernik PH, Block JB: Rectal abscesses in cancer patients. Lancet 1972; 2: 844-847.

19. *O'Connell MJ, Wiernik PH: Remission of metastatic testicular carcinoma. N Engl J Med 1972; 287: 989. (letter to the editor).

20. *Sickles EA, Sklansky D, Wiernik PH: Benign intrathoracic lesions mimicking recurrent cancer. JAMA 1973; 225:156-158.

21. Weil M, Glidewell OJ, Jacquillat C, Levy R, Serpick AA, Wiernik PH, Cuttner J, Hoogstraten B, Wasserman L, Ellison R, Garlani S, Brunner K, Silver RT, Rege VB, Cooper, R, Lowenstein L, Nissen NI, Haurani F, Blom J, Borron M, Bernard J, Holland JF: Daunorubicin in the therapy of acute granulocytic leukemia. Cancer Res 1973; 33: 921-928.

22. *Brace K, Serpick AA, Block JB, Wiernik PH: Combination radiotherapy and chemotherapy in the treatment of early Hodgkin's disease. Oncology 1973; 27: 484-492.

23. Sickles EA, Young VM, Greene WH, Wiernik PH: Pneumonia in acute leukemia. Ann Intern Med 1973; 79: 528-534.

24. Greene WJ, Moody M, Schimpff S, Young VM, Wiernik PH: Pseudomonas aeruginosa resistant to carbenicillin and gentamicin - Epidemiologic and clinical aspects in a cancer center. Ann Intern Med 1973; 79: 684-689.


41



25. *Greene WH, Schimpff SC, Vermuelen G, Young VM, Wiernik PH: The diagnostic value of routine cerebrospinal fluid and bone marrow cultures - A negative report. Am J Clin Pathol 1973; 60: 404-411.

26. Presant CA, Wiernik PH, Serpick AA: Factors affecting survival in nocardiosis. Am Rev Resp Dis 1973; 108: 1444-1448.

27. Schimpff SC, Greene WH, Young VM, Wiernik PH: Pseudomonas septicemia: Incidence, epidemiology, prevention and therapy in patients with advanced cancer. Eur J Cancer 1973; 9: 449-455.

28. Schimpff SC, Greene WH, Young VM, Wiernik PH: Pseudomonas infections in cancer patients. Contemp Surg 1973; 2: 65-73.

29. Kirschner RH, O'Connell MJ, Sutherland JC, Abt AB, Sklansky BD, Greene WH, Wiernik PH: Problems in the staging of Hodgkin's disease. JAMA 1973; 225:635. (letter to the editor).

30. Rosenoff SH, Canellos GP, O'Connell MJ, Wiernik PH: Mediastinal adenopathy in granulocytic leukemia. Arch Intern Med 1974; 134: 135-138.

31. Sickles EA, Belliveau RE, Wiernik PH: Primary mediastinal choriocarcinoma in the male. Cancer 1974; 33: 1196-1203.

32. Greene WH, Schimpff SC, Wiernik PH: Cell-mediated immunity in acute nonlymphocytic leukemia: Relationship to host factors, therapy and prognosis. Blood 1974; 43: 1-14.

33. *Abt AB, Kirschner RH, Belliveau RE, O'Connell MJ, Sklansky BD, Greene WH, Wiernik PH: Hepatic pathology associated with Hodgkin's disease. Cancer 1974; 33: 1564-1571.

34. Sklansky BD, Jafek BW, Wiernik PH: Otolaryngologic manifestations of acute leukemia. Laryngoscope 1974; 84: 300-305.

35. *Belliveau RE, Wiernik PH, Abt AB: Liver enzymes and pathology in Hodgkin's disease. Cancer 1974; 34: 300-305.

36. *O'Connell MJ, Wiernik PH, Sklansky BD, Greene WH, Abt AB, Kirschner RH, Ramsey HE, Murphy WL: Staging laparotomy in Hodgkin's disease: further evidence in support of its clinical utility. Am J Med 1974; 57: 86-91.


42



37. Benjamin RS, Wiernik PH, Bachur NR: Adriamycin chemotherapy - Efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 1974; 33: 19-27.

38. Schiffer CA, Buchholz DH, Wiernik PH: Intensive multi-unit plateletpheresis of normal donors. Transfusion 1974; 14: 338-394.

39. *Kirschner RH, Abt AB, O'Connell MJ, Sklansky BD, Greene WH, Wiernik PH: Vascular invasion and hematogenous dissemination of Hodgkin's disease. Cancer 1974; 34: 1159-1162.

40. Schein PS, O'Connell MJ, Blom J, Hubbard S, Magrath IT, Bergenin P, Wiernik PH, Ziegler JL, DeVita VT: Clinical antitumor activity and toxicity of streptozotocin (NSC-85998). Cancer 1974; 34: 993-1000.

41. Weiss HD, Walker MD, Wiernik PH: The neurotoxicity of commonly used antineoplastic agents. N Engl J Med 1974; 291: 75-81 and 127-133.

42. *Belliveau RE, Yamamoto LA, Wassell AR, Wiernik PH: Regan isoenzyme in patients with hematopoietic tumors. Am J Clin Pathol 1974; 62:329-334.

43. *Wiernik PH: Hodgkin's disease. Johns Hopkins Med J 1974; 135: 25-32.

44. Aisner J, Sickles EA, Schimpff SC, Young VM, Greene WH, Wiernik PH: Torulopsis glabrata pneumonitis in patients with cancer. JAMA 1974; 230: 584-585.

45. *Greene WH, Moody M, Hartley R, Effman E, Aisner J, Young VM, Wiernik PH: Esophagoscopy as a source of Pseudomonas aeruginosa sepsis in patients with acute leukemia: The need for sterilization of endoscopes. Gastroenterol 1974; 67: 912-919.

46. Schimpff SC, Greene WH, Young VM, Wiernik PH: Significance of Pseudomonas aeruginosa with leukemia and lymphoma. J Infect Dis 1974; 130 (suppl.): 524-531.

47. Aisner J, Weiss HD, Chang P, Wiernik PH: Orthostatic hypotension during combination chemotherapy with vincristine. Cancer Chemother Rep. 1974; 58: 927-930.

48. Schimpff SC, Fortner CL, Greene WH, Wiernik PH: Cytosine arabinoside for localized herpes zoster in cancer patients - Failure in a controlled trial. J Infect Dis 1974; 130: 673-676.


43



49. Block JB, Serpick AA, Miller W, Wiernik PH: Early clinical studies with lapachol (NSC-11905). Cancer Chemother Rep 1974; 4: 27-28.

50. *Sickles EA, Greene, WH, Wiernik PH: Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975; 135: 715-719.

51. Schimpff SC, Greene WH, Young VM, Fortner CL, Jepson L, Cusack N, Block JB, Wiernik PH: Infection prevention in acute nonlymphocytic leukemia. Ann Intern Med 1975; 82:351-358.

52. *Benjamin RS, Wiernik PH, Bachur NR: Adriamycin: A new effective agent in the therapy of disseminated sarcomas. Med Pediatr Oncol 1975; 1: 63-67.

53. Byhardt R, Brace K, Ruckdeschel J, Chang P, Martin R, Wiernik P: Dose and treatment factors in radiation related pericardial effusion associated with the mantle technique for Hodgkin's disease. Cancer 1975; 35: 795-802.

54. *Martin RG, Ruckdeschel JC, Chang P, Byhardt R, Wiernik P: Radiation-related pericarditis. Am J Cardiol 1975; 35: 216-220.

55. *Ruckdeschel J, Chang P, Martin R, O'Connell M, Byhardt R, Sutherland J, Wiernik P: Radiation-related pericardial effusion. Medicine 1975; 54: 245-260.

56. *O'Connell MJ, Schimpff SC, Kirschner RH, Abt AB, Wiernik PH: Epithelioid granulomas in Hodgkin's disease - A favorable prognostic sign? J Am Med Assn 1975; 233: 886-889.

57. O'Connell MJ, Wiernik PH: Streptozotocin (NSC-85998) in lymphoreticular malig-nancies. Cancer Chemother Rep 1975; 59: 443-445.

58. *O'Connell MJ, Wiernik PH, Brace KC, Byhardt RW, Greene WH: A combined modality approach to the treatment of Hodgkin's disease. Cancer 35: 1055-1065, 1975.

59. Schimpff SC, Schiffer C, Brager D, Wiernik PH: Leukemia and lymphoma patients interlinked by prior social contact. Lancet 1975; 1: 124-129.

60. Schimpff SC, O'Connell MJ, Greene WH, Wiernik PH: Infection in ninety-two splenectomized patients with Hodgkin's disease: A clinical review. Am J Med 1975; 59: 695-701.


44



61. Schiffer CA, Sanel FT, Stechmiller BK, Wiernik PH: Functional and morphologic characteristics of the leukemic cells of a patient with acute monocytic leukemia: Correlation with clinical features. Blood 1975; 46: 17-26.

62. Buchholz DH, Schiffer CA, Wiernik PH, Betts SW, Reilly JA: Granulocyte harvest for transfusion: Donor hematologic response in repeated donation. Transfusion 1975; 15: 96-106.

63. *Levi JA, Wiernik PH: Management of mycosis fungoides - Current status and future prospects. Medicine 1975; 54: 73-88.

64. *Byhardt RW, Brace KC, Wiernik PH: The role of splenic irradiation in chronic lymphocytic leukemia. Cancer 1975; 35: 1621-1625.

65. Schiffer CA, Buchholz DH, Aisner J, Betts SW, Wiernik PH: Clinical experience with transfusion of granulocytes obtained by continuous flow filtration leukopheresis. Am J Med 1975; 58: 373-381.

66. *Levi JA, O'Connell MJ, Murphy WL, Sutherland JC, Wiernik PH: Role of 67-gallium citrate scanning in the management of non-Hodgkin's lymphoma. Cancer 1975; 36: 1690-1701.

67. Schiffer CA, Levi JA, Wiernik PH: The significance of abnormal circulating cells in patients with Hodgkin's disease. Br J Haematol 1975; 31: 177-184.

68. *Wernik PH: The use of Adriamycin in hematologic malignancies. Cancer Chemother Rep 1975; 6: 369.

69. *Wiernik PH: Recent progress in the therapy of acute leukemia. Connecticut Med 1975; 39: 681-685.

70. *Levi JA, Wiernik PH: Combination therapy with 5-azacytidine and methylglyoxal bis (guanylhydrazone) in previously treated adults with acute non-lymphocytic leukemia. Cancer Chemother Rep 1975; 59: 1043-1045.

71. *Wiernik PH, Lichtenfeld JL: Combined modality therapy for localized Hodgkin's disease. A seven-year update of an early study. Oncology 1975; 32: 208-213.

72. Gutin PH, Weiss HD, Wiernik PH, Walker MD: N, N', N", Triethylenethio-phosphoramide (Thio-tepa (NSC 6396) in the treatment of malignant meningeal


45


disease. Cancer 1976; 38: 1471-1475.


73. Lichtenfeld L, Desner MR, Wiernik PH, Mardiney Jr MR: Modulating effects of levamisole on human lymphocyte response in vitro. Cancer Treat Rep 1976; 60: 571-574.

74. *Aisner J, Shimpff SC, Bennett JE, Young VM, Wiernik PH: Aspergillus infections in-patients with cancer: In association with fireproofing materials in a new hospital. JAMA 1976; 235: 411-412.

75. *Lichtenfeld JL, Kirschner RH, Wiernik PH: Familial Sjorgen's syndrome with associated primary salivary gland lymphoma. Am J Med 1976; 60: 286-292.

76. Chang P, Levine MA, Wiernik PH, Walker MD: A phase II study of intravenously administered methyl CCNU in the treatment of advanced sarcomas. Cancer 1976; 37: 615-619.

77. *Levi JA, Wiernik PH: A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute non-lymphocytic leukemia. Cancer 1976; 38: 36-41.

78. *Wiernik PH, Sutherland JC, Stechmiller BK, Wolf J: Clinically significant cardiac infiltration in acute leukemia, lymphocytic lymphoma and plasma cell myeloma. Med Pediatr Oncol 1976; 2: 75-86.

79. *Wiernik PH: Spontaneous regression of hematologic malignancies. Natl Cancer Inst Monogr 1976; 44: 35-38.

80. *Wiernik PH: Advances in the management of acute nonlymphocytic leukemia. Arch Intern Med 1976; 136: 1399-1402.

81. *Schiffer CA, Buchholz DH, Aisner J, Wolff JH, Wiernik PH: Frozen autologous platelets in the supportive care of patients with leukemia. Transfusion 1976; 16: 321-329.

82. *Smyth CA, Wiernik PH: Combination chemotherapy of adult acute lymphocytic leukemia. Clin Pharmacol Ther 1976; 19: 240-245.

83. *Stechmiller BK, Wiernik PH, Shin M, Satterfield J: Maturation of metastatic teratocarcinoma following chemotherapy. Maturation to a mass pathologically indistinguishable from a mediastinal enteric cyst. Chest 1976; 69: 697-700.


46



84. Aisner J, Kvols LK, Schiffer CA, Schimpff SC, Wiernik PH: Transtracheal selective bronchial brushing for pulmonary infiltrates in-patients with cancer. Chest 1976; 69: 367-371.

85. Viola MV, Frazier M, Wiernik P, McCredie KB, Spiegleman S: Reverse transcriptase in leukocytes of leukemic patients in remission. N Engl J Med 1976; 294: 75-80.

86. Lichtenfeld JL, Wiernik PH, Mardiney MR, Zarco RM: Abnormalities of complement and its components in-patients with acute leukemia, Hodgkin's disease and sarcoma. Cancer Res 1976; 36: 3678-3680.

87. Schimpff SC, Brager DM, Schimpff CR, Comstock GW, Wiernik PH: Leukemia and lymphoma patients linked by prior social contact - Evaluation utilizing a case-control approach. Ann Intern Med 1976; 84: 547-550.

88. Aisner J, Schiffer CA, Wolff JH, Wiernik PH: A standardized technique for efficient platelet and leukocyte collection using the Model 30 Blood Processor. Transfusion 1976; 16: 437-445.

89. *Wiernik PH, Schimpff SC, Schiffer CA, Lichtenfeld JL, Aisner J, O'Connell MJ, Fortner C: A randomized comparison of daunorubicin alone with a combination of daunorubicin, cytosine arabinoside, thioguanine, and pyrimethamine for the treatment of acute nonlymphocytic leukemia. Cancer Treat Rep 1976; 60:41-53.

90. Aisner J, Schimpff SC, Sutherland JC, Young VM, Wiernik PH: Torulopsis glabrata infections in patients with cancer. Increasing incidence and relationship to colonization. Am J Med 1976; 61: 23-28.

91. Esterhay RJ, Vogel VG, Fortner CL, Shapiro HM, Wiernik PH: Cost analysis of leukemia treatment: A problem oriented approach. Cancer 1976; 37: 646-652.

92. *Benjamin RS, Wiernik PH, O'Connell MJ, Sutherland JC: A comparison of cyclophosphamide, vincristine, prednisone (COP) with nitrogen mustard, vincristine, procarbazine and prednisone (MOPP) in the treatment of nodular, poorly differentiated lymphocytic lymphoma. Cancer 1976; 38: 1896-1902.

93. Schiffer CA, Lichtenfeld JL, Wiernik PH, Mardiney MR, Joseph JM: Antibody response in-patients with acute nonlymphocytic leukemia. Cancer 1976; 37: 2177-2182.


47


94. *Schiffer CA, Aisner J, Wiernik PH: Clinical experience with transfusion of cryopreserved platelets. Br J Haematol 1976; 34: 377-386.


95. Schiffer CA, Weinstein HJ, Wiernik PH: Methicillin associated thrombocytopenia. Ann Intern Med 1976; 85: 338-339.

96. Holland JF, Glidewell O, Ellison RR, Schwartz J, Wallace HJ, Hoagland C, Wiernik PH, Rai K, Bekesi JC, Cuttner J: Acute myelocytic leukemia. Arch Intern Med 1976; 136: 1377-1381.

97. Jacobs A, Slater A, Whittaker JA, Canellos G, Wiernik PH.: Serum ferritin concentration in untreated Hodgkin's disease. Br J Cancer 1976; 34: 162-166.

98. *Chang P, Wiernik PH: Combination chemotherapy with Adriamycin and strepto-zotocin. 1. Clinical results in-patients with advanced sarcoma. Clin Pharmacol Ther 1976; 20: 605-610.

99. Chang P, Riggs CE, Scheerer MT, Wiernik PH, Bachur NR: Combination chemotherapy with Adriamycin and streptozotocin. II clinical-pharmacologic correlation of augmented Adriamycin toxicity caused by streptozotocin. Clin Pharmacol Ther 1976; 20: 611-616.

100. Woolley III PV, Osborne CK, Levi JA, Wiernik PH, Canellos GP: Extranodal presentation of non-Hodgkin's lymphomas in the testis. Cancer 1976; 38: 1026-1035.

101. Schimpff SC, Landesman S, Hahn DM, Standiford MC, Fortner CL, Young VM, Wiernik PH: Ticarcillin in combination with cephalothin or gentamicin as empiric antibiotic therapy in granulocytopenic cancer patients. Antimicrob Ag Chemother 1976; 10: 837-844.

102. Grove WR, Bender JF, Fortner CL, Strauss G, Wiernik PH: A benzyquinamide-induced extrapyramidal reaction. Drug Intelligence Clin Pharm 1976; 10: 638-639.

103. *O'Connell MJ, Wiernik PH, Sutherland JC: High-dose intermittent intravenous cyclophosphamide in non-Hodgkin's lymphomas: Long term patient follow up. Oncology 1977; 33: 170-172.

104. Lichtenfeld JL, Desner MR, Wiernik PH, Moore S, Mardiney Jr M.R: Amplification of human lymphocyte responsiveness to immunologic stimuli in vitro by levamisole. Fogarty Intl Center Proc, 1977; 128: 17-21.

105. *Levi JA, Wiernik PH, Diggs CH: Combination chemotherapy of advanced previously treated Hodgkin's disease with streptozotocin, CCNU, Adriamycin and bleomycin.


48


Med Pediatr Oncol 1977; 3: 33-40.


106. *Levi JA, Wiernik PH: Limited extranodal Hodgkin's disease: Unfavorable prognosis and therapeutic implications. Am J Med 1977; 63: 365-372.

107. Aisner J, Schimpff SC, Wiernik PH: Treatment of invasive aspergillosis: Relation of early diagnosis and treatment to response. Ann Intern Med 1977; 86: 539-543.

108. *Abt AB, Murphy WL, O'Connell MJ, Wiernik PH: False positive lymphography in Hodgkin's disease: A histologic-lymphadenographic correlation. Med Pediatr Oncol 1977; 3: 253-259.

109. *Levi JA, Diggs CH, Wiernik PH: Adriamycin therapy in advanced mycosis fungoides. Cancer 1977; 39: 1967-1970.

110. Diggs CH, Wiernik PH, Levi JA, Kvols LK: Cyclophosphamide, vinblastine, procarbazine and prednisone with CCNU and vinblastine maintenance for advanced Hodgkin's disease. Cancer 1977; 39: 1949-1954.

111. *Levi JA, Wiernik PH: Therapeutic implications of splenic involvement in Stage IIIA Hodgkin's disease. Cancer 1977; 39: 2158-2165.

112. Hahn DM, Schimpff SC, Young VM, Fortner CL, Standiford MD, Wiernik PH: Amikacin and cephalothin: An empiric regimen for granulocytopenic cancer patients. Antimicrob Ag Chemother 1977; 12: 618-624.

113. *Levi JA, Wiernik PH, O'Connell MJ: Patterns of relapse in stages I, II and IIIA Hodgkin's disease: Influence of initial therapy and implications for the future. Intl J Radiol Oncol Biol Biophys 1977; 2: 853-862.

114. *Van Echo DA, Lichtenfeld KM, Wiernik PH: Vinblastine (NSC 49852), 5-azacytidine (NSC 102816) and VP16-213 (NSC 141540) therapy in previously treated patients with acute nonlymphocytic leukemia. Cancer Treat Rep 1977; 61: 1599-1602.

115. Hahn DM, Schimpff SC, Ruckdeschel J, Wiernik PH: Single agent therapy for renal cell carcinoma: CCNU, vinblastine, thiotepa, and bleomycin. Cancer Treat Rep 1977; 61: 1585-1588.

116. Morris D, Aisner J, Wiernik PH: Horizontal pigmented banding of the nails in association with Adriamycin chemotherapy. Cancer Treat Rep 1977; 61: 499-501.


49


117. Gutin PH, Levi JA, Wiernik PH, Walker MD: Treatment of malignant meningeal disease with intrathecal thiotepa: A phase II study. Cancer Treat Rep 1977; 61: 885-888.


118. Levi JA, Schimpff SC, Slawson RG, Wiernik PH: Evaluation of radiotherapy for localized inflammatory skin and perianal lesions in adult leukemia: A prospectively randomized double blind study. Cancer Treat Rep 1977; 61: 1301-1306.

119. *Diggs CH, Wiernik PH, Smyth CA: IV methyl CCNU and ftorafur with or without methanol-extracted residue of BCG for metastatic adenocarcinoma of the colon. Cancer Treat Rep 1977; 61: 1581-1584.

120. Schiffer CA, Wiernik PH: Functional evaluation of circulating leukemic cells in acute nonlymphocytic leukemia. Leukemia Res 1977; 1: 271-277.

121. *Morris D, Aisner J, Elias EG, Wiernik PH: Mastectomy as an adjuvant to combination chemotherapy. Arch Surg 1978; 113: 282-284.

122. Aisner J., Schiffer CA, Wiernik PH: Granulocyte Transfusion: Evaluation of factors influencing results and a comparison of filtration and intermittent centrifugation leukapheresis. Br J Haematol 1978; 38: 121-129.

123. Aisner J, Wiernik PH: Chemioterapia nawrotowego i nieoperacyjnego raka sutka. Nowotwory 1978; 28: 80-89.

124. *Wiernik PH: Obecne poglady na stopniowanie i leczenie raka jajnika. Nowotwory 1978; 28: 131-136.

125. *Van Echo DA, Wiernik PH: A Phase I Study of Neocarcinostatin (NSC-157365) in patients with acute leukemia. Cancer Treat Rep 1978; 62: 1363-1366.

126. *Schiffer CA, Aisner J, Wiernik PH: Frozen autologous platelet transfusion for patients with leukemia. N Engl J Med 1978; 299: 7-12.

127. Aisner J, Satterfield Jr JR, Aisner SC, Pyeatte JC, Wiernik PH: Inflammatory changes related to active tuberculosis. Confusion with oat cell carcinoma of the lung on cytology specimens. Chest 1978; 73: 670-672.

128. Aisner J, Wiernik PH: Thiotepa (NSC-6396) and dimethyl sulfoxide (NSC-763) in the treatment of renal cell carcinoma. Cancer Clin Trials 1978; 1: 23-26.

129. Hahn DM, Schimpff SC, Fortner C, Smyth AC, Young VM, Wiernik PH: Infection in acute leukemia patients receiving oral nonabsorbable antibiotics. Antimicrob Ag


50


Chemother 1978; 13: 958-964.


130. Espana P, Wiernik PH, Walker MD: Phase II study of dianhydrogalactitol in malignant glioma. Cancer Treat Rep 1978; 62: 1199-1200.

131. Young VM, Morris MJ, Moody MR, Schimpff SC, Gerster JW, Wiernik PH: An analysis of Group D Streptococci recovered from cancer patients. Infection 1978; 6: 98-104.

132. Esterhay Jr RJ, Aisner J, Levi JA, Wiernik PH: High-dose 6-mercaptopurine in advanced refractory cancer. Cancer Treat Rep 1978; 62: 1229-1231.

133. Schimpff SC, Hahn DM, Brouillet MD, Young VM, Fortner CL, Wiernik PH: Comparison of basic infection prevention techniques with standard room reverse isolation or with reverse isolation plus added air filtration. Leukemia Res 1978; 2: 231-240.

134. Ostrow S, Hahn D, Wiernik PH, Richards RD: Opthalmologic toxicity after cis-dichlorodiammine platinum (II) therapy. Cancer Treat Rep 1978; 62: 1591-1594.

135. *Moody MR, Morris MJ, Young VM, Moye III LA, Schimpff SC, Wiernik PH: Effect of two cancer chemotherapeutic agents on the antibacterial activity of three antimicrobial agents. Antimicrob Ag Chemother 1978; 14: 737-742.

136. Aisner J, Wiernik PH: Malignant mesothelioma: Current status and future prospects. Chest 1978; 74: 438-443.

137. Diggs CH, Scoltock MJ, Wiernik PH: Phase II evaluation of anguidine (NSC-141537) for adenocarcinoma of the colon or rectum. Cancer Clin Trials 1978; 1: 297-299.

138. Daly PA, Schiffer CA, Aisner J, Wiernik PH: A comparison of platelets prepared by the Haemonetics Model 30 and multiunit bag plateletpheresis. Transfusion 1979; 19: 778-781.

139. Elias EG, Chrietien PB, Monnard E, Khan T, Bouchelle WH, Wiernik PH, Lipson SD, Hande KR: Chemotherapy prior to local therapy in advanced squamous cell carcinoma of the head and neck. Cancer 1979; 43: 1025-1031.

140. Aisner J, Ross DD, Wiernik PH: Tamoxifen in advanced male breast cancer. Arch Intern Med 1979; 139: 480-481.


51


141. Bender JF, Schimpff SC, Young VM, Fortner CL, Brouillet MD, Love LJ, Wiernik PH: Role of vancomycin as a component of oral nonabsorbable antibiotics for microbial suppression in leukemia patients. Antimicrob Ag Chemother 1979; 15: 455-460.


142. Love LJ, Schimpff SC, Hahn DM, Young VM, Standiford MC, Bender JF, Fortner, CL, Wiernik PH: Randomized trial of empiric antibiotic therapy with ticarcillin in combination with gentamicin, amikacin, or netilmicin in febrile, granulocytopenic cancer patients. Am J Med 1979; 66: 603-610.

143. Bender J, Fortner C, Schimpff S, Grove W, Hahn D, Love L, Wiernik PH: Comparative auditory toxicity of aminoglycoside antibiotics in leukopenic patients. Am J Hosp Pharm 1979; 36: 1083-1087.

144. *Voith MA, Lichtenfeld KM, Schimpff SC, Wiernik PH: Systemic complications of MER immunotherapy of cancer. Cancer 1979; 43: 500-504.

145. *Ross DD, Wiernik PH, Sarin PS, Whang-Peng J: Loss of terminal deoxynucleotidyl transferase (TdT) activity as a predictor of emergence of resistance to chemotherapy in a case of chronic myelogenous leukemia in blast crisis. Cancer 1979; 44: 1566-1570.

146. Belliveau RE, Abt AB, Wiernik PH: Hepatic enzymes in Hodgkin's and non-Hodgkin's lymphoma: Tumori 1979; 65: 215-220.

147. Levine AS, Sivulich M, Wiernik P, Levy HB: Initial clinical trials in cancer patients of poly (ICLC), a highly effective interferon inducer. Cancer Res 1979; 39: 1645-1650.

148. Moody MR, Young VM, Schimpff SC, Purvis DS, Wiernik PH: In vitro antibacterial activity of four aminioglycosides and two semisynthetic penicillin on fresh clinical isolates from cancer patients. Eur J Cancer 1979; 15: 25-33.

149. Bender JF, Schimpff SC, Young VM, Fortner CL, Love LJ, Brouillet M, Wiernik P: A comparative trial of tobramycin versus gentamicin in combination with vancomycin and nystatin for alimentary tract suppression in leukemic patients. Eur J Cancer, 1979; 15: 35-44.

150. Erlichman C, Strong JM, Wiernik PH, Edwards LS, Cohen MH, Levine AS, Hubbard SM, Chabner BA: Phase I trial of N-(Phosphonacety)-L-aspartate (PALA). Cancer Res 1979; 39:3992-3995.

151. Van Echo D, Chiuten DF, Gormley PE, Lichtenfeld JL, Scoltock M, Wiernik PH: A Phase I clinical and pharmacological study of m-AMSA (NSC 249992) employing an


52


intermittent every other week schedule. Cancer Res 1979; 39: 3881-3884.

152. *Wiernik PH, Gustafson J, Schimpff SC, Diggs CH: Combined modality treatment of Hodgkin's disease confined to lymph nodes: Results eight years later. Am J Med 1979; 67: 183-193.


153. Aisner J, Schiffer CA, Hedmann S, Wiernik PH: Gravity leukapheresis--a simple method of leukocyte collection for transfusion or in vitro study. Leukemia Res 1979; 3: 1-5.

154. *Schiffer CA, Aisner J, Daly PA, Wiernik PH: Increased leukocyte alkaline phosphatase activity following transfusion of leukocytes form a patient with chronic myelocytic leukemia. Am J Med 1979; 66: 519-522.

155. *Zaharko DS, Bolten BJ, Chiuten D, Wiernik PH: Pharmacokinetic studies during Phase I trials of high dose thymidine infusions. Cancer Res 1979; 39: 4777-4781.

156. Daly PA, Simon R, Schiffer CA, Aisner J, Terasaki PI, Wiernik PH: A study of HLA antigens and haplotypes in a population of Caucasians with acute nonlymphocytic leukemia. Leukemia Res 1979; 3: 75-82.

157. Aisner J, Aisner SC, Ostrow S, Govindan S, Mummert K, Wiernik P: Meningeal carcinomatosis from small cell carcinoma of the lung. Acta Cytol 1979; 23: 292-296.

158. Schiffer CA, Aisner J, Daly PA, Schimpff SC, Wiernik PH: Alloimmunization following prophylactic granulocyte transfusion. Blood 1979; 54: 766-774.

159. *Wiernik PH, Glidewell OJ, Hoagland HC, Brunner KW, Spurr CL, Cuttner J, Silver R, Carey RW, DelDuca V, Kung FH, Holland JF: A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia. Med Pediatr Oncol 1979; 6: 261-277.

160. *Daly PA, Schiffer CA, Aisner J, Wiernik PH: Successful transfusion of platelets cryopreserved for more than 3 years. Blood 1979; 54: 1023-1027.

161. DeVita Jr VT, Oliverio VT, Muggia FM, Wiernik PH, Ziegler J, Goldin A, Rubin, D, Henney J, Schepartz S: The drug development and clinical trials program of the Division of Cancer Treatment, National Cancer Institute. Cancer Clin Trials 1979; 2: 195-216.

162. Henderson ES, Scharlau C, Cooper MR, Haurani FI, Silver RT, Brunner K, Carey RW, Falkson G, Blom J, Nawabi IV, Levine AS, Bank A, Cuttner J, Cornell GG,


53


Henry P, Nissen NI, Wiernik PH, Leone L, Wohl H, Rai K, James GW, Weinberg V, Glidewell O, Holland JF: Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: results of CALGB protocol 7113. Leukemia Res 1979; 3: 395-408.

163. *Wiernik PH: Leukemias and Myeloma. In Pinedo HM (Ed.): Cancer Chemotherapy 1979. Amsterdam, Excerpta Medica 1979; pp. 182-208.


164. *Espana P, Chang P, Wiernik PH: Increased incidence of brain metastases in sarcoma patients. Cancer 1980; 45: 377-380.

165. Stein RS, Golomb HM, Diggs CH, Mauch P, Hellman S, Wiernik PH, Ultmann JE, Rosenthal DS: Anatomical substages of Stage IIIA Hodgkin's disease: a collaborative study. Ann Intern Med 1980; 92: 159-165.

166. Ostrow S, Egorin M, Aisner J, Bachur N, Wiernik PH: High dose cis-diamminedichloroplatinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity and therapeutic efficacy. Cancer Clin Trials 1980; 3: 23-27.

167. Reinstein L, Ostrow SS, Wiernik PH: Peripheral neuropathy after Cis-Platinum (II) (DDP) therapy. Arch Phy Med Rehab 1980; 61: 280-282.

168. Love LJ, Schimpff SC, Schiffer CA, Wiernik PH: Improved prognosis for granulocytopenic patients with gram-negative bacteremia. Am J Med 1980; 68: 643-648.

169. Daly PA, Schiffer CA, Aisner J, Wiernik PH: Platelet transfusion therapy. One hour post-transfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA 1980; 243: 435-438.

170. Daly PA, Chang P, Goodman L, Wiernik PH: Hypertrophic pulmonary osteo-arthropathy and metastases from a malignant fibrous histiocytoma. Cancer 1980; 45: 595-598.

171. *Chiuten DF, Wiernik PH, Zaharko DS, Edwards L: Clinical Phase I-II and pharmacokinetic study of high-dose thymidine given by continuous intravenous infusion. Cancer Res 1980; 40: 818-822.

172. *Schimpff SC, Diggs CH, Wiswell JG, Salvatore PC, Wiernik PH: Radiation-related thyroid dysfunction: implications for the treatment of Hodgkin's disease. Ann Intern Med 1980; 92: 91-98.

173. Burks LC, Aisner J, Fortner CL, Wiernik PH: Meperidine hydrochloride for the


54


treatment of shaking chills and fever. Arch Intern Med 1980; 140: 483-484.

174. LeRoy AF, Wehling M, Gormley P, Egorin M, Ostrow S, Bachur N, Wiernik P: Quantitative changes in cis-Dichlorodiammineplatinum (II) speciation in excreted urine with time after IV infusion in man: methods of analysis, preliminary studies, and clinical results. Cancer Treat Rep 1980; 64: 123-132.


175. *Wiernik PH: The management of infection in the cancer patient. JAMA 1980; 244:185-187.

176. Van Echo DA, Diggs CH, Scoltock M, Wiernik PH: Phase II evaluation of N-(Phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum. Cancer Treat Rep 1980; 64: 39-342.

177. Wade JC, Schimpff SC, Newman KA, Fortner CL, Moody MR, Young VM, Wiernik PH: Potential of mezlocillin as empiric single agent therapy in febrile granulocytopenic cancer patients. Anticancer Ag Chemother 1980; l8: 299-306.

178. *Daly PA, Schiffer CA, Wiernik PH: Acute promyelocytic leukemia-Clinical management of 15 patients. Am J Hematol 1980; 8: 347-359.

179. Ostrow S, Egorin MJ, Hahn D, Markus S, Leroy A, Chang P, Klein M, Bachur NR, Wiernik PH: Cis-dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms. Cancer 1980; 46: 1715-1721.

180. Van Echo DA, Markus S, Aisner J, Wiernik PH: Phase II trial of 4'-(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in-patients with metastatic renal cell carcinoma. Cancer Treat Rep 1980; 64: 1009-1010.

181. *Van Echo DA, Wiernik PH, Aisner J: High dose VP16-213 (NSC-141540) for the treatment of patients with previously treated acute leukemia. Cancer Clin Trials 1980; 3: 325-328.

182. Hankins JR, Satterfield JR, Aisner J, Wiernik PH, McLaughlin JS: Pericardial window for malignant pericardial effusion. Ann Thoracic Surg 1980; 30: 465-471.

183. Aisner J, Wiernik PH: Chemotherapy versus chemoimmunotherapy for small-cell undifferentiated carcinoma of the lung. Cancer 1980; 46: 2543-2549.

184. *Diggs CH, Wiernik PH, Sutherland JC: Treatment of advanced Hodgkin's disease with SCAB - an alternative to MOPP. Cancer 1980; 47: 224-228.


55


185. *Van Echo DA, Chiuten DF, Markus S, Wiernik PH: A clinical trial of pyrazofurin in combination with 5-azacytidine in acute adult nonlymphocytic leukemia. Cancer Clin Trials 1981; 4: 129-133.

186. *Diggs CH, Wiernik PH, Ostrow SS: Nodular lymphoma: prolongation of survival by complete remission. Cancer Clin Trials 1981; 4: 107-114.


187. *Applefeld MM, Slawson RG, Hall-Craggs M, Green DC, Singleton RC, Wiernik PH: Delayed pericardial disease following radiotherapy. Am J Cardiol 1981; 47: 210-213.

188. Newman KA, Schimpff SC, Young VM, Wiernik PH: Lessons learned from surveillance cultures in patients with acute nonlymphocytic leukemia. Amer J Med 1981; 70: 423-431.

189. Wade JC, Schimpff SC, Hargadon MT, Fortner CL, Young VM, Wiernik PH: A comparison of trimethoprim/sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infection in acute leukemia. N Engl J Med 1981; 304: 1057-1062.

190. Dutcher J, Schiffer CA, Aisner J, Wiernik PH: Platelet alloimmunization: The absence of a dose response relationship. Blood 1981; 57: 395-398.

191. *Applefeld MM, Cole JF, Pollock SH, Sutton F, Slawson RG, Singleton RT, Wiernik PH: The late appearance of chronic pericardial disease in-patients treated by radiotherapy for Hodgkin's disease. Ann Intern Med 1981; 94: 338-341.

192. Van Echo DA, Whitacre MY, Aisner J, Wiernik PH: A phase I trial of dihydroxyanthracenedione. Cancer Treat Rep 1981; 65:831-834.

193. Fuks JZ, Van Echo DA, Aisner J, VonHoff D, Wiernik PH: A phase II trial of AMSA in-patients with refractory small cell carcinoma of the lung. Cancer Treat Rep 1981; 65: 133-134.

194. Aisner J, Ostrow S, Govindan S, Wiernik PH: Leptomeningeal carcinomatosis in small cell carcinoma of the lung. Med Pediatr Oncol 1981; 9: 47-60.

195. Wade JC, Newman KA, Schimpff SC, Van Echo DA, Gelber RA, Reed WP Wiernik PH: Two methods for improved venous access in acute leukemia patients. J Am Med Assn 1981; 246: 140-144.

196. Ostrow S, Egorin MJ, Hahn D, Markus S, Aisner J, Chang P, LeRoy A, Bachur NR, Wiernik PH: High dose cisplatin therapy using mannitol versus furosemide diuresis:


56


comparative pharmacokinetics and toxicity. Cancer Treat Rep 1981; 65: 73-78.

197. *Van Echo DA, Chiuten DF, Whitacre M, Aisner J, Lichtenfeld JC Wiernik PH: Phase I trial of pentamethylmelamine in-patients with previously treated malignancies. Cancer Treat Rep 1981; 64: 1335-1339.


198. Bishop JF, Schimpff SC, Diggs CH, Wiernik PH: Infections in non-Hodgkin's lymphoma patients undergoing intensive chemotherapy. Ann Intern Med 1981; 95:549-554.

199. Riggs Jr CE, Egorin MJ, Fuks JZ, Schnaper N, Duffey P, Colvin OM, Aisner J, Wiernik PH: Initial observations on the effects of 9 - tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin. J Clin Pharmacol 1981; 21:90S-98S.

200. Brenner DE, Chang P, Wiernik PH: Doxorubicin and dactinomycin therapy for advanced sarcomas. Cancer Treat Rep 1981; 65:231-236.

201. *Ostrow S, Van Echo D, Whitacre M, Aisner J, Simon R, Wiernik PH: Physiologic response and toxicity in patients undergoing whole-body hyperthermia for the treatment of cancer. Cancer Treat Rep 1981; 65:323-325.

202. *Ostrow S, Diggs CH, Sutherland J, Wiernik PH: Causes of death in patients with non-Hodgkin's lymphoma. Cancer 1981; 48: 779-782.

203. Aisner J, Wiernik PH: Chemotherapy in the treatment of malignant mesothelioma. Semin Oncol 1981; 8: 335-343.

204. Wade JC, Schimpff SC, Newman KA, Fortner CL, Standiford H, Wiernik PH: Piperacillin or ticarcillin plus amikacin: A double blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med 1981; 71: 983-990.

205. Konits PH, Aisner J, Van Echo DA, Lichtenfeld K, Wiernik PH: Mitomycin C and vinblastine chemotherapy for advanced breast cancer. Cancer 1981; 48: 1295-1298.

206. *Wiernik PH: Leukemias and Myeloma. In Pinedo HM (Ed.): Cancer Chemotherapy 1981, 1981; Amsterdam, Excerpta Medica, pp. 203-235.

207. Dutcher JP, Schiffer CA, Aisner J, Wiernik PH: Long-term followup of patients with leukemia receiving platelet transfusions: identification of a large group of patients


57


who do not become alloimmunized. Blood 1981; 58: 1007-1011.

208. *Ostrow SS, Diggs CH, Sutherland JC, Gustafson J, Wiernik PH: Nodular poorly differentiated lymphocytic lymphoma: changes in histology and survival. Cancer Treat Rep 1981; 65: 929-934.


209. Wade JC, Schimpff SC, Wiernik PH: Antibiotic combination-associated nephrotoxicity in granulocytopenic patients with cancer. Arch Intern Med 1981; 141: 1789-1793.

210. Dutcher JP, Wiernik PH: Adult Leukemia: How to recognize the early signs. Your Patient & Cancer 1981; 1: 37-40.

211. Dutcher JP, Wiernik PH: Adult leukemia: Treatment of Choice, Maintenance Therapy, Supportive Care. Your Patient and Cancer 1981; 1: 32-46.

212. Fuks JZ, Van Echo DA, Aisner J, Mitchell EP, Woolley III PV, Wiernik PH: Phase II trial of methyl-G (methylglyoxal bis-guanylhydrazone) in-patients with metastatic renal cell carcinoma. Cancer Clin Trials 1981; 4: 411-414.

213. Rai KR, Holland JF, Glidewell OH, Weinberg V, Brunner K, Obrecht JP, Priesler HD, Nawabi IW, Prager D, Carey RW, Cooper MR, Haurani F, Hutchinson JL, Silver RT, Falkson G, Wiernik P, Hoagland HC, Bloomfield CD, James GW, Gottlieb A, Ramanan SV, Blom J, Nissen NI, Bank A, Ellison RR, Kung F, Henry P, McIntyre OR, Kaan SK: Treatment of acute myelocytic leukemia: A study by Cancer and Leukemia Group B. Blood 1981; 58: 1203-1212.

214. Fuks JZ, Egorin MJ, Aisner J, Ostrow SS, Klein ME, Bachur NR, Colvin M, Wiernik PH: Cyclophosphamide and dimethylsulfoxide in the treatment of squamous carcinoma of the lung. Therapeutic efficacy, toxicity, and pharmacokinetics. Cancer Chemother Pharmacol 1981; 6: 117-120.

215. *Wiernik PH: Sequential studies of daunorubicin and Adriamycin in acute non-lymphocytic leukemia. Cancer Treat Rep 1981; 65 (suppl 4):67-71.

216. Morris DM, Vuthiganon C, Chang P, Wiernik PH, Elias EG: Adriamycin in management of malignant hemangiopericytoma. Ann Surg 1981; 47:441-446.

217. Aisner J, Whitacre M, Van Echo DA, Wiernik PH: Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations. Cancer Treat Rep 1982; 66: 221-230.


58


218. *Schiffer CA, DeBellis R, Kasdorf H, Wiernik PH: Treatment of blast crisis of chronic myelogenous leukemia with 5-azacytidine and VP16-213. Cancer Treat Rep 1982; 66: 267-271.

219. *Esterhay RJ Jr, Wiernik PH, Grove WR, Markus SD, Wesley MN: Moderate dose methotrexate, vincristine, asparaginase and dexamethasone for treatment of adult acute lymphocytic leukemia. Blood 1982; 59: 334-345.


220. Fuks JZ, Aisner J, Carney DN, Van Echo DA, Ostrow SS, Ihde DC, Wiernik PH: A phase II trial of vindesine in-patients with refractory small-cell carcinoma of the lung. Am J Clin Oncol 1982; 5: 49-52.

221. Whitley N, Brenner D, Francis A, Kwon T, Villasanta V, Aisner J, Wiernik P, Whitley J: Use of the computed tomographic whole body scanner to stage and follow patients with advanced ovarian carcinoma. Invest Radiol 1982; 16: 479-486.

222. Whitley NO, Brenner DE, Francis A, Villasanta V, Aisner J, Wiernik PH, Whitley J: Computed tomographic evaluation of carcinoma of the cervix. Radiol 1982; 142: 439-446.

223. Kaplan RS, Wiernik PH: Neurotoxicity of antineoplastic drugs. Semin Oncol 1982; 9: 103-130.

224. Yates J, Glidewell OH, Wiernik PH, Cooper MR, Steinberg D, Dosik H, Levy R, et al: Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB Study. Blood 1982; 60:454-462.

225. Ostrow S, Van Echo D, Egorin M, Whitacre M, Grochow L, Aisner J, Colvin M, Bachur N, Wiernik P: Cyclophosphamide pharmacokinetics in-patients receiving whole body hyperthermia. Natl Cancer Inst Monogr 1982; 61:401-405.

226. *Wiernik PH, Slawson RG: Hodgkin's disease with direct extension into pulmonary parenchyma from a mediastinal mass: A presentation requiring special therapeutic considerations. Cancer Treat Rep 1982; 66:711-716.

227. Joshi JH, Wang KP, DeJongh CA, Newman KA, Wiernik PH, Schimpff SC: A comparative evaluation of two fiberoptic broncoscopy catheters: The plugged telescoping catheter versus the single sheathed nonplugged catheter. Am Rev Resp Dis 1982; 126:860-863.

228. Brenner DE, Garbino C, Kasdorf H, Villasanta V, Polcaro R, Yovarone J, Aisner J, Schiffer CA, Wiernik PH: A phase II trial of m-AMSA in the treatment of advanced


59


gynecologic malignancies. Am J Clin Oncol 1982; 5:291-296.

229. *Applefeld MM, Slawson RG, Spicer KM, Singleton RT, Wesley MN, Wiernik PH: Long-term cardiovascular evaluation of patients with Hodgkin's disease treated by thoracic mantle radiation therapy. Cancer Treat Rep 1982; 66:1003-1013.


230. Stein RS, Golomb HM, Wiernik PH, Mauch P, Hellman S, Ultmann JE, Rosenthal DS, Flexner JM: Anatomic substages of stage IIIA Hodgkin's disease: Followup of a collaborative study. Cancer Treat Rep 1982; 66:733-741.

231. *Van Echo DA, Whitacre MY, Aisner J, Applefeld MM, Wiernik PH: Phase I trial of Aclacinomycin A. Cancer Treat Rep 1982; 66:1127-1132.

232. Fuks JZ, Van Echo DA, Aisner J, Schipper H, Levitt M, Wiernik PH: Phase II evaluation of AMSA in-patients with stage III-IV malignant melanoma. Cancer Treat Rep 1982; 66:1237-1238.

233. Aisner J, Van Echo DA, Whitacre M, Wiernik PH: A phase I trial of continuous infusion VP16-213 (etoposide). Cancer Chemother Pharmacol 1982; 7:157-160.

234. Aisner J, Whitacre M, Van Echo DA, Wesley M, Wiernik PH: Doxorubicin, cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer. Cancer Chemother Pharmacol 1982; l 7:187-194.

235. *Duffey P, Campbell Jr EW, Wiernik PH: Hydrocele following treatment for Hodgkin's disease. Cancer 1982; 50:305-307.

236. De Jongh CA, Wade JC, Schimpff SC, Newman KA, Finley RS, Salvatore PC, Moody MR, Standiford HC, Fortner CL, Wiernik PH: Empiric antibiotic therapy for suspected infection in granulocytopenic cancer patients. A comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacin. Am J Med 1982; 73:89-96.

237. Van Echo DA, Schulman P, Budman DR, Ferrari A, Wiernik PH: A phase I trial of aziridinylbenzaquinone (NSC 182986) in patients with previously treated acute leukemia. Am J Clin Oncol 1982; 5:405-4l0.

238. Egorin MJ, Kaplan RS, Salcman M, Aisner J, Colvin M, Wiernik PH, and Bachur, N.R.: Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide. Clin Pharmacol Ther 1982; 32:122-128.


60


239. Aisner J, Morris D, Elias EG, Wiernik PH: Mastectomy as an adjuvant to chemotherapy for locally advanced or metastatic breast cancer. Arch Surg 1982; 117:882-887.

240. Konits PH, Egorin MJ, Van Echo DA, Aisner J, Andrews PA, May ME, Bachur NR, Wiernik PH: Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma. Cancer Chemother Pharmacol 1982; 8:l99-203.


241. Poplin EA, Aisner J, Van Echo DA, Whitacre M, Wiernik PH: CCNU, Vincristine, methotrexate, and procarbazine treatment of relapsed small cell lung carcinoma. Cancer Treat Rep 1982; 66: l557-l559.

242. Konits PH, Aisner J, Whitacre M, Wiernik PH: Lung cancer as a complication of prolonged survival in-patients with lymphomas. Med Pediatr Oncol 1982; l0:33l-338.

243. Finley RS, Fortner CL, DeJongh CA, Wade JC, Newman KA, Caplan E, Britten J, Wiernik PH, Schimpff SC: Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients. Antimicrob Ag Chemother 1982; 22:193-197.

244. Finley RS, Schimpff SC, Fortner CL, Wiernik PH: Rifampin and cloxacillin in the reduction of staphylococcus aureus colonization. Clin Pharm 1982; l:370-372.

245. Fuks JZ, Aisner J, Van Echo DA, Wiernik PH: Phase II study of medroxy-progesteroneacetate with tamoxifen in advanced renal cell cancer. Cancer Treat Rep 1982; 66:l773-4.

246. Konits PH, Van Echo DA, Aisner J, Morris D, Wiernik PH: Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma. Am J Clin Oncol 1982; 5:515-520.

247. Konits PH, Aisner J, Sutherland JC, Wiernik PH: Possible pulmonary toxicity secondary to vinblastine. Cancer 1982; 50:227l-2274.

248. Forastiere AA, Crain SM, Callahan K, Van Echo D, Mattox D, Thant M, Von Hoff DD, Wiernik PH: Phase II trial of aziridinylbenzaquinone (AZQ) in head and neck cancer. Cancer Treat Rep 1982; 66: 2097-2098.

249. Grove WR, Fortner CL, Wiernik PH: Review of amsacrine, an investigational antineoplastic agent. Clin Pharm 1982; l:320, 326.


61


250. Danhauer FJ, Fortner CL, Schimpff SC, DeJongh CA, Wesley MN, Wiernik PH: Ototoxicity and pharmacokinetically determined dosages of amikacin in cancer patients. Clin Pharm 1982; 1:539-543.

251. *Testa JR, Jumamoy LM, Wiernik PH: Variant Philadelphia chromosome translocation in two patients with chronic myelogenous leukemia. Cancer Genet Cytogenet 1982; 7:79-84.


252. Rosen ST, Aisner J, Makuch RW, Matthews MJ, Ihde DC, Whitacre M, Glatstein EJ, Wiernik PH, Lichter AS, Bunn PA: Carcinomatous leptomeningitis in small cell lung cancer: A clinicopathologic review of the National Cancer Institute experience. Med 1982; 61:45-53.

253. Fuks JZ, Wiernik PH: Adjuvant chemotherapy of cancer. Hosp Formulary 1982; 17:1351-1374.

254. Wade JC, Schimpff SC, Newman KA, Wiernik PH: Staphylococcus epidermidis: An increasing cause of infection in-patients with granulocytopenia. Ann Intern Med 1982; 97:503-508.

255. Brenner DE, Whitley NO, Houk TL, Aisner J, Wiernik PH, Whitley J: Volume determinations by computed tomography. J Am Med Assn 1982; 247:1299-1302.

256. *Coker RD, Morris DM, Coleman JJ, Schimpff SC, Wiernik PH, Elias G: Infection among 210 patients with surgically staged Hodgkin's disease. Am J Med 1983; 75:97-109.

257. *Testa JR, Oguma N, Pollak A, Wiernik PH: Near-tetraploid clones in acute leukemia. Blood 1983; 61:7l-78.

258. Wade JC, Gaffey M, Wiernik PH, Schimpff SC, Schiffer CA, Wesley M, Hoofnagle JM: Hepatitis among patients with acute nonlymphocytic leukemia. Am J Med 1983; 75:413-422.

259. *Wiernik PH, Riggs C Jr, Dutcher JP: Adriamycin or daunorubicin in combination with cytosine arabinoside for the treatment of acute nonlymphocytic leukemia. Drugs Exper Clin Res 1983; 9:403-406.

260. Schnaper N, Wiernik PH: The hospice: New wine in old bottles? Maryland State Med J 1983; 32:102-105.


62


261. *Appelfeld MM, Wiernik PH: Cardiac disease after radiation therapy for Hodgkin's disease. Am J Cardiol 1983; 51:1679-1681.

262. Brenner DE, Jones HW, Rosenshein NB, Forastiere A, Dillon M, Grumbine F, Tipping S, Burnett L, Greco FA, Wiernik PH: Phase II evaluation of spirogermanium in advanced ovarian carcinoma. Cancer Treat Rep 1983; 67:l93-194.

263. Morris DM, Steinert HR, Wiernik PH: Ineffectiveness of chemotherapy in-patients with metastatic ependymoma of the cauda equina. J Surg Oncol 1983; 22:33-36.


264. Aroney RS, Aisner J, Wesley MN, Whitacre MY, Van Echo DA, Slawson RG, Wiernik PH: Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma. Cancer Treat Rep 1983; 67:675-682.

265. *Coker DD, Morris DM, Coleman JJ, Wiernik PH, Elias G: Restaging laparotomy for Hodgkin's disease. Ann Surg 1983; 197:79-83.

266. *Fuks JZ, Aisner J, Wiernik PH: Restaging laparotomy in the management of the non-Hodgkin lymphomas. Med Pediatr Oncol 1983; l0:429-438.

267. Fuks JZ, Aisner J, Van Echo DA, Levitt M, Ihde DC, Carney D, Wiernik PH: Phase II trial of aziridinylbenzoquinone (AZQ) in-patients with refractory small cell carcinoma of the lung. Am J Clin Oncol 1983; 6:171-174.

268. Fuks JZ, Egorin MJ, Aisner J, Van Echo DA, Ostrow S, Bachur NR, Wiernik PH: Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma. Cancer Chemother Pharmacol 1983; 10:104-108.

269. *Van Sloten K, Wiernik PH, Schimpff SC, Schiffer CA: Evaluation of levamisole as an adjuvant to chemotherapy for treatment of acute nonlymphocytic leukemia. Cancer 1983; 51:1576-1580.

270. Fuks JZ, Aisner J, Van Echo DA, Schipper H, Levitt M, Ostrow S, Wiernik PH: Randomized study of cyclophosphamide, doxorubicin, and etoposide (VP16-213) with or without Cisplatinum in non-small cell lung cancer. J Clin Oncol 1983; 1:295-301.

271. deJongh CA, Wade JC, Finley RS, Joshi JH, Aisner J, Wiernik PH, Schimpff SC: Trimethoprim/sulfamethoxazole versus placebo: a double-blind comparison of infection prophylaxis in-patients with small cell carcinoma of the lung. J Clin Oncol 1983; 1:302-307.

272. Wade JC, deJongh CA, Newman KA, Crowley J, Wiernik PH, Schimpff SC:


63


Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia-Trimethoprim-sulfamethoxazole vs. naldixic acid. J Infect Dis 1983; 147:624-634.

273. Schiffer CA, Dutcher JP, Aisner J, Hogge D, Wiernik PH, Reilly JP: A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in-patients with leukemia. Blood 1983; 62 815-820.


274. Dutcher JP, Schiffer CA, Johnston GS, Papenburg D, Daly PA, Aisner J, Wiernik PH: Alloimmunization prevents the migration of transfused indium-111-labeled granulocytes to sites of infection. Blood 1983; 62:354-360.

275. Reed WP, Newman KA, deJongh C, Wade JC, Schimpff SC, Wiernik PH, McLaughlin JS: Prolonged venous access for chemotherapy by means of the Hickman catheter. Cancer 1983; 52:185-192.

276. Koch TR, Lichtenfeld KM, Wiernik PH: Detection of central nervous system metastasis with cerebrospinal fluid beta-2-microglobulin. Cancer 1983; 52:101-104.

277. *Testa JR, Oguma N, Misawa S, Wiernik PH: Chromosome abnormalities in acute leukemia: A higher incidence than previously assumed. Cancer Genet Cytogenet 1983; 9:305-6.

278. Schiffer CA, Keller C, Dutcher JP, Aisner J, Hogge D, Wiernik PH: Potential HLA-matched platelet donor availability for alloimmunized patients. Transfusion 1983; 23:286-289.

279. *Schiffer CA, Aisner J, Dutcher JP, Wiernik PH: Sustained post-transfusion granulocyte count increments following transfusion of leukocytes obtained from donors with chronic myelogenous leukemia. Am J Hematol 1983; 15:65-74.

280. Reed WP, Newman KA, Schimpff SC, deJongh CA, Wiernik PH: Dual lumen catheters for angioaccess in-patients with leukemia. Am Surgeon 1983; 49:373-378.

281. Maluish AE, Ortaldo JR, Conlon JC, Sherwin SA, Leavitt R, Strong DM, Wiernik P, Oldman RK, Herberman RB: Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon. J Immunol 1983; 131:503-7.

282. Brenner DE, Wiernik PH, Wesley M, Bachur NR: Acute doxorubicin toxicity: Relationship to pretreatment liver function, response and pharmacokinetics in patients


64


with acute nonlymphocytic leukemia. Cancer 1984; 53:1042-1048.

283. *Gerad H, Van Echo DA, Donehower M, Pocelinko R, Wiernik PH: A Phase I-II trial of anthracenedicarboxaldehyde (ADC, NSC 337766) in patients with refractory adult acute leukemia. Cancer Treat Rep 1984; 68:535-537.

284. Gerad H, Van Echo DA, Whitacre M, Ashman M, Helrich M, Foy J, Ostrow S, Wiernik PH, Aisner J: Doxorubicin, cyclophosphamide and whole body hyperthermia for treatment of advanced soft tissue sarcoma. Cancer 1984;53:2585-2951.


285. Gottlieb AJ, Weinberg V, Ellison RR, Henderson ES, Terebelo H, Rafla S, Cuttner J, Silver RT, Carey RW, Levy RN, Hutchinson JL, Raich P, Cooper MR, Wiernik P, Anderson JR, Holland JF: Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: A prospective randomized trial by Cancer and Leukemia Group B (CALGB). Blood 1984; 64:267-274.

286. Dutcher JP, Wiernik PH: Long term survival of a patient with multiple myeloma - a cure? Cancer 1984; 53:2069-2072.

287. *Wiernik PH: The current status of therapy for and prevention of blast crisis of chronic myelocytic leukemia. J Clin Oncol 1984; 2:329-335.

288. Dutcher JP, Schiffer CA, Aisner J, O'Connell BA, Levy C, Kendall JA, Wiernik PH: Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors. Cancer 1984; 53:557-562.

289. Dutcher JP, Haney PJ, Whitley NO, Finley R, Pearl P, Didolkar MS, Wiernik PH: Ethiodized oil emulsion 13 in computed tomography of hepatoma. J Clin Oncol 1984; 2:118-123.

290. Taylor AL, Appelfeld MM, Wiernik PH, Grochow LB, Mader LC, Bulkley BH: Acute anthracycline cardiotoxicity: Comparative morphologic study of three analogues. Cancer 1984; 53: 1660-1666.

291. Aroney RS, Dermody WC, Aldenderfer P, Parsons P, McNitt K, Marangos PJ, Whitacre MY, Ruddon RW, Wiernik PH, Aisner J: Multiple sequential biomarkers in monitoring patients with carcinoma of the lung. Cancer Treat Rep 1984; 68:859-866.

292. *Wiernik PH: Selected studies of daunorubicin in adult in adult acute nonlymphocytic leukemia. Semin Oncol 1984; 11:12-14.

293. Dutcher JP, Wiernik PH, Gray WC: Tonsillectomy for recurrent throat infections in


65


acute leukemia patients. N Engl J Med 1984; 311:408 (letter to the editor).

294. Paietta E, Wiernik PH: Acute versus chronic leukemic cells: Is phenotyping a good prognostic indicator ? Diagnostic Med 1984; 7:20-34.

295. Paietta E, Tudoriu CD, Goldstein M, Papenhausen P, D'Olimpio J, Wiernik PH: Plasmacytoid blast crisis in B-cell chronic lymphocytic leukemia: Effect of estradiol on growth and differentiation in vitro. Leuk Res 1985; 9:19-29.


296. Allegra JC, Bertino J, Bonomi P, Byrne P, Carpenter J, Catalano R, Creech R, Dana B, Durivage H, Einhorn L, Ettinger D, Greco FA, Greenwald E, Henderson I, Holmes F, Kinzbrunner B, Luedke S, Muss H, Nimeth N, Talley R, Wampler G, Weinreb N, Weisberg J, Wheeler R, Wiernik P: Metastatic breast cancer: Preliminary results with oral hormonal therapy. Semin Oncol 1985; 12 (suppl. 6): 61-64.

297. Testa JR, Misawa S, Oguma N, Van Sloten K, Wiernik PH: Chromosomal alterations in acute leukemia patients studied with improved culture methods. Cancer Res 1985; 45:430-434.

298. Brenner DE, Rosenshein NB, Dillon M, Jones HW, Forastiere A, Tipping S, Burnett LS, Greco FA, Wiernik PH: Phase II study of spirogermanium in patients with advanced carcinoma of the cervix. Cancer Treat Rep 1985; 69:457-458.

299. D'Olimpio JT, Camacho F, Chandra P, Lesser M, Maldonado M, Wollner D, Wiernik PH: Antiemetic efficacy of high-dose dexamethasone versus placebo in-patients receiving cisplatin-based chemotherapy: A randomized double blind controlled clinical trial. J Clin Oncol 1985; 3:1133-1135.

300. Paietta E, Dutcher JP, Wiernik PH: Terminal transferase positive acute promyelocytic leukemia: In-vitro differentiation of a T-lymphocytic promyelocytic hybrid phenotype. Blood 1985; 65:107-114.

301. Paietta E, Goldstein M, Papenhausen P, Ciobanu N, Wiernik PH: Transformation of myeloma into Ph1-negative CML with plasma cell antigens. Am J Hematol 1985; 19:289-292.

302. Strauman JJ, Rosen NL, Soifer I, Wiernik PH: Localized subcutaneous toxicity following bleomycin administration. Cancer Treat Rep 1985; 69:561-562.

303. Conjalka MS, Gold EJ, Reynolds TF, Wiernik PH: Retroviruses, chromosomes, and neoplasia: Mechanisms of oncogene activation. Resident and Staff Phys. 1985; 31:21-


66


35.

304. Morris DM, Coker DD, Coleman JJ, Wiernik PH, Elias EG: The effect of postoperative radiotherapy on the development of small bowel obstruction in patients undergoing staging laparotomy for Hodgkin's disease. Am J Clin Oncol 1985; 8:463-467.

305. Ciobanu N, Paietta E, Papenhausen P, Andreef M, Wiernik PH: Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation. Expl Hematol 1986; 14:626-635.

\Publications A. Original, Peer Reviewed Articles (cont.)

306. Paietta E, Papenhausen P, Ciobanu N, Dutcher JP, Wiernik PH: Biphenotypic leukemia with unusual chromosomal translocation in a patient treated for melanoma. Cancer Genet Cytogenet 1986; 21:355-369.

307. Ettinger DS, Allegra J, Bertino JR, Bonomi P, Browder H, Byrne P, Carpenter J, Catalano R, Creech R, Dana B, Durivage H, Einhorn L, Greco FA, Greenwald E, Henderson I, Holmes F, Keller J, Kinzbrunner B, Losada M, Luedke S, Muss H, Nimeh N, Wampler G, Weinreb N, Weisberg J, Wheeler R, Wiernik PH: Megestrol acetate versus tamoxifen in advanced breast cancer: Correlation of hormone receptors and response. Semin Oncol 1986; 13 (suppl 4):9-14.

308. Paietta E, Papenhausen P, Dutcher JP, Wiernik PH: Cytogenetic and phenotypic evolution in a case of acute promyelocytic leukemia. Cancer Genet Cytogenet 1986; 21:181-182.

309. Paietta E, Saltzman B, Klein RS, Friedland GH, Stein H, Wiernik PH: Activation antigen (ki-1) expressed on lymphocytes from patients with AIDS or AIDS-related complex (letter to the editor). Ann Intern Med 1986; 104:890-891.

310. Misawa S, Hogge DE, Oguma N, Wiernik PH, Testa JR: Detection of clonal karyotypic abnormalities in most patients with acute nonlymphocytic leukemia examined using short-term culture techniques. Cancer Genet Cytogenet 1986; 22:239-251.

311. Paietta E, Stockert RJ, Morell AG, Diehl V, Wiernik PH: Lectin activity as a marker for Hodgkin disease cells. Proc Natl Acad Scis (USA) 1986; 83:3451-3455.

312. Paietta E, Stockert RJ, Morell AG, Diehl V, Wiernik PH: Unique antigen of cultured Hodgkin's cells: A putative sialyltransferase. J Clin Invest 1986; 78:349-354.


67


313. *Dutcher JP, Fisher M, Spivack M, Wiernik PH: Porphyria cutanea tarda in a patient with acute leukemia. Am J Hematol 1986; 23:69-75.

314. Dutcher JP, Wiernik PH: Acute leukemia in a patient cured of diffuse histiocytic lymphoma. J Cancer Res Clin Oncol 1986; 112:67-70.

315. Wadler S, Fuks JZ, Wiernik PH: Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. J Clin Pharmacol 1986; 26:491-509.


316. Terebelo HR, Anderson K, Wiernik PH, Cuttner J, Cooper RM, Faso L, Berenberg JL: Therapy of refractory adult acute lymphoblastic leukemia with vincristine and prednisone plus tandem methotrexate and L-asparaginase: Results of a Cancer and Leukemia Group B Study. Am J Clin Oncol 1986; 9:411-415.

317. Ciobanu N, Wiernik PH: Malignant lymphomas, AIDS and the pathogenic role of Epstein-Barr virus. Mt Sinai J Med 1986; 53:627-635.

318. *D'Olimpio JT, Miller M, Sheridan CA, Carlisle P, Wollner DI, McKitrick JC, Wiernik PH: A comparative trial of moxalactam plus ticarcillin and clavulanic acid or piperacillin as empiric antibiotic therapy for febrile cancer patients. J Clin Pharmacol 1987; 27:673-677.

319. *Paietta E, Rosen N, Roberts M, Papenhausen P, Wiernik PH: Philadelphia-chromosome positive essential thrombocythemia evolving into lymphoid blast crisis. Cancer Genet Cytogenet 1987; 25:227-231.

320. *Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E: Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47:2486-2493.

321. Paietta E, Papenhausen P, Azar C, Wiernik PH, Spielvogel A: Inv (16) occurring in a case of acute biphenotypic leukemia lacking monocytic markers: Multiple but short remissions. Cancer Genet Cytogenet 1987; 25:367-368.

322. *Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP: Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol 1987; 5:1232-1239.

323. Gallagher RE, Lurie KJ, Leavitt RD, Wiernik PH: Effects of interferon and retinoic acid on the growth and differentiation of clonogenic leukemic cells from acute


68


myelogenous leukemia patients treated with recombinant leukocyte- -A interferon. Leukemia Res 1987; 11:609-620.

324. Paietta E, Hubbard AL, Wiernik PH, Diehl V, Stockert RJ: The Hodgkin's cell lectin: An ectosialyltransferase and lymphocyte agglutinant related to the hepatic asialoglycoprotein receptor. Cancer Res 1987; 47:2461-2467.

325. Dutcher JP, Ciobanu N, Paietta E, Marcus S, Strauman J, Wiernik PH: The clinical importance of interleukin-2: 1986. Einstein Quart J Biol Med 1987; 5:1-9.


326. Dutcher JP, Schiffer CA, Wiernik PH: Hyperleukocytosis in adult acute nonlymphocytic leukemia: Impact on remission rate and duration, and survival. J Clin Oncol 1987; 5:1364-1372.

327. Marcus SL, Dutcher JP, Paietta E, Ciobanu N, Strauman J, Wiernik PH, Hutner SH, Frank O, Baker H: Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin - 2 and lymphokine-activated killer cells. Cancer Res 1987; 47:4208-4212.

328. Paciucci PA, Dutcher JP, Cuttner J, Wiernik PH, Holland JF: Mitoxantrone and Ara-C in previously treated patients with acute myelogenous leukemia. Leukemia 1987; 1:565-567.

329. *Bishop JF, Wiernik PH, Wesley MN, Kaplan RS, Diggs CH, Barcos MP, Sutherland JC: A randomized trial of high dose cyclophosphamide, vincristine, and prednisone plus or minus doxorubicin (CVP versus CAVP) with long-term follow-up in advanced non-Hodgkin's lymphoma. Leukemia 1987; 1:508-513.

330. Paietta EP, Stockert RJ, Calvelli T, Papenhausen P, Seremetis SV, Fotino M, Wiernik PH, Chang L, Bollum FJ: HL - T, a new cell line derived from HL - 60 promyelocytic leukemia cell cultures expressing terminal transferase and secreting suppressor activity. Blood 1987; 70:1151-1160.

331. *Wiernik PH, Sciortino D, Paietta E, Papenhausen P, Ciobanu N, Roberts M: Plasma cell leukemia with an unusual karyotype and prolonged survival with oral alkylating agent therapy. J Cancer Res Clin Oncol 1987; 113:495-497.

332. *Bishop JF, Schiffer CA, Aisner J, Matthews JP, Wiernik PH: Surgery in acute leukemia: A review of 167 operations in thrombocytopenic patients. Am J Hematol 1987; 26:147-156.


69


333. Fuks JZ, Wadler S, Wiernik PH: Phase I and II agents in cancer therapy: II. Cisplatin analogs and high - dose cisplatin in hypertonic saline or with thiosulfate protection. J Clin Pharmacol 1987; 27:357-365.

334. Wadler S, Subar M, Green MD, Wiernik PH, Muggia FM: Phase II trial of oral methotrexate and dipyridamole in colorectal carcinoma. Cancer Treat Rep 1987; 71:821-824.

335. Morris DM, Coker DD, Coleman JJ, Wiernik PH, Elias EG: Effect of incidental appendectomy on development of wound infection in-patients undergoing staging laparotomy for Hodgkin's disease. Am J Surg 1987; 153:226-229.


336. Lipton RB, Galer BS, Dutcher JP, Portenoy RK, Berger A, Arezzo JC, Mizruchi M, Wiernik PH, Schaumberg HH: Quantitative sensory testing demonstrates that subclinical sensory neuropathy is prevalent in-patients with cancer. Arch Neurol 1987; 44:944-946.

337. Paietta E, Papenhausen P, Gucalp R, Reed J, Wiernik PH: The 5q- deletion: Correlation of breakpoints with the immunophenotype of leukemic blast cells. Leukemia 1987; 1:822-824.

338. Ciobanu N, Runowicz C, Gucalp R, Charuvanki V, Kaufman D, Wiernik PH: Reversible central nervous system toxicity associated with high-dose chlorambucil in autologous bone marrow transplantation for ovarian carcinoma. Cancer Treat Rep 1987; 71:1324-1325.

339. Dutcher JP, Wadler S, Wiernik PH: Biologic response modifiers in gynecologic malignancies. Yale J Biol Med 1988; 61:367-378.

340. Fisher RI, Coltman CA, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, Mc Mannis JD, Weiss GR, Margolin KA, Gemlo BT, Hoth DF, Parkinson DR, Paietta E: Metastatic renal cancer treated with interleukin-2 and lymphokine activated killer cells: A phase II clinical trial. Ann Intern Med 1988; 108:518-523.

341. *Wiernik, PH, Schiffer CA: Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin. J Cancer Res Clin Oncol 1988; 114:105-107.

342. Paietta E, Gallagher R, Wiernik PH, Stockert RJ: A membrane bound lectin responsive to monocytic maturation in the promyelocytic leukemia cell line HL-60. Cancer Res 1988; 48:280-287.


70


343. Wadler S, Wiernik PH: Partial reversal of doxorubicin resistance by forskolin and 1,9-dideoxyforskolin in murine sarcoma S180 variants. Cancer Res 1988; 48:539-543.

344. Wadler S, Einzig AI, Dutcher JP, Ciobanu N, Landau L, Wiernik PH: Phase II trial of recombinant alpha-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma. Am J Clin Oncol 1988; 11:55-59.

345. *Dutcher JP, Wiernik PH, Markus S, Weinberg V, Schiffer CA, Harwood KV: Intensive maintenance therapy improves survival in adult acute non-lymphocytic leukemia: An eight year follow-up. Leukemia 1988; 2:413-419.


346. Leventhal B, Poplack DG, Weiner MA, Wiernik PH: Primary care in childhood leukemia. Patient Care 1988; 22:211-224.

347. *Gucalp R, Lia S, McKitrick JC, Wiernik PH: Cefoperazone plus tobramycin versus ticarcillin plus tobramycin in febrile granulocytopenic cancer patients. Am J Med 1988; 85(suppl 1A):31-35.

348. Paietta E, Gallagher R, Wiernik PH, Stockert RJ: Leukemic promyelocyte (HL-60) lectin responsive to monocytic maturation. Lectins-Biol Biochem Clin Biochem 1988; 6:427-430.

349. Paietta E, Papenhausen P, Gucalp R, Wiernik PH: Translocation t(12;19)(q13;q13.3). A new recurrent abnormality in acute nonlymphocytic leukemia with atypical erythropoiesis. Cancer Genet Cytogenet 1988; 34:19-23.

350. Simon KE, Dutcher JP, Runowicz CD, Wiernik PH: Adenocarcinoma arising in vulvar breast tissue. Cancer 1988; 62:2234-2238.

351. *Schwartz EL, Wiernik PH: Differentiation of leukemia cells by chemotherapeutic agents. J Clin Pharmacol 1988, 28:779-794

352. *Dutcher JP, Wiernik PH: Extension of remission in acute nonlymphocytic leukemia (letter). J Clin Oncol 1988; 6:1783-1784.

353. Ciobanu N, Runowicz CD, Wiernik PH, Strauman T, Sheridan C, Bast Jr RC: CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantation. Am J Obstet Gynecol 1989; 160:354-355.

354. Dutcher JP, Kendall J, Papenberg D, Schiffer C, Aisner J, Wiernik PH: Granulocyte transfusion therapy and amphoterecin B - Adverse reactions ? Am J Hematol 1989;


71


31:102-108.

355. Walewski J, Paietta E, Dutcher J, Wiernik PH: Evaluation of in-vivo natural killer and lymphokine-activated killer (LAK) cell activity in-patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells. J Cancer Res Clin Oncol 1989; 115:170-174.

356. Lipton RB, Apfel S, Dutcher JP, Rosenberg R, Kaplan J, Berger A, Einzig AI, Wiernik PH, Schaumburg HH: Taxol produces a predominantly sensory neuropathy. Neurol 1989; 39:368-373.


357. *Wiernik PH: Current status of chemotherapy for Hodgkin's disease. Recent Results in Cancer Res 1989; 117:132-141.

358. Paietta E, Stockert RJ, Morell A, Racevskis J, Wiernik PH: A marker and putative pathoantigen of Hodgkin's cells. Recent Results in Cancer Res, 1989; 117:91-98.

359. Wadler S, Egorin MJ, Zukowski EG, Tortorello L, Salva K, Runowicz CD, Wiernik PH: Phase I clinical and pharmacokinetic study of thiotepa administered intraperitoneally in-patients with advanced malignancies. J Clin Oncol 1989; 7:132-139.

360. Berman E, Raymond V, Gee TS, Gulati S, Andreeff M, Gabrilove J, Young CW, Clarkson BD, Wiernik PH, Case DE, Arlin ZA, Vogler WR, Velez-Garcia E, Omura G, Raney M: Idarubicin in acute leukemia: results of US trials. Bone Marrow Transpl 1989; 4(suppl 1):49.

361. Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshow JH, Jaffe HS, Roper M, Parkinson DR, Wiernik PH, Creekmore SP, Boldt DH: Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 1989; 7:486-498.

362. *Wiernik PH, Case Jr DC, Periman PO, Arlin ZA, Weitberg AB, Ritch PS, Todd MB: A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia. Semin Oncol 1989; 16(suppl 2):25-29.

363. *Dutcher JP, Riggs CE, Strauman JJ, Link B, Wiernik PH: A phase I-II trial of 4'-deoxydoxorubicin (esorubicin) in refractory or relapsed acute leukemia. Clin Pharmacol Ther 1989; 45:424-428.

364. Schiffer, CA, Lee EJ, Tomiyasu T, Wiernik PH, Testa JR: The prognostic impact of


72


cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 1989; 73:263-270.

365. Paietta E, Andreeff M, Papenhausen P, Gucalp R, Wiernik PH: Distinct antigen expression related to DNA ploidy in a case of biphenotypic leukemia. Leukemia 1989; 3:76-78.

366. Wadler S, Tai K, Chervu LR, Rafii S, Landau L, Blaufox MD, Wiernik PH: Iodine-131 MIBG scintigraphy in small cell lung cancer. Eur J Nuclear Med 1989; 15:108-110.


367. Athan ES, Paietta E, Papenhausen PR, Augenlicht L, Wiernik PH, Gallagher RE: Stability of multiple antigen receptor gene rearrangements and immunophenotype in Hodgkin's disease-derived cell line L428 and variant subline L428KSA. Leukemia 1989; 3:505-510.

368. Gallagher RE, Said F, Pua I, Papenhausen PR, Paietta E, Wiernik PH: Expression of retinoic acid receptor-a mRNA in human leukemia cells with variable responsiveness to retinoic acid. Leukemia 1989; 3:789-795.

369. Baker H, Marcus SL, Frank O, Petrylak DP, De Angelis B, Dutcher JP, Wiernik PH: Interleukin 2 enhances biopterins and catecholamines production during adoptive immunotherapy for various cancers. Cancer 1989; 64:1226-1231.

370. Paietta E, Gucalp R, Papenhausen P, Dutcher JP, Wiernik PH: TdT+/nonlymphoid antigen + acute leukemias: Immunologic and karyotypic monitoring during therapy and at relapse suggests the transformation of a bipotential stem cell. Leukemia 1989; 3:485-491.

371. Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, Itri L, Weinberg V, Wiernik PH: 5-fluorouracil and recombinant alpha-2a-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 1989; 7:1769-1775.

372. Wadler S, Lyver A, Wiernik PH: Clinical toxicities of the combination of 5-fluorouracil and recombinant interferon alfa-2a: An unusual toxicity profile. Oncol Nursing Forum 1989; 16:12-15.

373. Paietta E, Stockert RJ, McManus M, Thompson D, Schmidt S, Wiernik PH: Hodgkin's cell lectin, a lymphocyte adhesion molecule and mitogen. J Immunol 1989; 143:2850-2857


73


374. Arlin Z, Case D, Moore J, Wiernik P, Saletan S, Desai P, Sia L, Cartwright K, and the Lederle Cooperative Group: Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute non-lymphocytic leukemia (ANLL). Leukemia 1990; 4:177-183.

375. Olver IN, Pearl P, Wiernik PH, Aisner J: Small bowel obstruction as a late complication of the treatment of Hodgkin's disease. Austral NZ J Surg 1990; 60:585-588.


376. Winter JN, Ritch PS, Rosen ST, Oken MM, Wolter JM, Wiernik PH, O'Connell MJ: Phase II trial of methylglyoxal bis (guanylhydrazone) (MGBG) in-patients with refractory multiple myeloma: An Eastern Cooperative Oncology Group (ECOG) study. Cancer Invest 1990; 8:143-146.

377. *Dutcher JP, Salva K, Wiernik PH: Successful treatment of hairy cell leukemia with 2'-deoxycoformycin after failure of interferons alpha or beta. Am J Clin Oncol 1990; 13:290-293.

378. *Wiernik PH, Rader M, Becker NH, Morris, S: Inflammatory pseudotumor of spleen. Cancer 1990; 66:597-600.

379. Dutcher JP, Riggs Jr C, Fox JJ, Johnston GS, Norris D, Wiernik PH, Schiffer CA: The effect of histocompatibility factors on pulmonary retention of indium-111-labeled granulocytes. Am J Hematol 1990; 33:238-243.

380. *Wiernik PH, Schwartz B, Dutcher JP, Turman N, Adinolfi C: Successful treatment of hairy cell leukemia with -ser interferon. Am J Hematol 1990; 33:244-248.

381. Dutcher JP, Marcus SL, Tanowitz HB, Wittner M, Fuks JZ, Wiernik PH: Disseminated Strongyloidiasis with central nervous system involvement diagnosed antemortem in a patient with the acquired immunodeficiency syndrome and Burkitts lymphoma. Cancer 1990; 66:2417-2420.

382. Abrams JS, Rayner AA, Wiernik PH, Parkinson DR, Eisenberger M, Aronson FR, Gucalp R, Atkins MB, Hawkins MJ: High dose recombinant interleukin-2 alone: A regimen with limited activity in the treatment of advanced renal cell carcinoma. J Natl Cancer Inst 1990; 82:1202-1206.

383. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker Jr


74


JR, Van Echo DA, Von Hoff DD, Leyland-Jones B: Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8:1263-1268.

384. Paietta E, Racevskis J, Stanley ER, Andreeff M, Papenhausen P, Wiernik PH: Expression of the macrophage growth factor, CSF-1, and its receptor, C-FMS by a Hodgkin's disease derived cell line and its variants. Cancer Res 1990; 50:2049-2055.

385. Sparano JA, Schwartz EL, Salva KM, Pizzillo MF, Wadler S, Wiernik PH: Phase II trial of etoposide (VP-16), doxorubicin (adriamycin) and cisplatin (EAP) in advanced gastric cancer. Am J Clin Oncol 1990; 13:374-378.


386. Wadler S, Wiernik PH: Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma. Semin Oncol 1990; 17(suppl 1):16-21.

387. Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA, Sznol M, Dutcher JP, Aronson FR, Doroshow JH, Atkins MB, Hawkins MJ: Interleukin-2 therapy in patients with metastatic malignant melanoma:A phase II study.J Clin Oncol 1990; 8:1650-1656.

388. Sparano J, Ramirez M, Wiernik PH: Increasing recognition of corticosteroid induced tumor lysis syndrome in non-Hodgkin's lymphoma. Cancer 1990; 65:1072-1073.

389. Shalmi CL, Dutcher JP, Feinfeld DA, Chun KJ, Freeman LM, Lynn RI, Saleemi KR, Wiernik PH: Acute renal dysfunction during interleukin-2 treatment: Evidence for an intrinsic renal lesion. J Clin Oncol 1990; 8:1839-1846.

390. Wadler S, Goldman M, Lyver A, Wiernik PH: Phase I trial of 5-fluorouracil and recombinant alpha-2a-interferon in-patients with advanced colorectal carcinoma. Cancer Res 1990; 50:2056-2059.

391. *Salva-Martin KM, Wiernik PH: Focus on idarubicin: An anthracycline analogue with significant activity against acute leukemia. Hosp Form 1990; 25:1143-1156.

392. Longo DL, Glatstein E, Duffey PL, Young RC, Hubbard SM, Urba WJ, Wesley MN, Raubitschek A, Jaffe ES, Wiernik PH, DeVita Jr VT: Radiation therapy versus combination chemotherapy in the treatment of early stage Hodgkin's disease: Seven-year results of a prospective randomized trial. J Clin Oncol 1991; 9:906-917.

393. Longo DL, Duffey PL, DeVita Jr VT, Wiernik PH, Hubbard SM, Phares JC, Bastian AW, Jaffe ES, Young RC: Treatment of advanced stage Hodgkin's disease:


75


Alternating non-cross-resistant 8-drug regimen (MOPP/CABS) is not superior to MOPP. J Clin Oncol 1991; 9:1409-1420.

394. Einzig AI, Hochster H, Wiernik PH, Trump DL, Dutcher JP, Garowski E, Sasloff J, Smith TJ: A phase II study of taxol in-patients with malignant melanoma. Invest New Drugs 1991; 9:59-64.

395. Paietta, E, Van Ness B, Bennett JM, Pellone C, Billadeau, Cassileth P, Wiernik PH: Unexpected immunoglobulin light chain gene rearrangements in myeloid antigen positive acute lymphoid leukemia. Leukemia Res 1991; 15:149-155, 1991.


396. Einzig AI, Gorowski E, Sasloff J, Wiernik PH: A phase II study of taxol in-patients with metastatic renal cell carcinoma. Cancer Invest 1991; 9:133-136.

397. Sparano JA, Beckwith JB, Mitsudo S, Wiernik PH: Complete remission in refractory anaplastic adult Wilm's tumor treated with cisplatin and etoposide. Cancer 1991; 67:956-959.

398. *Gucalp R, Paietta E, Weinberg V, Papenhausen P, Dutcher JP, Wiernik PH: Terminal transferase expression in acute myeloid leukemia: Biology and prognosis. Br J Haematol 1991; 78:48-54.

399. Sklarin NT, Dutcher JP, Wiernik PH: Lymphoma following cardiac transplantation. Am J Hematol 1991; 37:105-111.

400. *Wiernik PH, Dutcher JP, Paietta E, Hittelman WN, Vyas R, Strack M, Castaigne S, Degos L, Gallagher RE: Treatment of promyelocytic blast crisis of chronic myelogenous leukemia with all trans-retinoic acid. Leukemia 1991; 5:504-509.

401. Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J, Salva K, Wiernik PH, Holroyde CP, Hammill S, Shepard K, Plasse T: Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Management 1991; 6:352-359.

402. Feinfeld DA, D'Agati V, Dutcher JP, Werfel SB, Lynn RI, Wiernik PH: Interstitial nephritis in a patient receiving adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells. Am J Nephrol 1991; 11:489-492.

403. Kramer ZB, Boros L, Wiernik PH, Andersen J, Bennett JM, Cassileth P, Oken M: 13-cis-retinoic acid in the treatment of elderly patients with acute myeloid leukemia: A phase II pilot study of the Eastern Cooperative Oncology Group. Cancer 1991;


76


67:1484-1486.

404. Sparano JA, Dutcher JP, Kaleya R, Caliendo G, Fiorito J, Mitsudo S, Shechner R, Boley SJ, Gucalp R, Ciobanu N, Grima K, Wiernik PH, Brandt LJ: Colonic ischemia complicating immunotherapy with interleukin-2 and alpha-interferon. Cancer 1991; 68:1538-1544.

405. Gucalp R, Ciobanu N, Sparano J, Motyl M, Carlisle P, Wiernik PH: Aspergillus fungemia in a patient with extragonadal germ cell tumor undergoing autologous bone marrow transplantation. Cancer 1991; 68:1842-1844.


406. Marcus SL, Petrylak DP, Dutcher JP, Paietta E, Ciobanu N, Strauman J, Wiernik PH, Hutner SH, Frank O, Baker H: Hypovitaminosis C in-patients treated with high-dose interleukin 2 and lymphokine-activated killer cells. Am J Clin Nutrition, 1991; 54 (Suppl):1292S-1297S.

407. .Paietta E, Gucalp R, Wiernik PH: Monosomy 7 in multilineage and acute lymphoblastic leukemia. Br J Haematol 1991;79:152-155.

408. Lipton RB, Galer BS, Dutcher JP, Portenoy RK, Pahmer V, Meller F, Arezzo JC, Wiernik PH: Large and small fiber type sensory dysfunction is prevalent in patients with cancer. J Neurol Neurosurg Psychiatry 1991; 54:706-709.

409. *Wiernik PH: New agents in the treatment of acute myeloid leukemia. Semin Hematol 1991; 28(suppl 4):95-98.

410. *Wiernik PH, Dutcher JP: Clinical importance of anthracyclines in the treatment of acute myeloid leukemia. Leukemia 1991; 5(suppl 2):2-5.

411. *Wiernik PH, Banks PLC, Case Jr DC, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB: Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79:313-319.

412. *Cassileth PA, Andersen JW, Bennett JM, Harrington DP, Hines JD, Lazarus HM, Mazza JJ, McGlave PP, O'Connell MJ, Paietta E, Wiernik P: Escalating the intensity of postremission therapy improves the outcome in acute myeloid leukemia: The ECOG experience. Leukemia 1992; 6(suppl 2):116-119.

413. Gucalp R, Ritch P, Wiernik PH, Sarma R, Keller A, Richman SP, Tauer K, Neidhart J, Mallette LE, Siegel R, VandePol CJ: Comparative study of pamidronate disodium and


77


etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992; 10:134-142.

414. Robert F, Doroshow JH, Rosen PJ, Jolivet J, Ruckdeschel JC, Robert NJ, Velez-Garcia E, Bergsagel DE, Panasci LC, van der Merwe AM, Longueville JJ, Leiby J: A phase II trial of CI-921 in advanced malignancies. Invest New Drugs 1992; 10:309-312.

415. Dutcher JP, Eudey L, Wiernik PH, Paietta E, Bennett JM, Arlin Z, Kellermeyer R, Rowe J, O'Connell M, Oken M, Cassileth PA: Phase II study of mitoxantrone and 5-azacytidine for blast crisis of chronic myelogenous leukemia: A study of the Eastern Cooperative Oncology Group. Leukemia 1992; 6:770-775.


416. *Cassileth PA, Andersen JW, Bennett JM, Hoagland HC, Mazza JJ, O'Connell MJ, Paietta E, Wiernik P: Adult acute lymphocytic leukemia: The Eastern Cooperative Oncology Group Experience. Leukemia 1992; 6(suppl 2):178-181.

417. *Sklarin NT, Wiernik PH, Grove WR, Benson L, Mittelman A, Maroun JA, Stewart JA, Robert F, Doroshow JH, et al: A phase II trial of CI-921 in advanced malignancies. Invest New Drugs 1992;10:309-312.

418. Paietta E, Van Ness B, Bennett J, Racevskis J, Gucalp R, Cassileth P, Wiernik PH: Lymphoid lineage-associated features in AML: phenotypic and genotypic correlations. Br J Haematol 1992; 82:324-331.

419. *Moskowitz C, Dutcher JP, Wiernik PH: Association of thyroid disease with acute leukemia. Am J Hematol 1992;39:102-107.

420. Paietta E, Van Ness B, Le Beau MM, Bennett J, Cassileth P, Wiernik PH: Translocation (2;9)(p12;23) in a case of acute leukemia with t(4;11)(q21;q23): lack of rearrangement of the kappa and interferon gene loci. Cancer Genet Cytogenet 1992; 60:82-85.

421. *Tallman M, Wiernik PH: Retinoids in cancer treatment. J Clin Pharmacol 1992; 32:868-88.

422. Ciobanu N, Weinberg V, Sparano JA, Zervos G, Walewski J, Spivack M, Wiernik PH: Experience with autologous bone marrow harvesting and transfusion of marrow derived red cells. Transfusion 32:231-234, 1992.

423. Sparano JA, Gucalp R, Llena JF, Moser FG, Wiernik PH: Cerebral infection complicating systemic aspergillosis in acute leukemia: Clinical and radiographic presentation. J Neuro-Oncol 1992; 13:91-100.


78


424. *Wiernik PH: Advances in treatment for Hodgkin's disease. Mt Sinai J Med 1992; 59:405-407.

425. *Wiernik PH, Yeap B, Vogl SE, Kaplan BH, Comis RL, Falkson G, Davis TE, Fazzini E, Cheuvart B, Horton J: Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: A study of the Eastern Cooperative Oncology Group. Cancer Invest 1992; 10:1-9.

426. Baker H, Marcus SL, Frank O, Petrylak DP, De Angelis B, Baker ER, Dutcher JP, Wiernik PH: Effect of interleukin-2 on some micronutrients during adoptive immunotherapy for various cancers. J Am Coll Nutr 1992; 11:482-486.


427. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL: A phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10:1748-1753.

428. *Rowe JM, Oken MM, Cassileth PA, Andersen JW, Bennett JM, Wiernik PH: Clinical trials in adults with relapsed and refractory acute myelogenous leukemia. Hematol Blood Transfusion 1992; 34:392-396.

429. *Rowe JM, Andersen JW, Cassileth PA, Oken MM, Bennett JM, Wiernik PH: Post-remission therapy in adults with acute myelogenous leukemia: The Eastern Cooperative Oncology Group (ECOG) experience. Leukemia 1992; 6(suppl 4):75-77.

430. Gucalp R, Motyl M. Carlisle P, Dutcher, J, Fuks J, Wiernik PH: Clostridium cadaveris bacteremia in the immunocomprised host. Med Pediatr Oncol 1993; 21:70-72.

431. *Runowicz, CS, Wiernik PH, Einzig AI, Goldberg GL, Horwitz SB: Taxol in ovarian cancer. Cancer 1993; 71:1591-1596.

432. Wadler S, Fell S, Haynes H, Katz HJ, Rozenblitt A, Kaleya R, Wiernik PH: Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon. Cancer 1993; 71:1726-1730.

433. Aisner J, Wiernik PH, Pearl P: Pregnancy outcome in-patients treated for Hodgkin's disease. J Clin Oncol 1993; 11:507-512.

434. Paietta E, Racevskis J, Bennett JM, Wiernik PH: Differential expression of terminal transferase (TDT) in acute lymphocytic leukemia expressing myeloid antigens and TDT positive acute myeloid leukemia as compared to myeloid negative acute lymphocytic leukemia. Br J Haematol 1993; 84:416-422.


79


435. *Sparano JA, Wiernik PH, Strack M. Leaf A, Becker N, Valentine ES: Infustional cyclophosphamide doxorubin, and etopside in HIV-and HTLV-I-related non-Hodgkin's lymphoma: A highly active regimen. Blood 1993; 81:2810-2815.

436. *Sparano JA Wiernik PH, Leaf A, Dutcher JP: Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: Evidence for a schedule dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 1993; 11:1071-1079.

Publications Original, Peer Reviewed Articles (cont.)

437. Sparano JA, Wadler S, Diasio RB, Zhang R, Lu Z, Schwartz EL, Einzig A, Wiernik PH: A phase I trial of low-dose, prolonged continuous infusion 5-fluorouracil plus interferon-: Evidence for enhanced 5-fluorouracil toxicity without pharmacokinetic pertubation. J Clin Oncol 1993; 11:1609-1617.

438. *Wiernik PH, Dutcher JP, Paietta E, Gucalp R, Markus S, Weinberg V, Azar C, Garl S, Benson L: Long term followup of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: A non-anthracycline containing regimen. Leukemia 1993; 7:1236-1241.

439. Carlisle PS, Gucalp R, Wiernik PH: Nosocomial infections in neutropenic cancer patients. Infect Control Hosp Epidemiol 1993; 14:320-324.

440. Walpole ET, Dutcher JP, Sparano J, Gucalp R, Einzig A, Paietta E, Ciobanu N, Grima K, Caliendo G, Cavasotto G, Wiernik PH: Survival after phase II treatment of advanced renal cell carcinoma with taxol or high dose interleukin-2. J Immunother 1993; 13:275-281.

441. Mazurek C, Dutcher JP, Schwartz EL, Garl S, Benson L, Wiernik PH: Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemia. Invest New Drugs 1993; 11:313-322.

442. *Dutcher JP, Wiernik PH: The role of recombinant interleukin-2 in therapy for hematologic malignancies. Semin Oncol 1993; 20(suppl 9):33-40.

443. *Wiernik PH, Einzig AI: Taxol in malignant melanoma. Monogr Natl Cancer Inst 1993; 15:185-187.

444. *Sparano JA, Wiernik PH: Infusional cyclophosphamide-based therapy for the


80


treatment of lymphoma. J Infusional Chemother 1994; 4:28-32.

445. Paietta E, Andersen J, Racevskis J, Gallagher R, Bennett J, Yunis J, Casileth P, Wiernik PH: Significantly lower p-glycoprotein expression in acute promyelocytic leukemia than other types of acute myeloid leukemia: Immunological, molecular and functional studies. Leukemia 1994; 8:968-973.

446. Oleksowicz L, Sparano J, O'Boyle K, Venkatraj U, Wiernik PH, Dutcher JP: Interleukins in cancer therapy: Rationale and current status. Clin Immunother 1994;1:271-281.

Publications Original, Peer Reviewed Articles (cont.)

447. Martinelli DJ, Bakal CW, Cynamon J, Rozenblit A, Haynes H, Wiernik PH, Wadler S: Utility of embolization or chemoembolization as second line treatment in-patients with advanced or recurrent colorectal carcinoma. Cancer 1994; 74:1706-1712.

448. Sagayadan G, Wiernik P, Sun N, Ahearn G, Thompson D, Hallam S, Hu X-P, Dutcher J, Gallagher R: Effect of retinoic acid and interferon alpha on granulocyte-macrophage colony forming cells in chronic myeloid leukemia: Increased inhibition by all-trans-and 13-cis-retinoic acids in advanced stage disease. Leukemia Res 1994; 18:741-748.

449. *Paietta E, Andersen J, Gallagher R, Bennett J, Yunis J, Cassileth P, Rowe J, Wiernik PH: The immunophenotype of acute promyelocytic leukemia (APL): An ECOG study. Leukemia 1994; 8:1108-1112.

450. *Sparano JA, Wiernik PH, Strack M, Leaf A, Becker NH, Sarta C, Carney D, Elkind R, Shah M, Valentine ES, Dutcher JP: Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report of a highly active regimen. Leukemia & Lymphoma 1994; 14:263-271.

451. Oleksowicz L, Strack M, Dutcher J, Sussman I, Caliendo G, Sparano J, Wiernik PH: A distinct coagulopathy associated with interleukin 2 therapy. Br J Haematol 1994; 88:892-894.

452. *Welles L, Dorfman H, Valentine ES, Wiernik PH: Low grade malignant hemangioendothelioma of bone: A disease potentially curable with radiotherapy. Med Pediatr Oncol 1994; 23:144-148.

453. *Wiernik PH, Dutcher JP, Todd M, Caliendo G, Benson L: Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second


81


remission. Am J Hematol 1994; 47:41-44.

454. Wadler S, Tenteromano L, Cazenave L, Sparano JA, Greenwald ES, Rozenblit A, Kaleya R, Wiernik PH: Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. Cancer Chemother Pharmacol 1994; 34:266-269.

455. Gucalp R, Sparano J, Dutcher JP, Wiernik PH: Introduction to bone marrow transplant symposium held at the Albert Einstein Cancer Center at Bronx, NY, USA, March 23 to 25, 1994. Medical Oncol 1994; 11:31-33.

456. *Wiernik PH, Sklarin NT, Dutcher JP, Sparano JA, Greenwald ES: Adjuvant radiotherapy for breast cancer as a risk factor for the development of lung cancer. Med Oncol 1994; 11:121-126.


457. *Wiernik PH, Dutcher JP, Leaf AN, Liao Z, Paietta E, Rosenstreich DL: Objective response of multiple myeloma to cyclosporin A. Leukemia & Lymphoma 1994; 16:167-170.

458. *Rowe JM, Andersen JJW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer E, Wiernik PH: A randomized placebo-controlled phase III study of grnaulocyte-macrophage colony stimulating factor (rhu-GM-CSF) in adult patients (>55-70 years) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86:457-462.

459. *Racevskis J, Wiernik PH, Kirshner ED, Virargahavan V, Paietta E: Absence of hereditary p53 mutations in 8 familial Hodgkin's disease pedigrees. Leukemia 1995; 9:1966-1969.

460. Gallagher RE, Yun-Ping L, Rao S, Paietta E, Andersen J, Etkind P, Talllman M, Wiiernik PH: Characterization of acute promyelocytic leukemia cases with PML-RAR break/fusion sites in PML exon 6: Identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. Blood 1995; 86:1540-1547.

461. Wadler S, Burk RD, Neuberg D, Rameau R, Runowicz CD, Goldberg G, McGill F, Tachezy R, Comis R, Edmonson J, Wiernik PH: Lack of efficacy of interferon- therapy in recurrent, advanced cervical cancer. J Interferon Cytokine Res 1995; 15:1011-1016.

462. Paietta E, Andersen MS, Racevskis J, Ashigbi M, Cassileth P, Wiernik PH: Modulation of multidrug resistance in de novo adult acute myeloid leukemia: Variable efficacy of reverting agents in vitro. Blood Rev 1995; 9:47-52.


82


463. Chang AY, Tu N, Smith JL, Bonomi P, Smith TJ, Wiernik PH, Blum R: Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer: An Eastern Cooperative Oncology Group Study (E2588). Invest New Drugs 1995; 13:137-141.

464. Wadler S, Haynes H, Wiernik PH: Phase I trial of the somatostatin analogue, octreotide acetate, in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol 1995; 13:222--226.

465. *Schwartz EL, Hallam S, Gallagher RE, Wiernik PH: Inhibition of all-trans retinoic acid metabolism by fluconazole in vitro and in-patients with acute promyelocytic leukemia. Molecular Pharmacol 1995; 50:923-928.


466. Dutcher JP, Leong T, Makary AZ, Bennett J, Frontiera M, Miller H, Wiernik PH: A phase II study of menogaril (7r-o-methylnogarol) in patients with relapsed/refractory acute myeloid leukemia. Leukemia 1995; 9:1638-1642.

467. Khalil A, Ciobanu N, Gucalp R, Dutcher J, Wiernik PH: A pilot study of high-dose mitoxantrone and busulfan plus autologous bone marrow transplantation in-patients with advanced malignancies. Bone Marrow Transplantation 1995; 15:93-97.

468. Paietta E, Nelson DL, Andersen J, Dutcher JP, Wiernik PH: Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells. Med Oncol 1995, 12:121-124.

469. Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, Herzig RH, Hurd DD, Jagannath S, Klein JP, Lazarus HM, McCarthy Jr PL, Pavlovsky S, Petersen FB, Rowlings PA, Russell JA, Silver SM, Vose JM, Wiernik PH, Bortin MM, Horowitz MM: Bone marrow transplants from HLA-identical siblings in advanced Hodgkin disease. J Clin Oncol 1996; 14:572-578.

470. Tallman MS, Gray R, Bennett JM, Variakojis D, Robert N, Wood WC, Rowe JM, Wiernik PH: Leukemogenic potential of adjuvant chemotherapy for early stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol 1995; 13:1557-1563.

471. *Einzig AI, Lipsitz S, Wiernik PH, Benson III AB: Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology Group (ECOG) results. Invest New Drugs 1995; 13:223-227.

472. Paietta E, Andersen J, Wiernik PH: A new approach to analyzing the utility of


83


immunophenotyping for predicting clinical outcome in acute leukemia. Leukemia 1966; 10:1-4.

473. Secco C, Wiernik PH, Bennett JM, Paietta E: Acute leukemia with t(10;11)(p11-15;q13-23). Cancer Genet Cytogen 1996; 86:31-34.

474. *Subar M, Gucalp R, Benstein J, Williams G, Wiernik PH: Acute leukemia following renal transplantation. Med Oncol 1996; 13:9-13.

475. *Wiernik PH, DeBellis R, Muxi P, Dutcher JP: Extramedullary acute promyelocytic leukemia. Cancer 1996; 78:2510-2514.


476. Mazza JJ, Leong T, Rowe JM, Wiernik PH, Cassileth PA: Treatment of adult patients with acute lymphocytic leukemia in relapse. Leukemia & Lymphoma 1996; 20:317-319.

477. *Hui L, Wiernik PH: Avascular necrosis of bone after adult acute lymphocytic leukemia treatment with methotrexate, vincristine, L-asparaginase and dexamethasone (MOAD). Am J Hematol 1996; 52:184-188.

478. O'Boyle KP, Colletti D, Mazurek C, Wang Y, Ray SK, Diamond B, Rosenblum MG, Epstein AL, Shochat D, Blattler WA, Dutcher JP, Wiernik PH, Klein RS: Potentiation of antiproliferative effects of monoclonal antibody LYM-1 and immunoconjugate LYM-1-gelonin on human Burkitt's lymphoma cells with gamma interferon and tumor necrosis factor. J Immunother 1996; 18:221-230.

479. *Sparano JA, Wiernik PH, Hu X, Sarta C, Schwartz EL, Soeiro R, Henry DH, Mason B, Ratech H, Dutcher JP: A pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and filgrastim in-patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 1996; 14:3026-3035.

480. Wadler S, Haynes H, Beitler JJ, Hu X, Fell S, Camacho M, Levine B, Wiernik PH: Phase II clinical trial of 5-fluorouracil, recombinant interferon alfa-2b, and cisplatin in-patients with metastatic or regionally advanced carcinoma of the esophagus. Cancer 1996; 78:30-34.

481. Bennett JM, Cassileth PA, Paietta E, Rowe JM, Wiernik PH: Morphologic classification of acute myeloid Leukemia: Concordance among Eastern Cooperative Oncology Group investigators. A comment. Leukemia 1996; 10:1365.


84


482. *Wiernik PH: Interpreting data in AML. Leukemia 1996; 10 (Suppl 1):S44-S45.

483. Wadler S, Haynes H, Schechner R, Rozenblit A, Wiernik PH: Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon--2a in-patients with advanced malignancies. Invest New Drugs 1996; 13:315-320.

484. *Wiernik PH: Lessons learned about treatment of the more common neoplasms from the study of acute leukemia (adapted from the Janeway Lecture, American Radium Society, April 1996). Cancer J Sci Amer 1996; 2:356-359.

485. Einzig AI, Schuchter LM, Recio A, Coatsworth S, Wiernik PH: Phase II trial of docetaxel (taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Med Oncol 1996; 13:111-118.


486. Einzig AI, Neuberg D, Wiernik PH, Grochow LB, Ramirez G, O'Dwyer PJ, Petrelli NJ: Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy: An Eastern Cooperative Oncology Group trial (PA286). Am J Therapeutics 1996; 3:750-754.

487. Bennett JM, Young M, Andersen JW, Cassileth PA, Tallman M, Paietta E, Wiernik P, Rowe JM: Long term survival in acute myeloid leukemia: The Eastern Cooperative Group experience. Cancer 1997; 80:2205-2209.

488. *Novik Y, Oleksowicz L, Wiernik PH: Therapeutic effect of cyclosporin A in thrombocytopenia after myeloablative chemotherapy in acute myeloid leukaemia. Med Oncol 1997; 14:43-46.

489. Malik UR, Dutcher JP, Ratech H, Borowitz MJ, Wiernik PH: Epstein-Barr virus (EBV) positive clonal T-cell proliferation simulating T-cell malignant lymphoma. Med Oncol 1997; 13:207-214.

490. *Dutcher JP, Coletti D, Paietta E, Wiernik PH: A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia. Leukemia Res 1997; 21:375-380.

491. Sklarin NT, Lathia CD, Benson L, Grove WR, Thomas S, Roca J, Einzig AI, Wiernik PH: A phase I trial and pharmacokinetic evaluation of CI-980 in-patients with advanced solid tumors. Invest New Drugs 1997; 15:235-246.

492. Dutcher JP, Venkatraj U, Makower D, Wiernik PH: Interleukin-4 is a pleotropic cytokine with effects on B-cell malignancies. Leukemia Res 1997; 21:17-19. (Commentary)


85


493. Gucalp R, Dutcher JP, Wiernik PH: What are the imaging needs of the oncologist and oncologic surgeon ? Semin Nuclear Med 1997; 27:3-9.

494. *Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JE, Woods WG, Ogden A, Weinstein HJ, Shepherd L, Rowe JM, Wiernik PH: All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337:1021-1028.

495. Gallagher RE, Willman CL, Slack J, Andersen JW, Li Y-P, Viswanatha D, Bloomfield CD, Appelbaum FR, Schiffer CA, Tallman MS, Wiernik PH: Association of PML-RAR fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study. Blood 1997; 90:1656-1663.


496. Li Y-P, Andersen J, Zelent A, Rao S, Paietta E, Tallman MS, Wiernik PH, Gallagher RE: RAR1/RAR2-PML mRNA expression in acute promyelocytic leukemia cells: A molecular and laboratory-clinical correlative study. Blood 1997; 90:306-312.

497. Malik UR, Dutcher JP, Caliendo G, La Sala P, Mitnick R, Wiernik PH: Phase II trial of merbarone in patients with malignant brain tumors. Med Oncol 1997; 14:159-162.

498. O'Boyle KP, Wang Y, Schwartz EL, Regl DL, Einzig A, Dutcher JP, Wiernik PH, Horwitz SB: Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids. Cancer 1997; 79:1022-1030.

499. Sparano JA, Hu X, Wiernik PH, Sarta C, Reddy DM, Hanau L, Henry DH: Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy. J Natl Cancer Inst 1997; 89:301-307.

500. Berman E, Wiernik P, Vogler R, Velez-Garcia E, Bartolucchi A, Whaley FS: Long-term follow up of three randomized trials comparing idarubicin and daunorubicin for induction therapy for patients with untreated acute myelogenous leukemia. Cancer 1997; 80:2181-2185.

501. Paietta E, Racevskis J, Neuberg D, Rowe JM, Goldstone AH, Wiernik PH: Expression of CD25 (interleukin-2 receptor chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: Results of a preliminary laboratory analysis of ECOG/MRC intergroup study E2993. Leukemia 1997; 11:1887-1890.

502. Horowitz RW, Wadler S, Wiernik PH: A review of the clinical experience with


86


irinotecan (CPT-11). Am J Ther 1997; 4:203-210.

503. *Novik Y, Marino P, Makower DF, Wiernik PH: Familial erythroleukemia: a distinct clinical and genetic type of familial leukemias. Leukemia & Lymphoma 1998; 30:395-401.

504. Ozer H, Wiernik P, Giles F, Tendler C: Recombinant interferon alfa therapy in follicular lymphoma. Cancer 1998; 82:1821-1830.

505. Paietta E, Andersen J, Yunis J, Rowe JM, Cassileth PA, Tallman MS, Bennett JM, Wiernik PH: Acute myeloid leukemia expressing the leucocyte integrin CD11b: Result of an ECOG database analysis. Br J Haematol 1998; 100:265-272.


506. *Wiernik PH, Moore DF, Bennett JM, Vogl SE, Harris JE, Luger S, Oken MM, Glick JH: Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: An Eastern Cooperative Oncology Group study (PE481). Leukemia & Lymphoma 1998; 30:601-607.

507. Einzig AI, Wiernik PH, Wadler S, Kaplan J, Benson LT, Tentoramano L, Tan V: Phase I study of paclitaxel (Taxol) and granulocyte colony stimulating factor (G-CSF) in-patients with unresectable malignancy. Invest New Drugs 1998; 16:29-36.

508. Rosenthal MA, Green M, Wiernik PH, Borden EC, Marsh JC, Haller DG: Epirubicin has modest single agent activity in head and neck cancer but limited activity in metastatic melanoma and colorectal cancer: Phase II studies by the Eastern Cooperative Oncology Group. Am J Clin Oncol 1998; 21:509-512.

509. *Wiernik PH, Phillips V, Camacho FJ, Oken MM, O'Connell: Methylguazone, vindesine and cisplatin for the treatment of patients with relapsed or refractory malignant lymphoma: An Eastern Cooperative Oncology Group study (PA482). Leukemia & Lymphoma 1998; 30:619-624.

510. Gale RP, Park RE, Dubois R, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR: Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute lymphoblastic leukemia in first remission. Leuk Res 1998; 22:973-981.

511. *Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, Cassileth PA, Crowther D, Diehl V, Fisher RI, Hoppe RT, Jacobs P, Pater JL, Pavlovsky S, Thompson E, Wiernik PH: Meta-analysis of chemotherapy versus


87


combined modality treatment trials in Hodgkin's disease. J Clin Oncol 1998; 16:818-829.

512. *Makower D, Marino P, Frank M, Wiernik PH: Familial hairy cell leukemia. Leukemia & Lymphoma 1998; 29:193-197.

513. Ding W, Li Y-P, Nobile LM, Grills G, Carrera I, Paietta E, Tallman MS, Wiernik PH, Gallagher RE: Leukemic cellular retinoic acid resistance and missense mutations in the PML-RAR fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy, Blood 1998; 92:1172-1183.

514. *Wiernik PH, Dutcher JP, Einzig AI, Sparano JA, Frank M, Friedenberg W: Mitoxantrone, vinblastine and lomustine (CCNU) (MVC): A highly active regimen for advanced and poor prognosis Hodgkin's disease. Cancer J Sci Am 1998; 4:254-260.


515. Sparano JA, Wiernik PH, Hu X., Sarta C, Henry DH, Ratech H: Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in-patients with HIV-associated non-Hodgkin's lymphoma. Med Oncol 1998; 15:50-57.

516. *Dutcher JP, Lee S, Paietta E, Bennett JM, Stewart JA, Wiernik PH: Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group Study E1992. Leukemia 1998; 12:1037-1040.

517. *Deshpande HA, Hu X, Marino P, Jan NA, Wiernik PH: Anticipation in familial plasma cell dyscrasias. Br J Haematol 1998; 103:696-703.

518. *Paietta E, Racevskis J, Bennett JM, Neuberg D, Cassileth PA, Rowe JM, Wiernik PH: Biologic heterogeneity in Philadelphia chromosome positive acute leukemia with myeloid morphology: The Eastern Cooperative Oncology Group experience. Leukemia 1998; 12:1881-1885.

519. Dutcher JP, Wiernik PH, Huguet F, Polin V, Reiffers J, Sotto JJ, Stoppa AM, Mandelli F, Petti MC, Harousseau JL, Mercier M, Tellier Z, Berman E, Stagg M, Vogler WR, Bezwoda WR, Alison R, Clarke M, Evans V, Gray R, Greaves E, Hall E, Hicks C, james S, Peto R, Richards S, Sinclair D, Tooth A, Wheatley K for the AML Collaborative Group): A systematic collaborative overview of randomised trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol 1998; 103:100-109.

520. Zhou D, Hallam SJ, Lee SJ, Klein RS, Wiernik PH, Tallman MS, Gallagher RE: Constitutive expression of cellular retinoic acid binding protein II and lack of correlation with sensitivity to all-trans retinoic acid in acute promyelocytic leukemia cells. Cancer Res 1998; 58:5770-5776.


88


521. Wadler S, Haynes H, Rozenblit A, Hu XP, Kaleya R, Wiernik PH: Sequential phase II trials of fluorouracil and interferon B (ser) with or without sargramostim in patients with advanced colorectal carcinoma. Cancer J Sci Am 1998; 4:331-337.

522. *Wiernik PH, Greenwald ES, Ball H, Young JA, Vogl S: High-dose megestrol acetate in the treatment of patients with ovarian cancer who have undergone previous treatment. Am J Clin Oncol 1998; 21:565-567.

523. Jan N, Einzig A, Suhrland MJ, Wiernik PH: Non Hodgkin’s lymphpoma in acquired immunodeficiency syndrome manifesting as bilateral hypopyon. Am J Clin Oncol 1999; 22:82-83.


524. Huang X-J, Wiernik PH, Klein RS, Gallagher RE: Potentiation of arsenic trixoide-induced apoptosis by retinoic acid sensitive and resistant HL-60 myeloid leukemia cells. Med Oncol 1999; 16:58-64.

525. Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR: Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission. Leukemia Res 23:709-718, 1999.

526. Colovic MD, Wiernik PH, Jankovic GM, Vidovic AD, Janosevic S, Basara NM: Circulating haematopoietic progenitor cells in primary and secondary myelofibrosis: relation to collagen and reticulin fibrosis. Eur J Haematol 1999; 62:155-159.

527. Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR: Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in chronic myelogenous leukemia in chronic phase. Leukemia Res 1999; 23:817-826.

528. *Wiernik PH: The war on health (adapted from the Presidential Address to the American Radium Society, April 1994). Cancer Invest 1999; 17:164-169.

529. Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, Greenberg PL: Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 1999; 93:787-795.

530. Tallman MS, Lee S, Sikic BI, Paietta E, Wiernik PH, Bennett JM, Rowe JM:


89


Mitoxantrone, etoposide, and cytarabine plus cyclosporin for patients with relapsed or refractory acute myeloid leukemia: An Eastern Cooperative Oncology Group pilot study. Cancer 1999; 85:358-367.

531. *Wiernik PH, Gordon LI, Oken MM, Harris JE, O’Connell MJ: Evaluation of mitoguazone in patients with refractory chronic lymphocytic leukemia: a phase II study (P-H482) of the Eastern Cooperative Oncology Group. Leuk Lymphoma 1999; 35:375-377.

532. Horwitz M, Wiernik PH: Pseudoautosomal linkage of Hodgkin’s disease. Am J Hum Genet 1999; 65:1413-1422.

533. *Makower D, Malik U, Novik Y, Wiernik PH: Therapeutic efficacy of theophylline in chronic lymphocytic leukemia. Med Oncol 1999; 6:69-71.


534. Jankovic GM, Colovic MD, Wiernik PH, Antic NB, Rajic ZA, Vidovic AD, Pantic MD, Colovic NR: Multiple karyotypic aberrations in a polymorphous variant of Waldenstrom macroglobulinemia. Cancer Genet Cytogenet 1999; 111:77-80.

535. Advani R, Visani G, Milligan D, Saba H, Tallman M, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Covelli A, Sikic B, Greenberg P: Treatment of poor prognosis AML patients using PSC833 (valdospar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). Adv Exp Med Biol 1999; 457:47-56.

536. CLL Trialists’ Group: Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst 1999; 91: 861-868.

537. *Wiernik PH: Current status of and future prospects for the medical management of adenocarcinoma of the exocrine pancreas. J Clin Gastroenterol 2000; 30:357-363.

538. Badve S, Blumstein A, Wiernik P, Ratech H: Non-Hodgkin’s malignant lymphoma with tissue neutrophilia: A report of 3 cases. Arch Pathol Lab Med 2000; 124:735-738.

539. Robles C, Kim K-M, Oken MM, Bennett JM, Letendre L, Wiernik PH, O’Connell MJ, Cassileth PA: Low-dose cytarabine maintenance therapy versus observation after remission induction in advanced acute myeloid leukemia: An Eastern Cooperative Group Trial (E5483). Leukemia 2000; 14:1349-1353.

540. Lee S, Tallman MS, Oken MM, Cassileth PA, Bennett JM, Wiernik PH, Rowe JM: Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Leukemia 2000; 14: 1345-1348.


90


541. Lee S, Tallman MS, Oken MM, Cassileth PA, Bennett JM, Wiernik PH, Rowe JM: Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Leukemia 2000; 14: 1345-1348.

542. *Wiernik PH, Wang SQ, Hu X-P, Marino P, Paietta E: Age of onset evidence for anticipation in familial non-Hodgkin’s lymphoma. Br J Haematol 2000; 108:72-79.

543. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Rowe JM, Francois C, Larson RS, Wiernik PH: Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000; 95:90-95.


544. Tallman MS, Neuberg D, Bennett JM, Francois C, Paietta E, Wiernik PH, Dewald G, Cassileth PA, Oken MM, Rowe JM: Acute megakaryocytic leukemia: The Eastern Cooperative Oncology Group experience. Blood 2000; 96:2405-2411.

545. *Etkind P, Du J, Khan A, Pillitteri J, Wiernik PH: Mouse mammary tumor virus-like ENV gene sequences in human breast tumors and in a lymphoma of a breast cancer patient. Clin Cancer Res 2000; 6:1273-1278.

546. *Dutcher JP, Wiernik PH: Accelerated and blastic phase of chronic myeloid leukemia. Current Treat Options Oncol 2000; 1:51-62.

547. *Wiernik PH, Hu X, Ratech H, Fineberg S, Etkind P, Walewski JA: Non-Hodgkin’s lymphoma in women with breast cancer. Cancer J 2000; 6:336-342.

548. Dutcher JP, Novik Y, O’Boyle K, Marcoullis G, Secco C, Wiernik PH: Twentieth century advances in drug therapy in oncology. Part I. J Clin Pharmacol 2000; 40:1007-1024.

549. Dutcher JP, Novik Y, O’Boyle K, Marcoullis G, Secco C, Wiernik PH: Twentieth century advances in drug therapy in oncology. Part II. J Clin Pharmacol 2000; 40:1079-1092.

550. Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S, Wiernik PH, Chiaramida S: Torsade de pointes in three leukemia patients treated with arsenic trioxide. Blood 2001; 97:1514-1516.

551. *Wiernik PH, Leong T, Oken MM, Neiman RS, Habermann TM, Bennett JM, Schuster S, Glick JH: Bleomycin, lomustine, cyclophosphamide, vincristine,


91


procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin’s disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481). Leuk Lymphoma 2001; 40:357-363.

552. *Wiernik PH, Ashwin M, Hu X-P, Paietta E, Brown K: Anticipation in familial chronic lymphocytic leukaemia. Br J Haematol 2001; 113:407-414.

553. Rajdev L, Yu Z-F, Wadler S, Weller E, Kahn SB, Tormey D, Skeel R, Wiernik PH: N-methylformamide in advanced squamous cancer of the uterine cervix: An Eastern Cooperative Oncology Group phase II trial. Invest New Drugs 2001; 19:233-237.


554. Paietta E, Neuberg D, Richards S, Bennett JM, Han L, Racevskis J, Dewald G, Rowe JM, Wiernik PH: Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity. Am J Hematol 2001; 66:189-196.

555. Giantonio BJ, Hochster H, Blum R, Wiernik PH, Hudes GR, Kirkwood J, Trump D, Oken MM: Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: A report of two clinical trials of the Eastern cooperative Oncology Group. Invest New Drugs 2001; 19:89-92.

556. *Wiernik PH: Treatment of HIV-related lymphoma. Semin Hematol 2001; 38(suppl 10):27-31.

557. *Xu Y, Wiernik PH: Systemic lupus erythematosis and B-cell hematologic neoplasm. Lupus 2001; 10:841-850.

558. Weisdorf D, Bishop M, Dharan B, Bolwell B, Cahn JY, Cairo M, Giralt S, Klein J, Lazarus H, Litzow M, Marks D, McCarthy P, Miller C, Milone G, Russell J, Schultz K, Sierra J, Wiernik P, Keating A, Loberiza F, Kollman C, Horowitz M: Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: Comparative toxicity and outcomes. Biol Blood Marrow Transplant 2002; 8:213-220.

559. *Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH: All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100:4298-4302.


92


560. Marcoullis G, Abebe L, Jain D, Talusan R, Bhagwati N, Wiernik PH: Microangiopathic hemolysis refractory to plasmapheresis responding to docetaxel and cisplatin. Med Oncol 2002; 19:189-192.

561. Salman H, Perez A, Sparano JA, Ratech H, Negassa A, Hopkins U, Villani G, Fuks J, Wiernik PH: Phase II trial of infusional cyclophosphamide, idarubicin and etoposide in poor prognosis non-Hodgkin’s lymphoma. Am J Clin Oncol 2003; 26:338-343.

562. Reece DE, Bredeson C, Perez WS, Jagannath S, Zhang MJ, Ballen KK, Elfenbein GJ, Freytes CO, Gale RP, Gertz MA, Gibson J, Giralt SA, Keating A, Kyle RA, Maharaj D, Marcellus D, McCarthy PL, Milone GA, Nimer SD, Pavlovsky S, To LB, Weisdorf DJ, Wiernik PH, Wingard JR, Vesole DH: Autologous stem cell transplantation in multiple myeloma. Patients < 60 versus > 60 years of age. Bone Marrow Transplant 2003; 32:1135-1143.


563. *Wiernik PH, Cassileth PA, Leong T, Hoagland HC, Bennett JM, Paietta E, Oken M: A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group study (E3486). Leukemia & Lymphoma 2003; 44:1515-1521.

564. Paietta E, Neuberg D, Bennett JM, Dewald G, Rowe JM, Cassileth PA, Cripe L, Tallman MS, Wiernik PH: Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: Study of 711 patients enrolled in ECOG trials. Leukemia 2003; 17:1544-1550.

565. *Abbasi MR, Sparano JA, Sarta C, Wiernik PH: Phase I trial of fludarabine and paclitaxel in non-Hodgkin’s lymphoma. Med Oncol 2003; 20:53-58.

566. Radin AI, Kim HT, Grant BW, Bennett JM, Stewart JA, Hahn RG, Kirkwood J, Dutcher JP, Wiernik PH, Oken MM: Phase II study of alpha-2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): A trial of the Eastern Cooperative Oncology Group. Cancer 2003; 98:100-109.

567. Dorai T, Dutcher JP, Dempster DW, Wiernik PH: Therapeutic potential of curcumin in prostate cancer. IV: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate 2004; 60:1-17.

568. Ferrando AA, Neuberg DS, Dodge RK, Paietta E, Larson RA, Wiernik PH, Rowe JM, Caliguri MA, Bloomfield CD, Look AT: Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet 2004; 363:535-536.


93


569. *Etkind PR, Stewart AFR, Dorai T, Purcell DJ, Wiernik PH: Clonal isolation of different strains of mouse mammary tumor virus-like DNA sequences from both breast tumors and non-Hodgkin’s lymphomas of individual patients diagnosed with both malignancies. Clin Cancer Res 2004; 10:5656-5664.

570. Paietta E, Ferrando AA, Neuberg D, Bennett JM, Racevskis J, Lazarus H, Dewald G, Rowe JM, Wiernik PH, Tallman M, Look AT: Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood 2004; 104:558-560.

571. *Unnikrishnan D, Dutcher JP, Garl S, Varshneya N, Lucariello R, Wiernik PH: Cardiac monitoring of patients receiving arsenic trioxide therapy. Br J Haematol 2004; 124:610-617.


572. *Karbasian-Esfahani M, Wiernik PH, Novik Y, Dutcher JP: Idarubicin (IDA) and standard dose cytosine arabinoside (AraC) in relapsed and refractory adult acute lymphocytic leukemia (ALL). Cancer 2004; 101:1414-1419.

573. Tallman MS, Kim HT, Paietta E, Bennett JM, Dewald G, Cassileth PA, Wiernik PH, Rowe JM: Acute myeloid leukemia FAB M5 does not have a worse prognosis than other subtypes. J Clin Oncol 2004; 22:1276-1286.

574. *Wiernik PH: Second neoplasms in patients with chronic lymphocytic leukemia. Curr Treat Options Oncol 2004; 5:215-223.

575. *Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, Liesveld JL, Abboud CN, Dewald G, Hayes FA, Tallman MS, Wiernik PH: A phase III study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia. A trial by the Eastern Cooperative Oncology Group. Blood 2004; 103:479-485.

576. Paietta E, Goloubeva O., Bennett JM, Gallagher R, Racevskis J, Dewald G, Wiernik PH, Tallman MS: A surrogate marker profile for PML/RAR expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. Cytometry 2004; 59B:1-9.

577. Vose JM, Rizzo JD, Tao-Wu J, Armitage JO, Bashey A, Burns LJ, Christiansen NP, Freytes CO, Gale RP, Gibson J, Giralt SA, Herzig RH, LeMaistre CF, McCarthy Jr PL, Nimer SD, Petersen FB, Schenkein DP, Wiernik PH, Wiley JM, Loberiza FR, Lazarus HM, van Biesen K, Horowitz MM: Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant 2004; 10:116-127.


94


578. *Wiernik PH, Paietta E, Goloubeva O, Lee SJ, Makower D, Bennett JM, Wade JL, Ghosh C, Kaminer LS, Pizzolo J, Tallman MS: Phase II study of theophylline in chronic lymphocytic leukemia. A study of the Eastern Cooperative Oncology Group (E4998). Leukemia 2004; 18:1605-1610.

579. *Alexandrescu DT, Dutcher JP, Hughes JT, Kaplan J, Wiernik PH: Strokes after intravenous gamma globulin: thrombotic phenomenon in patients with risk factors or just conincidence? Am J Hematol 2005; 78:216-220.

580. *Dutcher JP, Lee S, Gallagher R, Makary A, Hines J, Londer H, Farnen J, Bennett J, Paietta E, Rowe J, Goloubeva O, Wiernik P: Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia. A study of the Eastern Cooperative Oncology Group (E1993). Leuk Lymphoma 2005; 46:377-385.


581. Koulova L, Alexandrescu D, Dutcher JP, O’Boyle KP, Eapen S, Wiernik PH: Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): Report of three cases. Am J Hematol 2005; 78:49-54.

582. *Sparano JA, Negassa A, Lansigan E, Locke R, De Silva CR, Wiernik PH: Phase I trial of infusional cyclophosphamide, doxorubicin and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin’s lymphoma. Med Oncol 22:257-268, 2005.

583. Alexandrescu DT, Maddukuri P, Wiernik PH, Dutcher JP: Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome associated with high-dose interleukin-2 for the treatment of metastatic melanoma. J Immunother 2005; 28:144-147.

584. Lynch HT, Watson P, Tarantolo S, Wiernik PH, Quinn-Laquer B, Bergsagel KI, Huiart L, Olopade OI, Sobol H, Sanger W, Hogg D, Weisenburger D: Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol, 2005; 23:685-693.

585. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, Prentice HG, Durrant J, Tallman MS, Goldstone AH: Induction therapy for adults with acute lymphoblastic leukemia: Results of more than 1,500 patients from the international ALL trial (MRC UKALL XII / ECOG2993). Blood 2005; 106:3760-3767.

586. Baker KS, Loberiza FR, Yu H, Cairo MS, Bolwell BJ, Bujan-Boza WA, Camitta BM, Garcia JJ, Ho WG, Liesveld JL, Maharaj D, Marks DI, Schultz KR, Wiernik P, Zander


95


AR, Horowitz MM, Keating A, Weisdorf DJ: Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem cell transplantation in the United States. J Clin Oncol 2005; 23:7032-7042.

587. Koulova L, Novik Y, Caliendo G, Wiernik PH, Dutcher JP: A phase II study of moderate dose IL-2 and granulocyte-macrophage colony-stimulating factor in patients with metastatic or unresectable renal cell carcinoma. J Immunother 2005; 28:576-581.

588. *Wiernik PH, Etkind PR: The association between breast cancer and lymphoma. Clin Adv Hematol Oncol 2005; 3:695-696.

589. Alexandrescu DT, Dutcher JP, Wiernik PH: Metastatic melanoma: is biochemotherapy the future? Med Oncol 2005; 22:101-112.


590. Dorai T, Sawczuk I, Pastorek J, Wiernik PH, Dutcher JP: Role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer 2005; 18: 2935-2947.

591. Alexandrescu DT, Karri S, Wiernik PH, Dutcher JP: Mitoxantrone, vinblastine and CCNU (MVC): Long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin’s disease. Leuk Lymphoma 2006; 47: 641-656.

592. Lazarus HM, Richards SM, Cook L, Chopra R, Litzow MR, Burnett AK, Wiernik PH, Franklin IM, Tallman MS, Buck G, Durrant IJ, Rowe JM, Goldstone AH: Adult acute lymphoblastic leukemia patients who present with central nervous system involvement at diagnosis do not have a worse prognosis. Results from the international ALL trial MRC UKALL-XII/ ECOG E2993. Blood 2006; 108:465-472.

593. Henschke C, Lee I-J, Wu N, Farooqi A, Khan A, Yankelevitz D, Altorki NK, Libby D, McCauley DI, McGuinness G, Naidich D, Miettinen OS, Pasmantier MW, Smith JP, Vazquez M, Rifkin M, Fiori E, Kopel S, Klippenstein D, Litwin A, Loud PA, Kohman L, Scalzetti EM, Shah R, Austin JHM, Pearson GDN, Shiau MC, Mendelson DS, Heelan R, Ginsberg MS, Matalon TAS, Wiernik PH: CT screening for lung cancer: prevalence and incidence of mediastinal masses. Radiol 2006; 239: 586-590.

594. *Alexandrescu DT, Garino A, Brown-Balem KA, Wiernik PH: Anticipation in families with Hodgkin’s and non-Hodgkin’s lymphoma in their pedigrees. Leuk Lymphoma 2006; 47:2115-2127.

595. Kunthur A, Wiernik PH, Dutcher JP: Renal parenchymal tumors and lymphoma in the same patient: A case series and review of the literature. Am J Hematol 2006; 81:271-280.


96


596. O’Boyle KP, Coatsworth S, Anthony G, Ramirez M, Greenwald E, Kaleya R, Steinberg JJ, Dutcher JP, Wiernik PH: Effects of desialylation of ovine submaxillary gland mucin (OSM) on humoral and cellular immune responses to Tn and sialylated Tn. Cancer Immunol 2006; 6:5.

597. Dorai T, Sawczuk I, Pastorek J, Wiernik PH, Dutcher JP: Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis. Cancer Invest 2006; 24:1-26.

598. Dasanu CA, Alexandrescu DT, Wiernik PH: Recognizing nail and skin changes associated with chemotherapy. Resident & Staff Phys 2006; 52:16-20.

599. *Karbasian-Esfahani M, Morris EL, Dutcher JP, Wiernik PH: Blastic phase of chronic myelogenous leukemia. Curr Treat Options Oncol 2006; 7:189-199.


600. Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF: Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin’s lymphoma resulting in durable clinical responses. J Clin Oncol 2006; 24:3107-3112.

601. *Wiernik PH: Plasma cell dyscrasia and leukemia, in: Giaccone G, Schilsky R, Sondel P (eds), Update on Cancer Therapeutics 2006; Elsevier Science, Amsterdam, 1:339-367.

602. Hall MJ, Li L, Wiernik PH, Olopade I: BRCA2 mutation and the risk of hematologic malignancy. Leuk Lymphoma 2006; 47:765-767.

603. Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik P, Rowe JM, Goldstone AH, O’Dwyer P, Paietta E, Sikic BI: Differential gene expression patterns and interaction networks in BCR/ABL- positive and -negative adult acute lymphoblastic leukemias J Clin Oncol 2007; 25:1341-1349.

604. *Alexandrescu DT, Wiernik PH: The influence of parental age and gender on anticipation in familial B-cell malignancies. Med Oncol 2007; 24:55-62.

605. Moorman AV, Harrison CJ, Richards SM, Secker-Walker LM, Martineau M, Vance G, Cherry A., Higgins R, Fielding A, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW: Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia (ALL): Analysis of cytogenetic data from over 1,500 patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood


97


2007; 109:3189-3197.

606. *Wiernik PH: Plasma cell dyscrasia and leukemia, in: Giaccone G, Schilsky R, Sondel P (eds), Update on Cancer Therapeutics 2007; 2: 73-99.

607. Henschke CI, Yankelevitz DF, McCauley DI, Rifkin M, Fiore ES, Austin JHM, Pearson GDN, Shiau MC, Kopel S, Klippenstein D, Litwin A, Loud PA, Kohman LJ, Scalzetti EM, Khan A, Shah R, Mendelson DS, Heelan RT, Ginsberg MS, Matalon TAS, Wiernik PH, Altorki N, Farooqi A, Faustini Y, Libby DM, Miettinen OS, Ostroff J, Pasmantier MW, Reeves AP, Smith JP, Vasquez MF, Yip R, Angello KK, Kramer AL, Hess JM, Carter D, Brambilla E, Gazdar A, Noguchi M, Travis WD: CT screening for lung cancer: Diagnoses resulting from the New York Early Lung Cancer Action Project. Radiol 2007; 243:239-249.


608. Bishop MR, Logan BR, Gandham S, Bolwell BJ, Cahn J-Y, Lazarus HM, Litzow MR, Marks DI, Wiernik PH, McCarthy PL, Russell JA, Miller CB, Sierra J, Milone G, Keating A, Loberiza Jr FR, Giralt S, Horowitz MM, Weisdorf DJ: Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant 2008; 41:635-642.

609. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding A, Burnett AK, Chopra R, Wiernik PH, Foroni L, Paietta E, Litzow MR, Marks DI, Durrant J, McMillan A, Franklin IM, Luger S, Ciobanu N, Rowe JM: In adults with standard-risk acute lymphoblastic leukemia (ALL) the greatest benefit is achieved from a matched sibling allogeneic transplant in first complete remission (CR) and an autologous transplant is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the international ALL trial (MRC UKALL XII/ECOG E2993. Blood 2008; 111:1827-1833.

610. *Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM: Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2008; 26:4952-4957.

611. Figueroa ME, Reimers M, Thompson RF, Ye K, Li Y, Selzer RR, Fridriksson J, Paietta E, Wiernik P, Green RD, Greally JM, Melnick A: An integrative genomic and epigenomic approach for the study of transcriptional regulation. PloS ONE 2008; 3:e1882.


98


612. Marks DI, Perez WS, He W, Z M-J, Bishop MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Keating A, Klumpp T, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ: Unrelated donor stem transplantation for adults with Philadelphia chromosome negative acute lymphoblastic leukemia in first complete remission: A Center of the International Blood and Marrow Transplant Research analysis. Blood 2008; 112:426-434.

613. *Etkind PR, Stewart AAF, Wiernik PH: Mouse mammary tumor virus (MMTV)-like DNA sequences in the breast tumors of father, mother and daughter. Infectious Ag Cancer 2008; 3:2.


614. Smith SM, van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, Gale RP, Hale GA, Hayes-Lattin B, Holmberg LA, Keating A, Maziarz RT, McCarthy PL, Navarro WH, Pavlovsky S, Schouten HC, Seftel M, Wiernik PH, Vose JM, Lazarus HM, Hari P: Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant 2008; 14:904-912.

615. *Wiernik PH: Serum CA125 and PSA concentrations in patients with lymphoma. Clin Adv Hematol Oncol 2008; 6:527-531.

616. *Alexandrescu DT, Wiernik PH: Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia. Med Oncol 2008; 25:309-314.

617. Kumar S, Perez WS, Zhang M-J, Ballen K, Bashey A, To LB, Bredeson CN, Cairo MS, Elfenbein GJ, Freytes CO, Gale RP, Gibson J, Kyle RA, Lacy MQ, Lazarus HM, McCarthy PL, Milone GA, Moreb JS, Pavlovsky S, Reece DE, Vesole DH, Wiernik PH, Hari P: Comparable outcomes in non-secretory and secretory multiple myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant 2008; 14:1134-1140.

618. Fielding AK, Rowe JM, Richards SM, Buck G, Durrant IJ, Foroni L, Franklin I, marks DI, McMillan AK, Moorman AV, Litzow MR, Luger SM, Lazarus H, Paietta E, Wiernik PH, Tallman MS, Goldstone AH: Prospective outcome data on 267 unselected patients with Philadelphia-chromosome positive adult acute lymphoblastic leukaemia confirms superiority of allogeneic transplant over chemotherapy: The pre-imatinib era results from the international ALL trial MRC UKALLXII/ECOG2993. Blood 2009; 113:4489-4496.


99


619. *Wiernik PH: Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDS). Curr Treat Options Oncol 2009; 10:1-15.

620. Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, Wride K, Ervin-Haynes A, Takeshita K, Pietronigro D, Zeldis JB, Tuscano JM: Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009; 145:344-349.

621. Kane GC, Grever MR, Kennedy JI, Kuzma MA, Saltzman AR, Wiernik PH, Baptista NV: The anticipated physician shortage: Meeting the nation’s needs for physician services. Am J Med 2009; 122:1156-1162, 2009.


622. Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, Jenkinson S, Allen CG, Gale RE, Linch DC, Palomero T, Real P, Murty V, Yao X, Richards SM, Goldstone A, Rowe J, Basso G, Wiernik PH, Paietta E, Pieters R, Horstmann M, Meijerink JPP, Ferrando A: WT1 mutations in T-ALL. Blood 2009; 114:1038-1045.

623. Gregory J, Kim H, Alonzo T, Gerbing R, Woods W, Weinstein H, Shepherd L, Schiffer C, Applebaum F, Willman C, Wiernik P, Rowe J, Tallman M, Feusner J: Treatment of children with acute promyelocytic leukemia: Results of the first North American Intergroup trial INT0129. Pediatr Blood Cancer 2009; 53:1005-1010.

624. Salipante SJ, Mealiffe ME, Wechsler J, Krem MM, Liu Y, Namkoong S, Bhagat G, Kirchhoff T, Offit K, Lynch H, Wiernik PH, Roshal M, McMaster M, Tucker M, Fromm JR, Goldin LR, Horwitz MS: Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells. Proc Natl Acad Sci (USA) 2009; 106:14920-14925.

625. Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM: Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant 2009; 15:1455-1464.

626. *Wiernik PH, Hong F, Glick JH, Bennett JM: Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin’s lymphoma: A study by the Eastern Cooperative Oncology Group (E1476)


100


with >20 years follow-up. Leukemia & Lymphoma 2009; 50:1632-1641.

627. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Vose JM: Phase II multi-center study of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol 2009; 27:5404-5409

628. *Dutcher JP, Morris EL, Gaynor B, Paietta E, Wiernik PH: A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia. Med Oncol 2010, 27:728-735.

629. Koc ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Carter WD, Gold DP, Stewart ME, Ghalie RG, Bender JF: A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. J Immunother 2010; 33:178-184.


630. Reece DE, Vesole DH, Shrestha S, Zhang M-J, Perez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, Lohar PV, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hari PN: Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplants: A retrospective CIBMTR study. Clin Lymphoma Myeloma Leuk 2010; 10:458-463.

631. Hari PN, Majhail NS, Zhang M-J, Hassebroek A, Siddiqui F, Ballen K, Bashey A, Bird J, Freytes CO, Gibson J, Hale G, Holmberg L, Kamble R, Kyle RA, Lazarus HM, LeMaistre CF, Loberiza F, Maiolino A, McCarthy PL, Milone G, Omondi N, Reece DE, Seftel M, Trigg M, Vesole D, Weiss B, Wiernik P, Lee SJ, Rizzo JD, Mehta P: Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2010; 16:395-402.

632. Van Vlieberghe P, Palomero T, Khiabanian H, Van der Meulen J, Castillo M, Van Roy N, De Moerloose B, Phillipe J, González-García S, Toribio ML, Taghon T, Zuurbier L, Cauwelier B, Harrison CJ, Schwab C, Pisecker M, Strehl S, Langerak AW, Gecz J, Sonneveld E, Pieters R, Paietta E, Rowe J, Wiernik PH, Benoit Y, Soulier J, Poppe B, Yao X, Cordon-Cardo C, Meijerink J, Rabadan R, Speleman F, Ferrando A: PHF6 mutations in T-cell acute lymphoblastic leukemia. Nature Genetics 2010; 42:338-342.

633. Rowe JM, Kim HT, Cassileth PA, Lazarus HM, Litzow MR, Wiernik PH, Tallman MS: Adult patients with acute myeloid leukemia who achieve complete remission sfter either 1 or 2 cycles of induction therapy have a similar prognosis: A report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative oncology


101


Group. Cancer 2010; 116:5012-5021.

634. *Wiernik PH: FLT3 kinase inhibitors in the treatment of acute myeloid leukemia. Clin Adv Hematol Oncol 2010; 8:429-437.

635. Ballen KK, Shrestha S, Sobocinski KA, Zhang M-J, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kröger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M: Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16:358-367.

636. *Wiernik PH, Dutcher JP, Yao X, Venkatraj U, Falkson CI, Rowe J, Cassileth PA: Phase II study of interleukin-4 in indolent B-cell non-Hodgkin’s lymphoma and B-cell chronic lymphocytic leukemia: A study of the Eastern Cooperative Oncology Group (E5Y92). J Immunother 2010; 33:1006-1009.


637. Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH, Gonzalez M, Gallagher R, Gonzalez-San Miguel JD, Larson RA, Milone G, Paietta E, Rayon C, Rowe JM, Rivas C, Schiffer CA, Vellenga E, Shepherd L, Slack JL, Wiernik PH, Willman CL, Sanz MA: Does microgranular morphology of acute promyelocytic independently predict for a less favorable outcome compared with classical M3 APL?: A joint study of the North American Intergroup and the PETHEMA group. Blood 2010; 116:5650-5659.

638. Adiga GU, Rehman KL, Wiernik PH: Permanent localized hair repigmentation following herpes zoster. Arch Dermatol 2010; 146:569-570.

639. De Keeremaecker K, Real PJ, Gatta GD, Palomero T, Sulis ML, Tosello V, Van Vierberghe P, Barnes K, Castillo M, Sole X, Hadler M, Lenz J, Aplan PD, Kelliher M, Kee B, Pandolfi PP, Kappes D, Gounan F, Petrie H, Van der Meulen J, Speleman F, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Soulier J, Avran D, Cavé H, Dastugue N, Raimondi S, Meijerink J, Cordon-Cardo C, Califano A, Ferrando AA: The TLX1 oncogene drives aneuploidy in T-cell transformation. Nature Medicine 2010; 16:1321-1327.

640. *Wiernik PH, Elkadi D, Luongo-Cespedes A, Battistoni J, Rossi S, Caceres S, Platero R, Piriz N, Lamas A: Detection of a new embryonic antigen (ESA-10) in the blood of patients with cancer: Preliminary results in the United States. Medical Oncol 2011; 28:67-70.

641. Kumar S, Zhang M-J, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan AY,


102


Malolino A, Wirk B, Weiss BM, Freytes CO, Vogl DT, Vesole DH, Lazarus HM, Meehan KR, Hamadani M, Lill M, Callander NS, Majhail NS, Wiernik PH, Nath R, Kamble R, Vij R, Kyle RA, Gale RP, Hari P: Trends in allogeneic stem cell transplantation for multiple myeloma: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011; 118:1979-1988.

642. Wiernik PH*, Adiga GU: Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia. Curr Med Res Opin 2011; 27:1987-1993.

643. Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, Haydu E, Rigo I, Hadler M, Tosello V, Gatta GD, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Rue M, Ferrando AA: ETV6 mutations in early immature T-cell leukemias. J Expl Med 2011; 208:2571-2579.


644. Farag SS, Maharry K, Zhang MJ, Perez WS, George SL, Mrόzek K, DiPersio J, Bunjes DW, Marcucci G, Baer MR, Copelan E, Cutler CS, Isola L, Lazarus HM, Litzow MR, Marks DI, Ringdén O, Rizzieri DA, Soiffer R, Larson RA, Tallman MS, Bloomfield CD, Weisdorf DJ, Artz A, Bredeson C, Gale RP, Gupta V, Jakubowski A, Klumpp T, Schiller G, Wiernik P: Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2011; 17:1796-1803.

645. Della Gatta G, Palomero T, Perez-Garcia A, Ambesi-Impiombato A, Bansal M, Carpenter ZW, De Keersnaecker K, Sole X, Xu L, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Meijerink JP, Califano A, Ferrando AA: Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nat Med 2012; 18:436-440.

646. Samon JB, Castillo-Martin M, Hadler M, Ambesi-Impiombato A, paietta E, Racevskis J, Wiernik PH, Rowe JM, Jakubczak JL, Randolph S, Cordon-Cardo C, Ferrando AA: Preclinical analysis of the gamma-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther 2012; 11: 1565-1575.

647. Haydu JE, De Keersmaecker K, Duff MK, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Ferrando A: An activating intragenic deletion in NOTCH1 in human T-ALL. Blood 2012; 119:5211-5214.

648. Wiernik PH*, Sun Z, Gundacker H, Dewald G, Slovak ML, Paietta E, Kim HT, Appelbaum FR, Cassileth PA, Tallman MS: Prognostic implications of additional


103


chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17). Med Oncol 2012; 29:2095-2101.

649. Foran JM, Pavletic SZ, Logan BR, Agovi-Johnson MA, Perez WS, Bredeson CN, Copelan EA, Dehn J, Gale RP, George B, Gupta V, Hale GA, Lazarus HM, Marks DI, Martino R, Maziarz RT, Rowlings PA, Waller EK, Wiernik PH, Weisdorf DJ: Secondary unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myeloid leukemia: A study from the CIBMTR. Blood 2012, in press.

650. Wiernik PH*, Li H, Weller E, Hochster HS, Horning SJ, Nazeer T, Gordon LI, Habermann TM, Minniti CJ, Shapiro GR, Cassileth PA: Activity of toptecan 21-day infusion in patients with previously treated large cell lymphoma: Long-term follow-up of an Eastern Cooperative Oncology Group Study (E5493). Leukemia and Lymphoma 2012; 53:1137-1142.


651. Henschke CI, Yankelevitz DF, Yip R, Reeves AP, Farooqi A, Xu D, Smith JP, Libby DM, Pasmantier MW, Miettinen OS, Zhang L, mendelson DS, Mc Cauley DI, Chenm M, Biancardi A, Miller A, Shuzuke S, Hanaoka T, Zulueta J, Montuenga L, Bastarrika G, Hiunta S, Aye R, Austin JH, N GD, Cole E, McGuinness G, Aylesworth C, Rifkin M, Kopel S, Klippenstein D, Loud P, Litwin A, Kohman LJ, Scalzetti EM, Sheppard B, Thorsen M, Kham A, Shah R, Thurer R, Vafai D, Liu X, Andaz S, Deval JC, Smith MV, Meyers P, Yeh DY, Luedke D, Ginsberg MS, Matalon TA, Odzer SL, Mayfield W, Grannis F, Rotter A, Ray D, Olson D, Salvatore M, Wiernik PH, Korst R, Mullen D, DeCunzo L, Pass H, Endress C, Kalafer M, Straznicka M, Lim M, Cecchi G, Koch A, Scheinberg P, Cheung E: Lung cancers diagnosed at annual CT screening: volume doubling times. Radiology 2012; 263:578-583.

652. Bacher U, Klyuchnikov ES, Le-Rademacher, Carreras JA, Armand P, Bishop MR, Bredeson CN, Cairo MS, Fenske, TS Freytes CO, Gale RP, Gibson JN, Isola LM, Inwards DJ, Laport GG, Lazarus HM, Maziarz RT, Wiernik PH, Schouten HC, Slavin S, Smith SM, Vose JM, Waller EK, Hari PN: Conditioning regimens for allotransplants for diffuse large B-cell lymphoma–myeloablative or reduced intensity?Blood2012;120:4256-4262.

653. Dy IA, Wiernik PH: Cocaine-levamisole thrombotic vasculopathy. Semin Thromb Hemost 2012; 38:780-782.

654. Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H, Allawadhi S, Akard L, Baer M, Baccarani M, Emmons R, Etienne G, Guerci A, Guilhot F, Hellman A, Huget-Rigal F, Khoury H, Laneuville P, Coutre PL, Legros L, Leitner A, Maloisel F, Marin D,


104


Masszi T, Parikh P, Rivera C, Rousselot P, Facon T, Van Etten R, Warzocha K, Wetzler M, Wiernik P: Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 2012; 120:2573-2580.

655. Marks DI, Moorman AV, Chilton L, Paietta E, Enshaie A DeWald G, Harrison C, Fielding AK, Foroni L, Goldstone AH, Litzow MR, Luger SM, McMillan AK, Racevskis J, Rowe JM, Tallman MS, Wiernik P, Lazarus HM: The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated on UKALLXII/ECOG2993. Haematologica 2013; 98:945-952.


656. Smith SM, Burns LJ, van Besien KM, LeRademacher J, He W, Fenske TS, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PN: Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 2013; 31:3100-3109.

657. *Douer D, Zickl LN, Schiffer CA, Appelbaum FR, Feusner JH, Shepherd L, Willman CL, Bloomfield CD, Paietta E, Gallagher RE, Park JH, Rowe JM, Wiernik PH, Tallman MS: All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American intergroup study I0129. Leuk Res 2013; 37:795-801.

658. Foran JM, Pavletic SZ, Logan BR, Agovi-Johnson MA, Pérez WS, Bolwell BJ, Bornhäuser M, Bredeson CN, Cairo MS, Camitta BM, Copelan EA, Dehn J, Gale RP, George B, Gupta V, Hale GA, Lazarus HM, Litzow MR, Maharaj D, Marks DI, Martino R, Mazizrz RT, Rowe JM, Rowlings PA, Savani BN, Savoie ML, Szer J. Waller EK, Wiernik PH, Weisdorf DJ: Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myeloid leukemia: A study from the CIBMTR. Biol Blood Marrow Transplant 2013; 19:1102-1108.

659. Wirk B, Fenske TS, Hamadani M, Hu Z-H, Alpek G, Aljurf MD, Armand P, Ayala E, Machanova V, Bolwell B, Cairo MS, Cashen A, Chen Y-B, Costa LJ, Farhan S, Freytes CO, Gajewski JL, Gibson J, Hale GA, Holmberg LA, Hsu JW, Inwards DJ, Kamble RT, Maharaj D, Maziarz RT, Munker R, Nath R, Reddy NM, Reeder CB, Rizzieri DA, Sauter CS, Savani BN, Schouten HC, Sureda A, Vose JM, Waller EK,


105


Wiernik PH, Gale RP, Burns LJ, Saber W: Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. Biol Blood Marrow Transplant 2014; in press.

660. Bacanova V, Marks DI, Zhang M-J, Wang H, De Lima M, Aljuri MD, Arellano M, Artz AS, Bacher U, Cahn J-Y, Chen Y-B, Copelan EA, Drobyski W, Gale RP, Greer JP, Gupta V, Hale GA, Kebriaei P, Lazarus HM, Lewis ID, Lewis VA, Liesveld JL, Litzow MR, Loren AW, Miller AM, Norkin M, Oran B, Pidala J, Rowe JM, Savani BN, Saber W, Vij R, Waller EK, Wiernik PH, Weisdorf DJ: Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allotransplantation: impact of imatinib and minimal residual disease. Leukemia 2014; 28: 658-665.


661. Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, Hale GA, Maharaj D, Gale RP, Rowlings PA, Freytes C, Miller AM, Vose JM, Maziarz RT, Montoto S, Maloney DG, Hari PN: Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant 2014; 49: 1360-5.

662. Altorki NK, Yip R, Hanaoka T, Bauer T, Aye R, KOhman L, Sheppard B, Thurere R, Andaz S, Smith M, Mayfield W, Grannis F, Korst R, Pass H, Stranznicka M, Flores R, Henschke CI, Yankelevitz DF, Yip R, Mendelson DS, Miettinen OS, McCauley DI, Chen M, Libby DM, Smith JP, Pasmantier M, Reeves A, Biancardi A, Markowitz S, Miller A, Stone S, Roberts H, Patsios D, Zulueta J, Montuenga L, Lozano MD, Care C, Bauer T, Giunta S, Klingler K, Aye R, Austin JH, Pearson GD, Shaham D, Cole E, Naidich D, McGuinness G, Aylesworth C, Rifkin M, Kopel S, Klippenstein D, Litwin A, Loud PA, Kohman LJ, Scalzetti EM, Schneider DE, Sheppard B, Thorsen M, Hamsen R, Khan A, Shah R, Thurer R, Vafai D, Liu X, Andaz S, Deval JC, Smith MV, Meyers P, Yeh D, Luedke D, Heelan RT, Ginsberg MS, Matalon TA, Odzer SL, Mayfield W, Grannis F, Rotter A, Ray D, Olsen D, Salvatore M, Wiernik PH, Korst R, Mullen D, De Cunzo L, pass H, Endress C, Kalafer M, Stranznicka M, Lim M, Cecchi G, Koch A, Scheinberg P, Cheung EH: Sublobar resection is equivalent to lobectomy for clinical stage 1A lung cancer in solid nodules. J Thorac Cardiovasc Surg 2014; 147: 754-62.

663. Gale RP, Wiernik PH, Lazarus HM: Should persons with acute myeloid leukemia have a transplant in 1st remission? Leukemia 2014; 28:1949-52.


106


664. Werner B, Gallagher RE, Paietta E, Litzow MR, Tallman MS, Wiernik PH, Slack J, Willman C, Sun Z, Traulsen A, Dingli D: Dynamics of leukemia stem-like cells extinction in acute promyelocytic leukemia. Cancer Res 2014; 74:5386-96.

665. Saber W, Bachanova V, Burns L, Wang T, Carreras J, Gale R, Wiernik P, Ballen K, Wirk B, Munker R, Chen Y-B, Gibson J, Akpek G, Costa L, Kamble R, Aljurf MD, Hsu J, Cairo M, Schouten H, Bacher U, Savani B, Wingard J, Lazarus H, Rizzieri D, Laport G, Montoto S, Maloney D, Brunstein C: Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. Bone Marrow Transplant 2014; in press.

666. Mahindra A, Raval G, Mehta P, Brazauskas R, Zhang M-J, Zhong X, Bird JM, Freytes CO, Hale GA, Herzig R, Holmberg LA, Kamble RT, Kumar S, Lazarus HM, Majhail NS, Marks DI, Moreb JS, Olsson R, Saber W, Savani BN, Schiller GJ, Tay J, Vogl DT, Waller EK, Wiernik PH, Wirk B, Lonial S, Krishnan AY, Dispenzieri A, Brandenburg NA, Gale RP, Hari P: New cancers after autotransplants for multiple myeloma. Biol Blood Marrow Transplant 2015; 21: 738-45.


668. Bachanova V, Burns LJ, Wang T, Carreras J, Gale RP, Wiernik PH, Ballen KK, Wirk B, Munker R, Rizzieri DA, Chen YB, Gibson J, Apek G, Costa LJ, Kamble RT, Aljurf MD, Hsu JW, Cairo MS, Schouten HC, Bacher U, Savani BN, Wingard JR, Lazarus HM,

Laport GG, Montoto S, Maloney DG, Smith SM, Brunstein C, Saber W: Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. Bone

Marrow Transplant 2015; 50: 197-203.

669. Seftel MD, Neuberg D, Zhang M-J, Wang H-L, Akpek G, Bachanova V, Bacher U, Ballen

KK, Baron F, Bashey A, Bergeron J, Cahn J-Y, Camitta BM, Copelan EA, Couban S, DeAngelo DJ, de Lima M, Deol A, Freytes CO, Gale RP, Gergis U, Hamadani M, Hogan WJ, Kebriael P, Kharfan-Dabaja MA, Lazarus HM, Litzow MR, Loren AW, Miller AM, Nishihori T,Norkin M, Olsson RF, Paulson K, Reshef R, Saber W, Sabloff M, Sandmaier BM, Sallan SE, Savani BN, Schouten HC, Tallman MS, Vij R, Woolfrey AE, Wiernik PH, Wirk B, Wood WA, Weisdorf DJ: Pediatric-inspired therapy versus allografting for Philadelphia chromosome negative adult ALL in first complete remission. Blood 2015; submitted.


107


Publications B. Case Reports

1. *Wiernik PH, Serpick AA: Development of herpes zoster in an acute leukemia patient after cytosine arabinoside (NSC-63878) therapy. Cancer Chemother Rep 1969; 53: 49-51.

2. Kanner SP, Wiernik PH, Serpick AA, Walker MD: Central nervous system leukemia mimicking progressive multifocal leukoencephalopathy. Am J Dis Child 1970; 119: 264-266.

3. Presant CA, Wiernik PH, Serpick AA: Disseminated extrapulmonary nocardiosis presenting as a renal abscess. Arch Pathol 1970; 89: 560-564.

4. *Wiernik PH, Duncan JH: Cyclophosphamide in human milk. Lancet 1971; 1: 912.

5. Greene W, Wiernik PH: Candida ophthalmitis. Successful treatment in a patient with acute leukemia. Am J Ophthalmol 1972; 74: 1100-1114.

6. *Wiernik PH: Blue sclerae. Lancet 1972; 2:1199 .

7. Belliveau RE, Wiernik PH, Sickles EA: Blood carcinoembryonic antigen, Regan isoenzyme, and human chorionic gonadotropin in a man with primary mediastinal choriocarcinoma. Lancet 1973; 1: 22-23.

8. O'Connell MJ, Ramsey HE, Whang-Peng J, Wiernik PH: Testicular feminization syndrome in three sibs. Emphasis on gonadal neoplasia. Am J Med Scis 1973; 265: 321-333.

9. Van Echo DA, Sickles EA, Wiernik PH: Thoracic outlet syndrome caused by supraclavicular adenopathy in a patient with Hodgkin's disease. Ann Intern Med 1973; 78: 608-609.

10. *Esterhay RJ, Shapiro HM, Sutherland JC, McIntire KR, Wiernik PH: Serum alpha fetoprotein concentration and tumor growth dissociation in a patient with ovarian teratocarcinoma. Cancer 1973; 31: 835-839.

11. *Wainer RA, Wiernik PH, Thompson WL: Metabolic and therapeutic studies of an acute leukemia patient with severe lactic acidosis. Am J Med 1973; 55: 255-260.

12. Greene WH, Benjamin RS, Glusman S, Ward S, Wiernik PH: Arterial embolism of tumor causing fatal myocardial and cerebral infarction - Report of a case with review of the literature. Arch Intern Med 1974; 134: 545-548.

13. *Reich SD, Wiernik PH: Von Recklinghausen neurofibromatosis and acute leukemia Am J Dis Child 1976; 130:888-889.


108


Publications B. Case Reports (cont.)

14. Gutin PH, Green MR, Bleyer WA, Bauer VL, Wiernik PH, Walker MD: Methotrexate pneumonitis induced by intrathecal methotrexate therapy: A case report with pharmacokinetic data. Cancer 1976; 38: 1529-1534.

15. Diggs CH, Eskenasy GM, Sutherland JC, Wiernik PH: Fungal infection of muscle in acute leukemia. Cancer 1976; 38: 1771-1772.

16. Cohen RJ, Wiernik PH, Walker MD: Acute nonlymphocytic leukemia associated with nitrosourea chemotherapy: Report of two cases. Cancer Treat Rep 1976; 60: 1257-1261.

17. Davies GE, Wiernik PH: Hairy cell leukemia with chylous ascites. JAMA 1977; 238: 1541-1542.

18. Brenner DE, Aisner J, Wiernik PH: Severe skin necrosis produced by piperazinedione extravasation. Cancer Treat Rep 1981; 64:1392-1394.

19. Catanese J, Dutcher JP, Dorfman HD, Andres DF, Wiernik PH: Mediastinal osteosarcoma with extension to lungs in a patient irradiated for Hodgkin's disease. Cancer 1988; 62:2252-2257.

20. Merer DM, Dutcher JP, Mercando A, Brodman R, Suhrland MJ, Bhandari A, Zimmerman D, Mitchell MS, Wiernik PH: Clinical findings and successful resection of metastatic melanoma to the right atrium. Cancer Invest 1994; 12:409-413.

21. Dutcher JP, Benchabbat A, Jones JG, Wiernik PH: Unique dermatological complication of rhM-CSF treatment. Leukemia & Lymphoma 1994; 15:347-349.

22. *Hoffman MA, Wiernik PH, Kleiner GJ: Acute promyelocytic leukemia and pregnancy. Cancer 1995; 76:2237-2241

23. *Wiernik PH, Muse IM: Acute promyelocytic leukemia after treatment of malignant glioma in a patient with Von Recklinghausen's disease: Case report and review of the literature. Leukemia 1996; 10:178-191.

24. Horowitz R, Glicklich D, Sablay LB, Wiernik PH, Wadler S: Interferon-induced acute renal failure: a case report and literature review. Medical Oncol 1995; 12:55-57

25. *Makower D, Venketraj U, Dutcher JP, Wiernik PH: Occurrence of myeloma in a chronic lymphocytic leukemia patient after response to differentiation therapy with interleukin-4. Leukemia & Lymphoma 1996; 23:617-619.


109



26. *Ashigbi MY, Venkatraj U, Agarwal V, Bello J, Wiernik PH: Intracranial Hodgkin's disease in two patients with familial Hodgkin's disease. Med Pediatr Oncol 1997; 29:255-258.

27. Jan N, Villani GM, Trambert J, Fehmian C, Sood B, Wiernik PH: Thymoma: Case report of a novel second line chemotherapy. Med Oncol 1997; 14:163-168.

28. Colovic M, Jankovic G, Bila J, Djordjevic V, Wiernik PH: Inversion of chromosome 16 in accelerated phase of chronic myeloid leukemia: report of a case and review of the literature. Med Oncol 1998; 15:199-201.

29. *Adiga GU, Abebe L, Wiernik PH: Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin’s disease. Case report and literature review. Am J Hematol 2003; 72:267-273.

30. O’Boyle KP, Ashwin M, Jain D, Dauber L, Dutcher JP, Wiernik PH: Probable veno-occlusive disease after treatment with gemtuzumab ozogamicin in a patient with acute myeloid leukemia and a history of liver transplantation for familial hemochromatosis. Med Oncol 2003; 20:379-383.

31. *Blokh I, Oiseth SJ, Fuks J, Jain D, Eapen S, Koulova L, Alexandescu D, Li YY, Dutcher J, Wiernik PH: Metastatic choriocarcinoma in a middle-aged man presenting as a right thigh mass with venous thrombosis: A case report. Med Oncol 2003; 20:189-194.

32. *Bhagwati NS, Oiseth SJ, Abebe L, Wiernik PH: Intravascular lymphomatosis associated with hemophagocytic syndrome: a rare but aggressive clinical entity. Ann Hematol 2004; 83:247-250.

33. Alexandrescu DT, Dutcher JP, Oiseth S, Albulak M, Wiernik PH: Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin’s lymphoma. Leuk Lymphoma 2004; 45:2321-2325.

34. Alexandrescu DT, Bhagwati NS, Wiernik PH: Chemotherapy-inducd scleroderma: A pleomorphic syndrome. Clin Exptl Dermatol 2005; 30:141-5.

35. Alexandrescu DT, Bhagwati NS, Fomberstein B, Wolfe DE, Feliz A, Wiernik PH: Steroid-responsive inclusion body myositis associated with endometrial cancer. Clin Exptl Rheumatol 2005; 23:93-96.

36. Alexandrescu DT, Koulova L, Wiernik PH: Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a


110


case report and review of the literature. Clin Exptl Dermatol 2005; 30:391-394.Publications B. Case Reports (cont.)

37. Alexandrescu DT, Wiernik PH: Multiple eruptive dermatofibromas occurring in a patient with chronic myelogenous leukemia. Arch Dermatol 2005; 141:397-8.

38. Alexandrescu DT, Wiernik PH: Cutaneous manifestations of a catheter-related thrombus. Arch Dermatol 2005; 141:1049.

39. Alexandrescu DT, O’Boyle K, Feliz A, Fueg A, Wiernik PH: Metastatic solid-pseudopapillary tumour of the pancreas: clinico-biological correlates and management. Clin Oncol 2005; 17:358-363.

40. Alexandrescu DT, Vaillant J, Yahr LJ, Kelemen P, Wiernik PH: Unusually large colon cancer cutaneous and subcutaneous metastases occurring in resection scars. Dermatol Online J 2005; 11:22.

41. *Alexandrescu DT, Vaillant J, Wiernik PH: Trastuzumab/docetaxel-induced nail dystrophy. Intl J Dermatol 2006; 45:1334-1336.

42. Lee SH, Wiernik PH: Adult T-cell leukemia/lymphoma presenting with bilateral hearing loss: A case report. Med Oncol 2007; 24:109-113.

43. Dasanu CA, Wiernik PH, Vaillant J, Alexandrescu DT: A complex pattern of melanonychia aand onycholysis after treatment with pemetrexed for lung cancer. Skinmed 2007; 6:95-6.

44. Alexandrescu DT, Dutcher JP, Wiernik PH: Capecitabine-induced pancolitis. Intl J Colorectal Dis 2007; 22:455.

45. *Karbasian-Esfahani M, Wiernik PH, Yeddu M, Abebe L: Leukemic infiltration of the breast in acute lymphocytic leukemia. Hematol 2008; 13:101-106.

46. *Lee SH, Paietta E, Racevskis J, Wiernik PH: Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia with FLT3-ITD mutation. Am J Hematol 2009; 84:701-702.

47. *Lee SH, Abebe LS, Paietta E, Wiernik PH: Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission. Am J Hematol 2009; 84:455-457.

48. *Elkadi D, Wiernik PH, Tong TR: Resolution of massive pleural effusion due to lymphoma with intrapleural interleukin-2. Am J Hematol 2010; 85:711-712.

49. *Wiernik PH, Baig MA, Lee SH, Dutcher JP, Paietta E, Racevskis J: Survival more than


111


19 years after the diagnosis of accelerated phase of chronic myelocytic leukemia. Clin Adv Hematol Oncol 2011;9:242-247.


50. Dy I, Pokuri V, Olichney J, Wiernik P: Levamisole-adulterated in cocaine causing agranulocytosis, vasculopathy and acquired protein S deficiency. Ann Hematol 2011; 91:477-488, 2012.

51. *Chintapatla R, Battini R, Wiernik PH: Chronic lymphocytic leukemia with essential thrombocythemia: asbestos association? Clin Adv Hematol Oncol 2012; 10:752-755.


112


Publications C. Reviews, Chapters and Editorials

1. Wallace Jr HJ, Holland JF, Glidewell OJ, Ellison RR, Weil M, Carey RW, Schwartz JM, Hoagland HC, Henderson ES, Wiernik P, Yates JW: Therapy of acute myelocytic leukemia - Acute Leukemia Group B Studies. Proc First Intl Meeting on the Therapy of Acute Leukemia: Centro Minerva Med., Rome 1975, 255-269.

2. Buchholz DH, Schiffer CA, Wiernik PH, Betts SW, Reilly JA: Granulocyte transfusion: A low cost method for filtration leucapheresis. In Goldman, J.M. and Lowenthal, R.M. (Eds.): Leucocytes: Separation, Collection and Transfusion. Academic Press, New York, 1975, 137-144.

3. Schiffer CA, Aisner J, Wiernik PH: Transient neutropenia during continuous flow filtration leucapheresis. In Goldman, J.M. and Lowenthal, R.M. (Eds.): Leucocytes: Separation, Collection and Transfusion. Academic Press, New York, 1975, 160-167,

4. Buchholz DH, Schiffer CA, Wiernik PH, Betts SW, Reilly JA: Granulocyte transfusion: Donor response to repeated leucapheresis. In Goldman, J.M. and Lowenthal, R.M. (Eds.): Leucocytes: Separation, Collection and Transfusion. Academic Press, New York, 1975, 177-190.

5. Sanel FT, Aisner J, Tillman CH, Schiffer CA, Wiernik PH: Evaluation of granulocytes harvested by filtration leucapheresis: Functional, histochemical and ultrastructural studies. In Goldman, J.M. and Lowenthal, R.M. (Eds.): Leucocytes: Separation, Collection and Transfusion. Academic Press, New York, 1975, 236-250.

6. Schiffer CA, Buchholz DH, Aisner J, Wiernik PH: Transfusion of granulocytes obtained by filtration leucapheresis. In Goldman, J.M. and Lowenthal, R.M. (Eds.): Leucocytes: Separation, Collection and Transfusion, Academic Press, New York, 1975, 316-323.

7. Wiernik PH: The therapy of acute leukemia in the adult. A progress report. In Neth R, Gallo RC, Mannweiler K, Moloney WC (Eds.): Modern Trends in Human Leukemia II, Lehmanns, Munich, 1976, 271-284.

8. Schiffer CA, Aisner J, Wiernik PH: Current status of granulocyte transfusion therapy. In Jamieson GA, Greenwalt TJ (Eds.): The Granulocyte: Function and Utilization, Lippincott, New York, 1977, 281-291.

9. Aisner J, Wiernik PH, Esterhay RJ: Treatment of small cell carcinoma of the lung with cyclophosphamide, Adriamycin, and VP16-213 with or without MER. In Salmon SE, Jones SE (Eds.): Adjuvant Therapy of Cancer. Elsevier-North Holland Press, Amsterdam, 1977, 245-250.


113


Publications C. Reviews, Chapters and Editorials (cont.)

10. Lichtenfeld JL, Wiernik PH, Shortridge DG: Phase I trial of levamisole in-patients with non-resectable bronchogenic carcinoma. In Chirigos MA (Ed.): Control of Neoplasia by Modulation of the Immune System. New York, 1977, 135-145.

11. Wiernik PH: Acute Leukemia in Adults. In Conn HF (Ed.): Current Therapy. W.B. Saunders Co., Philadelphia, 1977, 309-313.

12. Wiernik PH. Current concepts of the treatment of cancer: Recent advances in solid tumor management derived from lessons learned from the treatment of hematologic malignancies. Med Clin N Am 1977; 61: 945-951.

13. Schiffer C, Aisner J, Wiernik PH: Platelet transfusion therapy for patients with leukemia. In Greenwalt TJ, Jamieson GA (Eds.): The Blood Platelet in Transfusion Therapy. Alan R. Liss, Inc., New York, 1978, 267-280.

14. Wiernik PH: Treatment of Acute Leukemia in Adults. Clin Haematol 1978; 7: 259-273.

15. Wiernik PH: Chapter 30: Hodgkin's Disease. In Tice F (Ed.): Practice of Medicine Volume VI, Harper & Row, Hagerstown, 1978.

16. Chang P, Wiernik PH: Chapter 29: The Leukemias. In Tice F (Ed.): Practice of Medicine Volume VI, Harper & Row, Hagerstown, 1978.

17. Diggs CH, Wiernik PH: Chapter 31: The Non-Hodgkin's Lymphomas. In Tice F, (Ed.): Practice of Medicine Volume VI. Harper & Row, Hagerstown, 1978.

18. Wiernik PH: Summary of clinical poster sessions. In Neth R, Hofschneider P-H, Manweiler K (Eds.): Modern Trends in Human Leukemia III. Springer Verlag, Heidelberg, 1979; 157-162.

19. Wiernik PH, Edwards LS, Sarin P: Terminal deoxynucleotidyl transferase activity in adult acute leukemia. In Neth R, Hofschneider P-H, Manweiler K (Eds.): Modern Trends in Human Leukemia III. Springer Verlag, Heidelberg, 1979; 125-130.

20. Chang P, Wiernik PH, Reich SD, Coleman CN, Stoller RG, Hande KR, Chabner BA, Bachur NR: Prediction of response to cytosine arabinoside and daunorubicin in acute nonlymphocytic leukemia. In Mandelli F (Ed.): Therapy of Acute Leukemias. Lombardo Editore, Rome,1979; 148-156.

21. DeVita Jr VT, Glatstein EJ, Young RC, Hubbard SM, Simon RM, Ziegler JL, Wiernik PH: Changing concepts: The lymphomas. In Salmon SS, Jones SE (Eds.) Adjuvant Therapy of Cancer II. Grune and Stratton, Inc., New York, 1979; 173-190.


114



22. Wiernik PH, Jones B, Weinberg V, Holland JF: Present day results in young patients with acute nonlymphocytic leukemia (ANLL). The Cancer and Leukemia Group B Experience. In Mandelli F (Ed.): Therapy of Acute Leukemias, Lombardo Editore, Rome,1979; 430-443.

23. Schimpff SC, Aisner J, Wiernik PH: Infection in acute non-lymphocytic leukemia. The alimentary canal as a major source of pathogens. In van der Waaij D, Verhaef J, (Eds.): New Criteria for Antimicrobial Therapy. Excerpta Medica, Amsterdam, 1979; 12-27.

24. Muggia FM, Chiuten DF, Von Hoff DD, Rozencweig M, Wiernik PH: New drugs against human acute leukemia. In Crowther DG (Ed.): Advances in Medical Oncology, Research and Education, Vol 7: Leukemia and Non-Hodgkin Lymphoma. Pergamon Press, New York, 1979; 55-62.

25. Wiernik PH: Polycythemia. In Hartman PM (Ed.): Guide to Hematologic Disorders. Grune & Stratton, Inc., New York, 1980; 181-190.

26. Chang P, Wiernik PH: Chapter 12: Leukemia. In Spivak JL (Ed.): Fundamentals of Clinical Hematology, Harper & Row, Hagerstown, 1980.

27. Wiernik PH: Current issues in the management of patients with Hodgkin's disease. In Aisner J, Chang P (Eds.): Advances in Cancer Treatment Research. Martinus Nijhoff BV, Amsterdam, 1980; 51-61.

28. Diggs CH, Wiernik PH: Chapter 13: The Non-Hodgkin Lymphomas. In Spivak JL (Ed.): Fundamentals of Clinical Hematology, Harper & Row, Hagerstown, 1980.

29. Wiernik PH: Chapter 14: Hodgkin Disease. In Spivak JL (Ed.): Fundamentals of Clinical Hematology, Harper & Row, Hagerstown,1980.

30. Aisner J, Schiffer CA, Wiernik PH: Chapter 21: Cell Support. In Spivak JL (Ed.): Fundamentals of Clinical Hematology, Harper & Row, Hagerstown, 1980; 357-368.

31. Wiernik PH: Current status of adriamycin and daunorubicin in cancer treatment. In Crook S (Ed): Anthracyclines: Current Status and New Developments. Academic Press, New York, 1980; 273-294.

32. Wiernik PH: Principles of Cancer Treatment. In Lichtman MA (Ed): Hematology and Oncology (Volume 6: The Science and Practice of Clinical Medicine), Grune & Stratton, New York, 1980; 264-268.


115



33. Wiernik PH: Anticancer Drugs: Uses and Toxicities. In Lichtman MA (Ed): Hematology and Oncology (Volume 6: The Science and Practice of Clinical Medicine), Grune & Stratton, New York, 1980; 271-277.

34. Wiernik PH: Cancer Treatment Research. In Lichtman MA (Ed): Hematology and Oncology (Volume 6: The Science and Practice of Clinical Medicine), New York, Grune & Stratton, New York, 1980; 281-283.

35. Freireich EJ, Bennett JM, Vogler RW, Wiernik PH: Adult acute leukemia, in Hoogstraten B (Ed.): Cancer Research, Impact of the Cooperative Groups, Masson Pub.USA, Inc., New York, 1980; 25-38.

36. Wiernik PH: Leukemias and Myeloma. In Pinedo HM (Ed.): Cancer Chemotherapy 1980. Excerpta Medica, Amsterdam, 1980; 176-207.

37. Wiernik PH: Adult Acute Leukemia. In DeVita VT, Hellman S, Rosenberg S (Eds.): Cancer: Principles and Practice of Oncology, J. B. Lippincott Co., Philadelphia, 1982; 1402-1426.

38. Wiernik PH: Acute Nonlymphocytic Leukemia in Young People. In Levine AS (Ed.): Cancer in Children and Adolescents. CRC Press, New York, 1982; 461-472.

39. Esterhay Jr RJ, Wiernik PH: The therapy of Adult Acute Lymphoblastic Leukemia. In Bloomfield CD (Ed.): Acute Leukemia, Martinus Nyhoff, Amsterdam, 1982; 309-349.

40. Wiernik PH, Schimpff SC: Predisposing factors, sites, organism, and general approach to diagnosis of infection. In Silver RT, (ed.): Clinical Topics in Cancer Diagnosis and Treatment, Le Jacq Pub. Inc., New York, 1982; 445-453.

41. Wiernik PH, Schimpff SC: Therapy for infection in granulocytopenic patients, In Silver RT (ed.), Clinical Topics in Cancer Diagnosis and Treatment, Le Jacq Pub, Inc., New York, 1982; 455-465.

42. Schimpff SC, Wiernik PH: Infections in-patients with cellular immune dysfunction. In Silver RT (ed.), Clinical Topics in Cancer Diagnosis and Treatment, Le Jacq Pub Inc, New York, 1982; 467-475.

43. Schimpff SC, Wiernik PH: Prevention of infection in cancer patients. In Silver RT (ed..), Clinical Topics in Cancer Diagnosis and Treatment, Le Jacq Pub Inc, New York, 1982; 477-487.


116



44. Schiffer CA, Aisner J, Dutcher JP, Daly P, Wiernik PH: A clinical program of platelet cryopreservation. In Vogler WR (ed.), Cytapheresis and Plasma Exchange: Clinical Indications, Alan R. Liss, Inc., New York, 1982, pp. 165-180.

45. Hunter H, Browder H, Aisner J, Wiernik P, Bedikian A, Bodey G, Costanzi J, Engstrom P, Levin B, Morgan L, Knight W, Schein P, Smith F: Oral tegafur (Ftorafur) treatment of colon and rectal cancer. Proc 12th Intl Congr Chemother 1982; 1313-1315.

46. Gallagher RE, Wiernik PH: Acute leukemia: New perspectives on pathogenesis; Progress in therapy of children and adults, in Fairbanks VF (ed.), Current Hematology John Wiley & Sons, New York, 1983; 2: 3-l22.

47. Wiernik PH: Mycosis fungoides. In Brain MC, McCulloch PB (eds.,) Current therapy in Hematology-Oncology l983-l984, B.C. Decker Inc., Toronto, l983, pp ll9-l20.

48. Reed WP, Newman KA, deJongh CA, Schimpff SC, Wiernik PH: Seventy-five patient-years' experience with right atrial catheters for chemotherapy. In Kootstra, G, Jorning PJG (eds.), Access Surgery, GA Bogden & Son Inc., Rigewood, NJ 1983 pp. 275-280.

49. Dutcher JP, Wiernik PH: The Leukemias, in Spittell JA (ed.), Clinical Medicine 1983; 5:1-26 (Chapter 16).

50. Wiernik PH: Hodgkin Disease, in Spittell JA (ed.), Clinical Medicine 1983; 5:1-13, (Chapter 17).

51. Kaplan RS, Diggs CH, Wiernik PH: The Non-Hodgkin's Lymphomas, in Spittell JA (ed.), Clinical Medicine 1983; 5:1-19 (Chapter 18).

52. Schiffer CA, Aisner J, Wiernik PH: Platelet and Granulocyte Transfusion, in Spittell JA (ed.), Clinical Medicine 1983; 5:1-17 (Chapter 26).

53. Wiernik PH, Dutcher JP: Some new drugs in acute nonlymphocytic leukemia (ANLL). Proc 13th Intl Cong Chemother 1983; 237:52-55.

54. Park CH, Amare M, Wiernik PH, Dutcher JP, Morrison FS, Maloney TR: In vitro drug sensitivity of leukemia colony-forming cells in acute nonlymphocytic leukemia. Clinical correlation update with various exposure methods. In Salmon SS, Jones SE (eds.), In Vitro Studies of Leukemic Cells. Grune and Stratton, New York, 1984; 619-626.

55. Dutcher JP, Wiernik PH: Leukemia. In Spivak JL, (ed.), Harper and Row Pub., Philadelphia, 1984; 229-254.


117



56. Kaplan RS Diggs CM, Wiernik PH: Non-Hodgkin's lymphomas. In Spivak JL (ed.), Fundamentals of Clinical Hematology. Harper and Row Pub., Philadelphia, 1984; 255-274.

57. Wiernik PH: Hodgkin's disease. In Spivak JL (ed.), Fundamentals of Clinical Hematology. Harper and Row Pub., Philadelphia, 1984; 275-288.

58. Schiffer CA, Aisner J, Wiernik PH: Cell Support. In Spivak JL (ed.), Fundamentals of Clinical Hematology. Harper and Row Pub., Philadelphia,1984; 424-440.

59. Kaplan RS, Wiernik PH: Neurotoxicity of Antitumor Agents. In Perry MC, Yarbro JW (Eds.), Toxicity of Chemotherapy, Grune and Stratton, New York, 1984; 365-431.

60. Dutcher JP, Wiernik PH: Hodgkin's disease, in Wiernik PH (ed.), Leukemias and Lymphomas, Churchill Livingstone Inc., New York, 1985; 63-96.

61. Wiernik PH: Adult Acute Leukemia, In DeVita VT Jr, Hellman S, Rosenberg S (Eds.), Cancer: Principles and Practice of Oncology, J.B. Lippincott Co., Philadelphia, 1985; 1711-1737.

62. Wiernik PH: Diagnosis and Treatment of Adult Acute Nonlymphocytic Leukemia. In Wiernik PH, Canellos GP, Kyle RA, Schiffer CA (Eds.): Neoplastic Diseases of the Blood, Churchill Livingstone Inc., New York, 1985; 335-355.

63. Wiernik PH, Slawson RG: Hodgkin's disease with direct extension into pulmonary parenchyma from a mediastinal mass: a presentation requiring special therapeutic considerations. In Veronesi U, Polli E, Bonadonna G, Santoro A, Emanuelli H (eds.), Leucemie e Linfomi, Casa Editrice Ambrosiana, Milano, 1985; 137-142.

64. Applefeld MM, Wiernik PH: Cardiac disease after radiation therapy for Hodgkin's disease, in Veronesi U, Polli E, Bonadonna G, Santoro A, Emanuelli H (eds.), Leucemie e Linfomi, Casa Editrice Ambrosiana, Milano, 1985; 155-159.

65. Holland JF, Glidewell O, Cuttner J, Ellison RR, Weil M, Rai K, Carey RW, Yates J, Wallace HJ, Preisler H, Wiernik P, Bekesi JG, Coleman M: Clinical trials in acute leukemia. In Veronesi U, Bonadonna G (eds.), Clinical Trials in Cancer Medicine, Academic Press, Orlando, 1985; 219-238.

66. Schiffer CA, Wiernik PH: Hematologic considerations in cancer. In Medical Oncology, Calabresi P, Schein PS, Rosenberg SA (eds.), Macmillan Publishing Co., New York, 1985; 1358-1370.


118



67. Young RC, Longo DL, Glatstein E, Duffey PL, Winkler CF, Wiernik PH, DeVita Jr VT: The current status of NCI trials in Hodgkin's disease. In Cavalli F, Bonadonna G, Rozencweig M (Eds.): Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances, Martinus Nijhoff Pub., Boston,1985; 293-298.

68. Dutcher JP, Wiernik PH: Combined modality treatment of Hodgkin's disease confined to lymph nodes. Results 14 years later. In Cavalli F, Bonadonna G, Rozencweig M (Eds.): Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances, Boston, Martinus Nijhoff Pub., Boston, 1985; 317-328.

69. O'Dwyer PJ, Wiernik PH, Stewart MB, Slawson RG: Treatment of early stage Hodgkin's disease: A randomized trial of radiotherapy plus chemotherapy versus chemotherapy alone. In Cavalli F, Bonadonna G, Rozencweig M (Eds.): Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances, Martinus Nijhoff Pub.,Boston, 1985; 329-336.

70. Fuks JZ, Wiernik PH: Lung Cancer. In Spittell JA (ed.), Clinical Medicine, JB Lippincott, Philadelphia, 1986;6:1-21.

71. Paietta E, Stockert RJ, Khorshidi M, Dutcher JP, Wiernik PH: Activation-associated antigen expression by human lymphokine-activated killer (LAK) cells. In: McMichael AJ (ed.), Leucocyte Typing III, Oxford University Press, New York 1987; pp 528-530.

72. Wiernik PH: Typhilitis and related acute gastrointestinal problems, in Dutcher JP, Wiernik PH (eds.), Handbook of Hematologic and Oncologic Emergencies, Plenum Pub.Corp., New York 1987; 185-188.

73. Wiernik PH: Acute nonlymphocytic leukemia in adults. In Brain MC, Carbone PP (eds.), Current Therapy in Hematology-Oncology-3, B.C. Decker, Inc., Toronto 1988; 63-67.

74. Paietta E, Stockert RJ, Racevskis J, Diehl V, Wiernik PH: A surface lectin as mediator of lymphocyte mitogenicity in Hodgkin's cells expressing monocyte/macrophage features. In: Grignani F, Mantelli MF, Mason DY (eds.): Genotypic, Phenotypic and Functional Aspects of Haematopoesis. Raven Press, New York 1988; 323-327.

75. Wadler S, Wiernik PH: Advances in medical oncology: 1988. Medical Times 1988; 116:23-31.

76. Wiernik PH: Chemotherapy of Hodgkin's Disease. In DeVita Jr VT, Hellman S, Rosenberg SA (eds.), Cancer: Principles & Practice of Oncology Updates J.B.Lippincott Co., Philadelphia, 1988; 2: 1-12.


119



77. Dutcher JP, Wiernik PH: Lymphomas involving the mediastinum. In Roth JA, Ruckdeschel JC, Weisenburger TH (eds.), Thoracic Oncology, WB Saunders Co., Philadelphia 1988; 448-465.

78. Wiernik, PH: Leukemias and myeloma. In Pinedo HM, Longo DL, Chabner BA, (eds.), Cancer Chemotherapy and Biological Response Modifiers Annual 10, Elsevier Science Pubs., Amsterdam 1988; pp 129-147.

79. Paietta E, Gallagher R, Wiernik PH, Stockert RJ: Leukemic promyelocyte (HL-60) lectin responsive to monocytic maturation, in Bog-Hansen TC, Freed DLJ, (eds.), Lectins, Biology, Biochemistry, Clinical Biochemistry, Sigma Chemical Co., St. Louis, 1988; 6: 427-430.

80. Wiernik PH: The acute leukemias. In Kelley WN (ed.), Textbook of Internal Medicine, J.B. Lippincott Co., Philadelphia 1989; 1173-1177.

81. Wiernik PH: The chronic leukemias. In Kelley WN (ed), Textbook of Internal Medicine, J.B. Lippincott Co., Philadelphia 1989; 1177-1181.

82. Wiernik PH: Diagnosis and treatment of the patient with leukemia. In Kelley WN (ed.), Textbook of Internal Medicine, J.B. Lippincott Co., Philadelphia 1989, pp 1298-1306.

83. Wiernik PH: Acute leukemia of adults. In DeVita VT Jr, Hellman S, Rosenberg SA, (eds)., Cancer: Principles and Practice of Oncology, J.B. Lippincott Co., Philadelphia 1989; 1809-1835.

84. Ritch P, Gucalp R, Wiernik P, Sarma P, Keller A, Richman S, Tauer K, Neidhart J, Mallette L, Siegel R, Vandepol C: Pamidronate (APD) and etidronate disodium (EHPD) in hypercalcemia of malignancy - preliminary report of a comparative multicentre trial. In Rubens RD (ed), The Management of Bone Metastases and Hypercalcemia by Osteoclast Inhibition, Hogrefe and Huber, Pubs., London 1989; 47-49.

85. DeVita Jr VT, Longo DL, Glatstein E, Duffey PL, Hubbard SM, Wiernik PH, Young RC: A randomized comparison of radiotherapy versus primary treatment with MOPP chemotherapy in early stage Hodgkin's disease. In Salmon SE (ed.), Adjuvant Therapy of Cancer VI, WB Saunders Co., Philadelphia, 1990; 601-609.

86. *Wiernik PH: Acute promyelocytic leukemia: Another pseudoleukemia? Blood 1990; 76:1675-1677 (Editorial).

87. Wiernik PH: Acute nonlymphocytic leukemia, in Kassirer JP (ed.), Current Therapy in Internal Medicine, BC Decker, Inc., Philadelphia, 1991; 843-847


120



88. Rowe JM, Cassileth PA, Oken MM, Andersen JW, Bennett JM, Wiernik PH: Clinical trials in adults with acute myelogenous leukemia: The ECOG experience, in Acute Myelogenous Leukemia: Progress and Controversies, Wiley-Liss, Inc., New York, 1990; 293-302.

89. Wiernik PH: Recent advances in chemotherapy for certain leukemias, in New Approaches to the Treatment of Leukaemias, Freireich EJ, ed., Springer Verlag, Heidelberg, 1990; 187-193.

90. Wiernik PH: Leukemias and myeloma. In Pinedo HM, Longo DL, Chabner BA (eds.), Cancer Chemotherapy and Biological Response Modifiers Annual 11, Elsevier Science Pub., Amsterdam 1990; 321-342.

91. Einzig AI, Wiernik PH, Schwartz EL: Taxol: A new agent active in melanoma and ovarian cancer, in Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances, Muggia FM (ed.), Kluwer Academic Pub, Boston, 1991; 89-100.

92. Wiernik PH: Leukemias and myeloma, in Pinedo HM, Longo DL, Chabner BA (eds.), Cancer Chemotherapy and Biological Response Modifiers Annual 12, Elsevier Science Pub., Amsterdam 1991; 327-346.

93. Wiernik PH: Acute leukemias, in Textbook of Internal Medicine, 2nd ed., Kelley WN, ed., JB Lippincott Co., Philadelphia 1991; 1079-1082.

94. Wiernik PH, Canellos GP: Approach to the management of leukemia, in Textbook of Internal Medicine, 2nd ed., Kelley WN (ed.), JB Lippincott Co., Philadelphia 1991; 1177-1184.

95. Dutcher JP, Wiernik PH: Leukemia. In The Fundamentals of Clinical Hematology, Spivak JL, Eichner ER (eds.), Johns Hopkins Unversity Press, Baltimore 1993; 231-258.

96. Dutcher JP, Wiernik PH: Hodgkin's Disease, in The Fundamentals of Clinical Hematology, Spivak JL, Eichner ER (eds.), John Hopkins University Press, Baltimore 1993; 271-286.

97. Rowe JM, Andersen JW, Cassileth PA, Oken MM, Bennett JM, Wiernik PH: Clinical trials in acute myelogenous leukemia: Experience of the Eastern Cooperative Oncology Group. In Acute Leukemias IV: Prognostic Factors, Buchner, Hiddemann, Wormann (eds.), Springer Verlag, Berlin 1994; 541-546.

98. Wiernik PH: Leukemias and myeloma. In Cancer Chemotherapy and Biological Response Modifiers Annual 15, Pinedo HM, Longo DL, Chabner BA (eds.), Elsevier, Amsterdam,


121


1994.Publications C. Reviews, Chapters and Editorials (cont.)

99. Wiernik PH: Treatment for adult acute myeloid leukemia: Where we stand in 1995. Acta Haematol Polonica 1995; 26:231-237. (editorial).

100. Einzig AI, Wiernik PH: Melanoma. In McGuire WP (ed.), Paclitaxel in Cancer Treatment, Marcel Dekker, Inc., New York, 1995; 321-328.

101. Wiernik PH: Leukemias and myeloma. In Pinedo HM, Longo DL, Chabner BA (eds.), Cancer Chemotherapy and Biological Response Modifiers Annual 16, Elsevier, Amsterdam, 1996; 347-375.

102. Wiernik PH: Acute Myeloid Leukemia. In Fischer DS (ed.), Follow-up of Cancer, 4th edition, Lippincott, Philadelphia, 1996; 116-117.

103. Sparano JA, Dutcher JP, Wiernik PH: Low-dose interleukin-2 for advanced renal cell carcinoma. In Volgelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds.), Comprehensive Textbook of Genitourinary Oncology, Williams & Wilkins, Baltimore, 1996; 248-255.

104. Wiernik PH: Acute Leukemias. In Kelley WN (ed.), Textbook of Internal Medicine, 3 ed, JB Lippincott Co., New York, 1996; 1370-1378.

105. Rowe JM, Rubin A, Mazza JJ, Bennett JM, Paietta E, Andersen JW, Ghalie R, Wiernik PH: Incidence of infections in adult patients (>55 years) with acute myeloid leukemia treated with yeast-derived GM-CSF (Sarramostim): Results of a double-blind prospective study by the Eastern Cooperative Oncology Group. In Hiddemann W, Buchner T, Wormann B, Ritter J, Creutzig U, Keating MJ, Plunkett (eds.), Acute Leukemias V, Springer Verlag, Berlin, 1996; 178-184.

106. Paietta E, Andersen J, Yunis J, Rowe JM, Cassileth PA, Wiernik PH: Expression of the multidrug-resistance gene product, p-glycoprotein in adult acute myeloid leukemia: Association with stem cell factor CD34 and specific cytogenetic abnormalities. In Abraham G, Asano S, Brittinger G, Maestroni GJM, Shadduck RK (eds.), Molecular Biology of Hematopoiesis, Vol. 5, Plenum Pub Corp, New York, 1996; 201-206.

107. Wiernik PH: Overview of current treatment for acute myeloid leukemia. In Büchner T, Hiddemann W, Wörmann B, Schellong G, Ritter J, Creutzig U (eds.), Acute Leukemias VI, Springer, Berlin, 1997; 400-405.

108. Wiernik PH: Leukemias and myeloma. In Pinedo HM, Longo DL, Chabner BA (eds.), Cancer Chemotherapy and Biological Response Modifiers Annual 17, Elsevier, Amsterdam, 1997; 390-407.


122



109. Wiernik PH, Dutcher JP: Therapy of acute myeloid leukemia. In Medical Management of Hematological Diseases, Freireich EJ, Kantarjian HM (eds.), Marcel Dekker, Inc., New York, 1998; 5-18.

110. Advani R, Saba H, Tallman M, Rowe JM, Wiernik P, Ramek J, Dugan M, Litchman BI, Sikic BI, Davis E, Paietta E, Greenberg P: Treatment of poor prognosis acute myelogenous leukemia with PSC-833 and mitoxantrone, etoposide, cytarabine. In Acute Leukemias VII-Experimental Approaches and management of Refractory Disease. Hiddeman W et al. (eds.) Springer-Verlag, Berlin, 1998; 456-460.

111. Wiernik PH: Spontanremissionen bei lymphomen. In Spontanremissionen in der Onkologie. Theoretische Modelle und Klinische Befunde. Heim ME, Schwarz R (eds.), Schattauer, Stuttgart, 1998; 193-199.

112. Wiernik PH: Leukemias and myeloma. In Pinedo HM, Longo DL, Chabner BA (eds.), Cancer Chemotherapy and Biological Response Modifiers Annual 18, Elsevier Science B.V., Amsterdam, 1999; 268-292, 1999.

113. Dutcher JP, Wiernik PH: Novel biologic approaches to hematologic malignancies. In Tallman MS, Gordon LI (eds.) Diagnostic and Therapeutic Advances in Hematologic Malignancies. Kluwer Academic Pubs, Boston, 1999; 275-306.

114. Wiernik PH: Leukemias and plasma cell myeloma. In Pinedo HM, Longo DL, Chabner BA (eds.), Cancer Chemother Biol Response Modif . Elsevier, Amsterdam, 1999; 18:268-292.

115. Wiernik PH: Leukaemias and lymphomas. In Encyclopedia of Life Sciences, Macmillan Reference, Ltd., London, 2000.

116. Wiernik PH: Acute Leukemias. In Kelley’s Textbook of Internal Medicine, Humes HD (ed.), Lippincott Williams & Wilkins, Philadelphia, 2000; 1663-1672.

117. Wiernik PH: Plasma cell dyscrasia and leukemia. Iin: Giaccone G, Schilsky R, Sondel P (rds.) Cancer Chemother Biol Response Modif Annual 19, Elsevier Science, Amsterdam, 2001; 395-424

118. Wiernik PH: Complications of treatment. In Adult Leukemias, Wiernik PH (ed.), BC Decker, Hamilton, 2001; 263-274.

119. Wiernik PH: Extramedullary manifestations of adult leukemia. in Adult Leukemias, Wiernik PH (ed.), BC Decker, Hamilton, 2001; 275-306.


123



120. Dutcher JP, Wiernik PH: Clinical impact of multidrug resistance in acute leukemia. Commentary. Leukemia Res 2002; 26:323-325.

121. Wiernik PH: Acute myelocytic leukemia. In Encyclopedia of Cancer, Bertino JR, ed, Academic Press, New York, 2002;1:19-24.

122. Wiernik PH: Plasma cell dyscrasia and leukemia. Iin Giaccone G, Schilsky R, Sondel P Cancer Chemother Biol Response Modif Annual 21, Elsevier Science, Amsterdam, 2002; 365-398.

123. Dutcher JP, Wiernik PH: Oncologic disorders in older adults. In Clinical Geriatrics, Dharmarajan TS, Norman RA (eds.), Parthenon Publishing, Boca Raton, 2003; 501-515.

124. Wiernik PH: Acute Leukemias. In MKSAP 13, Epstein PE (ed.), Am Coll Physicians, Philadelphia, 2003; 13-17.

125. Wiernik PH: Plasma cell dyscrasia and leukemia. In: Giaccone G, Schilsky R, Sondel P (eds), Cancer Chemother Biol Response Modif Annual 22, Elsevier Science, Amsterdam, 2005; 343-389.

126. Alexandrescu DT, Wiernik PH, Dutcher JP: Chemotherapy toxicities and complications. In Young NS, Gerson SL, High KA (eds), Clinical Hematology, Mosby Elsevier, Philadelphia, 2006; 1144-1154.

127. Wiernik PH: Current status of the development of lenalidomide as treatment for mantle cell lymphoma. Haematologica 2011, in press.

128. Wiernik PH: Acute lymphoblastic leukemia of adulthood: Progress or not? Curr Treat Options Oncol 2011; 12:303-311.

129. Wiernik PH: Lenalidomide in lymphomas and chronic lymphocytic leukemia. Expert Opin Pharmacother 2013; 14:475-488.

130. Dutcher JP, Wiernik PH: Deconstructing and re-inventing the IL-2 paradigm: Can alternate dosing schedules enhance tumor effect? Kidney Cancer J 2013; 11:22-27.

131. *Wiernik PH: Optimal therapy for adult patients with acute myeloid leukemia in first complete remission. Curr Treat Options Oncol 2014; 15: 171-186.

132. *Freireich EJ, Wiernik PH, Steensma DP: The Leukemias: A Half-Century of Discovery. J Clin Oncol 2014; 32: 3463-9.


124



133. *Wiernik PH: Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years. Med Oncol 2014; 31:136-46.

134. *Wiernik PH: Familial leukemias. Curr Treat Options Oncol 2015; 16: 323. Doi 10.1007/s11864-014-0323-3.


125


Publications D. Books Edited

1. Wiernik PH: Advances in the Treatment of Cancer, Med Clin N Am 61(5), 1977.

2. Lichtman MA, Adamson JW, Lessin LS, Marder VJ, Wiernik PH: Hematology and Oncology, Grune & Stratton, New York, 1980.

3. Wiernik PH: Controversies in Oncology, John Wiley & Sons, New York, 1982.

4. Wiernik PH: Supportive Care of the Cancer Patient, Futura Pub.Co., Mt. Kisco, 1983.

5. Wiernik PH: Leukemias and Lymphomas, Churchill Livingstone, New York, 1985.

6. Wiernik PH, Canellos GP, Kyle RA, Schiffer CA: Neoplastic Diseases of the Blood, Churchill Livingstone, New York, 1985.

7. Wiernik PH, Canellos GP, Kyle RA, Schiffer CA: Neoplastic Diseases of the Blood, (2nd Edition ) Churchill Livingstone, New York,), 1991.

8. Dutcher JP, Wiernik PH: Handbook of Hematologic and Oncologic Emergencies, Plenum Pub. Co., New York, 1988.

9. Treleaven J, Wiernik P: Color Atlas and Text of Bone Marrow Transplantation, Mosby-Wolfe, London, 1995.

10. Wiernik PH, Canellos GP, Dutcher JP, Kyle RA: Neoplastic Diseases of the Blood (3rd Edition), Churchill Livingstone, New York, 1996.

11. Spivak JL, Bell WR, Ness PM, Quesenberry PJ, Wiernik PH: Year Book of Hematology, Year Book Pubs. Inc., Chicago, 1987-1998 (annual).

12. Wiernik PH: Adult Leukemias, BC Decker Pub. Inc., Hamilton, 2001 (American Cancer Society Atlas of Clinical Oncology Series), Steele Jr GD, Phillips TL, Chabner BA, eds.), BC Decker Pubs., Inc., Hamilton, 2001.

13. Wiernik PH, Dutcher JP, Goldman JM, Kyle RA: Neoplastic Diseases of the Blood (4 th

Edition), Cambridge University Press, London, 2003.

14. Wiernik PH, Dutcher JP, Goldman JM, Kyle RA: Neoplastic Diseases of the Blood (5 th

edition), Springer, New York, 2013.


126


Publications E. Misc. Publications: Letters to the editor, book reviews etc.

1. Wiernik PH: Treatment of acute granulocytic leukemia in adults. N Engl J Med 1972; 287: 308. (letter to the editor).

2. O'Connell MJ, Wiernik PH: Remission of metastatic testicular carcinoma. N Engl J Med 1987; 287: 989. (letter to the editor).

3. Wiernik PH: Blue sclerae. Lancet 1972; 2:1199 (letter to the editor).

4. Ruckdeschel JC, Wiernik PH: Reaction to radiation therapy. N Engl J Med 1975; 293: 668-669. (letter to the editor)

5. Wiernik PH: Cytarabine: Therapeutic trials and editorial standards. Ann Intern Med 1975; 83:578. (letter to the editor)

6. Lichtenfeld JL, Wiernik PH: Levamisole in a Phase I trial. Cancer Treat Rep 1976; 60: 963-964. (letter to the editor)

7. deJongh, C.A., Schimpff, S.C., and Wiernik, P.H.: Antibiotic prophylaxis in acute leukemia. Ann Intern Med 1981; 95: 783-784. (letter to the editor).

8. Schnaper N, Wiernik PH: Pseudocancer: Symptoms in copinig. Ann Intern Med 1982; 96:257. (letter to the editor)

9. Dutcher JP, Wiernik PH, Gray WC: Tonsillectomy for recurrent throat infections in acute leukemia patients. N Engl J Med 1984; 311:408 (letter to the editor).

10. Ciobanu N, Paietta E, Karten M, Ramos S, Naylor P, Wiernik PH: Thymus fragment transplantation in the acquired immunodeficiency syndrome. Ann Intern Med 1985; 103:479 (letter to the editor).

11. Wiernik PH: Granulocytic Sarcoma of Breast (letter to the editor): Cancer 1989; 63:l624.

12. Gallagher RE, Wiernik PH: All-trans retinoic acid in myelogenous leukemia. Lancet 1991;2:1603. (letter to the editor).

13. Wiernik, PH: Chemotherapy Source Book. N Engl J Med 1992;326:1298. (book review).

14. Wiernik, PH: Current Therapy in Hematology-Oncology, N Engl J Med 1992;326:1298. (book review).


127


Publications E. Misc. Publications: Letters to the editor, book reviews etc. (cont.)

15. Wiernik PH: Elements of Human Cancer (Book Review). N Engl J Med 1993;328:67-68.

16. Paietta E, Wiernik PH, Andersen J, Bennett J, Yunis J: Acute myeloid leukemia M4 with inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression. Blood 1993; 82:2595-2596. (letter to the editor)

17. Paietta E, Wiernik PH, Andersen J: Immunophenotypic features of t(8;21(q22;q22) acute myeloid leukemia in adults. Blood 1993; 81:1975. (letter to the editor)

18. Paietta E, Gallagher RE, Wiernik PH: Myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as FAB-M3 acute myeloid leukemia. Blood 1994; 84:2824-2825. (letter to the editor).

19. Wiernik PH: The molecular basis of human cancer. N Engl J Med 1994; 330:1163. (book review).

20. Einzig AI, Dutcher JP,, Wiernik PH: Life-threatening hyperleukocytosis and pulmonary compromise after priming with rhGM-CSF in a patient with AML. J Clin Oncol 1995; 13:304-305. (letter to the editor).

21. Wiernik PH: Oxford textbook of oncology. N Engl J Med 1996; 334:546. (book review)

22. Wiernik PH: Authors reply. Cancer 1997; 79:2264. (Correspondence)

23. Wiernik PH: Author reply. Cancer 1997; 80:519. (Correspondence)

24. Wiernik PH: Review of typhlitis with concurrent appendicitis in a patient with chronic lymphocytic leukemia. Cin Adv Hematol Oncol 2003; 1:286.

25. Wiernik PH: Treatment of acute leukemias: New directions for clinical research. C-H Pui, (ed.) Med Oncol 2003; 20: 195, 2003 (book review).

26. Wiernik PH, Etkind PR: Is mouse mammary tumor virus an etiologic agent of human breast cancer and lymphoma? Southern Med J 2006; 99:108-110. (Editorial).

27. Darabi K, Kantamnei S, Wiernik PH: Lenalidomide-induced warm autoimmune hemolytic anemia. J Clin Oncol 2006; 24:e59. (Letter to the Editor).

28. Wiernik PH: Chemotherapy in AML. Turkish J Hematol 2007; 24(suppl 1):1-3. (Meeting Summary).


128


Publications E. Misc. Publications: Letters to the editor, book reviews etc. (cont.)

29. Wiernik PH: Update: APOR. Clin Transl Sci 2011; 6:399.


129


Publications F. Abstracts

1. Wiernik PH, Serpick AA: Serum and urinary muramidase activity in acute leukemia. Proc Am Soc Clin Oncol 1968; 1:7.

2. Wiernik PH, Serpick AA: Prognostic significance of hydroxyurea responsiveness in acute myelocytic leukemia. Intl Soc Hematol, 1968.

3. Wiernik PH: Starvation effect on ribonuclease activity of corticoid sensitive and resistant lymphosarcoma P1798. Proc Am Assoc Cancer Res 1968; l0:99.

4. Wiernik PH, Serpick AA: An analysis of factors affecting survival in 100 cases of acute nonlymphocytic leukemia. Cancer Chemother Rep 1969; 53: 96.

5. Presant CA, Wiernik PH, Serpick AA: In vitro inhibition of serum alkaline phosphatase (SA). Clin Res 1969; 17: 405.

6. Serpick AA, Wiernik PH: Remission induction in adult acute nonlymphocytic leukemia (ANLL). A comparison of daunomycin with combination therapy. Xth Intl Cong Cancer, 1970.

7. Block JB, Serpick AA, Wiernik PH, Nayak PK, Molins D.: Early clinical trials with lapachol. Fed Proc 1970; 29: 682.

8. Wiernik PH, Serpick AA: Serum muramidase concentrations and remission duration in adult acute monocytic and myelomonocytic leukemia. XIIIth Cong IntL Soc Hematol, 1970.

9. Smith KA, Wiernik PH, Walker MD: The cytocentrifuge in the diagnosis of CNS leukemia. Proc Am Soc Hematol 1971.

10. Benjamin RS, Huffman DH, Wiernik PH, Bachur NR: Pharmacokinetics of Adriamycin (A) in man. Proc Am Assoc Cancer Res 1972; 13: 115.

11. Brace K, Serpick AA, Wiernik PH, Block JB: Combination radiotherapy and chemotherapy in the treatment of early Hodgkin's disease. Proc Am Soc Clin Oncol, Abstract #6, 1972.

12. Schimpff S, Young VM, Vermeulen G, Greene W, Wiernik P: Acquisition of potential pathogens and subsequent infection in-patients with acute nonlymphocytic leukemia. Clin Res 1972; 20: 537.


130


Publications F. Abstracts (cont.)

13. Benjamin RS, Wiernik PH, Huffman DH, Bachur NR: Clinical and biochemical studies of intermittent Adriamycin (A) and daunorubicin (D) dosage schedules in solid tumor patients. Clin Res 1972; 20: 563.

14. Wiernik PH: Carcinoembryonic antigen (CEA) in hematologic malignancies. XIVth Intl Cong Hematol, 1972.

15. Benjamin RS, Huffman DJ, Wiernik PH, Bachur NR: Pharmacokinetics and metabolism of Adriamycin (A) in-patients with hematologic neoplasms and other malignancies. XIVth Intl Cong Hematol, 1972.

16. Buchholz DH, Wiernik PH, Mardiney MR: Granulocyte procurement by leukocyte filtration. Am Assn Blood Banks--Intl Soc Blood Transfusions, 1972.

17. Greene W, Schimpff S, Bondroff S, Wiernik P, Vermeulen G, Young VM: The diagnostic value of routine cerebrospinal fluid and bone marrow cultures negative report. XIIth Interscience Conf. Antimicrob Ag Chemother, 1972.

18. Schimpff S, Greene W, Young VM, Vermeulen G, Moody M, Wiernik, P.: Hospital-acquired pathogens and subsequent infection in-patients with acute nonlymphocytic leukemia. XIIth Interscience Conf Antimicrob Ag Chemother, 1972.

19. Greene W, Schimpff S, Moody M, Young VM, Wiernik, P.H.: The emergence of carbenicillin and gentamicin resistance to Pseudomonas aeruginosa in a cancer center. Clin Res 1972; 20: 881.

20. Greene W, Schimpff S, Wiernik P: Cell-mediated immunity and prognosis in acute nonlymphocytic leukemia. Proc Am Soc Hematol 1972, p. 40.

21. Esterhay RJ, Wiernik PH, Fortner C: Antineoplastic drug displays for the Computerized Problem-Oriented Medical Information System (PROMIS). Proc Am Assn Cancer Res 1973; 14: 1.

22. Wiernik PH, Serpick AA: Plasma carcinoembryonic antigen (CEA) in patients with advanced cancer. Proc Am Assn Cancer Res 1973; 14: 14.

23. Walker MD, Mann-Kaplan RS, Sklansky DB, Levine MH, Weiss HD, Wiernik P.H.: Toxicity and pharmacology of intravenous methyl CCNU (IV Me CCNU) in Man (Phase I). Proc Am Assn Cancer Res 1973; 14: 38.

24. Benjamin RS, Wiernik PH, Bachur NR: Adriamycin (AMN) efficacy, safety, and pharmacologic basis of a single dosage schedule. Proc Am Soc Clin Oncol, 1973.


131



25. Benjamin RS, Wiernik PH, Bachur NR: Adriamycin: A new effective therapy for metastatic sarcoma. Ann Intern Med 1973; 78: 831.

26. Russell DH, Marton LJ, Wiernik PH: Elevated polyamines and other cancer markers in the sera of diagnosed cancer patients. Proc Am Assn Cancer Res 1973; 14: 74.

27. Greene WH, Schimpff SC, Young VM, Wiernik PH: Empiric carbenicillin, gentamicin and cephalothin therapy for presumed infection in-patients with granulocytopenia and cancer. Ann Intern Med 1973; 78: 825.

28. Greene W, Cusack N, Young VM, Wiernik PH: Factors affecting acquisition of nosocomial organisms in acute leukemia patients. Proc Am Fed Clin Res 1973; 21: 601.

29. Greene W, Moody M, Young VM, Schimpff S, Wiernik PH: The emergence of carbenicillin (C) and gentamicin (G) resistant Pseudomonas aeruginosa (PSA) in a cancer center. Proc Am Fed Clin Res 1973; 21: 601.

30. O'Connell MJ, Sklansky D, Greene W, Abt A, Kirschner R, Ramsey H, Murphy L, Wiernik P: Routine staging laparotomy in the management of Hodgkin's disease. Proc Am Fed Clin Res 1973; 21: 562.

31. Wiernik PH, O'Connell MJ, Abt A, Kirschner R, Murphy WL, Sutherland J, Sklansky DB: Splenic Hodgkin's disease (HD): Detection, incidence and prognostic significance. Symp Histopathol Spleen, Cluj, Rumania, May, 1973.

32. Esterhay RJ, Wiernik PH, Fortner CL: Antineoplastic drug displays for the computerized Problem-Oriented Medical Information System (PROMIS). Proc. Xth Symp. Biomathematics and Computer Science in Life Sciences, 1973, p. 16.

33. Benjamin RS, Wiernik PH, Bachur NR: Adriamycin (AMN) chemotherapy clinical and pharmacologic correlation. Proc VIIth Joint Meeting Professional Assn USPHS, 1973.

34. O'Connell MJ, Bianchine JB, Messeha FS, Wiernik PH: MK486 and streptozotocin in the management of metastatic carcinoid tumor. Proc. VIIIth Joint Meeting Professional Assn USPHS, 1973.

35. Buchholz DH, Schiffer CA, Wiernik PH: Description and evaluation of a low cost system for filtration leukopheresis. Am Assn Blood Banks, 1973.

36. Schiffer CA, Buchholz DH, Wiernik PH: Intensive platelet pheresis of normal donors and its clinical application. Am Assn Blood Banks, 1973.


132



37. Schiffer CA, Buchholz DH, Aisner J, Wiernik PH: Clinical experience with transfusion of granulocytes obtained by filtration leukopheresis. Am Soc Hematol, 1973.

38. Schimpff SC, Greene WH, Young VM, Fortner CL, Jepsen L, Cusack NE, Wiernik PH: Infection prevention in acute nonlymphocytic leukemia with consequent improved remission rates and survival duration. Am Soc Hematol, 1973.

39. Buchholz DH, Schiffer CA, Wiernik PH, Betts S: The use of frozen autologous platelets in the supportive care of patients with leukemia. Am Soc Hematol, 1973.

40. Young VM, Moody MR, Schimpff SC, Wiernik PH: Serotypes of Pseudomonas aeruginosa colonizing and infecting cancer patients. Am Fed Clin Res, 1973.

41. Greene WH, Moody M, Hartley R, Aisner J, Effman E, Wiernik P: Esophagoscopy as a source of fatal Pseudomonas aeruginosa sepsis in-patients with acute leukemia. Clin Res 1973; 21: 975.

42. Lichtenfeld JL, Mardiney Jr MR, Wiernik PH: Amplification of immunologically induced lymphocytes 3H thymidine incorporation by levamisole. Am Assn Immunologists, 1973.

43. Ruckdeschel J, Chang P, Martin R, O'Connell M, Sutherland J, Wiernik P: Pericarditis following radiation for Hodgkin's disease. Am Coll Phys, 1973.

44. Benjamin RS, Wiernik PH, Bachur NR: Chemotherapy of lung cancer with Adriamycin: An encouraging preliminary report. Am Coll Phys, 1973.

45. Young VM, Moody MR, Schimpff SC, Wiernik PH: Serotypes of Pseudomonas aeruginosa colonizing and infecting cancer patients. Clin Res 1973; 21: 978.

46. O'Connell M, Wiernik P, Brace K, Byhardt R, Greene W: Radiotherapy (RT) followed by chemotherapy (CT) in Hodgkin's disease (HD) confined to lymph nodes: Preliminary results of a prospectively randomized clinical trial. Am Soc Clin Oncol, 1974.

47. Schiffer S, O'Connell M, Greene W, Young V, Wiernik P: Transfusion of granulocytes obtained by filtration leukopheresis. Am Assn Cancer Res, 1974.

48. Schimpff S, O'Connell M, Greene W, Young V, Wiernik P: Infections following splenectomy in-patients with Hodgkin's disease. Am Coll Phys, 1974.

49. Byhardt R, Brace K, Ruckdeschel J, Chang P, Martin R, Wiernik P: Dose and treatment factors in radiation induced pericarditis from mantle techniques in Hodgkin's disease. James Ewing Soc, 1974.


133



50. Schein P, O'Connell MJ, Blom J, Hubbard S, Magrath P, Bergenin P, Wiernik P, DeVita V.: Clinical antitumor activity and toxicity of streptozotocin. Am Soc Cin Oncol, 1974.

51. O'Connell M, Wiernik P, Brace K, Byhardt R, Greene W: Radiotherapy followed by chemotherapy in Hodgkin's disease confined to lymph nodes: Preliminary results of a prospectively randomized clinical trial. Am Soc Clin Oncol, 1974.

52. Friedman NR, Young VM, Schimpff SC, Moody MR, Wiernik PH: Observation of a new air filtration system: A protected environment for the high risk patient. Comm Officers Soc, USPHS, 1974.

53. Weiss HD, Walker MD, Wiernik PH, Delgard D: Preclinical and Phase I clinical studies of intrathecal N, N', and N" triethylnephosphamide (Thiotepa NSC 6396). Am Assn Cancer Res, 1974.

54. Kirschner RH, Abt AB, O'Connell MJ, Sklansky BD, Greene WH, Wiernik PH: Prognostic significance of vascular invasion in Hodgkin's disease (HD). Am Soc Clin Oncol, 1974.

55. Greene WH, Schimpff SC, Young VM, Wiernik PH: Determinants of superinfection in-patients with cancer. Clin Res 1974; 22:443A.

56. Schimpff SC, Schimpff CR, Wiernik PH: Five clusters of lymphoma and leukemia patients interlinked by prior social contact. Clin Res 1974; 22: 495.

57. Sickles EA, Greene WH, Wiernik PH: Clinical presentation of infection in granulocytopenic patients. Am Fed Clin Res, 1974.

58. O'Connell M, Murphy L, Sklansky B, Abt A, Wiernik P.: Technetium sulfur colloid liver scanning in Hodgkin's disease (HD). Am Fed Clin Res, 1974.

59. Benjamin RS, O'Connell MJ, Wiernik PH: COP vs. MOPP therapy for poorly differentiated lymphocytic lymphoma (PDL). XIth Intl Cancer Cong 1974; 4: 806.

60. Benjamin RS, Riggs Jr CE, Wiernik PH, Bachur NR: Significance of Adriamycin metabolism in patients with liver disease. XIth Intl Cancer Cong 1974; 4: 751.

61. Aisner J, Sickles EA, Schimpff SC, Wiernik PH: Transtracheal selective bronchial brushing for pneumonitis in-patients with cancer. Am Soc Microbiol, 1974.

62. Schiffer CA, Buchholz DH, Aisner J, Wiernik PH: Clinical experience with transfusion of granulocytes obtained by continuous flow filtration leukopheresis. Leukocyte Separation Symp, 1974.


134



63. Schiffer CA. Aisner J, Wiernik PH: Transient neutropenia during continuous flow filtration leukopheresis. Leukocyte Separation Symp, 1974.

64. Buchholz DH, Schiffer CA, Wiernik PH, Betts SW: Granulocyte transfusion: A low cost method for filtration leukopheresis. Leukocyte Separation Symp, 1974.

65. Buchholz DH, Schiffer CA, Wiernik PH, Betts SW, Reilly JA: Granulocyte transfusion: Donor response to repeated leukopheresis. Leukocyte Separation Symp, 1974.

66. Sanel FT, Aisner J, Tillman CJ, Schiffer CA, Wiernik PH: Evaluation of granulocytes harvested by filtration leukopheresis. Functional, histochemical and ultrastructural studies. Leukocyte Separation Symp, 1974.

67. Moye L, Young V, Schimpff S, Wiernik P: Bactericidal activity of cancer chemotherapeutic agents alone and in combination with antimicrobial agents. Am Soc Microbiol, 1974.

68. Schimpff S, Schimpff C, Brager D, Wiernik PH: Fiber clusters of lymphoma and leukemia patients interlinked by prior social contact. Am Soc Mocrobiol, 1974.

69. Greene WH, Schimpff SC, Wiernik PH: Gentamicin (G) renal toxicity: Fact or fiction? Am Soc Microbiol, 1974.

70. Viola MV, Frazier M, Baxt WG, Wiernik P, Gee T.: Leukemia-specific DNA sequences in "normal" leukocytes of leukemic patients in remission. XIth Intl Cancer Cong 1974; 1:253.

71. Sanel FT, Aisner J, Schiffer CA, Wiernik P: Structure and function of granulocytes collected on nylon fibers and harvested for transfusion therapy. Am Soc Cell Biol, 1974.

72. Byhardt RW, Brace KC, Wiernik PH: Splenic irradiation in chronic lymphocytic leukemia. Am Soc Ther Radiol, 1974.

73. Buchholz DH, Schiffer CH, Wiernik PH, Betts SW: The use of frozen autologous platelets in the supportive care of patients with acute leukemia. Am Assn Blood Banks, 1974.

74. Aisner J, Kvols LK, Sickles EA, Schimpff SC, Wiernik PH: Transcricoid selective endobronchial brush biopsy for diagnosis of pulmonary infiltrate in-patients with cancer. XVth Maryland Thoracic Soc, 1975.

75. Wiernik PH, Glidewell O, Holland JF: Comparison of daunorubicin with cytosine arabinoside and thioguanine, and with a combination of all three drugs for induction therapy of previously untreated AML. Proc Am Assn Cancer Res 1975; 16: 327.


135



76. Levine MA, Wiernik PH, Aisner J, Walker MD: Intravenous CCNU (IV-CCNU) Phase I toxicity study and Phase II colorectal adenocarcinoma trial. Proc Am Soc Clin Oncol 1975; 16: 1127.

77. Smyth AC, Wiernik PH, Serpick AA: Therapy of adult acute lymphocytic leukemia (AALL) with thioguanine, oncovin, daraprim, and dexamethasone (TODD). Proc Am Soc Clin Oncol 1975; 16: 1110.

78. Wiernik PH, Schimpff SC: Daunorubicin (D) alone versus daunorubicin, pyrimethamine, cytosine arabinoside, and thioguanine (DDTA) for the treatment of acute nonlymphocytic leukemia (ANLL). Proc Am Soc Clin Oncol 1975; 16: 236.

79. Chang P, Reich S, Riggs C, Schein P, Bachur N, Wiernik P: Adriamycin (A) and streptozotocin (S) therapy for advanced sarcomas. Am Assn Cancer Res, 1975.

80. Smyth AC, Schimpff SC, Wiernik PH: Incidence and chronicity of HAA negative hepatitis in acute nonlymphocytic leukemia (ANLL). Clin Res 1975; 23: 343A.

81. Aisner J, Schimpff SC, Sutherland JC, Young VM, Wiernik PH: Torulopsis glabrata infections in-patients with cancer: An increasing incidence. Clin Res 1975; 23: 300A.

82. Aisner J, Schimpff SC, Wiernik PH: Fungal infections in patients with cancer: Changing frequency associated with broad-spectrum antibiotics. Clin Res 1975; 23: 586A.

83. Smyth AC, Schimpff SC, Wiernik PH: Incidence and chronicity of HBS Ag negative hepatitis in acute nonlymphocytic leukemia (ANLL). Am Soc Microbiol, 1975.

84. Hahn D, Schimpff SC, Fortner C, Smyth AC, Landesman S, Young VM, Wiernik PH: Changing spectrum of infection in acute leukemia patients receiving oral nonabsorbable antibiotic prophylaxis. Proc XVth Interscience Conf Antimicrob Ag Chemother, 1975.

85. Schiffer CA, Aisner J, Wiernik PH: Clinical experience with transfusion of cryopreserved platelets. Proc Am Soc Hematol, 1975; p. 102.

86. Levi JA, Wiernik PH: Unfavorable prognosis and therapeutic implications of limited extranodal (E stage) Hodgkin's disease. Proc Am Soc Hematol, 1975; p. 60, 1975.

87. Wiernik PH, Robinson L.: Radiotherapy followed by chemotherapy for early Hodgkin's disease. Proc Intl Soc Hematol, 1976.

88. Aisner J, Schimpff SC, Hahn DM, Wiernik PH: Fungal infections in-patients with cancer: Changing frequency associated with broad spectrum antibiotics. Clin Res 1976; 24: 339A.


136



89. Hahn DM, Schimpff SC, Standiford HC, Young VM, Fortner CL, Wiernik PH: Amikacin and cephalothin: Empiric therapy for febrile granulocytopenic cancer patients. Proc XVIth Interscience Conf Antimicrob Ag Chemother, 1976.

90. Aisner J, Schiffer CA, Wiernik PH: Granulocyte transfusion for infection: Comparison of filtration and intermittent centrifugation leukopheresis. Am Assn Blood Banks, 1976.

91. Van Echo DA, Wiernik PH: A Phase I study of neocarzinostatin (NSC) in-patients with previously treated acute leukemia. Proc Am Assn Cancer Res 1977; 18: 101.

92. Chang P, Wiernik PH, Reich N, Bachur R, Stoller N, Coleman K, Hande B, Chabner B.: Failure to predict response of acute non-lymphocytic leukemia (ANLL) using assays for deoxycytidine kinase (K), cytidine deaminase (D), and daunorubicin reductase (Red). Proc Am Soc Clin Oncol 1977; 18: 352.

93. Brouillet, MD, Schimpff SC, Wiernik PH, Young VM: The role of the infection control nurse in oncology. Proc Am Soc Clin Oncol 1977; 18: 318.

94. Hahn D, Schimpff S, Young V, Fortner C, Wiernik P, Standiford H: Randomized trial of empiric therapy of gentamicin, amikacin or netilmicin in combination with ticarcillin in febrile granulocyto-penic cancer patients. Proc Am Soc Clin Oncol 1977; 18: 318.

95. Schiffer C, Brager D, Wiernik P: Patient morbidity during maintenance therapy of acute non-lymphocytic leukemia (ANLL). Proc Am Soc Clin Oncol 1977; 18: 310.

96. Diggs C, Wiernik P: Cyclophosphamide, vincristine, and prednisone (CVP) vs. cyclophosphamide, Adriamycin, vincristine and prednisone (CAVP) for disseminated non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1977; 18: 288.

97. Schimpff SC, Brouillet MD, Bender J, Young VM, Fortner CL, Hahn DM, Wiernik PH: Attempts to improve compliance while maintaining efficacy of oral nonabsorbable antibiotics for infection prophylaxis. Proc Am Soc Clin Oncol 1977; 18: 319.

98. Aisner J, Esterhay RJ, Wiernik PH: Treatment of small cell carcinoma of the lung with cyclophosphamide, Adriamycin and VP16-213 with or without MER. Proc Am Soc Clin Oncol 1977; 18: 310.

99. Diggs CH, Wiernik PH, Smyth AC, Sutherland JC: Intravenous methyl CCNU (IV Me CCNU) and Ftorafur +/- MER for metastatic colorectal carcinoma. Proc Am Assn Cancer Res 1977; 18: 134.


137



100. Chang P, Wiernik PH, Reich SD, Coleman CN, Stoller R, Hande KR, Chabner BA: Prediction of response to cytosine arabinoside (Ara-C) and daunorubicin (DNR) in acute nonlymphocytic leukemia (ANLL). Proc 2nd Intl Symp Ther Acute Leukemias, 1977.

101. Wiernik PH, Esterhay RE: Treatment of acute lymphocytic leukemia (ALL) in adults. Proc 2nd Intl Symp Ther Acute Leukemias, 1977.

102. Wiernik PH, Jones B, Weinberg V, Holland JF: Present day results in young patients with acute nonlymphocytic leukemia (ANLL). Proc 2nd Intl Symp Ther Acute Leukemias, 1977.

103. Wiernik PH, Van Echo D, Lichtenfeld KM: Therapy for relapse of adult acute nonlymphocytic leukemia (ANLL) patients. Proc 2nd Intl Symp Ther Acute Leukemias, 1977.

104. Aisner J, Hedmann S, Schiffer CA, Wiernik PH: Gravity leukapheresis - A simple method of leukocyte collection for transfusion or in vitro study. Am Soc Hematol, 1977.

105. Shapiro HM, Young RE, Webb RH, Wiernik PH: Multiparameter flow cytometric characterization of cell population in acute leukemia. Blood 1977; 50:209.

106. Sanel FT, Clawson RE, Wiernik PH: Leukocyte adherence to nonphagocytosable substrates and recruitment into peritoneal exudates in complement (C) deficient mice. Am Soc Hematol, 1977.

107. Esterhay RJ, Schiffer CA, Wiernik PH: Computerized bone marrow reporting with flow sheet retrieval capability. Am Soc Hematol, 1977.

108. Schiffer CA, Aisner J, Wiernik PH: Frozen autologous platelet transfusion for patients with leukemia. Am Soc Hematol, 1977.

109. Van Echo DA, Wiernik PH, Aisner J: Reinduction therapy for relapsed adult acute nonlymphocytic leukemia (ANLL) patients. Proc Am Assn Cancer Res 1978; 19: 404.

110. Wiernik PH, Robinson L: Radiotherapy (R) vs. radiotherapy + MOP (R+C) for Hodgkin's disease (HD) confined to lymph nodes. Proc Am Soc Clin Oncol 1978; 19: 369.

111. Diggs CH, Wiernik PH, Aisner J: SCAB (Streptozotocin, CCNU, Adriamycin, bleomycin) for advanced untreated Hodgkin's disease. Proc Am Soc Clin Oncol 1978; 19: 370.

112. Wiernik PH, Jones B, Weinberg V, Holland JF: Current results in young patients (Pts) with acute nonlymphocytic leukemia (ANLL). Proc Am Assn Cancer Res 1978; 19: 145.


138



113. Chang P, Wiernik PH, Lichtenfeld JL, Schiffer CA: Levamisole (L), cytosine arabinoside (Ara-C), and daunorubicin (DNR) induction therapy of adult acute nonlymphocytic leukemia (ANLL). Proc Am Soc Clin Oncol 1978; 19: 370.

114. Espana P, Chang P, Wiernik PH: Increasing incidence of brain metastases in sarcoma patients. Proc Am Soc Clin Oncol 1978; 19: 370.

115. Schimpff SC, Wiernik PH, Wiswell J, Salvatore P: Radiation related thyroid dysfunction in Hodgkin's disease. Proc Am Soc Clin Oncol 1978; 19: 341.

116. Elias EG, Chretien PB, Monnard E, Wiernik PH: Combination chemotherapy in advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 1978; 19: 341.

117. Levine AS, Sivulich M, Wiernik PH, Levy HB: Phase I-II trial of stabilized polyriboinosinic acid polyribocytidylic acid (Poly I Poly C) in leukemia and solid tumors. Proc Am Assn Cancer Res 1978; 19: 86.

118. Love L, Hahn D, Schimpff S, Young VM, Standiford H, Bender J, Fortner C, Wiernik P: Randomized trial of empiric antibiotic therapy with ticarcillin in combination with gentamicin, amikacin or netilmicin in febrile, granulocytopenic cancer patients. Proc Am Assn Cancer Res 1978; 19: 203.

119. Bender J, Schimpff S, Brouillet M, Fortner C, Young V, Hahn D, Wiernik P: Necessity of vancomycin as a component of oral nonabsorbable antibiotics for microbial suppression in leukemic patients. Am Soc Microbiol, 1978.

120. Reinstein L, Ostrow S, Wiernik PH: Serial nerve conduction studies in cis-platinum (II) (DDP) peripheral neuropathy. Am Acad Physical Med Rehab, 1978.

121. Moody MR, Schimpff SC, Morris MJ, Young VM, Wiernik PH: In vitro activity of miconazole, miconazone nitrate, and R41-400 alone and combined with rifamycin against Candida spp and Torulopsis glabrata recovered from cancer patients. ICAAC, 1978.

122. Van Echo DA, Wiernik PH, Aisner J: Reinduction therapy for relapsed adult acute non-lymphocytic leukemia (ANLL) patients. Proc Am Assn Cancer Res 1978; 19: 144.

123. Esterhay RJ Jr, Walton PL, Wiernik PH: Computerized treatment protocols with flow sheet retrieval capability. Proc Am Soc Clin Oncol 1978; 19: 370.

124. Muggia FM, Wiernik PH, Von Hoff DD, Rozencweig M, Chiuten, D.F.: New drugs against human leukemia. XIIth Intl Cancer Cong, 1978.


139



125. Daly PH, Schiffer CA, Aisner J, Wiernik PH: A comparison of platelets prepared by the Haemonetics Model 30 and multiunit bag plateletpheresis. Am Assn Blood Banks, 1978.

126. Diggs CH, Wiernik PH: Nodular lymphoma - Complete remission prolongs survival. Blood 1978; 52(Suppl. 1): 248.

127. Esterhay RJ Jr, Grove WR, Wiernik PH: Therapy of adult acute lymphocytic leukemia (ALL) with methotrexate (M), oncovin (O), L-asparaginase (A), and dexamethasone (D) (MOAD). Blood 1978; 52(Suppl.): 248.

128. Schiffer CA, Schimpff SC, Chang P, Aisner J, Wiernik PH: Supportive care requirements during initial induction chemotherapy of adult acute nonlymphocytic leukemia (ANLL). Blood 1978; 52(Suppl. 1): 284.

129. Chiuten DF, Wiernik PH, Rozencweig M, Von Hoff DD, Muggia FM: New investigational agents of interest in hematologic malignancies. Blood 1978; 52(Suppl.1): 284.

130. Van Echo DA, Chiuten D, Gormley P, Lichtenfeld JL, Scoltock M, Wiernik PH: A Phase I study of m-AMSA. Proc Am Soc Clin Oncol 1979; 17:422.

131. Esterhay RJ Jr, Grove WR, Wiernik PH: Methotrexate (M), oncovin (O), L-asparaginase (A), and dexamethasone (D) (MOAD) therapy for adult lymphocytic leukemia (ALL). Proc Am Soc Clin Oncol 1979; 17: 350.

132. Diggs CH, Wiernik PH: SCAB (streptozotocin, CCNU, Adriamycin, bleomycin) for untreated IIIB, IVA, and IVB Hodgkin's disease. Proc Am Soc Clin Oncol 1979; 17: 435.

133. Stein RS, Golomb HM, Ultmann JE, Wiernik PH, Diggs C, Hellman S, Mauch P: Anatomic substages of Stage III Hodgkin's disease (HD): A collaborative study. Proc Am Soc Clin Oncol 1979; 17: 438.

134. Erlichman C, Strong J, Wiernik P, Edwards L, Cohen M, Levine A, Hubbard S, Chabner B: Phase I trial of PALA (N-phosphonacetyl-L-aspartate). Proc Am Soc Clin Oncol 1979; 17:314.

135. Aisner J, Weinberg V, Wiernik PH, Lesnick G, Perloff M, Weiss RB, Ellison RR, Yates J, Ginsberg SJ: Response and duration in-patients receiving combination chemotherapy for metastatic breast cancer. Impact of prior treatment. Proc Am Soc Clin Oncol 1979; 17: 421.

136. Wiernik P, Slawson RG, Burks LC, Diggs CH: A randomized trial of radiotherapy (RT) and MOPP (C) vs. MOPP alone for Stage IB-IIIA Hodgkin's disease. Proc Am Soc Clin Oncol 1979; 17: 314.


140



137. Aisner J, Govindan S, Wiernik PH, Serpick AA: Meningeal carcinomatosis with small cell carcinoma of lung (SCCL). Proc Am Assn Cancer Res 1979; 17: 228.

138. Chang P, Brenner DC, Wiernik PH: Adriamycin-Actinomycin D therapy of advanced sarcomas - Increasing response and toxicity. Proc Am Soc Clin Oncol 1979; 17: 422.

139. Ostrow S, Hahn D, Egorin M, Markus S, LeRoy A, Chang P, Wiernik PH, Bachur N: Cis-dichlorodiammine platinum (C-DDP) and Adriamycin (A) therapy for advanced gynecological (GYN) and genitourinary (GU) neoplasms. Proc Am Soc Clin Oncol 1979; 17: 350.

140. Wade J, Schimpff S, Hargadon M, Bender J, Aisner J, Young V, Wiernik P: Trimethoprim/sulfamethoxazole: Infection prophylaxis during granulocytopenia. Proc Am Soc Clin Oncol 1979; 17: 350.

141. Schiffer CA, Aisner J, Daly PA, Schimpff SC, Wiernik PH: Alloimmunization following prophylactic granulocyte transfusion. Proc Am Soc Cin Oncol 1979; 17: 346.

142. Chiuten DF, Wiernik PH, Zaharko DS, Edwards LE: Phase I-II trial and clinical pharmacology of continuously infused high dose thymidine (HD-TdR). Proc Am Assn Cancer Res 1979; 17: 76.

143. Ostrow S, Egorin M, Hahn D, LeRoy A, Markus S, Aisner J, Chang P, Foreman R, Bachur N, Wiernik PH: High dose Cis-dichlorodiammine platinum therapy: Pharmacokinetic analysis and toxicity using furosemide vs mannitol diuresis. Proc Am Assn Cancer Res 1979; 17: 88.

144. Diggs CH, Wiernik PH, Sutherland JC: Nodular lymphoma - Prolongation of survival by complete remission. Proc Am Assn Cancer Res 1979; 17:88.

145. Van Echo DA, Aisner J, Wiernik PH, Morris D, Serpick A: Combination chemotherapy of advanced breast cancer with Adriamycin and VP16-213. Proc Am Assn Cancer Res 1979; 17: 228.

146. Wade JC, Schimpff SC, Newman KA, Fortner CL, Moody MR, Young VM, Wiernik PH: Mezlocillin: A single agent as empiric antibiotic therapy. Proc Am Assn Cancer Res 1979; 17: 94.

147. Daly PA, Schiffer CA, Aisner J, Wiernik PH: Successful transfusion of platelets cryopreserved for more than 3 years. Proc Am Assn Cancer Res 1979; 17: 92.

148. Wade JC, Schimpff SC, Wiernik PH: Aminoglycoside-cephalosporin associated


141


nephrotoxicity. Clin Res 1979; 27: 481A.Publications F. Abstracts (cont.)

149. Sotman SB, Schimpff SC, Young VM, Wiernik PH: Staphylococcus aureus bacteremia in-patients with acute leukemia: Infrequency of endocarditis. Clin Res 1979; 27: 357A.

150. Daly PA, Schiffer CA, Aisner J, Wiernik PH: The value of 1-hour post transfusion counts in predicting the need for HLA-matched platelet transfusions. Clin Res 1979; 27: 292A.

151. DeVita VT, Glatstein EJ, Young RC, Ziegler JL, Wiernik PH: Changing concepts in the management of lymphomas. 2nd Intl Conf. Adjuvant Ther Cancer, 1979.

152. Chang P, Brenner D, Maurer S, Riggs C, Bachur N, Wiernik, P.: Adriamycin toxicity: Preliminary guidelines for dosage reduction. Clin Res 1979; 27: 382A.

153. Akman S, Ross D, Rosen H, Salinger C, Bachur N, Andrews P, Chou E, Wiernik P: Effects of thymidine on leukemia and normal human blood cell growth in vitro. Expl Hematol 1979; 7: 136.

154. Schiffer CA, DeBellis R, Kasdorf H, Wiernik PH: Treatment of the resistant phase of chronic myelogenous leukemia with 5-azacytidine and VP16-213. Proc Am Assn Cancer Res 1980; 21: 163.

155. Wade JC, Newman KA, Schimpff SC, Gelber RA, Wiernik, PH: Two methods for improved venous access in acute leukemia patients: Results. Proc Am Assn Cancer Res 1980; 21: 174.

156. Wiernik PH, Markus SD: Is the prognosis of a relapsed acute nonlymphocytic leukemia patient impaired by reinduction with a new drug? Proc Am Assn Cancer Res 1980; 21: 174.

157. Plaut SM, Esterhay Jr., RJ Sutherland, JC Wareheim, LE Friedman, SB Schnaper, N Kaplan, RS Wiernik PH: Psychological effects on resistance to spontaneous AKR leukemia in mice. Proc Am Assn Cancer Res 1980; 21: 108.

158. Brenner D, Chang P, Bachur N, Wiernik P: Adriamycin dosing: Relation-ship to pretreatment liver function, pharmacokinetics and response in leukemia patients. Proc Am Assn Cancer Res 1980; 21: 177.

159. Ostrow S, Egorin M, Van Echo D, Whitacre M, Grochow L, Aisner J, Colvin M, Bachur N, Wiernik P: Cyclophosphamide pharmacokinetics in-patients undergoing whole body hyperthermia. Proc Am Assn Cancer Res 1980; 21:178.

160. Schlossberger NM, Wiernik PH: The pulmonary function of post-therapy Hodgkin's disease patients. Proc Am Soc Clin Oncol 1980; 21: 468.


142



161. Ostrow S, Egorin M, Aisner J, Grochow L, Klein M, Bachur N, Colvin M, Wiernik PH: Chemotherapy of metastatic epidermoid carcinoma of the lung with cyclophosphamide and dimethylsulfoxide: Pharmacokinetics, toxicity and therapeutic efficacy. Proc Am Soc Clin Oncol 1980; 21: 332.

162. Konits PH, Aisner J, Van Echo DA, Lichtenfeld K, Wiernik PH: Mitomycin-C and vinblastine chemotherapy for advanced breast cancer. Proc Am Soc Clin Oncol 1980; 21: 410.

163. Morris D, Aisner J, Elias EG, Wiernik PH: Mastectomy as an adjunct to chemotherapy for locally advanced breast cancer. Proc Am Soc Clin Oncol 1980; 21: 410.

164. Schnaper N, Aisner J, Hahn A, Wiernik PH: Cancer therapy and the oncologist: Who me? Proc Am Soc Clin Oncol 1980; 21: 382.

165. Aisner J, Whitacre M, Van Echo DA, Esterhay Jr., RJ, Wiernik PH: Alternating non-cross resistant combination chemotherapy for small cell carcinoma of the lung. Proc Am Soc Clin Oncol 1980; 21:453.

166. Brenner D, Whiteley N, Francis A, Villasanta U, Aisner J, Wiernik, P: Use of computed-tomographic body scanner in the preoperative evaluation of locally advanced (Stage II-IVA) cervical carcinoma. Proc Am Soc Clin Oncol 1980; 21:427.

167. Fuks JZ, Van Echo DA, Aisner J, Kravitz S, Wiernik PH: A phase II trial of 4'-(9-Acridinlamino)-methanesulfon-m-anisidine in-patients with renal cell carcinoma and refractory small cell carcinoma of the lung. Proc Am Soc Clin Oncol 1980; 21:475.

168. Van Echo DA, Wiernik PH, Markus S: A phase II trial of arabinosyl-cytosine and thymidine (Ara-C + TdR) in acute leukemia. Proc Am Soc Clin Oncol 1980; 21:437.

169. Van Echo DA, Aisner J, Wiernik PH: A phase I trial of pentamethyl melamine (NSC 118742) in-patients with previously treated malignancies. Proc Am Soc Clin Oncol 1980; 21:347.

170. Cole J, Appelfeld M, Pollock S, Sutton F, Chang P, Slawson R, Wiernik PH: Constrictive pericarditis more than 5 years after radiation for Hodgkin's disease. Proc Am Soc Clin Oncol 1980; 21:466.

171. Peterson D, Overholser C, Williams L, Newman K, Schimpff S, Hahn D, Wiernik P: Reduced periodontal infection in-patients with acute nonlymphocytic leukemia following rigorous oral hygiene. Proc Am Soc Clin Oncol 1980; 21:438.


143



172. Wade JC, Wiernik PH, Schimpff SC, Schiffer CA: Hepatitis prolongation of complete remission and survival in acute nonlymphocytic leukemia patients. Proc Am Soc Clin Oncol 1980; 21:439.

173. Dutcher JP, Schiffer CA, Aisner J, Wiernik, P.H.: Platelet alloimmunization: absence of a dose response relationship. Proc Am Soc Clin Oncol 1980; 21:351.

174. Hsu LS, Elias JS, Wiernik PH, Serpick AA, Bachur NR: Natural killer cell activities against human leukemia cell line K562 and HL60 in-patients with acute nonlymphocytic leukemia. Proc Am Soc Clin Oncol 1980; 21:440.

175. Ross DD, Akman SA, Bachur NR, Wiernik PH, Groth DP: Herpes viral-like thymidine kinase activity in blast cells from patients with acute myelogenous leukemia. Proc Am Soc Clin Oncol 1980; 21:322.

176. Brown DE, Karpetsky T, Rahman A, Levy CC, Kaplan RS, Wiernik PH: Intra-cellular DNase activities of leukocyte subpopulations obtained using polynucleotide-polyacrylamide gel electrophoresis. Proc Am Soc Clin Oncol 1980; 21:326.

177. Brenner DE, Whiteley N, Aisner J, Wiernik PH: Computed tomographic scan directed biopsy or aspiration to diagnose intra-abdominal pathology. Clin Res 1980; 28:412A.

178. Wade JC, Schimpff SC, Newman KA, Young VM, Wiernik PH: Staphylococcus epidermis: an increasingly significant pathogen in granulocytopenic leukemia patients. The role of oral vancomycin. Clin Res 1980; 28:412A.

179. Ostrow S, Van Echo D, Whitacre M, Aisner J, Simon R, Wiernik PH: Physio-logic response and toxicity in-patients undergoing whole body hyper-thermia and chemotherapy. Clin Res 1980; 28:420A.

180. Riggs Jr, CE Benjamin, RS Bachur, NR Steele, MA Loveless, H, Wiernik PH: Alteration of plasma daunorubicin pharmacokinetics by combination chemotherapy. Clin Res 1980; 28:242A.

181. Ross DD, Akman SA, Rosen H, Salinger C, Rifkin S, Schrecker AW, Bachur NR Wiernik PH: Deoxynucleoside effects on growth and deoxynucleotide pools in cultured human leukemic cells. Expl Hematol 1980; 8:142.

182. Ostrow S, Egorin M, Duffey P, Shulman J, Aisner J, Wiernik PH, Bachur N: Pharmacokinetics of vindesine when given with Cis-dichloro-diammine platinum. Clin Res


144


1980; 28:652A.


183. Park CH, Amare M, Wiernik PH, Maloney TR: Correlation of clinical response of acute nonlymphocytic leukemia (ANLL) to colony formation of cells treated with conyinuous or pulse drug exposures. Proc Am Assoc Cancer Res 1981; 22:152.

184. Wiernik PH, Longo D, Duffey PL, Young RC, DeVita VT: MOPP vs MOPP alternating with streptozotocin, CCNU, adriamycin and bleomycin (SCAB) for advanced Hodgkin's disease. Proc Am Assoc Cancer Res 1981; 22:159.

185. Egorin M, Kaplan R, Salcman M, Miles L, Colvin M, Wiernik P, Bachur N: Plasma and cerebrospinal fluid (CSF) pharmacokinetics of cyclophosphamide (CYC) inpatients treated with and without dimethyl sulfoxide (DMSO). Proc Am Assn Cancer Res 1981; 22:210.

186. Van Echo DA, Markus SD, Schimpff SC, Wiernik PH: A phase II trial of 4'-(9-acridinylamino)-methanesulfon-m-aniside (AMSA) in adult relapsed acute leukemia. Proc Am Assn Cancer Res 1981; 22:230.

187. Konits PH, Van Echo DA, Egorin M, Aisner, J, Andrews P, May M, Kaplan R, Bachur NR, Wiernik PH: Phase II evaluation of 6-thioguanine (6TG) in-patients with metastatic colorectal carcinoma. Proc Am Assn Cancer Res 1981; 22:260

188. Brenner DE, Van Echo DA, Riggs CE, Wesley M, Whitacre M , Aisner J, Wiernik PH, Bachur NR: Hyperthermia induced changes in adriamycin pharmacokinetics in sarcoma patients receiving whole-body hyper-thermia, adriamycin and cyclophosphamide. Proc Am Assn Cancer Res 1981; 22:260.

189. Brenner DE, Whitley NO, Houk T, Aisner J, Wiernik PH, Whitley J: Tumor volume measurements by computed tomography. Proc Am Soc Clin Oncol 1981; 22:347.

190. Egorin MJ, Van Echo DA, Whitacre MY, Fox BM, Aisner J, Wiernik PH, Bachur NR: A phase I trial of aclacinomycin-A (ACM_A). Proc Am Soc Clin Oncol 1981; 22:353.

191. Kaplan RF, Riggs CE, Miles LM, Salcman M, Aisner J, Wiernik PH, Bachur NR: Preliminary observations on the effects of dimethyl sulfoxide on the metabolism and distribution of adriamycin. Proc Am Soc Clin Oncol 1981; 22:367.

192. Whitacre MY, Van Echo DA, Aisner J, Klein M, Wiernik PH: A phase I trial of dihydroxyanthracenedione (DHAD) employing an intravenous daily x 3 schedule. Proc Am Soc Clin Oncol 1981; 22:369.

193. Konits PH, Wiernik PH, Aisner J, Rulenz CA: Pregnancy outcome in-patients treated for


145


Hodgkin's disease (HD). Proc Am Soc Clin Oncol 1981; 22:381.


194. Schimpff SC, Bishop JO, Wiernik PH, Leavitt RD: Infections in non-Hodgkin's lymphoma patients undergoing intensive chemotherapy. Proc Am Soc Clin Oncol 1981; 22:417.

195. Aisner J, Weinberg V, Perloff M, Weiss R, Reich P, Perry M, Wiernik PH: Chemoimmunotherapy for advanced breast cancer: A randomized compari-son of 6 combinations (CMF, CAF vs CAFVP) each with or without MER immunotherapy. A CALGB study. Proc Am Soc Clin Oncol 1981; 22:443.

196. Garbino C, Brenner DE, Kasdorf H, Villasanta U, Pocaro R, Yovarone J, Konits P, Aisner J, Schiffer CA, Wiernik PH: A phase II study of AMSA in-patients with advanced gynecologic malignancies. Proc Am Soc Clin Oncol 1981; 22:465.

197. Van Sloten K, Wiernik PH, Riggs C, Brenner D, Wesley M, Schnaper N: Prognostic significance of vomiting after "7 + 3" for ANLL. Proc Am Soc Clin Oncol 1981; 22:482.

198. Van Echo DA, Markus S, Wiernik PH: A phase III trial of arabinosyl-cytosine and thymidine (Ara-C + TdR) in adult relapsed acute leukemia (AL). Proc Am Soc Clin Oncol 1981; 22:483.

199. Esterhay RJ, Mrakus SD, Grove WR, Newman KA, Schimpff SC, Wiernik PH: Infection in adult acute lymphocytic leukemia patients receiving oral prophylactic antibiotics. Proc Am Soc Clin Oncol 1981; 22:484.

200. Wiernik PH, Holland JF, Rai K, Cuttner J, Ellison RR, Glidewell O, Wesley M: Comparison of bone marrow transplantation (BMT) with chemotherapy alone for remission maintenance in acute myelogenous leukemia (AML). Proc Am Soc Clin Oncol 1981; 22:484.

201. Yates JW, Glidewell O, Wiernik P, Holland JF: A study of daunorubicin versus adriamycin induction in monthly vs. bi-monthly maintenance in acute myelocytic leukemia from CALGB. Proc Am Soc Clin Oncol 1981; 22:487.

202. Dutcher JP, Schiffer CA, Wesley M, Wiernik PH: Effect of hyperleukocytosis in acute leukemia on remission rate, duration and survival. Proc Am Soc Clin Oncol 1981; 22:491.

203. Fuks JZ, Aisner J, Ostrow SS, Wiernik PH: Restaging laparotomy in the management of the non-Hodgkin's lymphomas. Proc Am Soc Clin Oncol 1981; 22:511.

204. Coker DD, Morris DM, Coleman JJ, Cutait R, Wiernik PH: Restaging laparotomy in Hodgkin's disease. Proc Am Soc Clin Oncol 1981; 22:512.


146


205. Kaplan RS, Bishop JF, Diggs CH, Wiernik PH: VM-26 and bleomycin plus adriamycin or cis-dichlorodiammine platinum-II (DDP) in previously treated patients with non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 1981; 22:512.


206. Bishop JF, Wiernik PH, Kaplan RS, Wesley M, Diggs CH, Sutherland JC, Markus SD: High-dose cyclophosphamide, vincristine and prednisone plus or minus adriamycin (CAVP vs CVP) in advanced poorly-differentiated lymphocytic-histiocytic lymphoma (NHL): A randomized trial. Proc Am Soc Clin Oncol 1981; 22:518.

207. Bunn P, Rosen S, Aisner J, Matthews M, Glatstein E, Ihde D, Wiernik P: Carcinomatous leptominengitis in patients with small cell lung cancer: A frequent, treatable complication. Proc Am Assn Cancer Res 1981; 22:162.

208. deJongh D, Wade J, Schimpff S, Newman K, Finley R, Fortner C, Moody M, Wiernik P, Hahn D: Moxalactam plus amikacin or ticarcillin plus amikacin: double blind comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients. Proc Am Soc Clin Oncol 1981; 22:417.

209. McIntyre OR, Pajak TF, Wiernik P, Glowienka LP, Cornwell GG, Harley J, Leone L: Delayed acute leukemia in myeloma patients receiving pulsed vs. continuous treatment. Blood 1981; 58:167a.

210. Dutcher JP, Schiffer CA, Johnston GS, Papenberg D, Daly PA, Aisner J, Wiernik PH: The effect of histocompatibility factors on the migration of transfused 111indium-labeled granulocytes. Blood 1981; 58:181a.

211. Schiffer CA, AisnerJ, Dutcher JP, Wiernik PH: Short term engraftment following transfusion of leucocytes from patients with chronic myelogenous leukemia (CML). Blood 1981; 58:186a.

212. Aisner J, Fuks JZ, Van Echo DA, Budman D, Carney D, Levitt M, Klein M, Wiernik PH: Phase II study of aziridinylbenzoquinone (AZQ) in-patients with refractory small cell carcinoma of the lung (SCCL). Proc Am Soc Clin Oncol 1982; 1:148.

213. Aroney RS, Kaplan RS, Wiernik PH: A phase II trial of AZQ (NSC 182986) in patients with recurrent primary or metastatic brain tumors. Proc Am Soc Clin Oncol 1982; 1:24, 1982.

214. Coker DD, Morris DM, Coleman JJ, Schimpff SC, Wiernik PH, Elias EG: Infection among 210 patients with surgically staged Hodgkin's disease. Proc Am Soc Clin Oncol 1982; 1:55.

215. deJongh C, Wade J, Finley R, Joshi J, Aisner J, Schimpff SC, Wiernik P: Double blind, randomized comparison of trimethoprim/sulfamethoxazole versus placebo for prophylaxis of infection in-patients with oat cell carcinoma. Proc Am Soc Clin Oncol 1982; 1:55.


147



216. deJongh C, Wade JC, Finley RS, Joshi JH, Aisner J, Schimpff SC, Wiernik PH: A prospective, double blind, placebo controlled evaluation of trimethoprim/sulfamethoxazole for infection prevention in-patients with oat cell carcinoma of the lung. Intl Assn Small Cell Lung Cancer, 1982.

217. Dutcher JP, Schiffer CA, Aisner J, O'Connell BA, Levy C, Kendall JA, Wiernik PH: Incidence of thrombocytopenia and bleeding among patients with solid tumors. Proc Am Soc Clin Oncol 1982; 1:62.

218. Dutcher JP, Schiffer CA, Aisner J, Wiernik PH: Long term follow-up of patients with leukemia receiving platelet transfusion: identification of a large group of patients who do not become alloimmunized. Am Assn Blood Banks, 1982.

219. Klein ME, Akman SA, Wiernik PH: Deleterious effect of aspirin in the asymptomatic patient with spontaneous factor VIII inhibitor. Thromb Diath Haem 1982; 46:332.

220. Egorin MJ, Fuks JZ, Van Echo DA, Bishop J, Shulman G, Jones B, Aisner J, Wiernik P, Bachur NR: The effect of probenecid on the pharmacokinetics and toxicities of cisplatin (DDP). Proc Am Soc Clin Oncol 1982; 1:18.

221. Espana P, Kaplan R, Robichaud K, Gustafson P, Wiernik P, Smith F, Woolley P, Schein P: Phase II study of spirogermanium (SpiroG) in lymphoma patients. Proc Am Soc Clin Oncol 1982; 1:166.

222. Forastiere AA, Crain SM, Coker DD, Elias EG, Amor R, Wiernik PH: Cisplatin (P) and cyclophosphamide (C) combination chemotherapy in advanced head and neck squamous cell cancer (HNSCC). Proc Am Soc Clin Oncol 1982; 1:196.

223. Fuks JZ, Van Echo DA, Aisner J, Schipper H, Levitt M, Ostrow S, Klein M, Wiernik PH: Cyclophosphamide (C), adriamycin (A) and etoposide (E) with or without cis-platinum (P) (CAEP vs CAE) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1982; 1:145.

224. Fuks JZ, Van Echo DA, Aisner J, Ostrow S, Wiernik PH: Medroxyproges-terone plus tamoxifen for advanced renal cell carcinoma. Proc Am Assn Cancer Res 1982; 23:154.

225. Gerad H, Van Echo DA, Ostrow S, Whitacre MY, Aisner J, Wiernik PH: Adriamycin (ADR), Cytoxan (CY) and whole body hyperthermia (WBH) for soft tissue sarcoma (STS). Proc Am Soc Clin Oncol 1982; 1:175.


148



226. Joshi JH, deJongh CA, Schnaper N, Fortner CL, Wiernik PH: Amphetamine therapy for enhancing the comfort of terminally ill patients with cancer. Proc Am Soc Clin Oncol 1982; 1:55.

227. Leavitt RD, Duffey PL, Wiernik PH: A phase I trial of twice daily recombinant human leukocyte A interferon (IFL-rA) in cancer patients. Proc Am Soc Clin Oncol 1982; 1:41.

228. Park CH, Amare M, Wiernik PH, Van Sloten K, Morrison FA, Maloney TR: Clinical correlations of in vitro chemotherapy sensitivity on leukemic colony forming cells (CFC). Conf Human Tumor Cloning, 1982.

229. Pollak A, Dimery IW, Wiernik PH, Bachur NR: Ultrastructure of K562 cells induced to differentiate along the erythroid pathway. Proc Am Assn Cancer Res 1982; 23:37.

230. Poplin EA, Aisner J, Van Echo DA, Whitacre M, Esterhay RJ, Jr, Wiernik PH: Treatment of refractory small cell carcinoma of the lung (SCCL) with COMP. Proc Am Soc Clin Oncol 1982; 1:145.

231. Schiffer CA, Aisner J, Dutcher JP, Reilly J, Wiernik PH: A clinical program of autologous frozen platelet transfusion. Am Assn Blood Banks, 1982.

232. Van Echo DA, Shulman PN, Ferrari A, Budman D, Markus SD, Wiernik PH: A phase II trial of mitoxantrone (DHAD, NSC301739) in adult acute leukemia (AL). Proc Am Soc Clin Oncol 1982; 1:132.

233. Whitacre MY, Van Echo DA, Budman DR, Shulman P, Aisner J, Wiernik PH: A phase I trial of 5 day conyonuous infusion aziridinylbenzoquinone (AZQ, NSC 182986). Proc Am Soc Clin Oncol 1982; 1:24.

234. Brenner D, Forastiere A, Rosenschein N, Jones H, Dillon M, Grumbine F, Tipping S, Aisner J, Burnett L, Greco FA, Wiernik PH: A phase II study of spirogermanium in-patients with advanced carcinomas of the ovary and cervix. Proc Am Soc Clin Oncol 1982; 1:115.

235. Maluish AE, Ortaldo JR, Sherwin S, Leavitt R, Strong DM, Fine S, Wiernik P, Oldham RK, Herberman RB. Immunological monoitoring of patients receiving recombinant leukocyte A interferon. Proc Am Soc Clin Oncol 1982; 1:39.

236. Park CM, Amare M, Wiernik PH, Van Sloten K, Morrison FS, Maloney TR: Drug sensitivity of acute nonlymphocytic leukemia-colony forming cells (L-CFC) and clinical


149


correlations. Proc Am Soc Clin Oncol 1982; 1:138.


237. Applefeld MM, Johnston GS, Wiernik PH: Changes in left ventricular function in patients treated by radiotherapy for Hodgkin's disease. Clin Res 1982; 30:168A.

238. Finley R, deJongh C, Wade J, Newman K, Schimpff S, Fortner C, Britten J, Caplan E, Wiernik P: A comparison of standard vs pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients. Clin Res 1982; 30:366A.

239. Aisner J, Schnaper N, Duffey P, Vreeland F, Gans D, Wiernik PH: Levonantradol (LEV) vs placebo (PLB) for chemotherapy-induced nausea (N) and vomiting (V) resistant to conventional antiemetics. Clin Res 1982; 30: 366A.

240. Aroney RS, Aisner J, Wesley MN, Whitacre MY, Van Echo DA, Wiernik PH: The value of prophylactic cranial irradiation (PVI) given at complete remission in small cell lung carcinoma (SCLC). Clin Res 1982; 30:414A.

241. Aroney RS, Dermody WC, Aldenedrfer P, Parsons R, McNitt K, Marangos PJ, Whitacre MY, Aisner J, Ruddon RW, Wiernik PH: Multiple sequential biomarkers in monoritoring patients (pts) with small cell lung carcinoma (SCLC). Clin Res 1982; 30:413A.

242. deJongh C, Joshi J, Finley R, Newman K, Wiernik P, Schimpff S: Prospective, randomized evaluation of prophylactic ketoconazole in granulocytopenic leukemia patients. Clin Res 1982; 30:416A.

243. Peterson DE, Overholser CD, Williams LT, Newman KA, Schimpff SC, Wiernik PH: Acute periodontal infection at admission in acute nonlymphocytic leukemia patients. Clin Res 1982; 30:422A.

244. Riggs Jr CE, Wiernik PH, Bachur NR: Indocyanine green-possible predictor of altered doxorubicin (adriamycin) pharmacokinetics in patients with normal liver function. Clin Res 1982; 30:423A.

245. Joshi JH, Wang KP, deJongh CA, Newman KA, Wiernik PH, Schimpff SC: A comparative evaluation of two fiberoptic bronchoscopy cathers: the plugged telescoping cather versus the single sheathed nonplugged catheter. Clin Res 1982; 30:431A.

246. Applefeld MM, Whitley NO, Sutton FJ, Whitely JE, Wiernik PH: Comparison of noninvasive methods in the diagnosis of constrictive pericarditis. Am Heart Assn, 1982.

247. Taylor AL, Appelfeld MM, Wiernik PH, Grochow LB, Mader LC, Bulkley BM: Acute


150


anthracycline toxicity: Comparative study of four analogues. Am Heart Assn, 1982.


248. Schiffer CA, Dutcher JP, Aisner J, Hogge D, Wiernik PH, Reilly P: A randomized trial of leukocyte depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1982; 60(suppl):182a.

249. Bloomfield CD, Preisler H, Cuttner J, Yates J, Rai K, Wiernik P, Berkowitz E, Anderson J: Treatment-induced acute non-lymphocytic leukemia (t-ANLL): response to cytarabine-anthracycline therapy. Blood 1982; 60 (suppl):152a.

250. Schulman P, Van Echo D, Budman D, Ferrari A, Markus S, Wiernik PH: Phase II trial of mitoxantrone (DHAD NSC 301739) in blastic phase in chronic myelogenous leukemia (B-CML). Blood 1982; 60 (suppl):158a.

251. Wiernik PH: Prognostic factors in acute nonlymphocytic leukemia (ANLL). Proc 3rd Intl Symp Ther Acute Leukemias. 1982; p.12.

252. Dutcher JP, Wiernik PH, Van Sloten K, Schiffer CA, Schimpff SC, Aisner J, Angelou JE: Intensive maintenance therapy in acute nonlymphocytic leukemia (ANLL). Proc 3rd Intl Symp Ther Acute Leukemias. 1982; p.125.

253. Sutherland JC, Dutcher JP, Wiernik PH: Morphologic study of spleens taken from patients with acute nonlymphocytic leukemia (ANLL) in complete remission. Proc 3rd Intl Symp Ther Acute Leukemias. 1982; p.45.

254. Dutcher JP, Schiffer CA, Johnston GS, Papenberg D, Daly PA, Fox JJ, Aisner J, Wiernik PH: Indium-labelled granulocytes to evaluate histocompatibility factors in granulocyte transfusions. Proc 3rd Intl Symp Ther Acute Leukemias. 1982; p.125.

255. Esterhay RJ, Wiernik PH, Markus JP, Wesley MN: Treatment of acute lymphocytic leukemia in adults. Proc 3rd Intl Symp Ther Acute Leukemias. 1982; p. 303.

256. Park CH, Amare M, Wiernik PH, Morrison FS, Dutcher JP, Myers JA: Versatile drug exposure times for improved clinical chemotherapy correlation by cloning assay in acute nonlymphocytic leukemia. Proc Am Soc Clin Oncol 1983; 2:28.

257. Forshoff CA, Dutcher JP, Wiernik PH: Incidence of central nervous system leukemia (CNSL) in acute nonlymphocytic leukemia (ANLL). Proc Am Soc Clin Oncol 1983; 2:177.

258. Riggs CE, Tipping SJ, Angelou JE, Bachur NR, Wiernik PH: Human pharmacokinetics of continuous infusion adriamycin (ADR). Proc Am Soc Clin Oncol 1983; 2:32.


151



259. Gerad H, Van Echo DA, Donehower M, Wiernik P, Wiernik, PH, Aisner J: A phase I-II trial of anthracenedicarboxaldehyde (ADC, NSC 301739) in refractory adult leukemia (AL). Proc Am Soc Clin Oncol 1983; 2:176.

260. O'Dwyer PJ, Wiernik PH, Finlay R, Ungerleider RS: A randomized trial of radiotherapy (RT) and MOPP (C) vs. MOPP alone for stages IB-IIIA Hodgkin's disease. Proc Am Soc Clin Oncol 1983; 2:214.

261. Dutcher JP, Wiernik PH, Van Sloten K, Schiffer CA, Schimpff SC, Aisner J, Angelou JE: Intensive maintenance therapy (IMT) in acute nonlympho-cytic leukemia (ANLL). Clin Pharmacol Ther 1983; 33:221.

262. Whitacre MY, Van Echo DA, Appelfeld M, Wiernik PH, Aisner J: Phase I study of homoharringtonine (NSC-141633). Proc Am Soc Clin Oncol 1983; 2:33.

263. Aisner J, Whitacre M, Van Echo DA, Fuks JZ, Wiernik PH: Doxorubicin, cyclophosphamide, and etoposide (ACE) by bolus or continuous infusion for small cell carcinoma of the lung (SCCL). Proc Am Soc Clin Oncol 1983; 2:196.

264. Dutcher JP, Schiffer CA, Johnston GS, Papenberg D, Wiernik PH: Indium-labelled granulocytes to evaluate histocompatibility factors in granulocyte transfusions. Expl Hematol 1982; 11:171.

265. Dutcher JP, Markus S, Wiernik PH, Weinberg V, Schiffer CA, Aisner J, Van Sloten K: Intensive maintenance therapy in acute non-lymphocytic leukemia (ANLL). Blood 1983; 62(suppl 1):201a.

266. Camacho FJ, Oken MM, O'Connell MJ, Perri RT, Phillips V, Wiernik PH: A pilot study of methylglyoxal bisguanylhydrazone (MBGB), vindesine (VDS) and cis-platinum (CDDP) in-patients (pts.) with refractory malignant lymphoma. Blood 1983; 62(suppl 1):210a.

267. Camacho FJ, Moll B, Noel BE, Becker NH, Spigland I, Emeson E, Greenwald ES, Wiernik PH: Lymphadenopathy and immunodeficiency in patients with sickle cell disease. Blood 1983; 62(suppl 1):189a.

268. D'Olimpio JT, Camacho F, Bulkin W, Wiernik PH: Immune thrombocytopenia (ITP) in a spleenectomized female Hodgkin's disease (HD) patient seven years after complete remission. Blood 1983; 62(suppl 1):189a.


152


269. Leavitt RD, Duffey P, Wiernik PH: A phase I/II study of recombinant leukocyte-A interferon in previously treated acute leukemia. Blood 1983; 62 (suppl 1):205a.


270. Paietta E, Braunstein JD, Romney SL, Wiernik PH: Hormonal modulation of the cervix carcinoma cell line C41 and its interference with retinoic acid induced growth inhibition. J Steroid Biochem 1983; 19:S55.

271. Dutcher JP, Whitley NO, Pearl P, Finley R, Smardon C, Wiernik PH: Ethiodized oil emulsion-13 (EOE-13) for improved CT visualization of liver and spleen metastases. Clin Res 1983; 31:695A.

272. Kadakia AS, Dutcher JP, Wiernik PH: Association of thyroid disease (TD) with acute leukemias (AL). Clin Res 1983; 31:695A.

273. Paietta E, Dutcher JP, Wiernik PH: TdT-positive acute progranulocytic leukemia: Loss of TdT activity during differentiation with retinoids. Blood 1983; 62(suppl 1):179a.

274. Park CH Amare M, Wiernik PH, Morrison FS, Dutcher JP, Maloney TR: In vitro drug sensitivity of leukemic colony-forming cells in acute nonlymphocytic leukemia: Clinical correlation update with various drug exposure methods. Proc 4th Intl Conf Human Tumor Cloning, 1984.

275. Terebelo H, Anderson K, Cuttner J, Berenberg J, Wiernik PH: Tandem methotrexate (MTX) and L-asparaginase (ASP) combined with vincristine (VCR) and prednisone in relapsed or refractory adult acute lymphoblastic leukemia (ALL). Proc Am Soc Clin Oncol 1984; 3:207.

276. Paietta E, Dutcher JP, Wiernik PH: Retinoic acid induces maturation of leukemic lymphocytes in vitro. Proc Am Soc Clin Oncol 1984; 3:65.

277. Dutcher J, Moorehouse H, Pollack S, Wiernik P: Ethiodized oil emulsion-13 (EOE-13): A new contrast agent for CT demonstration of hepatic and splenic metastases. Proc Am Soc Clin Oncol 1984; 3:17.

278. Camacho F, Oken M, O'Connell M, Perri R, Phillips V, Wiernik P: Salvage therapy in-patients (PTS) with refractory malignant lymphoma using methylglyoxal bisguanylhydrazone (MGBG), vindesine (VDS) and cis-platinum (CDDP). Proc Am Soc Clin Oncol 1984; 3:242.

279. D'Olimpio JT, Camacho FJ, Chandra P, Lesser M, Maldonado M, Wollner D, Wiernik PH: Anti-emetic treatment of patients (PTS) receiving cisplatin (DDP) based chemotherapy (CTX) with high dose dexamethasone (DEX) vs. placebo (P).: A randomized double blind controlled clinical trial. Proc Am Soc Clin Oncol 1984; 3:95.


153


280. Schectman G, Camacho FJ, Vogl SE, Greenwald ES, Parkinson DR, Chervenick PA, Wiernik PH: A phase II study of vindesine (V) infusion and cis-platinum (DDP) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1984; 3:217.


281. Dutcher J, Wiernik P, Goldstein M, Berenzweig M, Camacho F, Ryan J: Low dose cytosine arabinoside (LD ARAC) for treatment of acute nonlymphocytic leukemia (ANLL and myelodysplastic syndrome (MDS) in elderly patients (PTS). Proc Am Assn Cancer Res 1984; 25:189.

282. Paietta E, Braunstein JP, Romney SL, Wiernik PH: Hormonal response to retinoic acid of the cervical carcinoma cell line C41. Proc Am Assn Cancer Res 1984; 25:45.

283. Paietta E, Goldstein M, Papenhausen P, D'Olimio J, Wiernik PH: Blast crisis in chronic lymphocytic leukemia (CLL): In vitro differentiation by estradiol (E2). Clin Res 1984; 32:318A.

284. Dutcher JP, Wiernik PH: Combined modality treatment of Hodgkin's disease confined to lymph nodes. Proc 2nd Intl Conf Malig Lymphoma, 1984.

285. O'Dwyer PJ, Stewart MB, Wiernik PH: MOPP vs. radiotherapy/MOPP for early-stage Hodgkin's disease (HD) - A six year follow-up. Proc 2nd Intl Conf Malig Lymphoma, 1984.

286. Doerr R, Chiuten D, Wiernik P, Reid L: Culture assay for predicting a tumor's metastatic potential. Proc Surg Forum, 1984.

287. Paietta E, Wiernik, PH: Influence of estradiol-receptor expression on cell cycle progression in B- and T-lymphocytic leukemia cell lines. Exptl Hematol 1984; 12:436.

288. Dutcher JP, Wiernik PH: Treatment of acute non-lymphocytic leukemia in-patients older than 60 years of age. Proc XX Cong Intl Soc Hematol, 1984.

289. Paietta E, Dutcher JP, Papenhausen P, Wiernik PH: Acute promyelocytic leukemia (APL) as diagnosed by cytogenetics and in vitro induction of differentiation. Clin Res 1984; 32:706A.

290. Young RC, Longo DL, Glatstein E, Duffey PL, Winkler CF, Wiernik PH, DeVita Jr VT: The current status of NCI trials in Hodgkin's disease. Proc 2nd Intl Conf Malig Lymphoma, 1984.

291. Paietta E, Jacobson G, Wiernik PH: Modulation of proliferation and estradiol-receptor (ER) expression by monoclonal antibodies in a B-lymphoblastoid cell line (NAMALVA). Proc 2nd Intl Workshop Conf Human Leukocyte Differentiation Antigens, 1984.


154


292. Markman HD, Wiernik PH, Dutcher JP, Charbonneau D: The unfulfilled obligation of many medical schools to teach colorectal cancer detection in clinical medicine. Med Pediatr Oncol 1984; 12:29A.


293. Paietta E, Jacobson G, Wiernik PH: New insights into malignant phenotypes by neuraminidase-treament (NT) of Hodgkin's and promyelocytic cell lines. Blood 1984; 64:195a.

294. Paietta E, Reed J, Dutcher JP, Ciobanu N, Jacobson G, Wiernik PH: Estradiol receptors (ER) in chronic lymphocytic leukemia (CLL): Effect of hydrocortisone in vivo and in vitro. Blood 1984; 64:171a.

295. Ciobanu N, Paietta E, Andreeff M, Papenhausen P, Wiernik PH: In vitro VP-16 purging for autologous marrow transplantation. Blood 1984; 64:212a.

296. Dutcher JP, Strauman JJ, Wiernik PH: Treatment of acute nonlymphocytic leukemia in-patients older than 60 years of age. Blood 1984; 64:163a.

297. Paietta E, Andreeff M, Papenhausen P, Roberts M, Wiernik PH: Biphenotypic leukemias. XIIth Symp Compar Res Leukemia Rel Diseases, 1985.

298. Paietta E, Wiernik PH: Hodgkin's cell lines: immunologically incompatible with any defined hematopoietic cell type. Clin Res 1985; 33:384A.

299. Paietta E, Reed J, Pazello T, Wiernik PH: Estradiol receptors (ER) in circulating lymphocytes: A new prognostic parameter in breast cancer. Proc Am Soc Clin Oncol 1985; 4:70.

300. Lira-Puerto V, Piccart M, Wiernik PH, Wernz J, Muggia F: A comparison of US and Mexican experience with single drug therapy in advanced cervical cancer. (NCI-PAHO and ECOG study). Proc Am Soc Clin Oncol 1985; 4:117.

301. Dutcher JP, Wiernik PH, Strauman JJ, Spielvogel A, Dukart G: Mitox-antrone (MITOX) and cytosine arabinoside (ARA-C) in acute nonlympho-cytic leukemia (ANLL) and blast crisis of chronic myelogenous leukemia (CML-B). Proc Am Soc Clin Oncol 1985; 4:170.

302. DeBellis R, Fuks J, Caneiro A, Wiernik PH, Schiffer CA: Intensive combination chemotherapeutic treatment of multiple myeloma. Proc Am Soc Clin Oncol 1985; 4:215

303. Lipton RE, Dutcher JP, Berger A, Arezzo J, Wiernik PH, Schaumberg HH: Early detection of peripheral neuropathy in cancer patients. Proc Am Soc Clin Oncol 1985; 4:261.


155


304. Engel S, Schwartz EL, Strauman JJ, Wiernik PH: High performance liquid chromatographic analysis (HPLC) and human pharmacokinetics of taxol (NSC 125973). Proc Am Assn Cancer Res 1985; 26:158.


305. Paietta E, Wiernik PH: Variable reactivity of monoclonal antibodies (MAB) against the X-hapten indicates structural differences in the X-determinant expressed on Hodgkin's (HD) and other cell lines: Effect of neuramidase treatment (NT). Proc Am Assn Cancer Res 1985; 26:293.

306. Engel SI, Schwartz EL, Strauman JJ, Wiernik PH: The pharmacokinetics of taxol at myelosuppressive doses. J Clin Pharmacol 1985; 25:457.

307. Paietta E, Saltzman BR, Klein RS, Friedland GH, Wiernik PH: A "Hodgkin's-specific" antigen (Ki-1) expressed on mononuclear cells from patients with AIDS. ICAAC, 1985.

308. Dutcher JP, Kendall J, Papenberg D, Schiffer CA, Aisner J, Wiernik PH: Concurrent administration of amphotericin B (AMPHO) and granulocyte transfusions (GRAN TX); lack of detrimental effect. Am Assn Blood Banks, 1985.

309. Paietta E, Stockert RJ, Morell AG, Wiernik PH: Hodgkin's cells and the hepatic asialoglycoprotein receptor express a common immuno-determinant. Proc Am Soc Cell Biol, 1985.

310. Paietta E, Papenhausen P, Dutcher JP, Wiernik PH: CML-blast crisis: Immunologic and karyotypic heterogeneity. Blood 1985; 66(5):181a.

311. Dutcher JP, Spivack M, Mohandas K, Wiernik PH: A clinical program of platelet cryopreservation. VIIIth Intl Soc Haematol, 1985.

312. Dutcher JP, Markus S, Schiffer CA, Wiernik PH: Intensive maintenance therapy (IMT) in acute non-lymphocytic leukemia (ANLL). Proc Am Soc Clin Oncol 1986; 5:152.

313. Paietta E, Andreeff M, Papenhausen P, Roberts M, Wiernik PH: Bipheno-typic and undifferentiated acute leukemias: In-vitro induction of differentiation. Proc Am Soc Clin Oncol 1986; 5:8.

314. Wiernik PH, Strauman JJ, Engel SI, Schwartz EL, Dutcher JP: Taxol (T) phase I and pharmacokinetic study. Proc Am Soc Clin Oncol 1986; 5:32.

315. Paietta E, Stockert RJ, Morell AG, Diehl V, Wiernik PH: Unique myeloid antigen of cultured Hodgkin's cells: A lectin and putative sialyltransferase. Proc Am Assn Cancer Res


156


1986; 27:364.

316. Athan ES, Gallagher RE, Papenhausen PR, Augenlicht LH, Diehl V, Wiernik PH: Immunoglobulin (Ig) gene rearrangements in cultured Hodgkin's disease (HD) cells. Proc Am Assn Cancer Res 1986; 27:51.


317. Park CH, Kimler BF, Amare M, Wiernik PH, Dutcher JP, Morrison FS, Maloney TR: The clinical implication and prognostic value of in vitro L-ascorbic acid (LAA) sensitivity of clonogenic cells in acute nonlymphocytic leukemia (ANLL). Proc Am Soc Clin Oncol, 1986.

318. Dutcher JP, Strauman JJ, Paciucci PA, Holland JF, Wiernik PH: Mitoxantrone (MITOX) and cytarabine for treatment of chronic myelogenous leukemia-blast crisis (CML-BC). Proc Am Soc Clin Oncol 1986; 5:166.

319. Paietta E, Gallagher R, Wiernik PH, Stockert RJ: HL-60 cells express a sialic acid/N-acetylglucosamine specific lectin responsive to monocytic maturation. Fed Proc 1986; 45:1573.

320. Dutcher JP, Kendall J, Papenberg D, Schiffer CA, Aisner J, Wiernik PH: Concurrent administration of amphotericin B (AMPHO) and granulocyte transfusion (GRAN TX): Lack of detrimental effect. Clin Res 1986; 34:561A.

321. Wiernik PH, Schiffer CA: Treatment of advanced untreated Hodgkin's disease (HD) with streptozotocin, lomustine, doxorubicin and bleomycin (SCAB) - Results 10 years later. Clin Res 1986; 34:572A.

322. Ciobanu N, Paietta E, Lalezari P, Dutcher JP, Thompson D, Wiernik PH: L-leucyl-leucine methyl ester prevents the generation and inhibits the activity of lymphokine activated killer (LAK) cells. Blood 1986; 68(suppl.):93a.

323. Paietta E, Stockert RJ, Calvelli T, Papenhausen P, Wiernik PH, Bollum FJ: TdT-positive variant of HL-60 cells: A biphenotype with cytogenetics of T-ALL and suppressor activity. Blood 1986; 68 (suppl.):261a.

324. Dutcher JP, Paciucci PA, Wiernik PH, Strauman JJ, Cuttner J, Holland JF: Mitoxantrone (M) + Ara-C in-patients with relapsed or refractory acute myelocytic leukemia. Blood 68(suppl.):221a, 1986.

325. Leiby J, Capizzi R, Maroun J, Wiernik P, Goldberg D, Robert F, Bersagel D, DeConti R, Stewart J, Velez-Garcia E, Arlin Z, Martelo O, Panassi L, Grace M, Robert N, Jolivet J, DeLap R, Grillo-Lopez R: Phase 2 evaluation of the anticancer efficacy of trimetrexate. Proc 5th NCI-EORTC Symp New Drugs Cancer Ther, 1986.


157


326. Lipton RB, Dutcher J, Arezzo J, Kaplan J, Wiernik P, Schaumberg HH: Taxol produces a predominantly sensory neuropathy. Ann Neurol 1986; 20:132.


327. Dutcher JP, Paciucci PA, Wiernik PH, Strauman JJ, Cuttner J, Holland JF: Mitoxantrone and Ara-C in the treatment of relapsed or refractory ANLL. 4th Intl Symp Ther Acute Leukemia, 1986.

328. Dutcher JP, Strauman JJ, Wiernik PH: Phase I-II study of deoxydoxo-rubicin (DxDx) for relapsed and refractory acute non-lymphocytic leukemia (ANLL). 4th Intl Symp Ther Acute Leukemia, 1987.

329. Paietta E, Hubbard A, Wiernik PH, Diehl V, Stockert RJ: The Hodgkin's cell lectin: An ectosialyltransferase and lymphocyte mitogen. Proc Am Assn Cancer Res 1987; 28:14

330. Wadler S, Wiernik PH: Forskolin (F) partially reverses doxorubicin (DOX) resistance in the multidrug resistant (MDR) variants of the S180 cell line. Proc Am Assn Cancer Res 1987; 28:290.

331. Marcus SL, Dutcher JP, Paietta E, Ciobanu N, Wiernik PH: Plasma free catecholamines in-patients during immunotherapy with high-dose interleukin-2 (IL-2). Proc Am Assn Cancer Res 1987; 28:369.

332. Robert F, Grever M, Maroun J, Velez-Garcia E, Wiernik P, Martelo O, Mittelman A, Harper G, Dallaire B, Grillo A: Phase 2 efficacy of tiazofurin in-patients with solid tumors. Clin Res 1987; 35:529A.

333. Paietta E, Gallagher R, Wiernik PH, Stockert RJ: Lectin in the promyelocytic leukemia cell line, HL-60, responsive to monocytic maturation. Clin Res 1987; 35:630A.

333. Dutcher JP, Strauman JJ, Riggs CE, Link B, Wiernik PH: Phase I-II clinical and pharmacologic study of deoxydoxorubicin (DXDX) for relapsed and refractory acute non-lymphocytic leukemia (ANLL). Proc Am Soc Clin Oncol 1987; 6:161.

334. Paietta E, Gucalp R, Papenhausen P, Radel E, Dutcher JP, Wiernik PH: Lineage promiscuity in acute leukemia. Proc Am Soc Clin Oncol 1987; 6:161.

335. Maroun J, Wiernik P, DeConti R, Capizzi R, Leiby J, Robert F, Bergsagel D, Stewart J, Jolivet J, Arlin Z, Goldberg D, Grace M, Velez-Garcia E, Martelo O, Robert N, Grillo-Lopez A, Dallaire B, Grove W: Phase 2 efficacy of trimetrexate in-patients with non-small cell


158


lung cancer. Proc Am Soc Clin Oncol 1987; 6:170.

336. Fisher RI, Coltman CA, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P: Phase II clinical trial of interleukin II plus lymphokine activated killer cells (IL-2/LAK) in metastatic renal cancer. Proc Am Soc.Clin Oncol 1987; 6:244.


337. Wadler S, Einzig A, Dutcher JP, Ciobanu N, Landau L, Wiernik PH: Phase II trial of recombinant alpha-2b-interferon (IFN) and low dose cyclophosphamide (CY) in advanced melanoma and renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 1987; 6:246.

338. Marcus SL, Dutcher J, Ciobanu N, Paietta E, Strauman J, Wiernik PH, Baker H, Frank O: Micronutrient depletion in-patients treated with high-dose interleukin-2 (IL-2) and lymphokine-activated killer cells. Proc Am Soc Clin Oncol 1987; 6:247.

339. Javier J, Bergsagel D, Velez-Garcia E, Goldberg D, Stewart D, Wiernik P, DeConti R, Leiby J, Jolivet J, Capizzi R, Grace M, Dallaire B, Grillo-Lopez A, Grove W: Phase 2 efficacy of trimetrexate in-patients with head and neck cancer. Proc Am Soc Clin Oncol 1987; 6:131.

340. Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, Reck K, Testa JR: The prognostic impact of cytogenetic abnormalities in patients with de novo acute non-lymphocytic leukemia (ANLL). Blood 1987; 70:208a.

341. Wiernik PH, Markus S, Esterhay RJ: Long-term results with MOAD for adult acute lymphocytic leukemia (ALL). Blood 1987; 70:241a.

342. Paietta E, Stockert RJ, Racevskis J, Stanley R, Diehl V, Wiernik PH: A surface lectin as mediator of lymphocyte mitogenicity in Hodgkin,s cells expressing monocyte/macrophage features. Proc Intl Meeting on Genotypic, Phenotypic and Functional Aspects of Hematopoesis, 1987.

343. Kleiner G, Pua I, Marcus S, Ciobanu N, Wiernik P, Gallagher R: Effects of human serum (HS) on the response of acute promyelocytic leukemia (APL) cultured cells (HL-60) to retinoic acid (RA). Blood 1987; 70:261a.

344. Einzig AI, Trump DL, Sasloff J, Gorowski E, Dutcher J, Wiernik PH: Phase II pilot study of taxol in-patients (PTS) with malignant melanoma (MM). Proc Am Soc Clin Oncol 1988; 7:249.

345. Gucalp R, Lia S, Wiernik PH: Cefaperazone + tobramycin (C + T) versus ticarcillin + tobramycin (T + T) as empirical antibiotic therapy for febrile neutropenic cancer patients. Proc Am Soc Clin Oncol 1988; 7:294.


159


346. Einzig AI, Gorowski E, Sasloff J, Wiernik PH: Phase II trial of taxol in patients (Pts) with renal cell carcinoma. Proc Am Assn Cancer Res 1988; 29:222.

347. Paietta E, Stockert RJ, McManus M, Thompson D, Diehl V, Wiernik PH: Lymphocyte activation mediated by Hodgkin's cells. Proc Am Assn Cancer Res 1988; 29:46.


348. Paietta E, Stockert RJ, McManus M, Thompson D, Wiernik PH: Hodgkin's (HD) cell-lymphocyte coactivation. Proc Intl Soc Hematol, 1988.

349. Dutcher JP, Adinolfi C, Garl S, Salva K, Azar C, Wiernik PH: Treatment of hairy cell leukemia (HCL) with B-ser interferon (B-IFN) in previously treated patients or deoxycoformycin (DCF) in-patients failing interferons. Proc Intl Soc Hematol, 1988.

350. Wiernik PH, Dutcher JP, Gucalp R, Garl S, Benson L: MOAD therapy in adult patients (pts) with acute lymphocytic leukemia (ALL). Proc Intl Soc Hematol, 1988; p.250.

351. Riggs Jr CE, Dutcher JP, Strauman JJ, Link B, Wiernik PH: Pharmacokinetics of esorubicin in a phase I trial in-patients with acute leukemia. Clin Pharmacol Ther 1988; 43:193.

352. Wiernik PH, Case DE, Arlin ZA, Periman PO, Weitberg AB, Ritch PS, Todd M: A multicenter trial of cytarabine (A) + idarubicin (I) or daunorubicin (D) for adult acute nonlymphocytic leukemia (ANLL). Proc Intl Soc Hematol, 1988; p.10.

353. Dutcher JP, Arlin Z, Paietta E, Rowe J, Kellermeyer R, Wiernik PH: Phase II study of mitoxantrone (MITOX) and 5-azacytidine (5AZA) in-patients (pts) with accelerated (AC) or blast crisis (BC) chronic myeloid (MY) leukemia (CML). Proc Intl Soc Hematol, 1988; p.172.

354. Wiernik PH, Dutcher JP, Benson L, Gucalp R: Aggressive treatment of acute non-lymphocytic leukemia (ANLL) in-patients older than 60 years of age. Proc Intl Soc Hematol, 1988; p.70.

355. Sparano J, Schwartz EL, Wiernik PH, Salva K, Pizzillo MF: Pharmaco-kinetic study of oral and intravenous etoposide (VP-16) in-patients with prior gastrectomy. Proc Am Assn Cancer Res 1988; 29:201.

356. Paietta E, Racevskis J, Papenhausen P, Stanley ER, Wiernik PH: Expression of the CSF-1 and c-FMS gene by cultured Hodgkin's disease cells. Proc 4th Ann Meeting Oncogenes, 1988.

357. Ciobanu N, Spivack M, Walewski J, Sparano J, Adinolfi C, Wallace W, Wiernik PH: Transfusion of marrow-derived packed red cells (PRBC) following autologous bone marrow


160


harvesting. Blood 1988; 72 :276a.

358. Wadler S, Egorin M, Zuhowski E, Tortorello L, Salva K, Wiernik PH: Phase I/pharmacokinetic (PK) study of intraperitoneal (IP) thio-tepa (ThTe). Clin Res 1988; 36:803A.


359. Wadler S, Schwartz EL, Goldman M, Lyver A, Itri L, Wiernik PH: Preclinical and clinical studies of 5-fluorouracil (FURA) and recombinant alpha-2a-interferon (IFN) against gastrointestinal (GI) malignancies. Clin Res 1988; 36:803A.

360. Wiernik PH, Dutcher JP: Treatment of relapse in acute non-lymphocytic leukemia (ANLL). Haematologica 1988; 73:120.

361. Dutcher JP, Adinolfi C, Garl S, Salva K, Azar C, Wiernik PH: Treatment of hairy cell leukemia (HCL) with B-ser interferon (B-IFN) in previously treated patients or deoxycoformycin (DCF) in-patients failing interferon. Haematologica 1988; 73:190.

362. Einzig AI, Wiernik PH, Dutcher JP, Saslof J, Gorowski E: Phase I/II trials of taxol: Responses observed in malignant melanoma. Proc NCI-EORTC Symp New Drugs, 1988.

363. Gallagher R, Papenhausen P, Said F, Pua I, Paietta E, Wiernik P: Expression of the retenoic acid (RA) receptor- gene in fresh acute promyelocytic leukemia (APL) cells and cultured HL-60 cells. Blood 1988; 72:178a.

364. Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J, Fuks J, Wiernik P, Holroyde CP, Blossom M, Shepard K, Plasse T: Dronabinol and prochlorperazine in combination are better than either single agent alone for treatment of chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 1989; 8:327.

365. Ciobanu N, Dutcher J, Gucalp R, Sparano J, Goldman M, Adinolfi C, Fitzgerald E, Wiernik PH: High dose chemotherapy with autologous bone marrow transplantation (ABMT) for malignant melanoma after failure of interleukin-2 (IL2) and lymphokine activated killer (LAK) cells. Proc Am Soc Clin Oncol 1989; 8:281.

366. Lipton RB, Galer B, Portenoy RK, Dutcher JP, Meller F, Pahmer V, Arezzo J, Wiernik PH, Schaumberg HH: Large and small fiber type sensory dysfunction in-patients with cancer. Neurol 1989; 39(suppl 1): 320.

367. Einzig AI, Wiernik PH, Sasloff J, Garl S, O'Hanlan KA: Phase II study of taxol in-patients (pts) with advanced ovarian cancer. Proc Am Soc Clin Oncol 1989; 8:158.

368. Gucalp R, Dutcher JP, Sparano J, Grima K, Sessa G, Ciobanu N, Wiernik PH: Phase I pilot


161


study of moderate dose continuous infusion (IVCI) recombinant interleukin-2 (rIL2) in-patients (pts) with refractory malignancy. Proc Am Soc Clin Oncol 1989; 8:190.

369. Paietta E, Racevskis J, Stanley ER, Wiernik PH: Hodgkin's disease cells: Origin from a bipotential lymphoid/macrophage progenitor cell? Proc Am Assn Cancer Res 1989; 30:430.


370. Wiernik PH, Schwartz B, Dutcher JP, Turman N, Adinolfi C: Treatment of patients (pts) with hairy cell leukemia (HCL) with B-ser-interferon (BIFN). Proc Am Assn Cancer Res 1989; 30:388.

371. Wadler S, Schwartz EL, Wersto R, Thompson D, Wiernik PH: Interferon (IFN) modulates the activity of 5-fluorouracil (5FU) against two human colon cancer cell lines. Proc Am Assn Cancer Res 1989; 30:568.

372. Dutcher JP, Wiernik PH, Arlin Z, Paietta E, Rowe J, Kellermyer R, Andersen J: Mitoxantrone (MITOX) and 5-azacytidine (5AZA) for patients (pts) with accelerated (Ac) or blast crisis (BC) Ph1+ chronic myeloid leukemia (CML). Proc Am Soc Clin Oncol 1989; 8:205.

373. Wadler S, Thompson D, Wiernik PH: Forskolin (F) phosphorylates a 35 kd protein in multidrug resistant (MDR) variants of murine sarcoma S180 cells. Proc Am Assn Cancer Res 1989; 30:506.

374. Abrams J, Rayner A, Wiernik P, Parkinson D: High dose interleukin-2 without lymphokine activated killer cells: Inactive in advanced renal cell cancer. Proc Am Assn Cancer Res 1989; 30:380.

375. Gallagher R, Pua I, Shao W-B, Papenhausen P, Dutcher J, Wiernik P: Multiple bcr gene rearrangements during the clinical course of a patient with chronic myelogenous leukemia. Proc Am Assn Cancer Res 1989; 30:56.

376. Wadler S, Lyver A, Goldman M, Wiernik PH: Therapy with 5-fluorouracil (5FU) and recombinant alpha-2a-interferon (IFN) in refractory GI malignancies. Proc Am Soc Clin Oncol 1989; 8:99.

377. Sparano J, Schwartz E, Salva K, Strack M, Wiernik PH: Severe myelotoxicity associated with etoposide (VP16), adriamycin (A), and cisplatin (DDP) in the treatment of advanced gastric cancer. Proc Am Assn Cancer Res 1989; 30:257.

378. Shalmi CL, Dutcher JP, Feinfeld DA, Chun KJ, Saleemi KR, Freeman LM, Lynn RI, Wiernik PH: Acute renal failure during interleukin-2 (IL-2) treatment - an intrinsic renal lesion. Clin Res 1989; 37:862A.


162


379. Gallagher RE, Wiernik PH: Retinoic acid-resistant HL60 cells: A model for differentiation-inducer resistance as a clinical problem. Proc 9th Sapporo Cancer Seminar, 1989.


380. Wadler S, Schwartz EL, Lyver A, Wiernik PH: Phase I trial of 5-fluorouracil and recombinant alpha-2a-interferon in-patients with advanced colorectal carcinoma. Proc Intl Soc Interferon Res, 1989.

381. Wadler S, Schwartz EL, Lyver A, Wiernik PH: Treatment of advanced colorectal carcinoma with 5-fluorouracil (5FU) and alpha-interferon. Proc ECCO-5, 1989.

382. Paietta E, Stockert RJ, Racevskis J, Wiernik PH: A new T-lymphocyte adhesion molecule on the surface of cultured Hodgkin's cells. J cell Biol 1989; 107:552a

383. Wadler S, Thompson D, Wiernik PH: Reversal of doxorubicin resistance by the plant diterpenes, forskolin and dideoxyforskolin, is not mediated by protein kinase C. Proc Conf Multidrug Resistance; Molecular Biol Clin Relevance, 1989.

384. Sparano JA, Wiernik PH, Reilly J, Salva K, Dutcher JP: Infusional cyclophosphamide (C), adriamycin (A), and etoposide (E) in relapsed/refractory Hodgkins (HD) and non-Hodgkins lymphoma (NHL). Proc Am Soc Clin Oncol 1990; 9:267.

385. Strack M, Wadler S, Lyver A, Wiernik P: Phas II trial of fluorouracil (5FU) and recombinant alpha-2a-interferon (rIFNa2a) in patients (pts) with advanced carcinoma of the esophagus. Proc Am Soc Clin Oncol 1990; 9:119.

386. Wiernik PH, Dutcher JP, Gucalp R, Markus S, Esterhay R, Schiffer C, Weinberg V, Paietta E, Garl S, Benson L: MOAD therapy for adult acute lymphocytic leukemia (ALL). Proc Am Soc Clin Oncol 1990; 9:205.

387. Sklarin N, Wiernik P, Mittelman A, Maroun J, Stewart J, Robert F, Doroshow J, Akman S, Rosen P, Gota C, Jolivet J, Belanger K, DeConti R, Robert N, Velez-Garcia E, Bergsagel D, Panasci L, van der Merwe A, Leiby J, Grove W, Hawkins E, Kowal C: A phase II study of CI-921 in-patients with solid tumors. Proc Am Soc Clin Oncol 1990; 9:285.

388. DeVita VT, Longo DL, Glatstein E, Duffey P, Hubbard SM, Wiernik PH, Young RC: A randomized comparison of radiotherapy (RRX) versus primary treatment with MOPP chemotherapy (M-CRX) in early stage Hodgkin's disease (HD). Proc 6th Intnl Conf Adjuvant Ther Cancer, 1990.


163


389. Wadler S, Schwartz EL, Thompson D, Wiernik PH: Effects of recombinant interferon (IFN) on thymidylate synthetase (TS) expression and ternary complex (TC) formation in human tumor cell lines. Proc Am Assn Cancer Res 1990; 31:402.


390. Paietta E, Racevskis J, Stockert RJ, Wiernik PH: The Hodgkin's cell lectin: Molecular cloning and characterization of secreted and membrane bound forms. Proc Am Assn Cancer Res 1990; 31:300.

391. Einzig AI, Wiernik PH, Sasloff J, Garl S, Runowicz C, O'Hanlan KA, Goldberg G: Phase II study of taxol (T) in-patients (Pts) with advanced ovarian cancer. Proc Am Assn Cancer Res 1990; 31:187.

392. Hoffman M, Wadler S, Schwartz EL, Wiernik PH: Effects of recombinant interferon-alpha (IFN) on anaboloism of (6-3H) 5-fluorouracil (5FU) in human colon cancer cell lines. Proc Am Assn Cancer Res 1990; 31:408.

393. Wallerstein R, Davidson W, Dutcher J, Freireich E, Hester J, Wiernik P, Deisseroth A, Block J: Safety, efficacy, and preliminary anti-cancer activity ob blood tryptophan depletion (BTD) therapy using a new extracorporally placed device. Proc Am Soc Clin Oncol 1990; 9:82.

394. Sklarin N, Wiernik PH: Adjuvant radiotherapy for breast cancer as a risk factor for the development of lung cancer. Proc Am Assn Cancer Res 1990; 31:165.

395. Moskowitz C, Dutcher JP Wiernik PH: Impact of thyroid disease (TD) on acute leukemia (AL). Clin Res, 1990; 38:397A.

396. Sparano JA, Gucalp R, Llena JF, Moser FG, Wiernik PH: Risk of cerebral aspergillosis in acute leukemia. Proc Am Soc Clin Oncol 1990; 9:333.

397. Vogler WR, Lazarus HM, Winton EF, Harrington DP, Wiernik PH: A phase II clinical trial of carboplatin in relapsed and refractory leukemia by the Eastern Cooperative Oncology Group. Blood 1990; 76:332a.

398. Sparano J, Walpole E, Paietta E, Dutcher J, Pellone C, Wiernik PH: Cytotoxicity of peripheral blood mononuclear cells in-patients treated with interleukin-2 and alpha-interferon. Clin Res 1990; 38:776A.


164


399. Gallagher R, Ahearn G, Thompson D, Strack M, Paietta E, Dutcher J, Wiernik P: Retinoic acid-enhanced neutrophilic differentiation of granulocyte-macrophage progenitors in blastic crisis chronic myelocytic leukemia (CML). Blood 1990; 76:272a.

400. Carlisle P, Gucalp R, Wiernik PH: Viridans streptococcal bacteremias (VSB) in a cancer research unit. Proc 3rd Intl Conference Nosocomial Infections, 1990.


401. Carlisle P, Gucalp R, Wiernik PH: Nosocomial infection (NI) in neutropenic patients (NP) in a cancer research unit. Proc 3rd Intl Conference Nosocomial Infections, 1990.

402. Sparano J, Dutcher J, Caliendo G, Kaleya R, Fiorito J, Wiernik PH: Colonic ischemia complicating treatment with interleukin-2 and alpha interferon. Clin Res 1990; 38:776A.

403. Strack M, Grima K, Sussman I, Dutcher J, Wiernik P: Coagulation abnormalities associated with interleukin-2 (IL2) therapy for metastatic cancer. Clin Res 1990; 38:776A.

404. Ciobanu N, Weinberg V, Sparano JA, Zervos G, Walewski J, Spivack M, Wiernik PH: Experience with autologous marrow harvesting and transfusion of marrow derived red cells. Blood 1990; 76:397a.

405. Tenteromano L, Wadler S, Wiernik PH: Phase II trial of recombinant interferon beta-ser (rIFNB) and 5-fluorouracil (5FU) in-patients (pts) with advanced colorectal carcinoma. Proc Intl Soc Interferon Res, 1990.

406. Sparano JA, Goldstein J, Gucalp R, Davis L, Wiernik P: Patterns of failure and toxicity of chemotherapy (CT) in AIDS related non-Hodgkin lymphoma (NHL). Proc 6th Intl Conf on AIDS, 1990.

407. Ryan J, Dutcher JP, Wagner B, Grima K, Wiernik P: Therapeutic leuk-apheresis (LP) in chronic lymphocytic leukemia (CLL). Proc Intl Soc Blood Transfusion/Am Assn Blood Banks Joint Cong, 1991.

408. Gucalp R, Cimino M, Rotstein C, Carlilse P, Cesari C, Wiernik PH: Cefepime (C) versus piperacillin + gentamicin (P+G) as empirical antibiotic therapy for febrile neutropenic cancer patients. Proc Am Soc Clin Oncol 1991; 10:345.

409. Paietta E, Van Ness B, Bennett JM, Cassileth PA, Wiernik PH: Lack of association between terminal transferase (TDT) or lymphoid antigen expression in acute myeloid leukemia (AML) and immunoglobulin (JH) or T-cell receptor beta chain (TCR) gene rearrangements. Proc Am Soc Clin Oncol 1991; 10:37.

410. Sparano JA, Wadler S, Einzig A, Tortorello L, Benson L, Wiernik PH: Phase I trial of


165


prolonged, continuous infusion (PCI) 5-fluorouracil (FU) and alpha-2a interferon (IFN): Greater FU dose-intensity and responses in refractory cancer. Proc Am Soc Clin Oncol 1991; 10:160.

411. Wiernik PH, Albertini RJ, Fotino M, Paietta E: Increased peripheral blood T-cell mutant frequencies in healthy mothers of children with familial Hodgkin's disease (HD). Proc Am Soc Clin Oncol 1991; 10:287.


412. Dutcher JP, Martin K, Wiernik PH: Mitoxantrone (M), vinblastine (V), and CCNU (C): An active regimen in Hodgkin's disease. Proc Am Soc Clin Oncol 1991; 10:286.

413. Sparano JA, Wiernik PH, Trager M, Dutcher JP: Infusional cyclophos-phamide (C), doxorubicin (D), and etoposide (E): An active regimen in relapsed (RL) non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1991; 10:286.

414. Volterra F, Wiernik PH, Dutcher JP, Sklarin NT: Breast cancer (BC) and lymphoma (LY) in the same patients (pts). A possible relationship. Proc Am Assn Cancer Res 1991; 32:195.

415. Walpole E, Dutcher JP, Sparano J, Gucalp R, Einzig A, Paietta E, Ciobanu N, Grima K, Caliendo G, Cavasotto G, Wiernik PH: Survival after phase II treatment of advanced renal cell cancer (RCC) with taxol (T) or high dose interleukin-2 (IL-2). Proc Am Assn Cancer Res 1991; 32:186.

416. Sagayadan G, Dutcher J, Wiernik P, Gallagher R: Effect of trans-retinoic acid and interferon-alpha on clonogenic chronic myelogenous leukemia blast crisis cells. Proc Am Assn Cancer Res 1991; 32:32.

417. Dutcher JP, Schwartz EL, Wiernik PH, Brechbuhl AB, Benson L, Garl S: Phase I study of menogaril (M) with pharmacokinetics (PK) in acute leukemia (AL). Proc Am Assn Cancer Res 1991; 32:179.

418. Gallagher R, Paietta E, Strack M, Dutcher J, Wiernik P: Cell culture studies of a chronic myelogenous leukemia blast crisis patient responsive to clinical treatment with trans-retinoic acid. 4th Conf Differentiation Ther, Takaku F, Rossi G, Waxman S (eds.), Ares Serono Symposium 1991; p.117.

419. Lazarus HM, Creger RJ, Gucalp R, Ciobanu N, Carlisle P, Cooper BW, Wiernik PH: Cefoperazone/sulbactam vs cefoperazone plus mezlocillin in febrile granulocytopenic bone marrow transplant patients. Blood, 1991; 78(suppl 1): 504a.

420. Gaynor B, Dutcher JP, PAietta E, Wiernik PH: Carboplatin (CARBO) plus mitoxantrone (MITOX) therapy in relapsed/refractory acute leukemia (AL) and blast crisis of chronic myeloid leukemia (CMLBC). Blood 1991; 78(suppl 1): 31a.


166


421. Wiernik PH, Dutcher JP, Todd M, Duffy T, Caliendo G, Benson L: Polyethylene glycolated (PEG) interleukin-2 (IL2) as maintenance therapy for acute myelogenous leukemia (AML) in second remission (CR). Blood 1991; 78(suppl 1): 42a.


422. Strack M, Sussman I, Grima K, Solomon T, Merer D, Caliendo G, Wiernik P, Dutcher J: Unoque pattern of change of coagulation factors (CF) during interleukin 2 (IL2) therapy. Blood 1991; 78(suppl 1): 485a.

423. Wiernik PH, Banks PLC, Case Jr DC Arlin ZA: Cytarabine + idarubicin or daunorubicin for adults with previously untreated acute myeloid leukemia. Haematologica 1991; 76(suppl 4): 9.

424. Paietta E, Racevskis J, Gucalp R, Bennett J, Wiernik PH: Altered terminal transferase (TDT) message levels in acute lymphocytic leukemia expressing myeloid antigens (M+ALL) and TDT+ acute myeloid leukemia (TDT+AML) as compared to myeloid antigen negative ALL (M-ALL). Haematologica 1991; 76(suppl 4): 11.

425. Cassileth PA, Andersen JW, Bennett JM, Harrington DP, Hines JD, Lazarus HM, Mazza JJ, McGlave PB, O'Connell MJ, Wiernik P: Escalating the intensity of postremission therapy improves the outcome in acute myeloid leukemia (AML). The Eastern Cooperative Oncology Group (ECOG) experience. Haematologica 1991; 76(suppl 4): 102.

426. Dutcher JP, Wiernik PH, Gucalp R, Markus S, Esterhay R, Paietta E, Benson L, Azar C: MOAD therapy for adult acute lymphocytic leukemia (ALL). Haematologica 1991; 76(suppl 4): 66.

427. Cassileth PA, Andersen JW, Bennett JM, Hoagland HC, Mazza JJ, O'Connell MJ, Paietta E, Wiernik P: Adult acute lymphocytic leukemia (ALL): The Eastern Cooperative Oncology Group experience. Haematologica 1991; 76(suppl 4): 107.

428. Sagayadan G, Ahearn G, Dutcher J, Wiernik P, Gallagher R: Chronic myelogenous leukemia (CML) colony forming cells (CFC): Greater sensitivity to retinoic acid (RA) in accelerated phase/blastic crisis (AP/BC). Proc AM Assn Cancer Res 1991;32:32.

429. Paietta E, Racevskis J, Gucalp R, Bennett J, Wiernik PH: Differential regulation of terminal transferase (TdT) expression in acute lymphocytic leukemia expressing myeloid antigens (M+ALL) and TdT+ acute myeloid leukemia (TdT+AML) as compared to myeloid antigen-negative ALL (M-ALL). Proc Am Soc Clin Oncol 1992; 11:98.


167


430. O'Boyle K, Wright K, Stockert E, Welt S, Livingston P, Lloyd K, Old L, Wiernik P: Specificity analysis of four human monoclonal antibodies elicited by immunization of colorectal cancer patients with partially desiaylated ovine submaxillary mucin vaccine. Proc Am Assn Cancer Res 1992; 33:334.


431. Carlisle P, Gucalp R, Ciobanu N, Dixon D, Wiernik PH: Suppression of fluconazole-resistant yeasts in-patients receiving fluconazole prophylaxis. Proc Am Soc Clin Oncol, 1992.

432. Leventhal S, Jarwala S, Lien E, Wiernik PH, Wadler S: Growth inhibition of colon cancer cell lines by ribonucleotide reductase inhibition. Proc Am Assn Cancer Res 1992; 33:524.

433. O'Boyle K, Markowitz A, Wright K, Khorshidi M, Lalezari P, Welt S, Longenecker BM, Wiernik P: Characterization of murine monoclonal antibodies reactive with T/STn/Tn carcinoma antigens. Proc Am Assn Cancer Res 1992; 33:320.

434. Gallagher R, Rao S, Zhang H-S, Peng S, Zelent A, Wiernik P: PML-RAR- hybrid m RNAs provide effective markers for acute promyelocytic leukemia cells. Proc Am Assn Cancer Res 1992; 33:27.

435. Gallagher R, Zelent A, Zhang S, Peng S, Rao S, Sagayadan G, Waxman S, Wiernik P: Differential regulation of PML-RARa and RARa1 mRNAs following trans-retinoic acid (tRA) treatment of acute promyelocytic leukemia (APL) cells. Proc 5th Intl Conf Differentiation Therapy, 1992; pp292.

436. Sparano JA, Wadler S, Diasio R, Spears R, Schwartz E, Einzig A, Wiernik P: Phase I trial of prolonged infusion (PI) 5-fluorouracil (FU) and interferon-alpha (IFN). Proc Am Assn Cancer Res 1992; 33:533.

437. Rowe JM, Andersen JW, Cassileth PA, Oken MM, Wiernik PH: Adult acute myelogenous leukemia: Recent studies from the Eastern Cooperative Oncology Group (ECOG). Ann Hematol 1992; 64:161.

438. Rowe JM, Andersen JW, Mazza JJ, Hines JD, Cassileth PA, Bennett J, Wiernik PH, Oken MM: Mitoxantrone in the treatment of acute myelogenous and lymphoblastic leukemia. Ann Hematol 1992; 64:18.

439. Carlisle P, Gucalp R, Mazurek C, Wiernik PH: Infections in-patients treated with colony stimulating factors. Proc 7th Intl Symp Infections Immunocompromised Host, 1992.


168


440. Carlisle P, Gucalp R, Wiernik PH: Rates of infection in neutropenic cancer patients. Proc 7th Intl Symp Infections Immunocompromised Host, 1992.

441. Coletti D, Dutcher JP, Paietta E, Wiernik PH: Alpha-interferon (IFN) + plicamycin (PLICA) for accelerated phase chronic myelogenous leukemia (A-CML). Blood 1992; 80 (suppl 1):211a.


442. Gallagher R, Etkind P, Peng S, Qiu L, Rao S, Sagayadan G, Waxman S, Zelent A, Wiernik P: Aberrant PMLa/PML fusion products in a subset of acute promyelocytic leukemia (APL) patients. Blood 1992; 80: (suppl 1):300a.

443. Paietta E, Andersen J, Cassileth P, Rowe J, Bennett J, Wiernik PH: Prognostic implications of lymphoid-associated antigens in adult acute myeloid leukemia (AML): An Eastern Cooperative Oncology Group (ECOG) study. Blood 1992; 80 (suppl 1):256a.

444. Gallagher R, Sagayadan G, Dutcher J, Wiernik P: Clonogenic assays support a trial of trans-retinoic acid (tRA) therapy in accelerated phase/early blastic crisis chronic myelogenous leukemia (CML-AP/BC). Proc 5th Intl Conf Differentiation Therapy 1992; pp319.

445. Gallagher R, Rao S, Etkind P, Peng S, Qiu L, Wiernik P: Variable expression of PML-RARa mRNA isoforms in acute promyelocytic leukemia patients. Proc Am Assn Cancer Res 1993; 34:532.

446. Paietta E, Racevskis J, Heavey C, Lichtenstein A, Thomas D, Wiernik PH: Modulation of multidrug resistance in de novo adult acute myeloid leukemia (AML): Variable efficacy of reverting agents in vitro. Proc Am Soc Clin Oncol 1993; 12:302.

447. Ciobanu N, Sparano JA, Gucalp R, Dutcher J, Walewski J, Marcoullis G, Wiernik PH: High-dose cisplatin (P), carmustine (C) and thiotepa (T) plus autologous bone marrow transplantation (ABMT) in advanced cancer. Proc Am Soc Clin Oncol 1993; l12:463.

448. Sparano JA, Wiernik PH, Strack M, Leaf A: Infusional cyclophosphamide, doxorubicin, and etoposide (CDE) in HIV- and HTLV-1-related non-Hodgkin's lymphoma (NHL): A highly active regimen. Proc Am Soc Clin Oncol 1993; 12:50.

449. Bajaj R, Molinas S, Wiernik PH, Ryan L, Benson AB, Wadler S: Clinical correlations of ki-ras 2 mutations in-patients with metastatic colorectal carcinoma. Clin Res 1993; 41:363A.

450. Ciobanu N, Lazarus HM,, DeBellis R, Ascensao J, Sparano JA, Gucalp R, Dutcher J, Fox RM, Creger RJ, Cooper BE, Gerson SL, Nese M, Bello L, Wiernik PH: Autologous bone marrow transplantation (ABMT) using ex-vivo etoposide (VP-16) purged marrow in-patients (PTS) with poor risk lymphomas (LY) and acute leukemias (LEUK). Blood 1993; 10(suppl


169


1):629a.

451. Rowe JM, Andersen J, Mazza JJ, Paietta E, Bennnett JM, Hayes A, Oette D, Wiernik PH: Phase III randomized placebo-controlled study of granulocyte-macrophage colony timulating factor (GM-CSF) in adult patients (55-70 years) with acute myelogenous leukemia (AML). A study of the Eastern Cooperative Oncology Group (ECOG). Blood 1993; 10(suppl 1):329a.


452. Sparano JA, Wiernik PH, Dutcher JP, Sarta C, Strack M, Leaf A: Infusional cyclophosphamide (C), doxorubicin (D), and etoposide (E) in HIV-related non-Hodgkin's lymphoma (NHL): A followup report of a highly active regimen. Blood 1993; 10(suppl 1):386a.

453. Einzig A, Wiernik PH, Lipsitz S, Benson III AB: Phase II trial of taxol in-patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). Proc Am Soc Clin Oncol 1993; 12:194.

454. Paietta E, Andersen J, Racevskis J, Wiernik PH: P-glycoprotein (Pgp) in de novo acute myeloid leukemia (AML): Immunological, functional and molecular characterization. Proc 5th Intl Human Leukocyte Differentiation Antigen Conf, 1993.

455. Dutcher JP, Wiernik PH, Todd M, Caliendo G, Benson L: Interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission. Expl Hematol 1993; 21:1048.

456. Dutcher JP, Wiernik PH, Einzig AI, Cassileth P: Mitoxantrone, vinblastine and CCNU (MVC): A highly active regimen in poor prognosis Hodgkin's disease (HD). Blood 1993; 10(suppl 1): 143a.

457. Tallman M, Gray R, Bennett J, Variakolis D, Robert N, Wood W, Wiernik P: Leukemogenic potential of adjuvant chemotherapy for early stage breast cancer: The Eastern Cooperative Oncology Group (ECOG) experience. Blood 1993; 10(suppl 1):48a.

458. Dutcher JP, Leong T, Makary A, Paietta E, Bennett J, Cassileth P, Wiernik PH: Phase II study of menogaril in-patients (pts) with relapsed/refractory acute myeloid leukemia (AML)-EST 8490. Blood 1993; 10(suppl 1):130a.

459. Sparano JA, Wiernik PH, Dutcher JP, Leaf A, Khalil A: Infusional cyclophosphamide (C), doxorubicin (D), and etoposide (E) in relapsed, resistant, and poor-prognosis non-Hodgkin's lymphoma (NHL): A followup report. Blood 1993; 10(suppl 1):137a.

460. Paietta E, Andersen J, Racevskis J, Gallagher R, Bennett J, Yunis J, Wiernik PH: Acute promyelocytic leukemia (APL) cells lack p-glycoprotein expression by immunological,


170


molecular and functional analysis. Blood 1993; 10(suppl 1):252a.

461. Sparano JA, Dutcher JP, Wiernik PH, Wadler S, Caliendo G, Nobile L: A phase II trial of low-dose, continuous infusion (CI) 5-fluorouracil (FU) plus interferon-a (IFN) in-patients with advanced renal cell carcinoma (RCC). Proc Soc Biological Ther 1993.


462. Tallman M, Andersen J, Appelbaum F, Feusner A, Ogden C, Schiffer C, Shepard L, Weinstein H, Woods W, Wiernik P: Phase III randomized study of all-trans retinoic acid versus cytosine arabinoside and daunorubicin as induction therapy for patients with previously untreated acute promyelocytic leukemia (APL): Preliminary toxicity results. Proc Intl Acute Promyelocytic Leukemia Symp 1993.

463. Rao S, Wiernik P, Gallagher R: Variartion in G-CSF receptor mRNA isoform expression after tRA exposure of NB4 and HL60 cells. Blood: 1993; 10(suppl 1):252a.

464. Carlisle P, Gucalp R, Wiernik PH: Laminar air flow (LAF) unit humidifiers as a sourcee of microbial contamination of patients. Am J Infection Control 1993; 21:91.

465. Paietta E, Andersen J, Racevskis J, Wiernik PH: Classical multidrug resistance in de novo adult acute myeloid leukemia (AML) in vitro correlates with the expression of the stem cell antigen CD34. Proc XXV Cong Intl Soc Hematol 1994; Abstract #47.

466. Dutcher JP, Wiernik PH, Markus S, Schiffer CA: 15-year follow-up of adult patients (PTS) with acute myeloid leukemia (AML): Study BCRC 7802. Proc XXV Cong Intl SocHematol 1994; Abstract # 48.

467. Caliendo G, Dutcher J, Lasala P, Mitnick R, Wiernik P: Phase II trial of merbarone (M) in brain tumor patients. Proc Am Soc Clin Oncol 1994; 13:180.

468. O'Boyle K, Wang Y, Schwartz E, Einzig A, Regl D, Dutcher J, Wiernik P, Horwitz S: Detection of taxol in human sera, cerebrospinal fluid, ascites and pleural fluid using a novel monoclonal antibody and two radioimmunoassay techniques. Proc Am Assoc Cancer Res 1994; 35:241.

469. Gallagher R, Li Y-P, Rao S, Etkind P, Wiernik P: Molecular and response heterogeneity in acute promyelocytic leukemia patients with PML gene exon 6 break/fusion sites. Proc Am Assoc Cancer Res 1994; 35:215.

470. Gallagher R, Rao S, Li Y, Paietta E, Wiernik P, Zelent A: Correlative PML-RARa mRNA typing and trans-retinoic acid sensitivity testing in acute promyelocytic leukemia. Proc 6th


171


Conf Differentiation Ther Cancer, 1993.

471. Sparano JA, Wiernik PH, Dutcher JP, Sarta C, Leaf A, Hu XP: A pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide (CDE) plus didanosine (DDI) in HIV-related non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 1994; 13:51.


472. Einzig AI, Schuchter LM, Wadler S, Coatsworth S, Dutcher JP, Recii A, Mollman J, Wiernik PH: Phase II trial of taxotere (RP 56976) in-patients (pts) with metastatic melanoma previously untreated with cytotoxic chemotherapy. Proc Am Soc Clin Oncol 1994; 13:395.

473. Paietta E, Andersen J, Racevskis J, Bennett J, Rowe JM, Cassileth P, Wiernik PH: Multidrug resistance gene (mdr-1) transcript or CD34 antigen expression levels do not predict for complete remissions in de novo adult acute myeloid leukemia (AML): An Eastern Cooperative Oncology Group study. Blood 1994; 84(suppl 1):374a.

474. Einzig AI, Wiernik PH, Tenteromano L, Benson L, Tan V, Kaplan J: Phase I study of taxol and G-CSF in-patients (pts) with unresectable malignancy. Proc Am Soc Clin Oncol 1994; 13:401.

475. Carlisle P, Gucalp R, Wiernik PH: Colonization with resistant yeasts during fluconazole prophylaxis. Proc 8th Intnl Symp Infections Immunocompromised Host, 1994.

476. Gucalp R, Carlisle P, Wiernik PH: Fungal sinusitis (FS) in immunocompromised host (IH). Proc 8th Intnl Symp Infections Immunocompromised Host, 1994.

477. Sparano JA, Wiernik PH, Yu L, Sarta C, Dutcher JP, Leaf A: Central nervous system prophylaxis and therapy in-patients with HIV-related non-Hodgkin's lymphoma treated with infusional cyclophosphamide, doxorubicin, and etoposide (CDE). Proc Am Radium Soc, 1994.

478. Carlisle P, Gucalp R, Gialanella P, McKitrick J, Dutcher J, Wiernik PH: Amphotericin B (AB) resistant Paecilomyces fungal sinusitis. Proc 8th Intnl Symp Infections Immunocompromised Host, 1994.

479. Gucalp R, Lazarus H, Carlisle P, Creger R, Fox R, Wiernik, PH: Bacteremia due to viridans Streptococcus in-patients with cancer. Proc 8th Intnl Symp infections Immunocompromised Host, 1994.

480. Racevskis J, Kirshner ED, Virargahaven V, Paietta E, Wiernik PH: No evidence for germline p53 mutations in 8 familial Hodgkin's disease (HD) pedigrees. Blood 1994;


172


84(suppl1):612a.

481. Dutcher JP, Caliendo G, LaSala P, Sparano J, Oleksowicz L, O'Boyle K, Wiernik PH: Treatment and course of brain metastases in-patients with metastatic renal cell Cancer. Proc Am Radium Soc, 1994.


482. Paietta E, Andersen J, Rowe J, Cassileth P, Wiernik PH: Myeloid blast cell maturation determines response in adult de novo acute myeloid leukemia (AML): A response-driven antigen expression analysis in 382 Eastern Cooperative Oncology Group (ECOG) patients. Proc Am Soc Clin Oncol 1995; 14:87.

483. Einzig AI, Wiernik PH, Lipsitz S, Benson III AB: Phase II trial of taxotere in adenocarcinoma of the upper gastrointestinal tract (UGIT) previously untreated with cytotoxic chemotherapy: The Eastern Cooperative Oncology Group (ECOG) results. Proc Am Soc Clin Oncol 1995; 14:191.

484. Sparano JA, Wiernik PH, Leaf A, Henry D, Mason B, Sarta C, Hu X, Dutcher JP: Didanosine (ddi) ameliorates neutropenia in-patients with HIV-related non-Hodgkin's lymphoma (NHL) treated with infusional cyclophosphamide, doxorubicin, and etoposide (CDE). Proc Am Assn Cancer Res 1995; 36:203.

485. Tan V, Herrera C, Einzig AI, Wiernik PH: Taxol is active as a 3 hour or 24 hour infusion in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995; 14:1122.

486. Paietta E, Andersen J, Yunis J, Rowe JM, Cassileth PA, Wiernik PH: Expression of the multidrug-resistance gene product, p-glycoprotein (PGP), in adult acute myeloid leukemia (AML): Association with stem cell factor CD34 and specific cytogenetic abnormalities. Acta Haematol 1995; 93:261.

487. Sparano JA, Wiernik PH, Hu XP, Sarta C, Dutcher JP, Hanau L, Leaf A: Opportunistic infection in-patients with HIV-related non-Hodgkin's lymphoma treated with infusional cyclophosphamide, doxorubicin & etoposide (CDE): A case control study. Proc Am Soc Clin Oncol 1995;14:289.

488. Schwartz EL, Hallam S, Gallagher RE, Wiernik PH: Inhibition of all-trans retinoic acid metabolism by fluconazole in vitro and in a patient with acute promyelocytic leukemia. Proc Am Soc Clin Oncol 1995; 14:457.

489. Sklarin NT, Benson L, Roca J, Einzig AI, Wiernik PH, Whitfield LR, Lathia C, Kowal C,


173


Grove W: Phase I study of CI-980: 24-hr infusion schedule. Proc Am Soc Clin Oncol 1995; 14:479.

490. Wadler S, Haynes H, Tenteromano L, Kaleya R, Rozenblit A, Wiernik PH: Results of sequential phase II clinical trials of 5-fluorouracil (5FU) + interferon-Bser (INFB) in patients with advanced colorectal carcinoma. Proc Am Soc Clin Oncol 1995; 14:205.


491. Rao S, Wiernik P, Gallagher R: All-trans retinoic acid (TRA) causes a biphasic change in G-CSF receptor mRNA isoforms in NB4 and HL60 cells. Proc Am Assn Cancer Res 1995; 36:48.

492. Hallam SJ, Rao S, Wiernik PH, Gallagher RE: Cytoplasmic retinoic acid binding protein II mRNA measurements in acute promyelocytic leukemia. Proc Am Assn Cancer Res 1995; 36:215.

493. Wiernik PH, Schleider MA, Gold EG: Breast Cancer (BCA) and non-Hodgkin's lymphoma (NHL): Does one lead to the other in some patients (PTS) ? Proc Am Soc Clin Oncol 1995; 14:401.

494. Gallagher R, Willman C, Slack J, Andersen J, Li J, Viswanatha D, Bloomfield C, Appelbaum F, Schiffer C, Tallman M, Wiernik P: Correlation of PML-RAR mRNA type with pretreatment clinical characteristics and response in acute promyelocytic leukemia (APL): An intergroup laboratory study. Blood 1995; 86 (suppl 1):729a.

495. Gale RP, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Park ER, Rai K, Schiffer CA, Weisdorf DJ, Dubois R, Wiernik PH: CML in chronic phase: RAND-Delphi analysis of appropriateness of bone marrow transplants. Blood 1995; 86 (suppl 1):946a.

496. Wiernik PH: Idarubicin in induction therapy of AML. Ann Hematol 1995; 70(suppl 2):A995.

497. Gale RP, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Park ER, Rai K, Schiffer CA, Weisdorf DJ, Dubois R, Wiernik PH: AML in 1st remission: RAND-Delphi analysis of appropriateness of bone marrow transplants. Blood 1995; 86 (suppl 1):946a.

498. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Wiernik PH: The use of hematopoietic growth factors (HGF) in acute myelogenous leukemia (AML). Ann Hematol 1995; 70(suppl 2):A98.


174


499. Wiernik PH: 23 year follow-up after radiotherapy (RT) or radiotherapy + MOPP (RT+ C) for Hodgkin's disease (HD) stages I-IIIA: High death rate from causes other than HD. Proc Am Soc Clin Oncol 1995; 14:407.

500. Wiernik PH, Paietta E: Multidrug resistance in acute myeloid leukemia ? Cancer Invest 1995; 113(suppl 1):1.

501. Li J, Zelent A, Rao S, Andersen J, Paietta E, Tallman M, Wiernik P, Gallagher R: RAR2 and RAR2-PML expression in acute promyelocytic leukemia (APL). Blood 1995; 86:733.


502. Gale RP, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Park ER, Rai K, Schiffer CA, Weisdorf DJ, Dubois R, Wiernik PH: ALL in 1st remission: RAND-Delphi analysis of appropriateness of bone marrow transplants. Blood 1995;186 (suppl 1):946a.

503. Tallman M, Andersen J, Schiffer C, Appelbaum F, Feusner J, Woods W, Ogden A, Weinstein H, Shepherd L, Rowe J, Wiernik P: Phase III randomized study of all-trans retinoic acid (ATRA) vs daunorubicin (D) and cytosine arabinoside (A) as induction therapy for patients with previously untreated acute promyelocytic leukemia (APL). Blood 1995; 86 (suppl 1):125a.

504. Dutcher JP, Lee S, Paietta E, Bennett J, Stewart J, Wiernik PH: An ECOG phase II study of carboplatin in blast crisis of chronic myelogenous leukemia (CML-BC) (E1992). Blood 1995; 86 (suppl 1):757a.

504. Blumstein A, Wiernik P, Ratech H: Neutrophil rich large cell lymphoma in-patients with breast carcinoma. Proc Intl Acad Pathol, 1995.

505. Sparano JA, Wiernik PH, Hu X, Dutcher JP, Sarta C, Henry D, Mason B: Didanosine (ddI) ameliorates neutropenia and thrombocytopenia in-patients with HIV-associated non-Hodgkin's lymphoma (NHL) treated with infusional cyclophosphamide (C), doxorubicin (D), and etoposide (E) plus granulocyte-colony stimulating factor (G-CSF). Blood 1995; 86 (suppl 1): 934a

506. Wadler S, Haynes H, Beitler JJ, Hu X-P, Fell S, Camacho M, Levine B, Wiernik PH: Phase II trial of 5-fluorouracil (5FU), interferon--2b (IFN), and cisplatin (CDDP) in regionally advanced or metastatic esophageal cancer. Proc Am Soc Clin Oncol 1996; 15:210.

507. Rowe JM, Hayes FA, Andersen JW, Wiernik PH: Cytokines as therapy for fungal infections in acute leukemia. Exptl Hematol 1996; 24:1122

508. Paietta E, Andersen JW, Yunis JJ, Rowe JM, Cassileth PA, Tallman MS, Wiernik PH:


175


Immature acute monocytic leukemia (AMOL): Blast cells expressing the interleukin-2 receptor -chain and the stem cell factor receptor identify a new poor prognosis leukemic syndrome: An Eastern Cooperative Oncology Group (ECOG) database study. Proc Am Soc Clin Oncol 1996; 15:359.

509. Wadler S, Haynes H, Schechner R, Rozenblit A, Wiernik PH: Phase I trial of high-dose infusional hydroxyurea (HU) and 5-fluorouracil (5FU) + interferon--2a (IFN) in-patients (PTS) with advanced malignancies. Proc Am Soc Clin Oncol 1996; 15:225.


510. O'Boyle K, Coatsworth S, Anthony G, Rameriz M, Greenwald E, Kaleya R, Steinberg JJ, Wadler S, Dutcher J, Wiernik P: Effects of desialylation of ovine submaxillary mucin (OSM) on humoral and cellular immunity to Tn and sialylated Tn. Proc Am Assn Cancer Res 1996; 37:491.

511. Li Y-p, Rao S, Paietta E, Tallman M, Wiernik P, Gallagher R: Clinical relapse in retinoic acid-treated acute promyelocytic leukemia patients is associated with reduced leukemic cell sensitivity to retinoic acid-induced differentiation in vitro. Proc Am Assn Cancer Res 1996; 37:175.

512. .Wiernik PH, Dutcher JP: Should maintenance therapy (MT) for acute myeloid leukemia (AML) be revisited? Proc Intl Soc Expl Hematol, 1996.

513. Gale RP, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Park ER, Rai K, Schiffer CA, Weisdorf DJ, Dubois R, Wiernik PH: CML in chronic phase: Rand-Delphi analysis of appropriateness of bone marrow transplants. Proc Am Soc Clin Oncol 1996; 15:364.

514. Gale RP, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Park ER, Rai K, Schiffer CA, Weisdorf DJ, Dubois R, Wiernik PH: AML in 1 st remission: Rand-Delphi analysis of appropriateness of bone marrow transplants. Proc Am Soc Clin Oncol 1996; 15:365.

515. Wiernik PH, Dutcher JP: Should maintenance therapy (MT) for acute myeloid leukemia (AML) be revisited? Exptl Hematol 1996; 24:1123.

516. Dutcher JP, Wiernik PH: Mitoxantrone (M), vinblastine (V) and CCNU (C) (MVC): A highly active regimen in poor prognosis Hodgkin's disease (HD). Ann Oncol 1996; 7(suppl 3):115.

517. Gale RP, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Park ER, Rai K, Schiffer CA, Weisdorf DJ, Dubois R, Wiernik PH: ALL in 1 st remission: Rand-


176


Delphi analysis of appropriateness of bone marrow transplants. Proc Am Soc Clin Oncol 1996; 15:365.

518. Advani R, Saba H, Rowe J, Tallman M, Wiernik P, Ramek J, Dugan K, Litchman M, Dorr R, Lum B, Sikic B, Davis E, Paietta E, Greenberg P: Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC). Blood 1996; 88:215a.


519. Tallman MS, Lee S, Sikic B, Paietta E, Bennett JM, Rowe JM, Wiernik PH: Mitoxantrone, etoposide and cytosine arabinoside (MEC) plus cyclosporin (CSP) in-patients with relapsed or refractory acute myeloid leukemia (AML): An Eastern Cooperative Oncology Group (ECOG) pilot study. Blood 1996; 88:216a.

520. Nobile L, Li Y-P, Tallman MS, Wiernik PH, Gallagher RE: Sequence analysis of the PML zinc finger (ZF) region of the PML-RAR oncogene in acute promyelocytic leukemia (APL) relapse cases from protocol E2491. Blood 1996; 8:366a.

521. Slack JL, Willman CL, Li Y-P, Viswanatha D, Bloomfield CD, Wiernik PH, Tallman MS, Gallagher RE: Molecular characteristics and clinical features of adult APL patients with the type V PML-RAR isoform: Results from intergroup protocol 0129. Blood 1996; 88:635a.

522. Racevskis J, Neuberg D, Rowe JM, Wiernik PH, Paietta E: Expression of CD25 (interleukin-2 receptor alpha chain) by lymphoblasts predicts for the presence of bcr/abl fusion transcripts (molecular equivalent of the Philadelphia chromosome) in acute lymphoblastic leukemia (ALL): Results of a preliminary laboratory analysis of the Eastern Cooperative Oncology Group (ECOG) study, E2993. Proc Am Soc Clin Oncol 1997; 16:5a

523. Cassileth P, Harrington D, Paietta E, Lazarus H, Appelbaum F, Bennett J, Hurd D, Willman C, Magenis E, Wiernik P: Comparison of autlogous bone marrow transplant (AutoBMT) with high-dose cytarabine (HDAC) in adult acute myeloid leukemia (AML) in first remission (CR1): An ECOG intergroup study. Proc Am Soc Clin Oncol 1997; 16:89a.

524. Dutcher J, Lee S, Makary A, Hines J, Bennett J, Paietta E, Gallagher R, Rowe J, Wiernik PH: ECOG phase II study of all-trans retinoic acid (ATRA) in accelerated (Ac)/blastic (BC) chronic myeloid leukemia (CML) (E1993). Proc Am Soc Clin Oncol 1997; 16:30a.

525. Atkins M, Lotze M, Wiernik P, Fisher R, Margolin K, Weiss G, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Rosenberg SA: High-dose IL-2 therapy alone results in durable responses in-patients with metastatic melanoma. Proc Am Soc Clin Oncol 1997; 16:494a.


177


526. Paietta E, Neuberg D, Rowe JM, Cassileth PA, Wiernik PH: The prognostic significance of immuneprofiles in acute myeloid leukemia (AML) varies with age: A comparative analysis of the Eastern Cooperative Oncology Group (ECOG) database. Proc Am Soc Clin Oncol 1997; 16:5a.

527. Venkatraj U, Lee S, Logie K, Palackdharry C, Stewart J, Hamilton S, Wiernik PH, Cassileth P, Sznol M, Dutcher JP: ECOG phase II trial of interleukin-4 (IL4) in chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin's lymphoma (NHL) (E5Y92). Proc Am Soc Clin Oncol 1997; 16:126a.


528. Ding W, Li YP, Nobile LM, Grills G, Carrera I, Tallman MS, Wiernik PH, Gallagher RE: Retinoic acid receptor alpha (RAR)-region mutations in the PML-RAR fusion gene of acute promyelocytic leukemia (APL) patients after relapse from all-trans retinoic acid (ATRA) therapy. Blood 1997; 90(suppl 1): 415a.

529. Dutcher JP, Wiernik PH: Pilot study of carboplatin (carbo) and mitoxantrone (mitox) as treatment for blast crisis of chronic myeloid leukemia (CMLBC). XIV Meeting Intl Soc Hematol, 1997.

530. Gallagher RE, Ding W, Nobile L, Li Y-P, Tallman MS, Wiernik PH: Inconsistent alterations of PML-RAR mRNA in presenting and relapse acute promyelocytic leukemia cells with reduced retinoic acid sensitivity. Anticancer Res 1997; 17:3841.

531. Malik UR, Challagalla JD, Sparano JA, Gucalp R, Wiernik PH, Dutcher JP: Decreased platelet (PLT) transfusion requirement in patients (PTS) transplanted with peripheral blood stem cells (PBSC). Am Assn Blood Banks, 1997.

532. Dutcher JP, Caliendo G, Oleksowicz L, Sparano J, Suh J, Novik Y, Wiernik PH: Phase II study of moderate dose bolus IL2 plus GM-CSF in metastatic renal cell cancer (MRCC). J Immunother 1997; 20:402.

533. Tallman MS, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Andersen JW, Rowe JM, Wiernik PH: Incidence and clinical course of patients with acute promyelocytic leukemia who develop the retinoic acid syndrome. Blood 1997; 90(suppl 1):416a.

534. Wiernik PH: Spontaneous regression (SR) of malignant lymphoma (NHL). Onkologie 1997; 20:87.

535. Advani R, Saba H, Tallman M, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Sikic BI, Davis E, Paietta E, Litchman M, Greenberg P: Treatment of poor prognosis AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC). Blood 1997; 90(suppl


178


1):507a.

536. Estey E, Douer D, Wiernik P, Reed P, Thompson J, Gordon D: Treatment of recurrent acute promyelocytic leukemia (APL) with liposomal all-trans retinoic acid (L-ATRA). Blood 1997; 90(suppl 1):332a.

537. Hu X, Marino, P, Wiernik PH: Analyze associations between two events based on two-events data. Proc JSM, 1997.

538. Wiernik PH, Wang SQ, Hu X-P, Marino P: Anticipation occurs in familial Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). Blood 1997; 90(suppl 1):271b.


539. Huang XJ, Wiernik PH, Klein RS, Gallagher RE: Potentiation of arsenic trioxide (As2O3) induced apoptosis by retinoic acid (RA) in RA-sensitive (S) and RA-resistant (R) HL-60 myeloid leukemia cells. Blood 1997; 90(suppl 1):329a.

540. Paietta E, Neuberg D, Bennett JM, Rowe JM, Cassileth PA, Wiernik PH: Novel definition of undifferentiated (UNDIF) acute myeloid leukemia (AML) by low expression of the CD65s carbohydrate molecule: Analysis of 996 patients from the ECOG database. Blood 1997; 90(suppl 1):220b.

541. Gallagher RE, Ding W, Rao S, Wiernik PH, Tallman MS: Late-emerging subclones of acute promyelocytic leukemia (APL) cells with mutations in PML-RAR involved in relapse after sequential all-trans retinoic acid (ATRA) and chemotherapy (CT)). Proc Am Soc Clin Oncol, 1997.

542. Sparano JA, Wiernik PH, Hu X, Sarta C, Domenech G, Cioczek H, Racevskis J: Infusional cyclophosphamide, doxorubicin, and etoposide (CDE) for HIV-associated non-Hodgkin's lymphoma: long-term followup and analysis of prognostic factors. J AIDS Hum Retrovirol 1997; 14:A38.

543. Gallagher RE, Singh J, Yue Z, Rowe JM, Wiernik PH, Dutcher JP: Advanced chronic myelogenous leukemia patients clinically responsive to all-trans retinoic acid identifiable by clonogenic assays. Anticancer Res 1997; 17:3935.

544. Huang X-J, Wiernik PH, Klein RS, Gallagher RE: Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases via an alternative transduction pathway. Proc Am Assn Cancer Res, 1997.

545. Wiernik P, Ozer H, Oken M, Giles F, Solal-Celigny P, Coiffier B: Prognostic factors in-patient selection for treatment with interferon alfa in low-grade follicular lymphoma. Blood 1997; 90(suppl 1):337a


179


546. .Sparano JA, Wiernik PH, Hu X, Sarta C, Reddy D, Hannau L: Opportunistic infection and immunologic function in-patients with AIDS-associated lymphoma treated with chemotherapy. J AIDS Hum Retrovirol 1997; 14:A38.

547. Dutcher JP, Wu JJ, Caliendo G, Hu XP, Oleksowicz L, Sparano J, Wiernik PH: Mixed sarcomatoid/clear cell (CC) renal cell cancer (RCC) has an improved prognosis over pure sarcomatoid (S) RCC. Proc Am Assn Cancer Res 1998; 39:593.

548. Sparano JA, Wiernik PH, Hu X, Sarta C, Henry DH, Ratech H: Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin and etoposide in HIV-associated lymphoma. Proc Am Assn Cancer Res 1998; 39:325.


549. Wiernik PH, Lee S, Cassileth PA, Rowe JM, Hines JD, Oken MM, Mazza JJ, Saetiano G, Tartaglia A, Glick JH, Bennett JM, Tallman MS: Non-Caucasians with acute myeloid leukemia (AML) have a higher frequency of FAB M3 type than Caucasians. Proc Am Soc Clin Oncol 1998; 17:41a.

550. Racevskis J, Neuberg D, Rowe JM, Wiernik PH, Goldstone AH, Paietta E: Expression of CD25 (interleukin-2 receptor chain) by lymphoblasts predicts for the presence of BCR/ABL fusion transcripts (molecular equivalent of the Philadelphia chromosome) in adult acute lymphoblastic leukemia (ALL): Results of a preliminary laboratory analysis of ECOG/MRC intergroup study E2993. Proc Am Soc Clin Oncol, 1998.

551. Wiernik PH, Fears T, Sullivan LM, O'Neill JP, Paietta E, Tucker MA, Albertini RJ, Lin AY: In vivo mutant frequency (MF) of hypoxanthine-guanine phosphoriboysltransferase (HPRT) gene in T-lymphocytes from families with familial lymphoproliferative syndrome (FLPS). Proc Am Soc Clin Oncol 1998;17:552a.

552. Advani R, Saba H, Tallman M, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Coveli A, Sikic B, Greenberg P: Treatment of poor prognosis AML patients using PSC833 plus mitoxantrone, etoposide and cytarabine (PSC-MEC). Leukemia 1998; 12:257.

553. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary A, Tallman MS, Wiernik PH: A phase III study of duanorubicin vs idarubicin vs mitoxantrone for older patients (55 yrs) with acute myelogenous leukemia (AML): A study of the Eastern Cooperative Oncology Group (E3993). Blood 1998; 92:313.

554. Dutcher JP, Wiernik PH: Pilot study of carboplatin (C) and mitoxantrone (M) in blast crisis of chronic myeloid leukemia (CMLBC). Proc Am Soc Clin Oncol 1998; 17:23A.

555. Anand K, Sparano JA, Gucalp R, Malik U, Friedman K, Paietta E, Dutcher JP, Wiernik PH: Phase I trial of high-dose pacltaxel plus cyclophosphamide, thitepa, carboplatin, and


180


autologous stem cell transplatation. Proc Am Soc Clin Oncol 1998; 17:87a.

556. Huang X-J, Wiernik PH, Klein RS, Gallagher RE: Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of capases via an alternative transduction pathway. Proc Am Assn Cancer Res 1998; 39:90.

557. Zhou DC, Hallam SJ, Wiernik PH, Tallman MS, Gallagher RE: Constitutive expression of cellular retinoic acid binding protein II in acute promyelocytic leukemia cells. Proc Am Assn Cancer Res 1998; 39:106.


558. Catovsky D, Dighiero G, Hansen M, Jaksic B, Kimby E, Montserrat E, Richards S, Wiernik P: Collaborative meta-analysis of randomised trials in chronic lymphocytic leukaemia (CLL). Proc ISH-EHA, 1998.

559. Wiernik PH, Gallagher RE, Kim S, Paietta E, Dutcher JP: Pilot study of arsenic trioxide (ATO) in acute myeloid leukemia. Proc ISH-EHA, 1998.

560. Sparano JA, Wiernik PH, Hu X, Henry DH, Ratech H: Pilot trial of saquinavir and nucleoside analogues plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated lymphoma. J. Human Retrovirol, 1998.

561. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, haves FA, Makary A, Tallman MS, Wiernik PH: A phase III study of priming with yeast-derived granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) for older adult patients (55 yrs) with acute myelogenous leukemia (AML): A study of the Eastern Cooperative Oncology Group. Blood 1998; 92:679a.

562. Liesveld J, Abboud C, Harbol A, Rosell K, Belanger T, Tallman M, Neuberg D, Wiernik P, Rowe J: Cell cycle status and proliferative capacity of AML blasts in response to GM-CSF; A laboratory correlate of a phase III study of priming with RHU-GM-CSF in adult patients 55 years old. Blood 1998; 92:80a.

563. Cripe L, Neuberg D, Tallman M, Saba H, Wiernik P, Jones D, Ghalie R, Gordon M: A pilot study of recombinant human thrombopoietin (rh-TPO) and GM-CSF following induction therapy in-patients older than 55 years with acute myeloid leukemia (AML). Blood 1998; 92:616a.

564. Wiernik PH, Gallagher RE, Kim S, Paietta E, Dutcher JP: Pilot study of arsenic trioxide (ATO) in acute myeloid leukemia. Br J Haematol 1998; 102:329.

565. Binet JL, Dighiero G, Catovsky D, Hansen M, Jaksic B, Kimbry E, Montserrat E, Richards


181


S, Wiernik P: Collaborative meta-analysis of randomized trials in chronic lymphocytic leukemia (CLL). Br J Haematol 1998; 102:277.

566. Seno R, Kale A, Akker Y, Ho G, Wiernik PH, Ratech H: Clonal evolution in Hodgkin's disease. Proc Intnl Acad Pathol, 1998.

567. Dutcher JP, Caliendio G, Novik Y, Oleksowicz L, Sparano J, Wiernik PH: Phase II study of moderate dose bolus or continuous infusion (CI) IL2 plus GM-CSF in metastatic renal cell cancer (MRCC). Proc Am Soc Clin Oncol 1999; 18:451a.


568. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary A, Tallman MS, Wiernik PH: Delaying induction therapy in older adults may lead to a lower CR rate and overall survival: Implications from phase III studies of the Eastern Cooperative Oncology Group (E3993). Ann Hematol 1999; 78(suppl II):249.

569. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH: All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome results and prognostic factor analysis from intergroup protocol 0129. Blood 1999; 94 (suppl 1): 698a.

570. Goldstone AH, Richards S, Wiernik PH, Franklin IM, Burnett AK, Lazarus HM, Prentice HG, Neuberg D, Tallman MS, Harrison G, Rowe JM: Philadelphia chromosome +ve patients with adult acute lymphoblastic leukaemia (ALL). Early results from the international ALL trial (MRC UKALL-XII/ECOG E2993). Blood 1999; 94(suppl 1): 694a.

571. Rowe JM, Richards S, Wiernik PH, Franklin IM, Burnett AK, Lazarus HM, Prentice HG, Harrison G, Neuberg D, Tallman MS, Goldstone AH: Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR): Early results from the international ALL trial (MRC UKALL XII/ECOG E2993). Blood 1999; 94 (suppl 1): 168a.

572. Tallman MS, Neuberg D, Bennett JM, Francois C, Paietta E, DeWald G, Cassileth P, Oken M, Wiernik P, Rowe JM: Acute megakaryocytic leukemia: The Eastern Cooperative Oncology Group (ECOG) experience. Blood 1999; 94 (suppl 1): 596a.

573. Tallman M, Cassileth P, Wiernik P, Rowe J: Eastern Cooperative Oncology Group (ECOG) studies in the treatment of older adults with acute myelogenous leukemia (AML). Ann Hematol 1999; 78(suppl II):70a.

574. Novik Y, Paietta E, Dutcher JP, Wiernik PH: Idarubicin and standard dose Ara-C (I+A) for refractory and relapsed adult ALL. Blood 1999; 94(suppl 1): 234b.


182


575. Caliendo G, Dutcher JP, Wu JJ, Hu XP, Wiernik: Mixed sarcomatoid/clear cell (CC) renal cell cancer (RCC) has an improved prognosis over pure sarcomatoid (S) RCC. Proc 1st Intl Kidney Cancer Symp, 1999.

576. Novik Y, Dutcher JP, Caliendo G, Wiernik P: Phase II study of moderate dose bolus or continuous infusion (CI) IL2 plus GM-CSF in metastatic renal cell cancer (MRCC). Proc 1st

Intl Kidney Cancer Symp, 1999.


577. Wiernik PH, Dutcher JP, Gallagher R, Caliendo G, Garl S, Paietta E: Phase II trial of arsenic trioxide (AS203) in patients (PTS) with relapsed/refractory acute myeloid leukemia (AML), blast crisis of CML, or myelodysplasia (MDS). Blood 1999; 94(suppl 1): 510a.

578. Tallman MS, Lee S, Oken MM, Cassileth PA, Bennett JM, Wiernik PH, Rowe JM: Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Blood 1999; 94(suppl 1): 224b.

579. Weisdorf D, Cairo M, Dharan B, Keating A, Lazarus H, Litzow M, Loberiza F, Marks D, Miller C, Milone G, Prentice H, Russell J, Trigg M, Wiernik P, Horowitz M: Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia. Blood 2000; 96:413a.

580. Etkind P, Pillitteri J, Wiernik PH, Stewart AFR: Mouse mammary tumor virus (MMTV)-like envelope (ENV) gene sequences in human breast cancer, non-Hodgkin’s lymphoma, and prostate cancer. Proc 6th Intl Cong Adv Management of Malignancies, 2000.

581. Unnikrishnan D, Dutcher JP, Varshneya N, Choragudi N, Api M, Garl S, Wiernik PH, Chiaramida S: Torsades de Pointes in two patients on treatment with arsenic trioxide. Exptl Hematol 2000; 28 (Suppl 1):44.

582. Jankovic GM, Colovic MD, Wiernik PH, Andolina M: Ages of the Philadelphia (Ph) chromosome translocations in human leukemias: Dating the karyotype age of modern man. Proc Cold Spring Harbor Symposium, 2000.

583. Dutcher JP, Wiernik PH, Novik Y, Garl S, Hughes J, Arezzo J: Major hematologic response in a patient with myelodysplasia (NDS) to arsenic trioxide (ATO). Blood 2000; 96:260b.

584. Novik Y, Dutcher JP, Larkin M, Wiernik PH: Phase II study of thalidomide (T) in advanced refractory metastatic renal cell cancer (MRCC): A single institution experience. Proc Am Soc Clin Oncol 2001; 20:265a.


183


585. Unnikrishnan D, Varshneya N, Lucariello R, Dutcher JP, Wiernik PH, Chiaramida S: Torsade de pointes associated with arsenic trioxide treatment for hematological malignancies. Am J Cardiol 2001; 37(suppl A):631A.

586. Talman M, Kim H, Paietta E, Bennett JM, DeWald G, Cassileth PA, Wiernik PH, Rowe JM: Acute myeloid leukemia (AML) FAB M5 does not have a worse prognosis than other subtypes of AML. Blood 2001; 98:585a.


587. Rowe JM, Richards SM, Burnett AK, Wiernik PH, Harrison G, Lazarus HM, Franklin IM, Prentice HG, Durrant IJ, Tallman MS, Goldstone AH: Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): Results from the international ALL trial (MRC UKALL XII/ECOG E2993). Blood 2001; 98:481a.

588. Goldstone AH, Prentice HG, Durrant J, Franklin IM, Harrison G, Richards SM, Lazarus HM, Wiernik PH, Tallman MS, Rowe JM: Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadephia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993). Blood 2001; 98:856a.

589. Paietta E, Kim H, Rowe JM, Racevskis J, Dewald G, Richards S, Goldstone AH, Tallman MS, Wiernik PH: Prognostic significance of biologic parameters in adult acute lymphoblastic leukemia (ALL): Interim analysis of ECOG/MRC Phase III Intergroup trial, E2993. Blood 2001; 98:841a.

590. Wiernik PH, Kim H, Gundacker H, Dewald G, Slovak ML, Paietta E, Appelbaum FR, Tallman MS: Prognostic implication of additional cytogenetic aberrations in de novo acute myeloid leukemia (AML) with t(15;17), t(8;21) or inv(16)/t(16;16). Blood 2001;98:457.

591. Makower D, Lee S, Wiernik PH, Paietta E, Bennett JM, Wade J, Ghosh C, Kaminer L, Tallman MS: Phase II trial of theophylline for early stage chronic lymphocytic leukemia (CLL). Blood 2001; 98:290b.

592. Vadhan-Raj S, Lentz S, Budman DR, Hausner P, Blanchard R, Schilder R, Wiernik P, Abboud C, Louie AC: Mirostipen: A phase IIA study for prevention of chemotherapy-induced myelosuppression in patients receiving topotecan. Proc ASCO, 2001.

593. Ferrando AA, Neuberg DS, Dodge RK, Paietta E, Larson RA, Wiernik PH, Rowe JM, Bloomfield CD, Caliguri MA, Look AT: Adult T-cell ALL patients whose lymphoblasts


184


express the HOX11 oncogene have an excellent prognosis when treated with chemotherapy and are not candidates for allogeneic bone marrow transplantation in first remission. Blood 2002; 100:154.

594. Tallman M, Kim H, Andersen J, Skeel R, Sartiano G, Cassileth P, Cripe L, Wiernik P, Rowe J: Outcome of patients with acute promyelocytic leukemia (APL) in the pre-ATRA era: An analysis from the Eastern Cooperative Oncology Group (ECOG). Blood 2002; 100:766a.

595. Gallagher RE, Lee SJ, Sankoorikal B-J, Wiernik PH, Tallman M: Independent prognostic significance of FLT3 internal tandem duplication (ITD) mutations in acute promyelocytic leukemia (APL) patients treated on ECOG protocol E2491. Blood 2002; 100:326a.


596. Paietta E, Kim H, Racevskis J, Dewald G, Rowe JM, Richards S, Goldstone A, Tallman MS, Wiernik PH: Immunophenotypic characteristics, but not age or secondary cytogenetic changes, affect response and survival of BCR/ABL positive adult acute lymphoblastic leukemia (ALL): ECOG/MRC intergroup trial E2993. Blood 2002; 100:755a.

597. Redfern C, Guthrie TH, Smith MR, Adler M, Holman P, Leonard JP, Levy R, Densmore J, Just R, Rosenfelt F, Wiernik PH, Janakiraman N, Winter JN, Gold D, Bender JF: A phase II trial of FavidTM [Id-KLH] for relapsed indolent non-Hodgkin’s lymphoma. Blood 2002; 100:357a.

598. Paietta E, Goloubeva O, Bennett JM, Gallagher RE, Racevskis J, Wiernik PH, Tallman MS: A surrogate marker profile for acute promyelocytic leukemia (APL) and the association of immunophenotypic markers with morphologic and molecular subtypes of APL. Blood 2002; 100:229b.

599. Hulshizer C, Paietta E, Hicks G, Cassileth PA, Rowe JM, Wiernik PH, Tallman MS, DeWald G: Comparison of cytogenetics in patients with acute myeloid leukemia (AML): French-American-British (FAB) classification M5 versus non-M5. Blood 2002; 100:244b.

600. Henschke CI, Rifkin M, Kopel S, Klippenstein D, Kahn A, Shah R, Kohman L, Austin JHM, Mendelson DS, Heelan R, Matalon TAS, Wiernik PH: New York early lung cancer action project: A multi-institutional study of CT screening for lung cancer. Proc Radiol Soc N Amer, 2003.

601. Tarantolo S, Watson P, Wiernik PH, Weisenburger DD, Hogg D, Quinn-Laquer B, Sanger WG, Bersagel KI, Bergsagel L, Eisinger F, Sobol H, Huiart L, Ogmundsdottir H, Olopade OI, Thertulien R, Tlsty T, Kuehl M, Croce C, de la Chapelle A, Offit K, Lynch HT: Familial multiple myeloma (MM) registry: An international consortium for MM family studies. Blood 2003; 102: 376b.

602. Mannam P, Dutcher JP, Eapen J, O’Boyle K, Marcoullis G, Malik S, Khairkhan N, Sivadas


185


H, Garino A, Wiernik PH: Role of prognostic factors in patients with metastatic renal cell carcinoma (MRCC) eligible for treatment with interleukin-2 (IL2). Proc Am Soc Clin Oncol 2003; 22:441.

603. Watson P, Tarantolo S, Wiernik PH, Weisenburger DW, Hogg D, Quinn-Laquer B, Sanger WG, Lynch HT: Hereditary multiple myeloma (MM): An international consortium for MM family studies. Hematol J 2003; 4(suppl 1):S95.


604. Gold D, Redfern C, Wiernik PH, Guthrie TH, Rosenfelt F, Koc ON, Winter JN, Holman P, Kaplan L, Hainsworth J, Castillo RA, Lin T, Densmore J, Adler M, Smith J, Pickens PV, Gutheil J, Bender J: FavIdTM [Id-KLH vaccine] following rituximab for patients with indolent NHL. Blood 2003; 102:899

605. Redfern C, Gutherie TH, Adler M, Holman P, Smith MR, Levy R, Janakiraman N, Leonard JP, Rosenfelt F, Wiernik PH, Just R, Densmore J, Gold D, Gutheil J, Bender J: Single agent activity of FavIdTM [Id-KLH vaccine] for indolent NHL. Blood 2003; 102:898a.

606. Jain D, Dutcher JP, Wiernik PH: Complete clinical response with single-agent high doose rituximab in mantle cell lymphoma. Blood 102:305b, 2003.

607. Jain D, Dutcher JP, Wiernik PH: High dose rituximab in chronic lymphocytic leukemia. Blood 2003; 102:359b.

608. Goldstone AH, Chopra R, Buck G, Richards M, Franklin IM, Lazarus HM, Wiernik PH, Tallman MS, Prentice HG, Durrant J, Rowe JM: The outcome of 267 Philadelphia positive adults in the international UKALL 12/ECOG E2993 study. Final analysis and the role of allogeneic transplant in those under 50 years. Blood 2003; 102:80a.

609. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Prentice HG, Durrant J, Tallman MS, Goldstone AH: Induction therapy for adults with acute lymphoblastic leukemia (ALL): Results of nearly 1,400 patients from the international ALL trial (MRC UKALL XII/ECOG E2993. Blood 2003; 102:224a.

610. Chopra R, Goldstone AH, Buck G, Richards SM, Franklin I, Lazarus HM, Wiernik PH, Tallman MS, Prentice HG, Durrant J, Rowe JM: Adult patients with acute lymphoblastic leukaemia (ALL) who relapse have a dismal outlook: Results from MRC UKALL XII/ ECOG 2993 trial. Blood 2003; 102:880a.

611. Etkind PR, Stewart AF, Dorai T, Purcell DJ, Wiernik PH: Clonal isolation of different strains


186


of mouse mammary tumor virus (MMTV)-like DNA sequences from both the breast tumors and non-Hodgkin’s lymphomas of individual patients diagnosed with both malignancies. Proc Am Assn Cancer Res 2004; 45: 1102.

612. Dorai T, Dutcher JP, Dempster DW, Wiernik PH: Therapeutic potential of curcumin in prostate cancer: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Proc Am Assn Cancer Res 2004; 45: 477.


613. Koc ON, Redfern C, Wiernik P, Rosenfelt F, Winter J, Gutherie T, Kaplan L, Holman P, Densmore J, Hainsworth J: Successful anti-Id T-cell responses to Id-KLH immunotherapy in B-cell depleted patients with follicular lymphoma (FL) may prolong TTP after rituximab: Phase II trial of Favid. Proc Am Soc Clin Oncol 2004; 23:168.

614. Tallman MS, Kim HT, Schiffer CA, Appelbaum FR, Feusner JH, Ogden AK, Shepherd L, Willman CL, Bloomfield CD, Rowe JM, Larson RA, Wiernik PH, Sanz MA: Microgranular variant (M3V) of acute promyelocytic leukemia (APL) does not have a worse prognosis than classical APL in the ATRA era: A report of 153 patients treated with intergroup 0129 and Pethema LPA 96 and LPA99. Blood 2004; 104:116a.

615. Lazarus HM, Richards SM, Chopra R, Litzow MR, Burnett AK, Wiernik PH, Franklin IM, Tallman MS, Buck G, Durrant J, Rowe JM, Goldstone AH: Adult patients with acute lymphoblastic leukemia (ALL) and central nervous system (CNS) leukemia at diagnosis may attain durable complete remissions (CR). Results from the international ALL trial (MRC UKALL-XII/ECOG E2993). Blood 2004; 104:204b.

616. Koc ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Guthrie TH, Kaplan L, Holman P, Densmore J, Hainsworth J, Lin T, Castillo RA, Janakiraman N, Bender JF: Id/KLH vaccine (FavId™) following treatment with rituximab: An analysis of response rate improvement (RRI) and time-to-progression (TTP) in follicular lymphoma (FL). Blood 2004; 104:170a.

617. Henschke CI, Lee I, Rifkin M, Kpopel S, Klippenstein DL, Khan A, Farooqi A, Lee I-J, Wu N, Kohman L, Austin J, Mendelson D, Heelan R, Matalon T, Wiernik P, Gordon D: CT screening for lung cancer: mediastinal masses in the early lung cancer action project and the New York early lung cancer action project. Proc RSNA Ann Meeting, 2004.

618. Rowe JM, Kim HT, Cassileth PA, Litzow MR, Wiernik PH, Tallman MS: Time to complete remission is not a significant prognostic factor in AML: A report on 1,959 consecutive patients registered to 6 studies of the Eastern Cooperative Oncology Group (ECOG). Blood 2004; 104:246a.


187


619. Sankoorikal B-J, Zhou Da-C, Wiernik PH, Gallagher RE: Mutation of cellular retinoic acid-binding protein-II (CRABP-II) does not account for resistance to all-trans retinoic acid (ATRA) in relapse acute promyelocytic leukemia (APL). Blood 2004; 104:573a.

620. Dorai T, Sawczuk I, Wiernik PH, Dutcher JP: Biological significance of overexpression of carbonic anhydrase IX in renal cell carcinoma. Proc 3rd Intl Kidney Cancer Symp, 2004.

621. Goldstone AH, Lazarus HJ, Richards SM, Litzow MR, Chopra R, Burnett A, Wiernik PH, Franklin IM, Prentice HG, Tallman M, Harrison G, Durrant J, Rowe J: The outcome of 551 1st CR transplants in adult ALL from the UKALL XII/ECOG 2993 study. Blood 2004; 104:178a.


622. Alexandrescu DT, Karri S, Dutcher JP, Wiernik PH: Mitoxantrone, vinblastine, and lomustine (MVC): Long-term follow-up of patients treated for Hodgkin’s disease (HD). Blood 2004; 104:369a.

623. Dorai T, Sawczuk I, Wiernik PH, Dutcher JP: Biological significance of carbonic anhydrase IX in renal cell carcinoma. Proc Am Assn Cancer Res, 2005;46: abstract #1034.

624. Rowe JM, Li X, Cassileth PA, Appelbaum FR, Schiffer CA, Wiernik PH, Litzow MR, Cripe LD, Lazarus HM, Paietta E, Dewald GW, Weinstein HJ, Ogden AK, Woods WG, Shepherd L, Feusner JH, Bloomfield CD, Tallman MS: Very poor survival of patients with AML who relapse after achieving a first complete remission: The Eastern Cooperative Oncology Group experience. Blood 2005; 106:162a-163a.

625. Gregory J, Kim H, Alonzo T, Gerbing R, Ogden A, Woods W, Weinstein H, Shepherd L, Schiffer C, Appelbaum F, Willman C, Wiernik P, Rowe J, Tallman M, Feusner J: Phase III trial of all-trans retinoic acid (ATRA) vs daunorubicin (D) and cytosine arabinoside (A) as induction therapy and ATRA vs observation as maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL). Blood 2005; 106a: 263a.

626. Hugec V, Koulova L, Garino A, Wiernik PH, Dutcher JP: Single agent gemcitabine (gem) in metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol 2005; 23:452s.

627. Koc O, Redfern C, Wiernik P, Rosenfelt F, Winter J, Guthrie T, Kaplan L, Holman P, Densmore J, Hainsworth J, Lin T, Castillo R, Janakiraman N, Gold D, Gutheil J, Bender J: Extended follow-up and analysis with central radiological review of patients receiving FavId (Id/KLH) vaccine following rituximab. Blood 2005; 106a: 228a.

628. Natali LC, Maddukuri P, Malik S, Bhagwati N, Fernaine G, Wiernik P, Dutcher JP: Significant arrhythmias associated with interleukin-2 therapy. Proc Am Soc Clin Oncol 2005; 23:187s.


188


629. Hugec V, Alexandrescu DT, Oe Y, Paietta E, Wiernik PH: High dose of rituximab in B-cell malignancies. Blood 2005; 106: 340b.

630. Koc ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Guthrie TH, Kaplan L, Holman P, Densmore J, Hainsworth J, Lin TS, Castillo RA, Janakiraman N, Gold DP, Esquibel V, Melink TJ, Gutheil J, Bender JF: Active immunotherapy with FavId ® (Id/KLH) following Rituximab induction: Long term follow up of response rate improvement (RRI) and disease progression in follicular lymphoma patients (pts). Blood 2006; 108: 207a.


631. Wiernik PH, Lossos IS, Justice JB, Zeldis K, Takeshita D, Pietronigro T, Habermaan T, Witzig T: Preliminary results from two pahse II studies of Revlimid monotherapy in relapsed/refractory non-Hodgkin’s lymphoma. J Clin Oncol 2006; 24:685s.

632. Natali LC, Maddukuri P, Lucariello R, Malik S, Bhagwati N, Fernaine G, Wiernik P, Dutcher JP: Significant arrhythmias associated with IL-2 therapy. J Clin Oncol 2006; 24: 438s.

633. Wiernik P, Lossos IS, Justice G, Tuscano JM, Zeldis JB, Takeshita K, Pietronigro D, Habermann T: Preliminary results from a phase II study of lenalidomide monotherapy in relapsed/refractory aggressive non-Hodgkin’s lymphoma. Haematologica 2006; 91(Suppl 1):261.

634. Cui Q, Kim H, Wiernik PH, Tallman MS, Gallagher RE: Common gene expression changes in matched pretreatment and relapse samples from Eastern Cooperative Oncology Group acute promyelocytic leukemia (APL) patients treated on the chemotherapy (C) or all-trans retinoic acid (ATRA)-containing (A) randomization arms of protocol E2491. Blood 2006; 108: 156b.

635. Juric D, Lacayo NJ, Ramsey MC, Racevsjis J, Wiernik PH, Rowe JM, Goldstone AH, O’Dwyer PJ, Paietta E, Sikic BI: Differential gene expression patterns and interaction networks in BCR/ABL positive and negative adult acute lymphoblastic leukemias. Blood 2006; 108: 520a.

636. Witzig T, Vose J, Cole C, Kaplaan H, Wolf J, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis J, Wiernik PH: Early results from a phase II study of lenalidomide monotherapy in relapsed/refractory indolent non-Hodglin’s lymphoma. Blood 2006; 108: 703a

637. Wiernik PH, Lossos I, Tuscano J, Justice G, Vose J, Pietronigro D, Takeshita K, Ervin A, Zeldis JB, Habermann T: Preliminary results from a phase II study of lenalidomide


189


monotherapy in relapsed/refractory aggressive non-Hodgkin’s lymphoma. Blood 2006; 108: 160a.

638. Muniswamy H, Dutcher JP, Mannam P, Malik S, Rusciano V, Paul L, Wiernik PH: Role of prognostic factors in patients with metastatic renal cell carcinoma (MRCC) eligible for treatment with interleukin (IL2). J Clin Oncol 2006; 24:638s.

639. Dutcher JP, Dasanu C, Codreanu I, Yeddu M, Muniswamy H, Wiernik PH, Alexandrescu DT: Correlation between hemodynamic parameters and response to high-dose interleukin-2 in metastatic melanoma. J Clin Oncol 2006; 24:686s.

640. Wiernik PH, Lossos IS, Justice G, Tuscano JM, Zeldis JB, Takeshita K, Pietronigro D, Habermann T: Preliminary results from a phase II study of lenolidomide monotherapy in relapsed/refractory aggressive non-Hodgkins lymphoma. Hematologica 2006; 91 (s1):261.


641. Alexandrescu DT, et al: Correlation between hemodynamic parameters and response to high-dose interleukin-2 in metastatic melanoma. J Clin Oncol 2006; 24:685s.

642. Alexandrescu DT, Brown K, Dutcher JP, Wiernik PHl: The influence of parent age and gender on anticipation in familial B-cell malignancies. J Clin Oncol 2006; 24:435s.

643. Mealiffe M, Kirchhoff T, Wiernik PH, Lynch HT, Daibata M, Gerdes A-M, Offit K, Goldin LR, Horwitz MS: KLHDC8B is a novel, mitotically-regulated classical Hodgkin’s lymphoma candidate susceptibility gene. Blood 2006; 108:143a.

644. Rowe JM, Buck G, Fielding A, Tallman MS, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Foroni L, Paietta E, Litzow MR, Marks D, Durant J, Goldstone AH: In adults with standard-risk acute lymphoblastic leukemia (ALL) the greatest benefit is achieved from an allogeneic transplant in first complete remission (CR) and an autologous transplant is less effective than conventional consolidation/maintenance chemotherapy: Final results of the international ALL trial (MRC UKALL XII/ECOG 2993). Blood 2006; 108: 5a. (Plenary Session Presentation)

645. Wiernik PH, Lossos I, Tuscano J, Justice G, Vose JM, Pietronigro D, Takeshita K, Ervin-Hayes A, Zeldis JB, Habermann T: Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2007; 25:454s.

646. Wiernik PH: The current and future management of acute myeloid leukemia in adults. Arch Med Interna (Uruguay) 2007; 29 (suppl 1): S91-S92.

647. Moorman AV, Harrison CJ, Buck GAN, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow


190


MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW: Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia. Haematologica 2007; 92 (s1):139.

648. Moorman AV, Harrison CJ, Buck GAN, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW: Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia. Proc Br Soc Haematol, 2007.

649. Wiernik PH, Lossos IS, Tuscano J, Justice G, Vose JM, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermannn T: Efficacy and safety of lenalidomide oral monotherapy in relapsed/refractory aggressive non-Hodgkin’s lymphoma. Preliminary results of a phase II study. Proc Pan-Pacific Lymphoma Conf, 2007.


650. Koc O, Redfern C, Wiernik P, Rosenfelt F, Winter J, Guthrie T, Kaplan L, Holman P, Densmore J, Hainsworth J, Lin T, Castillo R, Janakiraman N, Bender J: Active immunotherapy with mitumprotimut-T (FavId®, Id-KLH) following rituximab induction in patients (pts) with follicular B-cell lymphoma (FL): progression free survival (PFS) at 4-year follow up. Blood 2007; 110:757a.

651. Cui Q, Kim H, Paietta E, Wiernik PH, Tallman M, Gallagher R: Differential gene expression in relapse acute promyelocytic leukemia (APL) cells after in vitro exposure to all-trans retinoic acid (ATRA). Proc Intl Conf Differentiation Ther, 2007.

652. Witzig T, Vose J, Moore T, Pietronigro D, Takeshita K, Ervin-Hayes A, Zeldis J, Wiernik PH: Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol 2007; 25: 457s.

653. Darabi K, Erfani M, Bash R, Wiernik PH: Treatment of refractory thrombotic thrombocytopenic purpura (TTP) in a patient with sickle cell-hemoglobin C disease. Proc Am Soc Apheresis, 2007.

654. Witzig T, Vose J, Moore T, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis J, Wiernik PH: Efficacy and safety of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin’s lymphoma: Preliminary results of a phase II study. Proc Pan-Pacific Lymphoma Conf, 2007.

655. Koc O, Redfern C, Wiernik PH, Rosenfelt F, Winter J, Guthrie T, Kaplan L, Holman P, Densmore J, Hainsworth J, Lin T, Castillo R, Janakiraman N, Ghalie RG: Continued late conversion to complete remission (CR/Cru) and durability of remission (DUR) in Pts with B-cell follicular lymphoma (FL) treated with rituximab followed y mitumprotimut-T ( Id-KLH, FavId®) active immunotherapy. Blood 2007; 110:1004a


191


656. Witzig T, Vose J, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Wolf J, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis J, Wiernik PH: Results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin’s lymphoma. Blood 2007; 110:754a.

657. Wiernik PH, Losos IS, Tuscano J, Justice G, Vose JM, Cole C, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann T: Lenalidomide response in relapsed/refractory aggressive non-Hodgkin’s lymphoma is related to tumor burden and time from rituximab treatment. Blood 2007; 110:756a.

658. Lossos IS, Wiernik PH, Justice G, Tuscano J, Cole C, Lam W, Vose JM, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann T: Lenalidomide response in relapsed/refractory diffuse large B-cell non-Hodgkin’s lymphoma. Blood 2007; 110:756a.


659. Witzig T, Reeder C, Polikoff J, Chowhan N, Esseessee I, Greenberg R, Patel H, Vafai D, Wiernik P, Ervin-Haynes A, Pietronigro D, Zeldis J, Cruczman M: Initial results from an international study to confirm the activity, safety and criteria for predicting response to lenalidomide monotherapy. Blood 2007; 110:758a.

660. Bojanapally PR, Alexandrescu DT, Rusciano V, Wiernik PH, Dutcher JP: Phase II single institution study of sequential biochemotherapy (BCT) for patients (pts) with stage IV melanoma (M). J Clin Oncology 2007; 25: 492s, 2007.

661. Cui Q, Kim H, Zhou D-C, Wiernik PH, Tallman M, Gallagher R: Treatment type determines gene expression changes from pretreatment (PTx) to relapse (Rel) in acute promyelocytic leukemia (APL). Blood 2007; 110:931a.

662. Dorai T, Pastorek J, Wiernik P, Dutcher J: Non-traditional roles of carbonic anhydrase IX in renal cell carcinoma. Proc Am Assn Cancer Res 2007;2007:3745.

663. Wiernik PH, Lossos IS, Tuscano J, Justice G, Vose JM, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann T: Results from a phase II trial investigating the efficacy and safety of lenalidomide oral monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. Haematologica 2008; 93(suppl 1): 243.

664. Wiernik PH, Vose JM, Moore TD, Reeder CB, Cole CE, Justice G, Kaplan HP, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Witzig TE: Results from a phase II study investigating the efficacy and safety of linalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma. Haematologica 2008; 93(suppl 1): 125.

665. Habermann TM, Lossos IS, Justice G, Tuscano JM, Cole CE, Vose JM, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Wiernik PH: Efficacy and safety of lenalidomide in


192


relapsed/refractory diffuse large B-cell lymphoma. Proc Int Conf Malignant Lymphoma, 2008.

666. Habermann TM, Witzig TE, Lossos IS, Vose JM, Wiernik PH, Weiss L, Ervin-Haynes A, Pietronigro D, Zeldis JB, Czuczman M: Safety of lenalidomide monotherapy in patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2008; 26(I):479s.

667. Paietta E, Li X, Richards SM, Racevskis J, Dewald G, Rowe JM, Tallman MS, Lazarus HM, Litzow MR, Goldstone AH, Wiernik PH: Outcome in Philadelphia chromosome positive (PH+), adult ALL patients (Pts) may be more determined by CD25 expression than by Ph status per se. Blood 2008; 112:533.


668. Paietta E, Li X, Richards SM, Racevskis J, Dewald G, Rowe JM, Tallman MS, Lazarus HM, Litzow MR, Goldstone AH, Wiernik PH: Implications for the use of monoclonal antibodies in future adult ALL trials: Analysis of antigen expression in 505 B-lineage (B-lin) ALL patients (pts) on the MRC UKALL IX/ECOG 2993 intergroup trial. Blood 2008; 112:666.

669. Rowe JM, Yao X, Cassileth PA, Appelbaum FR, Wiernik PH, Schiffer CA, Litzow MR, Luger S, Bennett JM, Lazarus HM, Tallman M: The pitfalls of early publication of data in acute myeloid leukemia: A report from the Eastern Cooperative Oncology Group (ECOG). Blood 2008; 112:1952

670. Witzig TE, Vose JM, Justice G, Kaplan HG, Reeder CB, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Wiernik PH: Lenalidomide oral monotherapy in relapsed/refractory small lymphocytic non-Hodgkin’s lymphoma. J Clin Oncol 2008; 26(I):472s.

671. Rowe JM, Sun Z, Cassileth PA, Appelbaum FR, Wiernik PH, Lazarus HM, Blume KG, Fernandez HF, Litzow MR, Tallman MS: Treatment-related mortality and relapse rate from time of initiation of post-remission treatment for patients receiving allogeneic transplantation, autologous transplantation or intensive chemotherapy: A report from the Eastern Cooperative Oncology Group (ECOG). Blood 2008; 112:49.

672. Rowe JM, Buck G, Moorman AV, Tallman MS, Richards SM, Fielding, Burnett AK, Franklin IM, Wiernik PH, Lazarus HM, Paietta E, Litzow MR, Marks DI, Luger S, Dewald GW, Goldstone AH: Standard consolidation/maintenance chemotherapy is consistently superior to a single autologous transplant for adult patients with acute lymphoblastic leukemia: Results of the international ALL trial (MRC UKALL XII/ECOG 2993). Blood 2008; 112:1138.


193


673. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Vose JM: Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s lymphoma: Final results of NHL-001. J Clin Oncol 2009; 27: 448s

674. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Vose JM: Durable responses in relapsed or refractory indolent non-Hodgkin’s lymphoma (NHL) with lenalidomide oral monotherapy: final results from NHL-001 study. Hematologica, 2009.

675. Lee S, Baig M, Rusciano Y, Gao Y, Malik S, Wiernik PH, Dutcher JP: Survival advantage in patients treated with high dose interleukin-2 (HDIL2) for metastatic renal cell carcinoma (mRCC). ASCO.org, 2009; abstract e16039.


676. Adiga GU, Dutcher JP, Wiernik PH: Prevalence and characterization of various cancers among hepatitis C infected patients in a community hospital . Am J Gastroenterol 2009; 104 (suppl 3): s127 (abstract 334).

677. Vevai X, O’Shea K, Keane S, Racevskis J, Gallagher R, Tallman MS, Wiernik PH, Paietta E: CD19/CD7 dual positive AML: A marker profile associated with FLT3_ITD positive, NPM1-mutated normal karyotype AML. Cytometry Part B: Clinical Cytometry 76B 2009;32:406.

678. Adiga GU, Wiernik PH: Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia. Blood 2009; 114:940

679. Dutcher JP, Wiernik PH: Renal cell carcinoma and hematologic malignancy in the same patients. J Invest Med 2011; 59: 634.

680. Douer D, Zickl L, Schiffer C, Appelbaum FR, Feusner JH, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH, Tallman MS. Very late relapses following all-trans retinoic acid for acute promyelocytic leukemia are uncommon, respond well to salvage therapy and occur independently of prognostic factors at diagnosis: Long-term follow-up of North American Intergroup study 0129. Blood 2011; 118:40. (Plenary Session Oral Presentation, ASH 2011).

681. Van Vlierberghe P, Ambesi A, Rigo I, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Rue M, Ferrando AA: ETV6 is an early T-cell progenitor (ETP) specific tumor suppressor gene in adult T-ALL. Blood 2011; 118:186.


194


682. Etkind PR, Stewart AAF, Wiernik PH, Melana SM, Holland JF, Pogo BGT. Mouse mammary tumor virus (MMTV) in human breast cancer and lymphoma. 3 rd International Conference on Viral Oncology Research 2011.

683. Dy IA, Patchett M, McDonald A, Wiernik PH: Treatment outcome of acute myeloid leukemia (AML) in HIV+ patients. Proc Am Soc Clin Oncol 2012.

684. Dy I, Pokuri V, Olichney J, Wiernik P: Levamisole-adulterated in cocaine causing agranulocytosis, vasculopathy, and acquired protein S deficiency. Ann Hematol 2012; 91:477-478.

685. Stratton KL, Schrader KA, Hakimi AA, Rau-Murthy R, Corines M, Dutcher JP, Wiernik PH, Lipkin SM, Palomba ML, Portlock CS, Murali R, Vijai J, Klein RJ, Coleman JA, Stadler ZK, Offit K: Renal cell carcinoma and non-Hodgkin’s lymphoma: Genomic approaches to identification of shared susceptibility. Proc Am Soc Clin Oncol 2013; in press.


686. Stratton KL, Schrader KA, Manschreck C, Rau-Murthy R, Corines M, Jacobs L, Dutcher JP, Wiernik PH, Palomba ML, Portlock CS, Murali R, Klein RJ, Coleman JA, Stadler ZK, Offit K, Vijai J: Renal cell carcinoma and non-Hodgkin’s lymphoma: Genomic approaches to identification of shared susceptibility. Proc Soc Urol Oncol 2013; in press.

687. Wiernik PH, Dutcher JP: Families with both Hodgkin’s lymphoma and myeloma: Anticipation and male transmission. J Invest Med 2014; 62: 760.


195


Publications G. Audiovisual/Media

1. Wiernik PH: Hematology Slide Bank Set N2: Acute Leukemia. Published by Am Soc Hematol (Text and microfiche teaching materials), 1978.

2. Holland JF, Thomas ED, Wiernik PH, Freeman AI, Frei III E, Freireich EJ, Arlin ZA: Progress and Controversies in Leukemia and Lymphoma. Audio Visual Med. Marketing, Inc., New York, 1983.

3. Sklarin NT, Dutcher JP, Wiernik PH: Hodgkin’s disease and the non-Hodgkin’s lymphomas, In Bank A (ed.): InforMed Electronic Textbook of Columbia University, BRS-Saunders Pub, Philadelphia, 1990.

4. Wiernik PH: Chronic lymphocytic leukemia. WebMD.com, 2000.

5. Wiernik PH: Practical Reviews in Medical Oncology, monthly audio taped literature reviews, Oakstone Publishing Co., Birmingham, AL, 1997-2001.

6. Wiernik PH: The Peter Wiernik Report, monthly live radio program. Discussion of cancer topic with guests. WVOX AM and WVIP FM, New Rochelle, NY Sponsored by Our Lady of Mercy Medical Center, 1999-2009.


196



197



198

CURRICULUM VITAE Wiernik CV.doc · Web viewCURRICULUM VITAE Date of Preparation March 13, 2014...

Documents

Transcript of CURRICULUM VITAE Wiernik CV.doc · Web viewCURRICULUM VITAE Date of Preparation March 13, 2014...